Acknowledgements

The IGCC 2019 Organisers wishes to acknowledge and thank following companies and institutions for their contribution and support.

SPONSORS & EXHIBITORS

PLATINUM

Lilly | ONCOLOGY

SILVER

BeiGene

MERCK

Pfizer

SERVIER

BRONZE

astellas

Bristol-Myers Squibb

HEXAL

MSD

GARNET

AMGEN

EXHIBITORS

BOWA

Novomics

wisepress.com

MEDIA PARTNER

CURRENT MEDIA

UNDER THE AUSPICES OF
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Letter</td>
<td>2</td>
</tr>
<tr>
<td>Practical Information A–Z</td>
<td>3</td>
</tr>
<tr>
<td>Floorplans</td>
<td>10</td>
</tr>
<tr>
<td>Exhibition</td>
<td>12</td>
</tr>
<tr>
<td>Program at a Glance</td>
<td>16</td>
</tr>
<tr>
<td>Instructions for Presenting Authors</td>
<td>21</td>
</tr>
<tr>
<td>Congress Program</td>
<td>26</td>
</tr>
<tr>
<td>Lunch Symposia</td>
<td>60</td>
</tr>
<tr>
<td>Social Program</td>
<td>61</td>
</tr>
<tr>
<td>Posters</td>
<td>62</td>
</tr>
<tr>
<td>Authors Index</td>
<td>141</td>
</tr>
</tbody>
</table>
Welcome Letter

Dear Participants of the International Gastric Cancer Congress 2019,

with great pleasure we welcome you to the 2019 International Gastric Cancer Congress to be held these days in Prague. Gastric Cancer continues to be a major health problem in Europe, in the Asian-Pacific Region, in America, Middle East and Africa. From a worldwide perspective, almost 1 Mio patients are diagnosed with gastric cancer / year and 750.000 die from this aggressive cancer.

Research on gastric cancer is developing fast. New insights into tumor biology and progress in health care delivery allow for more precise diagnostics, more efficacious treatment and better quality of care. This is more than one reason to profit from this most important and biggest scientific meeting on the topic of gastric cancer worldwide, bringing together delegates from many disciplines, reaching from basic researchers, clinical scientists and physicians from all disciplines and other health care professionals.

Prague is located in the very heart of Europe. It is the beautiful capital of the Czech Republic and has always been a landmark of European science and academic life. We believe that hosting this important event in Prague will inspire and boost the interest on Gastric Cancer in many parts of Europe and worldwide. It will strengthen and reinforce research and collaboration between the Western and the Central-Eastern European countries, where gastric cancer is a major health problem and will bring together professionals from all continents.

Prague is a city of stunning beauty and magnificent architecture, best of all the famous Charles Bridge which crosses the Vltava river. Prague can be called one of the most captivating cultural heritages in the World. We are confident that you will enjoy this city during your stay in Czech Republic.

BUILDING BRIDGES is the motto of the 2019 International Gastric Cancer Congress. When we are saying this we mean more than bringing together the Eastern and the Western Hemispheres of Europe and of the World: We believe that Prague’s bridges will connect the traditional medical standards with the new and innovative approaches to diagnose and treat gastric cancer, including novel molecular, imaging and robotic techniques which allow for more precision and better treatment outcomes. We also feel that our motto expresses the urgent need for bridging all medical disciplines being involved in gastric cancer care. We will make any effort to make this congress a most valuable experience for surgeons, gastroenterologists, pathologists, basic researchers, young investigators, students, patient advocates and all professions who have a dedicated interest in gastric cancer research and care.

We cordially welcome you to Prague and IGCC 2019!

Prof. Dr. Florian Lordick
University of Leipzig, Germany
Congress President

Prof. Dr. Petra Tesarova
Charles University Prague, Czech Republic
Congress Secretary

Dr. Radka Obermannová
Masaryk Memorial Cancer Institute

Prof. Stefan Mönig
Hôpitaux Universitaires Genève
Practical Information A–Z

A

Abstracts
Summaries of all oral / poster presentations are available in the downloadable Abstract Book.

Accommodation
Should you need any help with accommodation please contact our staff at the Registration desk.

Airport
Václav Havel Airport Prague handles flights from within Europe and from overseas. It is located 30–45 minutes by car from the centre of Prague. There are good connections between the airport and the city centre by public transport – buses and taxis.

Airport information – nonstop phone line
Tel.: +420 220 111 888 AFTN: LKPRYDYX
SITA: PRGCZ7X, PRVCZ7X
www.prg.aero
An airport shuttle service from your hotel to the airport can be ordered on the website www.prague-airport-transfers.co.uk or on phone 800 870 888.

Arrival by Public Transport
Prague has a sophisticated underground, tram and bus transportation system. During peak hours trains run every 1 or 2 minutes and during off-peak hours at least every 10 minutes. For more information about Prague public transportation visit www.dpp.cz.

Certificate of Attendance
All registered delegates present on site are entitled to receive a Certificate of Attendance. Certificates will be emailed to all on-site registered delegates after the congress.

City of Prague
For more information please visit following pages:
www.praguewelcome.cz
www.czechtourism.com
www.praha.eu
www.prague.cz
www.prague-czechrepublic.com
www.lonelyplanet.com/czech-republic/prague

Climate
Prague is a city with a mild continental climate. The average temperature in May varies around 20 °C. Umbrellas maybe useful, however the month of May is usually more on the sunny side.

B

Badges
Along with your registration, you will receive your name badge, which must be worn when attending all sessions and official congress programme. Participants without a badge will not be allowed to enter the venue building.

Badge Scanning at Exhibition / Lunch Symposia
Companies exhibiting/having a symposium could be using badge scanners, lead retrieve systems or exchange of business cards as ways to access your data. By submitting your badge for scanning, it automatically means that you consent to share your personal data (name, institute or company, country, emails address) with that third party. If you agree to have your badge scanned when visiting an exhibition stand or a lunch symposium, you are agreeing that those third parties receive your personal data and use it to communicate with you about their products.

Cash Points
Komerční banka cash point is located right between the entrances No. 5 and 6.
Ceska sporitelna cash point is located right next to the underground station Vysehrad entrance.

Komerční banka
Address: 5. kvetna 65, 140 00 Praha 4
Prague Congress centre Availability 24 hours
Wheelchair access

Ceska sporitelna
Address: Na Pankráci 127, 140 00 Praha 4
Vysehrad underground station
Availability 24 hours
Congress Language

The congress language is English. No simultaneous translation is provided.

Culture – What to do when in Prague?

There are a lot of concerts, exhibitions and other shows around Prague. It is hard to choose, but at this portal you can find all in one – https://goout.net/en/prague. Or look at our recommendations on the website.

Currency / Exchange

The Czech currency is called the Czech crown (CZK). Its circulation is in the form of banknotes of the following value: 5,000, 2,000, 1,000, 500, 200, 100 and coins of the following value: 50, 20, 10, 5, 2, 1 crowns.
Exchange offices are located all around the city centre (exchange offices, banks, post offices).
Always check the terms and conditions in exchange offices. Never exchange money at the street.

Disclaimer

The IGCC Congress Organisers have taken all reasonable care in making arrangements for the Congress, including accommodation and technical visits. In the event of unforeseen disruptions, neither IGCA nor the IGCC Congress Organiser nor their agents can be held responsible for any losses or damages incurred by delegates.
The programme is correct at the time of printing, but organisers reserve the right to alter the programme if and when deemed necessary. The IGCC Congress Organisers act as agents only in securing hotels, transport and travel services and shall in no event be liable for acts or omissions in the event of injury, damage, loss, accident, delay or irregularity of any kind whatsoever during arrangements organised through contractors or by the employees of such contractors. Hotel and transportation services are subject to the terms and conditions under which they are offered to the general public. Delegates should make their own arrangements with respect to personal insurance. The IGCC Congress Organisers reserve the right to make changes as and when deemed necessary without prior notice to the parties concerned. All disputes are subject to resolution under Czech Law.

Doctor / First Aid

Poliklinika Budejovicka is located at the station Budejovicka – 3 underground stations from the station Vysehrad (the location of the venue).
MEDICON a.s. – Poliklinika Budejovicka
Antala Staska 1670/80, 140 46 Praha 4
Tel.: +420 261 006 111, fax: +420 261 006 210
E-mail: info@mediconas.cz
www.mediconas.cz

Emergency Call

General emergency 112
Police 158
Fire Department 150
Medical Service 155

Exhibitors

Exhibition is located on the 2nd floor and all exhibitors are listed in the programme. For more information please see pages (12). Exhibition opening hours are listed below:

Wednesday 8 May 2019 17:00 – 20:00
Thursday 9 May 2019 8:00 – 18:00
Friday 10 May 2019 8:00 – 18:00
Saturday 11 May 2019 8:00 – 13:00

Electricity

The electricity used in Czech Republic is 220 Volts / 50 Hz (type E French 2-pin electrical adapter plug and electrical outlet identified by two round pins spaced 19 mm apart with a hole for the socket's male grounding pin. Type E outlet will also accept Type C plugs and Type E plugs will also work in Type F outlets. A transformer is necessary for your electrical and electronic equipment if using different voltage (ie USA, Canada).

Food and Beverages

Coffee-breaks and Lunches (included in the registration fees) will be served in 2nd floor foyer adjacent to Congress Hall in the Posters/Exhibition area. Seating area is available in the 3rd floor just above the Exhibition and Poster Area. Small refreshment will be also available during Poster Sessions, we strongly advise all participants to come and enjoy a glass of famous Czech beer or wine while listening to the poster presentations.

GSM Operators

There are 3 major GSM Operators in the Czech Republic: Telefonica O2, Vodafone, T-Mobile.

Information Desk

The registration staff will be happy to help you with questions you may have with regards to the congress or any other matters.
Insurance and Liability

The organizers will accept no liability for personal injuries sustained by or for loss or damage to property belonging to congress participants, accompanying persons either during or as a result of the congress or during all tours and events. Upon registration participants accept this proviso. Participants are strongly recommended to seek insurance coverage for health and accident, lost luggage and trip cancellation.

Internet

There is free Wi-Fi internet connection available. Network name: IGCC 2019 with a password: congress123. Please note the number of concurrent connections are limited.

Lost & Found

A lost and found service is available at the Information Desk at the Registration. Please hand in all found items and ask for lost items at the Information Desk. Lost or stolen credit cards: call one of the following services to take care of it:

- Visa: +420 800 142 121
- American Express: +420 850 882 028
- Master Card/Eurocard: +420 800 142 494

Maps

You have many online map providers today – Google Maps, HERE etc. But in Czech Republic we use mostly MAPY.CZ and its mobile app. You can easily download OFFLINE MAP of Czech Republic including all necessary touristic information. So, you can enjoy a nice touristic trek in Giant Mountains (or in Prague) without being lost and being online.

https://mapy.cz/zakladni?x=14.4667000&y=50.0833020&z=11&mobilepromo=1

Mobile Phones

Participants are kindly requested to keep their mobile phones in the off setting in all meeting rooms while sessions are being held.

Mobile Phone Application

The IGCC 2019 App will bring the congress to your smart phone or tablet. You will get instant access to the full scientific programme, latest news before, during and after the congress. Interactions will be facilitated by the App, allowing you to send messages to other participants. All registered participants received an invitation to download the application, should you not received it, please visit our website.

Parking

Participants arriving by car are advised to use the underground parking space available. Parking fees are not included in the registration fee.

Pharmacy

The nearest pharmacy is located in the shopping centre Arkady Pankrac – 2 underground stations from the Vysehrad station (venue location).

Shopping Centre Arkady Pankrac – 1st floor

Na Pankráci 86, 140 00 Praha 4
Tel.: +420 225 111 211
www.lekarnapankrac.cz
Opening hours: Monday–Sunday 9:00–21:00

Posters

All posters are to be presented in respective Poster Sessions. For more information about Poster Sessions please check respective pages in this Programme Book.

Presentations – Speaker’s ready room

Please hand in your presentations to the technician in the Meeting Room 2.1. Please make sure to hand in your presentation at least 2 hours prior to the start of your assigned session. Our staff in the room will be happy to assist you.

Programme Changes

The organizers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

Registration Opening Hours

Wednesday 8 May 2019 12:00–20:00
Thursday 9 May 2019 7:00–18:00
Friday 10 May 2019 7:30–18:00
Saturday 11 May 2019 8:00–13:00

Registration Desk

The registration desk is located on the ground floor of the Prague Congress Centre. Tel.: +420 261 177 000.

Registration Entitlements:

- Participation in the scientific programme of the congress
- Free lunches and coffee-breaks
- Participation in the Welcome Reception
Restaurants – Czech Cuisine

Czech cuisine is typical of Middle European gastronomy, yet clearly reflects a number of Czech elements – e.g. bread or fruit dumplings, various kinds of soups, sauces, numerous potato dishes, cakes and a wide range of festive dishes. In general, Czech gastronomy means roasted pork with dumplings and sauerkraut, potato pancakes, plum dumplings and bilberry cakes … and, of course, Czech drinks – primarily beer and first-rate wines from South Moravia, not to mention “Slivovice”, a clear Czech plum brandy and “Becherovka” a delicious herbal elixir with legendary aphrodisiac qualities. People usually have lunch between 12:00 and 14:00 and sit down for dinner between 18:00 and 21:00. However, it is possible to dine throughout the whole day and every visitor’s needs can be met.

How to find a good restaurant in Prague – Grand Restaurant

Czech culinary portal. Most of comments are in Czech, but at least you can find English description, rating and price level. www.grandrestaurant.cz/home
Check also with Google, Tripadvisor or Foursquare.

Breweries

Beer is part of our culture. We have many breweries around Prague and Czech Republic today. Usefull app with all breweries and their ratings. From micro to mega is https://play.google.com/store/apps/details?id=cz.novosvetsky.pivovary&hl=en

Vegetarians and other dietary requirements:

There is a wide selection of vegetarians and vegan restaurants in Prague, check:
www.happycow.net/europe/czech_republic/prague
Main allergens in the meals must be stated in the menu.

Social Events

For more information about Social Events, held during the congress please see the respective pages in the brochure.

Shopping

Most shops in Prague are open from 9:00 to 18:00, Monday through Saturday. Shops in the city centre are usually open from 9:00 – 20:00, Monday through Sunday.

Smoking Policy

Please note that smoking is not permitted anywhere within the venue. Since April 2017 smoking is prohibited in all restaurants, bars, pubs, public buildings and bus/train stops.

Taxi

There are hundreds of stories about taxi drivers in Prague and tourist rip-off. Simple rule to minimize the risk is – never ever stop taxi on street, always call taxi provider or use one of many mobile apps to order your taxi.

Uber works in Prague properly.
www.uber.com/en-CZ/ride

Liftago is a great Czech app. You can use it to hire taxi from different companies. Save and comfortable.
www.liftago.com

Some other relevant taxi providers are e.g. AAA (+420 14 014), City taxi (+420 257 257 257) or Speed cars (+420 224 234 234).
Boarding charge: approximately 40 CZK.
Journeys within the city: approximately 28 CZK / 1 kilometre. Do not board the taxi without finding out if there is a fixed rate.

Time Difference

The Czech Republic is in the Central European Time Zone. Central European Time (CET) is 1 hour ahead of Greenwich Mean Time (GMT +1). After the last Sunday in March the time in Czech Republic is shifted back by 1 hour to CET and this remains until the end of September.

Tipping

Service is usually included in the bill in bars and restaurants but tips are welcome. If you consider the service good enough to warrant a tip, suggested level is around 10 %.

Transportation in Prague

Prague Public Transit Co. Inc. is the main public transport operator in the Czech Republic. Almost two thousand metro trains, trams and buses are dispatched every day in Prague and the surrounding region. Tickets must be bought before starting your journey.
Metro/Underground
The Metro operates daily from 05:00 to 24:00. We recommend that you use this kind of transport as the fastest and cheapest way of moving around the city. The Metro network consists of 3 lines designated by letters and differentiated colours: A - green colour, B - yellow colour, C - red colour – with transfer possible at Muzeum station (line A and C), Mustek station (line A and B), Florenc station (line B and C).

Tram and Bus
Trams and buses operate 24 hours a day. Night trams from 00:30–4:30 (numbers 51–58) with traffic intervals of 30 minutes. Night buses from 00:30–4:30 (numbers 501–514). Bus schedules are located at individual stops.
Website: www.dpp.cz

Bike Sharing Prague
We do not have city system for bike renting. So, we have Rekola community service. Install this app. www.rekola.cz/en and look for pink bikes on street. Pay and bike.

Trains
Czech Railways (Ceske drahy)
Would you like to go to Karlstejn, Kutna Hora, Brno or Vienna? Check with CD timetable. CD provides good service, and are mostly on time. www.cd.cz/en/default.htm
Regiojet
Is an other option that provides both options – coaches and trains, excellent on board service, good prices. Best connection to Cesky Krumlov and many other Czech cities. www.regiojet.com/en

VAT
Czech legislation requires that all congress costs includes the Czech VAT (21% or 15%). In case the VAT rate changes, the change will automatically apply to the service ordered.

Venue
Prague Congress Centre
5 kvetna 65
140 21 Prague 4, Czech Republic
www.kcp.cz

Young Investigators Award
Awards will be presented to selected young scientists whose work show great potential to impact the gastric cancer field during the Opening Ceremony (Wednesday, 8 May, 17:00–18:30, Congress Hall).

Partners of the Awards:

AstraZeneca
Roche
Enrolling now: Pamiparib in platinum-sensitive gastric cancer

The PARALLEL 303 trial is a global phase 3, double-blind, randomized, placebo-controlled, multicenter study to compare the efficacy and safety of pamiparib, a PARP inhibitor, to placebo as maintenance therapy in patients with advanced gastric cancer who have responded to first-line platinum-based chemotherapy.

Key eligibility criteria*

- Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
- Received platinum-based first-line chemotherapy for ≤28 weeks
- Confirmed PR maintained for ≥4 weeks or CR
- ECOG PS ≤1

*Additional eligibility criteria apply.

Enroll your patients today
For more information, contact: clinicaltrials@beigene.com

Pamiparib (BGB-290) is an investigational product that has not yet been approved by any regulatory agency as a safe and effective treatment for any disease.

CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; PARP, poly (ADP-ribose) polymerase; PR, partial response.


0319-BGB-290-MRC-004  09Apr2019
Exhibition

1. CURRENT MEDIA
2. ROCHE
3. BOWA
4. BEIGENE
5. SERVIER
6. STRYKER
7. AMGEN
8. MERCK PFIZER ALLIANCE
9. WISEPRESS
10. KGCA
11. IGCC 2021
12. NOVOMICS
13. LILLY
Company Profiles

BOOTH 13: PLATINUM SPONSOR
Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

BOOTH 4: SILVER SPONSOR
BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a global team of over 2,200 employees, BeiGene is creating impactful medicines for cancer patients around the world.

BOOTH 8: SILVER SPONSOR
Merck-Pfizer Alliance
The alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities to develop and commercialize the anti-PD-L1 antibody avelumab initially discovered by Merck.

BOOTH 5: SILVER SPONSOR
Servier
Servier is a French global independent pharmaceutical company governed by a non-profit foundation. With a strong international presence in 149 countries, Servier employs 22,000 people worldwide.

BRONZE SPONSOR
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Now for the treatment of pretreated mCRC

Make time for more moments that matter

Change the pretreated mCRC story

LONSURF® (trifluridine/tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

mCRC=metastatic ColoRectal Cancer

Abridged prescribing information is available on the inside back cover.

Lonsurf® is licensed to Servier by Taiho, co-developed globally and marketed in their respective territories.
COMPOSITION*: Lonsurf 15 mg/6.14 mg: film-coated tablet containing 15 mg trifluridine and 6.14 mg tipiracil (as hydrochloride). Lonsurf 20 mg/8.19 mg: film-coated tablet containing 20 mg trifluridine and 8.19 mg tipiracil (as hydrochloride).

INDICATION*: Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents.

DOSAGE AND ADMINISTRATION*: Recommended starting dose: 35 mg/m²/dose taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle, within 1 hour after completion of the morning and evening meals. Dosage calculated according to body surface area, not exceeding 80 mg/dose. Possible dosing adjustments based on individual safety and tolerability: 3 permitted dose reductions to a minimum dose of 20 mg/m² twice daily, dose escalation not permitted after a dose reduction.

CONTRAINDICATIONS*: Hypersensitivity to the active substances or to any of the excipients.

WARNINGS*: Bone marrow suppression: Complete blood cell counts must be obtained prior to initiation of therapy, prior to each cycle and as needed. Treatment must not be started if absolute neutrophil count <1.5 x10⁹/L, if platelet counts <75x10⁹/L, or if unresolved Grade 3 or 4 non-haematological clinically relevant toxicity. Patient should be monitored closely for infections, appropriate measures should be administered as clinically indicated. Gastrointestinal toxicity: anti-emetic, anti-diarrhoeal and other measures should be administered as clinically indicated, dose modifications should be applied as necessary. Renal impairment: not recommended if severe renal impairment or end-stage renal disease. Patients with moderate renal impairment should be more frequently monitored for haematological toxicities. Hepatic impairment: not recommended if moderate or severe hepatic impairment.

Proteinuria: monitoring by dipstick urinalysis recommended prior to starting and during therapy. Excipients: contain lactose.

INTERACTIONS*: Precautions: medicinal products that interact with nucleoside transporters CNT1, ENT1 and ENT2, inhibitors of OCT2 or MATE1, human thymidine kinase substrates (e.g. zidovudine), hormonal contraceptives. FERTILITY*: PREGNANCY AND BREASTFEEDING*: Not recommended. CONTRACEPTION*: For women and men, highly effective contraceptive measures must be used during treatment and for 6 months after stopping treatment.

DRIVE & USE MACHINES*: Fatigue, dizziness or malaise may occur. UNDESIRABLE EFFECTS*: Very common: Neutropenia, leukopenia, anaemia, thrombocytopenia, decreased appetite, diarrhoea, nausea, vomiting, fatigue. Common: Lower respiratory tract infection, upper respiratory tract infection, febrile neutropenia, lymphopenia, monocytosis, hypoalbuminaemia, insomnia, dysgeusia, neuropathy peripheral, dizziness, headache, flushing, dyspnoea, cough, abdominal pain, constipation, stomatitis, oral disorder, hyperbilirubinaemia, Palmar-planter erythrodysaesthesia syndrome, rash, alopecia, pruritus, dry skin, proteinuria, pyrexia, oedema, mucosal inflammation, malaise, hepatic enzyme increased, blood alkaline phosphatase increased, weight decreased. Uncommon: Septic shock, enteritis infectious, lung infection, biliary tract infection, influenza, urinary tract infection, gingival infection, herpes zoster, lichen planus, candidiasis, bacterial infection, infection, cancer pain, pancytopenia, granulocytopenia, monocytopenia, erythropenia, leucocytosis, dehydration, hyperglycaemia, hyperkalaemia, hypokalaemia, hypophosphataemia, hypernatraemia, hyponatraemia, hypocalcaemia, gout, anxiety, neurotoxicity, dysaesthesia, hyperaesthesia, hypoaesthesia, syncope, paraesthesia, burning sensation, lethargy, visual acuity reduced, vision blurred, diplopia, cataract, conjunctivitis, dry eye, vertigo, ear discomfort, angina pectoris, arrhythmia, palpitations, embolism, hypertension, hypotension, pulmonary embolism, pleural effusion, rhinorrhea, dysphonia, opharyngitis, pain, epistaxis, enterocolitis haemorrhagic, gastrointestinal haemorrhage, pancreatitis acute, ascites, ileus, subileus, colitis, gastritis, reflux gastritis, oesophagitis, impaired gastric emptying, abdominal distension, anal inflammation, mouth ulceration, dyspepsia, gastroesophageal reflux disease, proctalgia, buccal polyph, gingival bleeding, glossitis, periodontal disease, tooth disorder, retching, flatulence, breath odour, hepatotoxicity, biliary dilatation, skin exfoliation, urticaria, photosensitivity reaction, erythema, acne, hyperhidrosis, blister, nail disorder, joint swelling, arthralgia, bone pain, myalgia, musculoskeletal pain, muscular weakness, muscle spasms, pain in extremity, sensation of heaviness, renal failure, cystitis noninfective, micturition disorder, haematuria, leukocyturia, menstrual disorder, general physical health deterioration, pain, feeling of body temperature change, xerosis, blood creatinine increased, electrocardiogram QT prolonged, international normalised ratio increased, activated partial thromboplastin time prolonged, blood urea increased, blood lactate dehydrogenase increased, protein total decreased, C-reactive protein increased, haematocrit decreased. Post-marketing experience: interstitial lung disease reported in Japanese patients. OVERDOSE*.

PROPERTIES*: Trifluridine is an antineoplastic thymidine-based nucleoside analogue and tipiracil hydrochloride is a thymidine phosphorylase (TPase) inhibitor. Following uptake into cancer cells, trifluridine, is phosphorylated by thymidine kinase, further metabolised in cells to a deoxyribonucleic acid DNA substrate, and incorporated directly into DNA, preventing cell proliferation. However, trifluridine is rapidly degraded by TPase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the TPase inhibitor, tipiracil hydrochloride. PRESENTATION*:

Pack of 20, 40 or 60 film-coated tablets. LES LABORATOIRES SERVIER, 50 rue Carnot, 92284 Suresnes cedex France. www.servier.com

* For complete information, please refer to the Summary of Product Characteristics for your country.

The medicinal product is subject to medical prescription. The product is reimbursed by public health insurance.
## Program at a Glance

**Thursday 9 May 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Panorama Hall</th>
<th>North Hall</th>
<th>South Hall 1A</th>
<th>South Hall 1B</th>
<th>South Hall 2A</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–08:45</td>
<td></td>
<td>SS01 Multidisciplinary treatment of EG junction cancer (page 27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45–09:00</td>
<td></td>
<td>SS02 Robot-assisted surgery for gastric cancer (page 27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00–09:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15–09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45–10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–10:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45–11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15–11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45–12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15–12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45–13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15–13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30–13:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45–14:00</td>
<td></td>
<td>SS08 Hot topics in gastric and EGJ cancer surgery (page 32)</td>
<td></td>
<td>SS09 Optimizing multidisciplinary management of localized disease (page 33)</td>
<td>SS10 Prevention of gastric cancer – Biology and Intervention (page 33)</td>
<td>SS11 Immune therapy: standards and perspectives (page 34)</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15–14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30–14:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45–15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00–15:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15–15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–15:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45–16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00–16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WS01 Basis of radiology for surgeons and medical oncologists, basis of chemotherapy for young surgeons, and basis of surgery for young medical oncologists (page 35)</td>
<td>WS02 Women in visceral surgery (page 36)</td>
</tr>
<tr>
<td>16:15–16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WS03 Multimodal treatment in stage IV gastric cancer (page 36)</td>
<td></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45–17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–17:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15–17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30–17:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45–18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15–18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sessions**
- **EV** Endoscopy Video Session
- **LS** Lunch Satellite Symposium
- **MT** Media Theatre
- **PL** Plenary Session
- **PW** Poster Session with Poster Walks
- **SL** IGCA Special Lecture
- **SM** Seminar
- **SS** Scientific Session
- **WS** Workshop
### Thursday, 9 May 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Panorama Hall</th>
<th>North Hall</th>
<th>South Hall 1A</th>
<th>South Hall 1B</th>
<th>South Hall 2A</th>
<th>South Hall 2B</th>
<th>Club A</th>
<th>Club B</th>
<th>Club C</th>
<th>Club D</th>
<th>Club E</th>
<th>Club H</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–08:45</td>
<td>SS01 Multidisciplinary treatment of EG junction cancer (page 27)</td>
<td>SS02 Robot-assisted surgery for gastric cancer (page 27)</td>
<td>SS03 Early onset and hereditary gastric cancer (page 28)</td>
<td>SS04 How to manage complications in gastric cancer surgery (page 28)</td>
<td>SS05 Evidence of laparoscopic surgery for advanced gastric cancer (page 29)</td>
<td>SS06 How can pathologists help in the selection of patients for target therapy (page 29)</td>
<td>SS07 Existential distress and psychological interventions for patients with advanced cancer (page 30)</td>
<td>EV01 Endoscopy video session (Part I) (page 30)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45–09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00–09:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15–09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30–09:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45–10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td>MT01 Technical aspects of resection, lymphadenectomy and anastomosis in gastric cancer (page 31)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–10:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45–11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15–11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45–12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:15</td>
<td>LS01 LILL Y lunch satellite symposium</td>
<td>LS02 STRYKER lunch satellite symposium</td>
<td>MT01 Media Theatre</td>
<td>MT02 Media Theatre</td>
<td>MT03 Media Theatre</td>
<td>MT04 Media Theatre</td>
<td>MT05 Media Theatre</td>
<td>MT06 Media Theatre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15–12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45–13:00</td>
<td>SS08 Hot topics in gastric and EGJ cancer surgery (page 32)</td>
<td>SS09 Optimizing multidisciplinary management of localized disease (page 33)</td>
<td>SS10 Prevention of gastric cancer – Biology and Intervention (page 33)</td>
<td>SS11 Immune therapy: standards and perspectives (page 34)</td>
<td>SS12 Proffered papers surgery (page 34)</td>
<td>SS13 Proffered papers pathology (page 34)</td>
<td>SS14 Proffered papers genetics (page 34)</td>
<td>EV02 Endoscopy video session (Part II) (page 35)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15–13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30–13:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45–14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00–14:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15–14:30</td>
<td>WS01 Basis of radiology for surgeons and medical oncologists, basis of chemotherapy for young surgeons, and basis of surgery for young medical oncologists (page 35)</td>
<td>WS02 Women in visceral surgery (page 36)</td>
<td>WS03 Multimodal treatment in stage IV gastric cancer (page 36)</td>
<td>WS04 Towards individualized treatment of localized disease (page 36)</td>
<td>WS05 Margin or not to margin – Controversies and discussion about resection margins (page 36)</td>
<td>WS06 Surviving gastric cancer – Bridging science and the patient perspective (page 39)</td>
<td>WS07 Early gastric cancer (page 40)</td>
<td>WS08 Multimodal treatment in stage IV gastric cancer (page 36)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30–14:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45–15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00–15:15</td>
<td>SL01 Jin Pok Kim lecture (page 35)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15–15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–15:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45–16:00</td>
<td>SM01 Radiotherapy as part of multimodal treatment in gastric and EG junction cancer (page 35)</td>
<td>WS01 Basis of radiology for surgeons and medical oncologists, basis of chemotherapy for young surgeons, and basis of surgery for young medical oncologists (page 35)</td>
<td>WS02 Women in visceral surgery (page 36)</td>
<td>WS03 Multimodal treatment in stage IV gastric cancer (page 36)</td>
<td>WS04 Towards individualized treatment of localized disease (page 36)</td>
<td>WS05 Margin or not to margin – Controversies and discussion about resection margins (page 36)</td>
<td>WS06 Surviving gastric cancer – Bridging science and the patient perspective (page 39)</td>
<td>SM02 Early gastric cancer (page 40)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00–16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15–16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45–17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–17:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15–17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30–17:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45–18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Session ID**
- **EV**: Endoscopy Video Session
- **LS**: Lunch Satellite Symposium
- **MT**: Media Theatre
- **PL**: Primary Session
- **PW**: Poster Session with Poster Walks
- **SL**: IGCA Special Lecture
- **SM**: Seminar
- **SS**: Scientific Session
- **WS**: Workshop
## Friday 10 May 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Panorama Hall</th>
<th>North Hall</th>
<th>South Hall 1A</th>
<th>Soth Hall 1B</th>
<th>South Hall 2A</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–08:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45–09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00–09:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15–09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30–09:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45–10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–10:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45–11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15–11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45–12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15–12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45–13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15–13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30–13:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45–14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00–14:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15–14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30–14:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45–15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00–15:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15–15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30–15:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45–16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00–16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15–16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45–17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00–17:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15–17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30–17:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45–18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15–18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Floorplans**

**Exhibition**

**Congress Program**

**Social Program**

**Posters**

Welcome Letter

Practical Information A–Z

Floorplans

Congress Program

Social Program

Posters

Authors Index

18

**Session ID**

**EV** Endoscopy Video Session

**LS** Lunch Satellite Symposium

**MT** Media Theatre

**PL** Plenary Session

**PS** Poster Session with Poster Walks

**PW** Poster Session with Poster Walks

**SL** IgCS Special Lecture

**SM** Seminar

**SS** Scientific Session

**WS** Workshop
<table>
<thead>
<tr>
<th>Time</th>
<th>Session ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–08:45</td>
<td>SS13</td>
<td>Quality assurance of gastric and EG junction surgery (page 41)</td>
</tr>
<tr>
<td></td>
<td>SS14</td>
<td>Current status and future directions of systemic treatment in stage IV gastric cancer (page 42)</td>
</tr>
<tr>
<td></td>
<td>SS15</td>
<td>Current controversies/debates in the treatment of localized disease (page 42)</td>
</tr>
<tr>
<td></td>
<td>SS16</td>
<td>Diagnosis and staging – Standards and controversies (page 43)</td>
</tr>
<tr>
<td></td>
<td>SS17</td>
<td>Early detection of gastric cancer – Standard and Future (page 43)</td>
</tr>
<tr>
<td></td>
<td>SS18</td>
<td>Economic burden of gastric cancer and treatment in different healthcare systems (page 44)</td>
</tr>
<tr>
<td></td>
<td>SS19</td>
<td>Perioperative supportive care needs of patients with gastric cancer (page 44)</td>
</tr>
<tr>
<td>08:45–09:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>09:00–09:15</td>
<td>PR02</td>
<td>Building bridges II – Connecting tradition and innovation (page 45)</td>
</tr>
<tr>
<td>09:15–09:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>09:30–09:45</td>
<td>MT02</td>
<td>EGJ cancer, imaging, Gist, Varix (page 45)</td>
</tr>
<tr>
<td>09:45–10:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td>LS03</td>
<td>TAIHO lunch satellite symposium</td>
</tr>
<tr>
<td></td>
<td>LS04</td>
<td>OL YMPUS - ESSO lunch satellite symposium</td>
</tr>
<tr>
<td>10:15–10:30</td>
<td>SS20</td>
<td>Don't be afraid of new molecular technologies (page 47)</td>
</tr>
<tr>
<td>10:30–10:45</td>
<td>SS21</td>
<td>Gastric cancer – bugs and genes (page 47)</td>
</tr>
<tr>
<td>10:45–11:00</td>
<td>SS22</td>
<td>Novel drugs (Non-immune therapy) (page 48)</td>
</tr>
<tr>
<td>11:00–11:15</td>
<td>SS23</td>
<td>Multimodal treatment concepts in stage IV disease (page 48)</td>
</tr>
<tr>
<td>11:15–11:30</td>
<td>SS24</td>
<td>Pathology of gastric cancer: Past, present and future (page 49)</td>
</tr>
<tr>
<td>11:30–11:45</td>
<td>SS25</td>
<td>Endoscopic treatment (page 49)</td>
</tr>
<tr>
<td>11:45–12:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>12:00–12:15</td>
<td>SM02</td>
<td>Challenges and innovation of laparoscopic surgery (page 50)</td>
</tr>
<tr>
<td></td>
<td>WS07</td>
<td>Reconstruction after laparoscopic total gastrectomy (page 50)</td>
</tr>
<tr>
<td></td>
<td>WS08</td>
<td>Signet ring cell cancer (page 50)</td>
</tr>
<tr>
<td>12:15–12:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td>SM03</td>
<td>How to deal with challenging cases: a cT2N0, an N+ Siewert I, and with a questionable milimetric M1 lymph nodes (page 51)</td>
</tr>
<tr>
<td>12:45–13:00</td>
<td>SS26</td>
<td>Where molecular pathology meets clinical practice (page 51)</td>
</tr>
<tr>
<td>13:00–13:15</td>
<td>WS09</td>
<td>Delivering serious news in oncology: Evidence-based recommendations for practice (page 51)</td>
</tr>
<tr>
<td>13:15–13:30</td>
<td>WS10</td>
<td>Endoscopic resection techniques (hands-on training) (page 54)</td>
</tr>
<tr>
<td>13:30–13:45</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>13:45–14:00</td>
<td>SM04</td>
<td>Where molecular pathology meets clinical practice (page 51)</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td>WS07</td>
<td>Reconstruction after laparoscopic total gastrectomy (page 50)</td>
</tr>
<tr>
<td>14:15–14:30</td>
<td>WS08</td>
<td>Signet ring cell cancer (page 50)</td>
</tr>
<tr>
<td>14:30–14:45</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>14:45–15:00</td>
<td>SM05</td>
<td>How to deal with challenging cases: a cT2N0, an N+ Siewert I, and with a questionable milimetric M1 lymph nodes (page 51)</td>
</tr>
<tr>
<td>15:00–15:15</td>
<td>WS10</td>
<td>Endoscopic resection techniques (hands-on training) (page 54)</td>
</tr>
<tr>
<td>15:15–15:30</td>
<td>SM02</td>
<td>Challenges and innovation of laparoscopic surgery (page 50)</td>
</tr>
<tr>
<td>15:30–15:45</td>
<td>WS07</td>
<td>Reconstruction after laparoscopic total gastrectomy (page 50)</td>
</tr>
<tr>
<td>15:45–16:00</td>
<td>WS08</td>
<td>Signet ring cell cancer (page 50)</td>
</tr>
<tr>
<td>16:00–16:15</td>
<td>WS09</td>
<td>Delivering serious news in oncology: Evidence-based recommendations for practice (page 51)</td>
</tr>
<tr>
<td>16:15–16:30</td>
<td>WS10</td>
<td>Endoscopic resection techniques (hands-on training) (page 54)</td>
</tr>
<tr>
<td>16:30–16:45</td>
<td>WS07</td>
<td>Reconstruction after laparoscopic total gastrectomy (page 50)</td>
</tr>
</tbody>
</table>

**SESSIONS**
- **EV**: Endoscopy Video Session
- **LS**: Lunch Satellite Symposium
- **MT**: Media Theatre
- **PL**: Primary Session
- **PW**: Poster Session with Poster Walks
- **SL**: IGCA Special Lecture
- **SM**: Seminar
- **SS**: Scientific Session
- **WS**: Workshop
**Saturday 11 May 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Panorama Hall</th>
<th>North Hall</th>
<th>South Hall 1A</th>
<th>South Hall 1B</th>
<th>South Hall 2A</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15–08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30–08:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45–09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00–09:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15–09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30–09:45</td>
<td>PR03 Building bridges III – Connecting science and treatment (page 55)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45–10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–10:15</td>
<td>Coffee-break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15–10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30–10:45</td>
<td>Highlights of the Congress</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45–11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00–11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15–11:30</td>
<td>General Assembly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45–12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15–12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45–13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00–13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Instructions for Presenting Authors

Oral Presentation

Oral presentations are always accompanied by PowerPoint presentations. All speakers are entirely responsible for the presentation content (order, graphics etc...). All presentations and questions must be delivered in English. Each speaker should also make sure that the name of the room and the time of her/his presentation or assigned session has not changed.

Presentation Format

Please make sure your presentation is in a commonly used and compatible format. Please prepare your presentation preferably using PowerPoint version 2016 or 2013, however older versions are also supported. Screens’ aspect ratio will be 16:9. Please note that Apple Keynote and Prezi presentations are not supported and they have to be converted into PDF files.

Comprehensive list of formats that are supported at IGCC 2019:

- Presentation: TXT, DOC, XLS, XLSX, PPT, PPA, PPTA, PPTX, PDF
- Video: AVI, MPG, MKV, MOV, MP4, WMV
- Audio: WMA, MP3, WAV
- Pictures: JPG, GIF, BMP, TIF

Uploading your Presentation

Presentations must be handed over on a USB stick to the personnel in the Speaker’s ready room as far in advance as possible and no later than two hours BEFORE the session beginning. The presentation for an early morning session (starting at 8:30 am) should be handed over the evening before.

Speaker’s ready room will be located in room 2.1. on the 2nd FLOOR, clearly marked and will be available at the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 8 May</td>
<td>15:00 – 20:00</td>
</tr>
<tr>
<td>Thursday 9 May</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Friday 10 May</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Saturday 11 May</td>
<td>08:00 – 13:00</td>
</tr>
</tbody>
</table>

In the Lecture Room

All presentations will be sent directly to the lecture room through the internal computer network. Please, we kindly ask all authors NOT to come at the last minute with their own computer into the lecture room. All presentations must be downloaded in the Speaker’s ready room beforehand.

Poster Presentations

Poster Area will be located on the 2nd floor foyer. We kindly ask you to be present throughout the whole poster session in order to showcase your work and to interact with the audience.

There will be two poster sessions during which all the posters should be presented by their authors:

- Thursday 9 May 2019 16:45 – 18:15
- Friday 10 May 2019 16:45 – 18:15

Mounting your Poster

Poster Area will be open for poster mounting from Wednesday 8 May 2019, 08:00.

Your poster should be set up before the Poster Session it is scheduled for. The posters will be displayed for the whole duration of the Congress. Each poster board was given a specific number. Authors are kindly asked to make sure to mount their poster on the poster board with the number corresponding to the number assigned to their poster presentation (e.g. P01-001-Thu).

Removing your Poster

All materials must be removed by the owner of the poster at the end of the congress after the closing session on Saturday 11 May, 13:00. Posters not dismantled by their authors by the end of the Meeting will be removed by the organisers and discarded. Storage for poster cases is not available.
I don’t want a fairy tale
I need everything you’ve got

Visit us at the Lilly booth.
oxaliplatin and a fluoropyrimidine. In combination with docetaxel is indicated for the treatment of stomach cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In combination with docetaxel is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression after platinum-based chemotherapy. Poseology and method of administration: The recommended dose of ramucirumab as a single agent is 8 mg/kg every 2 weeks, in combination with paclitaxel is 8 mg/kg on days 1 and 15 of a 28 day cycle, prior to paclitaxel infusion, in combination with FOLFIRI is 8 mg/kg every 2 weeks administered by intravenous infusion, prior to FOLFIRI administration. In combination with docetaxel, the recommended dose of ramucirumab is 10 mg/kg on day 1 of a 21 day cycle, prior to docetaxel infusion. It is recommended that treatment be continued until disease progression or until unacceptable toxicity has occurred. Cyramza should not be administered or mixed with dextrose solutions and after dilution is administered as an intravenous infusion over approximately 60 minutes (the maximum infusion rate of 25 mg/minute should not be exceeded, it should not be administered as an intravenous bolus or push). Premedication is recommended with a histamine H1 antagonist (for example diphenhydramine) prior to infusion of ramucirumab. If a patient experiences a Grade 1 or 2 infusion-related reaction premedication must be given for all subsequent infusions. If a patient experiences a severe Grade 1 or 2 infusion-related reaction (IRR) administer dexamethasone (or equivalent); then, for subsequent infusions, premedicate with the following or equivalent medicinal products: an intravenous histamine H1 antagonist (for example diphenhydramine hydrochloride), paracetamol and dexamethasone. At the same time, the infusion rate of ramucirumab should be reduced by 50% for the duration of the infusion and all subsequent infusions if the patient experiences a grade 1 or 2 IRR. Ramucirumab should be immediately and permanently discontinued in the event of a grade 3 or 4 IRR. No dose adjustments are recommended in elderly patients, patients with mild, moderate or severe renal impairment or mild or moderate hepatic impairment. There are no data regarding ramucirumab administration in patients with severe hepatic impairment and no data on the safety and efficacy of Cyramza in children and adolescents (<18 years). In case of overdose, supportive therapy should be used. Contraindications: Hypersensitivity to the active substance or to any of the excipients. For patients with NSCLC, ramucirumab is contraindicated where there is tumour cavitation or tumour involvement of major vessels. Special warnings and precautions: Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia have been reported in clinical studies. Ramucirumab should be permanently discontinued in patients who experience a severe ATE. Cases of gastrointestinal perforation have been reported in patients treated with ramucirumab. Ramucirumab should be permanently discontinued in patients who experience gastrointestinal perforations. Ramucirumab may increase the risk of severe bleeding, should be permanently discontinued in patients who experience Grade 3 or 4 bleeding. Blood counts and coagulation parameters should be monitored in patients with conditions predisposing to bleeding, and in those treated with anticoagulants or other concomitant medicinal products that increase the risk of bleeding. Severe gastrointestinal haemorrhage, including fatal events, were reported in patients treated with ramucirumab in combination with paclitaxel, and in combination with FOLFIRI. No excess of Grade 5 pulmonary haemorrhage was observed in ramucirumab treated patients with squamous NSCLC histology, however patients with recent pulmonary bleeding (>2.5 ml or bright red blood) as well as patients with evidence of baseline tumour cavitation, regardless of histology, those with any evidence of tumour invasion or encasement of major blood vessels, receiving any kind of therapeutic anticoagulation and/or chronic therapy with non-steroidal anti-inflammatory drugs or anti-platelet agents have been excluded from clinical trials. Aspirin use at doses up to 325 mg/day was permitted. Infusion-related reactions were reported in clinical studies with ramucirumab. The majority of events occurred during or following a first or second ramucirumab infusion. The patient should be monitored during infusion for signs of infusion-related reactions and the availability of appropriate resuscitation equipment should be ensured. An increased incidence of severe hypertension was reported in patients receiving ramucirumab as compared to placebo. In most cases hypertension was manageable by standard antihypertensive treatment. Ramucirumab treatment should not be initiated until and unless pre-existing hypertension is controlled. Patients should have their blood pressure monitored. Ramucirumab should be temporarily discontinued for severe hypertension until controlled with medical management and should be permanently discontinued if medically significant hypertension cannot be controlled with antihypertensive therapy. Ramucirumab may have the potential to adversely affect wound healing, ramucirumab treatment should be withheld for at least 4 weeks prior to scheduled surgery, if a patient develops wound healing complications during therapy, ramucirumab should be discontinued until the wound is fully healed. Ramucirumab should be used with caution in patients with severe liver cirrhosis (Child-Pugh B or C), cirrhosis with hepatic encephalopathy, clinically significant ascites due to cirrhosis, or hepatorenal syndrome and only be used if the potential benefits of treatment are judged to outweigh the potential risk of progressive hepatic failure. Patients may be at increased risk for the development of fistula when treated with ramucirumab, treatment should be discontinued in patients who develop fistula. An increased incidence of proteinuria was reported in patients receiving ramucirumab as compared to placebo. Patients should be monitored for the development, or worsening of proteinuria during ramucirumab therapy. If the urine protein is ≥2+ on a dipstick, a 24 hour urine collection should be performed. Ramucirumab therapy should be temporarily discontinued if the urine protein level is ≥2 g/24 hours. Once the urine protein level returns to <2 g/24 hours, treatment should be resumed at a reduced dose level. A second dose reduction is recommended if a urine protein level ≥2 g/24 hours reoccurs. Ramucirumab therapy should be permanently discontinued if the urine protein level is ≥3 g/24 hours or in the event of nephrotic syndrome. An increased incidence of stomatitis was reported in patients receiving ramucirumab in combination with chemotherapy as compared to patients treated with placebo plus chemotherapy. Symptomatic treatment should be instituted promptly if stomatitis occurs. Comorbidities associated with advanced age, performance status and the likely tolerability to chemotherapy should be thoroughly evaluated prior to the initiation of ramucirumab treatment in the elderly NSCLC patients because of trend towards less efficacy with increasing age. Each 10ml injection vial contains less than 1mmol sodium. Interactions: No drug-drug interactions were observed between ramucirumab and paclitaxel. The pharmacokinetics of irinotecan and its active metabolite, SN-38 or docetaxel were not affected when co-administered with ramucirumab. Fertility, pregnancy and lactation: Women of childbearing potential should be advised to avoid becoming pregnant while on Cyramza and should be informed of the potential hazard to the pregnancy and fetus. Women of childbearing potential should use effective contraception during and up to 3 months after the last dose of ramucirumab treatment. If the patient becomes pregnant while being treated with ramucirumab, she should be informed of the potential risk to the maintenance of pregnancy and the risk to the foetus. Cyramza should only be used if the potential benefit to the mother justifies the potential risk during pregnancy. Breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose. Effects on ability to drive and use machines: Cyramza has no known influence on the ability to drive and use machines. If patients experience symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides. Undesirable effects: The most serious adverse reactions associated with ramucirumab treatment (as a single agent or in combination with cytotoxic chemotherapy) were: gastrointestinal perforation, severe gastrointestinal haemorrhage, and arterial thromboembolic events. The most common adverse reactions observed in ramucirumab–treated patients are: neutropenia, fatigue/asthenia, leukopenia, epistaxis, diarrhea and stomatitis. Package, dispense and reimbursement: C2 available package of 2 injection vials 10 ml. Dispense of drug is prescription limited and drug is reimbursed from public health insurance in VILP regimen. Special precautions for storage: Store in a refrigerator (2 °C to 8 °C), do not freeze. Keep the vial in the outer carton in order to protect from light. Marketing Authorisation Holder: Eli Lilly Nederland B.V., Papendorpsweg 83, 3528 BZ Utrecht, The Netherlands. Marketing Authorisation Number and Date of last revision of the text: EU/1/14/957/001-003, 13.12.2018 Prior prescription please read carefully full Summary of Cyramza Product Characteristics, which you can obtain on website: https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza#product-information-section or at ELI LILLY CR, s.r.o., Pobrezni 394/12, 18600 Prague 8, tel.: 234 664 111, fax: 234 664 891. CYRAMZA® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. PP-RB-CZ-0079 03/2019 ELI LILLY CR, s.r.o., Pobrezni 394/12, 18600 Prague 8, Czech republic, phone: +420234464111
Bristol-Myers Squibb – at the intersection of DESIGN & DISCOVERY.
Discoveries in immuno-oncology (IO) have expanded the horizon of cancer therapy. But there is still much to uncover in how tumors evade the immune system and how we can harness the human body's cancer-fighting capabilities. Through an alliance between Merck and Pfizer, our combined talent and resources are pioneering the exploration of this innovative approach. Standing together with the physicians and patients who have participated in our clinical studies and trials, we continue to move closer to revealing the full potential of IO therapies in our pursuit for a brighter future.

Join us in our commitment to every patient, doctor, and researcher who inspire us to push forward in our fight against cancer.
### Congress Program

**Wednesday 8 May 2019**

Wednesday 8 May 2019, 17:00–18:30

**Congress Hall**

<table>
<thead>
<tr>
<th>PL01</th>
<th>Opening ceremony</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Official Opening</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: F. Lordick (Germany)</td>
</tr>
<tr>
<td></td>
<td>Speaker: P. Tesařová (Czech Republic)</td>
</tr>
<tr>
<td></td>
<td><strong>The history of gastric cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: F. Lordick (Germany)</td>
</tr>
<tr>
<td></td>
<td><strong>Art Light Show</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Gastric cancer etiology and management in Asia and in the West</strong></td>
</tr>
<tr>
<td></td>
<td>Keynote Speaker: V.E. Strong (USA)</td>
</tr>
<tr>
<td></td>
<td><strong>Leaving IGCA members appreciation</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: J. Ji (China)</td>
</tr>
<tr>
<td></td>
<td><strong>Young Investigator Awards</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: F. Lordick (Germany)</td>
</tr>
<tr>
<td></td>
<td>Partners of the Awards:</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Roche</td>
</tr>
</tbody>
</table>
Thursday 9 May 2019

Thursday 9 May 2019, 08:30–10:00

**SS01 Multidisciplinary treatment of EG junction cancer**

*Panorama Hall*

**Chairs:** A.H. Hölscher (Germany); M. Sasako (Japan)

**What is the best multimodal approach for EGJ cancer?**
Invited Speaker: A. Adenis (France)

**Total Gastrectomy vs Transthoracic Esophagectomy: When and Why? – The pattern of lymph node metastases in esophagogastric junction cancer: a nationwide prospective study in Japan**
Invited Speaker: Y. Kitagawa (Japan)

**EGJ stage IV: is there any perspective of Conversion Surgery?**
Invited Speaker: S. Möugin (Switzerland)

**Signet Ring Cell Adenocarcinoma of the EGJ: what should we do?**
Invited Speaker: G. Piessen (France)

**Minimally Invasive Surgery in Type II Cardia Cancer: Approach and Results**
Invited Speaker: T. Kinoshita (Japan)

---

Thursday 9 May 2019, 08:30–10:00

**SS02 Robot-assisted surgery for gastric cancer**

*North Hall*

**Chairs:** M. Terashima (Japan); I. Gockel (Germany)

**Japanese perspective**
Invited Speaker: I. Uyama (Japan)

**Korean perspective**
Invited Speaker: W.J. Hyung (Republic of Korea)

**European perspective**
Invited Speaker: R. van Hillegersberg (Netherlands)

**American perspective**
Invited Speaker: V.E. Strong (USA)

**South American perspective**
Invited Speaker: B. Zilberstein (Brazil)
**SS03 Early onset and hereditary gastric cancer**

*Chairs: R. Obermannová (Czech Republic); F. Carneiro (Portugal); D. Coit (USA)*

**Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria**  
*Invited Speaker: A. Cats (Netherlands)*

**Surgical management of hereditary gastric cancer and mutation carriers**  
*Invited Speaker: D. Coit (USA)*

**Which patients with a CDH1 mutation should not undergo prophylactic gastrectomy**  
*Invited Speaker: D. Coit (USA)*

**Early onset gastric cancer – specific care and research needs**  
*Invited Speaker: I. Ben-Aharon (Israel)*

**Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), experience from families in the Czech Republic**  
*Invited Speaker: L. Foretova (Czech Republic)*

**Gastric Adenocarcinoma and Proximal Polypsis Syndrome (GAPPS) – proposal of complex patient care based on single-institution experience**  
*Best Abstract Presenter: P. Grell (Czech Republic)*

**SS04 How to manage complications in gastric cancer surgery**

*Chairs: T. Sano (Japan); H.J. Meyer (Germany)*

**What have we learned from Esophageal Surgeons: from ERAS to international standardization and Benchmarking**  
*Invited Speaker: D.E. Low (USA)*

**Case presentation: Diagnosis and treatment. Interactive discussion**  
*Invited Speaker: A.C. Correia Lopes Mesquita (Portugal)*

**Discussant: L.L. Santos (Portugal)**

**Discussant: S.M. Chandramohan (India)**

**Discussant: O.A. Prado Castro (Brazil)**

**Case presentation: Diagnosis and treatment. Interactive discussion**  
*Invited Speaker: D. Marrelli (Italy)*

**Discussant: P. Morgagni (Italy)**

**Discussant: P. Matos Da Costa (Portugal)**

**Case presentation: Diagnosis and treatment. Interactive discussion**  
*Invited Speaker: S. Giacopuzzi (Italy)*

**Discussant: M. Pera (Spain)**

**Discussant: C.A. Malheiros (Brazil)**

**Discussant: H. Liang (China)**

**Case presentation: Diagnosis and treatment. Interactive discussion**  
*Invited Speaker: D. Reim (Germany)*

**Discussant: U. Fumagalli Ramario (Italy)**

**Discussant: P. Schneider (Switzerland)**

**Discussant: H. Cao (China)**
Thursday 9 May 2019, 08:30–10:00

**SS05 Evidence of laparoscopic surgery for advanced gastric cancer**

Chair: T. Yoshikawa (Japan); F. Roviello (Italy); D. Öfner-Velano (Austria)

- **KLASS-02 trial update**
  Invited Speaker: S.U. Han (Republic of Korea)

- **Chile trial**
  Invited Speaker: R. Funke (Chile)

- **Phase III study of laparoscopic distal gastrectomy for advanced gastric cancer in Japan (JLSSG0901): results of short term outcomes**
  Invited Speaker: T. Etoh (Japan)

- **LOGICA-trial and the STOMACH-trial**
  Invited Speaker: D.L. van der Peet (Netherlands)

- **Chinese trial**
  Invited Speaker: G. Li (China)

  - Benefits of laparoscopic distal gastrectomy compared with open gastrectomy for gastric cancer after neoadjuvant chemotherapy: short-term results of a RCT
    Best Abstract Presenter: Y. Wang (China)

  - Short-term surgical outcomes of laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer in North China: a multicenter RCT
    Best Abstract Presenter: X. Su (China)

Thursday 9 May 2019, 08:30–10:00

**SS06 How can pathologists help in the selection of patients for target therapy**

Chair: J. Gallardo Escobar (Chile); G. Bodoky (Hungary); C. Langner (Austria)

- **HER2**
  Invited Speaker: A. Ryška (Czech Republic)

- **Immunotherapy**
  Invited Speaker: R. Langer (Switzerland)

- **Liquid biopsies**
  Invited Speaker: N. van Grieken (Netherlands)

  - Central validation of HER2 in gastric cancer: high heterogeneity in HER2 expression and its impact on survival
    Best Abstract Presenter: I. Haffner (Germany)

  - Effect of perioperative treatment on microsatellite instable gastric cancer in the CRITICS trial
    Best Abstract Presenter: H. Biesma (Netherlands)
Thursday 9 May 2019, 08:30–10:00  
Club A

**SS07**  
**Existential distress and psychological interventions for patients with advanced cancer**

Chair: A. Mehnert (Germany); O. Sláma (Czech Republic)

- **Prognostic awareness and death anxiety**  
  Invited Speaker: S. Vehling (Germany)

- **Demoralization and associated factors in advanced cancer patients**  
  Invited Speaker: L. Quintero Garzón (Germany)

- **Psychological interventions for patients with advanced cancer**  
  Invited Speaker: A. Mehnert (Germany)

- **Symptoms and palliative care needs of patients with incurable gastrointestinal cancer at time of diagnosis and throughout disease trajectory**  
  Best Abstract Presenter: M. Tienken (Germany)

Thursday 9 May 2019, 08:30–10:00  
Club B

**EV01**  
**Endoscopy video session (Part I)**

Chair: N. Yahagi (Japan); W. Qi (China); Š. Suchánek (Czech Republic)

- **Endoscopic mucosal resection of gastric precancerous lesions**  
  Invited Speaker: O. Urban (Czech Republic)

- **Early gastric cancer ESD: Japanese experience**  
  Invited Speaker: T. Oyama (Japan)

- **Early gastric cancer ESD: European experience**  
  Invited Speaker: H. Messmann (Germany)

Thursday 9 May 2019, 10:15–11:45  
Congress Hall

**PR01**  
**Building bridges I – Connecting East and West**

Chair: P. Mansfield (USA); M. Ryska (Czech Republic); B. Zilberstein (Brazil)

- **Epidemiology of gastric cancer – a global perspective**  
  Invited Speaker: L. Dušek (Czech Republic)

- **Gastric cancer classification and most important medical needs, Eastern view**  
  Invited Speaker: T. Sano (Japan)

- **Gastric cancer challenges and research opportunities, Western view**  
  Invited Speaker: F. Lordick (Germany)

- **Central and Latin American (CELAC) and European (EU) consortium for a personalized medicine approach to Gastric Cancer (LEGACY)**  
  Invited Speaker: T. Fleitas Kanonnikoff (Spain)

- **Presidential lecture: Gastric cancer care, a global health problem**  
  Invited Speaker: J. Ji (China)
MT01 Technical aspects of resection, lymphadenectomy and anastomosis in gastric cancer

Chairs: D. Marrelli (Italy); S. Schoppmann (Austria); J. Varas (Chile)

A safe and feasible method for esophagojejunostomy intracorporeal hand-sewn reconstruction in totally laparoscopic total gastrectomy
Best Abstract Presenter: H. Hua (China)

Laparoscopic distal gastrectomy with D2 lymph nodes dissection in supra-pancreatic region
Best Abstract Presenter: B. Yang (China)

Laparoscopic distal gastrectomy with D2 lymph nodes dissection for a 50 years old male
Best Abstract Presenter: B. Yang (China)

Laparoscopic D2 lymph nodes dissection for a 56 male patient
Best Abstract Presenter: B. Yang (China)

Gastric cancer D2 laparoscopic lymphadenectomy of 8–12th stations
Best Abstract Presenter: A. Batista (Portugal)

Total laparoscopic gastrectomy with D2 lymphadenectomy extending to 8P chain
Best Abstract Presenter: A. Tinoco (Brazil)

Total laparoscopic radical gastrectomy for distal gastric cancer
Best Abstract Presenter: J. Wang (China)

Digestive reconstruction after totally laparoscopic total gastrectomy (OVERLAP)
Best Abstract Presenter: Z. Lyu (China)

Digestive reconstruction after totally laparoscopic total gastrectomy (FEE)
Best Abstract Presenter: Z. Lyu (China)

Digestive tract reconstruction after a laparoscopy-assisted distal gastrectomy for gastric cancer
Best Abstract Presenter: H. Weixian (China)

Robotic subtotal gastrectomy in a European patient- technical aspects of the lymph node dissection of station 6
Best Abstract Presenter: M.K. Jung (Switzerland)

Robot-assisted gastrectomy with D2 lymphadenectomy and a standardized circular end-to-side stapled anastomosis. Combining robotic surgery with standard stapling techniques
Best Abstract Presenter: E. Tagkalos (Germany)

Laparoscopic esophageal anastomosis after total gastrectomy: which technique?
Best Abstract Presenter: M. Gualtierotti (Italy)

An optimal surgical approach for suprapancreatic lymph node dissection with laparoscopic gastrectomy (D2+CME)
Best Abstract Presenter: J. Gong (China)

Laparoscopic D2 lymphadenectomy
Best Abstract Presenter: M. Gualtierotti (Italy)

Robotic subtotal D2 gastrectomy in Western patient: dissection of the hepatoduodenal ligament
Best Abstract Presenter: M.K. Jung (Switzerland)

Suprapancreatic dissection in D2 subtotal gastrectomy in a western patient
Best Abstract Presenter: M.K. Jung (Switzerland)

Lymphadenectomy in supra-pancreatic area via anterior approach with uncut duodenal transection during laparoscopy-assisted D2 radical gastrectomy
Best Abstract Presenter: X. Cheng (China)

Carpet lymphadenectomy in great curvature area during laparoscopy-assisted D2 radical gastrectomy
Best Abstract Presenter: X. Cheng (China)

Technical method of station 6 nodal dissection based on the principle of the outermost layer-oriented medial approach
Best Abstract Presenter: M. Tomatsu (Japan)
Tips for dissection of lymph node in laparoscopic gastrectomy  
Best Abstract Presenter: X. Ding (China)

Augmented Rectangle Technique (ART) as a Billroth-I anastomosis in totally laparoscopic gastrectomy  
Best Abstract Presenter: S. Kaji (Japan)

Lateral approach of the infra-pyloric lymphadenectomy in laparoscopic distal gastrectomy  
Best Abstract Presenter: H. Gunji (Japan)

Robot-assisted distal gastrectomy with D2 lymphadenectomy  
Best Abstract Presenter: S.S. Yoon (USA)

Esophagojejunostomy in robotic total gastrectomy using EndoWrist® Stapler  
Best Abstract Presenter: K. Kikuchi (Japan)

Laparoscopic gastrectomy  
Best Abstract Presenter: G.G. Orlando (Italy)

Introduction of an Intracorporeal anastomosis method in Laparoscopic pylorus preserving gastrectomy for early gastric cancer  
Best Abstract Presenter: T.H. Kim (Republic of Korea)

The application of “Ω”-shaped arterial dissociating path in the upper pancreatic region dissection of radical gastrectomy  
Best Abstract Presenter: D. Wang (China)

Thursday 9 May 2019, 13:15–14:45

SS08 Hot topics in gastric and EGI cancer surgery

Chairs: P. Mansfield (USA); Y.S. Shan (Taiwan, Province of China); W. Kielan (Poland)

What means D2 lymphadenectomy 2019 – Asian Pacific Chapter view  
Invited Speaker: K.M. Chu (Hong Kong)

What means D2 lymphadenectomy 2019 – European Chapter view  
Invited Speaker: P. Schneider (Switzerland)

What means D2 lymphadenectomy 2019 – Latin-American Chapter view  
Invited Speaker: P. Kassab (Brazil)

Discussion

Is there any indication for extended lymphadenectomy? – Asian Pacific Chapter view  
Invited Speaker: J. Bok Yan So (Singapore)

Is there any indication for extended lymphadenectomy? – European Chapter view  
Invited Speaker: G. De Manzoni (Italy)

Is there any indication for extended lymphadenectomy? – Latin-American Chapter view  
Invited Speaker: C. Benavides (Chile)

Discussion

How to avoid R1 resection? – Asian Pacific Chapter view  
Invited Speaker: H.J. Lee (Republic of Korea)

How to avoid R1 resection? – European Chapter view  
Invited Speaker: H. Hartgrink (Netherlands)

How to avoid R1 resection? – Latin-American Chapter view  
Invited Speaker: R. Funke (Chile)

Discussion
### Thursday 9 May 2019, 13:15–14:45

#### North Hall

**SS09** Optimizing multidisciplinary management of localized disease

*Chairs: S.E. Al-Batran (Germany); M. Oliverius (Czech Republic); A. Roth (Switzerland)*

- **How to implement minimally invasive/image-guided surgery?**  
  *Invited Speaker: M. Nilsson (Sweden)*

- **The potential value of novel drugs**  
  *Invited Speaker: A. Cervantes (Spain)*

- **Optimized radiotherapy strategies**  
  *Invited Speaker: K. Haustermans (Belgium)*

- **Preoperative or perioperative docetaxel, oxaliplatin, capecitabine GASTRODOC regimen in patients with locally advanced resectable gastric cancer: a randomized trial**  
  *Best Abstract Presenter: P. Morgagni (Italy)*

- **Neoadjuvant chemotherapy for locally advanced gastric cancer: 2 or 4 courses of cisplatin/S-1 (CS) vs docetaxel/cisplatin/S-1 (DCS)**  
  *Best Abstract Presenter: T. Yoshikawa (Japan)*

### Thursday 9 May 2019, 13:15–14:45

#### South Hall 1A

**SS10** Prevention of gastric cancer – Biology and Intervention

*Chairs: J. Špičák (Czech Republic); J. Regula (Poland)*

- **Standard of endoscopic surveillance of risk lesions**  
  *Invited Speaker: M. Knabe (Germany)*

- **Endoscopic innovations in diagnosis, screening and surveillance**  
  *Invited Speaker: Z. Vackova (Czech Republic)*

- **Inflammation, immunity, and vaccines for Helicobacter pylori infection**  
  *Invited Speaker: M. Gerhard (Germany)*

- **Prevention by H. pylori eradication-when and how?**  
  *Invited Speaker: P. Malfertheiner (Germany)*

- **Endoscopists’ Biopsy Rate (EBR) as a quality marker associated with gastric premalignant conditions detection and the rate of missed cancers**  
  *Best Abstract Presenter: W. Januszewicz (Poland)*
Thursday 9 May 2019, 13:15–14:45
South Hall 1B

SS11 Immune therapy: standards and perspectives

Chairs: M. Möhler (Germany); L. Petruželka (Czech Republic)

Asia vs Non-Asia: Are prognostic and predictive biomarkers for immunotherapy different?
Invited Speaker: K. Muro (Japan)

New immunotherapy combinations for perioperative and adjuvant indications
Invited Speaker: Y. Janjigian (USA)

Approvals and future development in metastatic first-line, maintenance and later lines
Invited Speaker: Y. Bang (Republic of Korea)

Precision medicine with 2nd line multicenter umbrella trial for recurrent/metastatic gastric cancer (GC)
Best Abstract Presenter: S.Y. Rha (Republic of Korea)

Feasibility and early findings of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma (NCT03288350)
Best Abstract Presenter: T. Alcindor (Canada)

Thursday 9 May 2019, 13:15–14:45
South Hall 2A

SS12 Proffered papers surgery

Chairs: P. Kolodziejczyk (Poland); W. Allum (United Kingdom); H.J. Meyer (Germany)

Association of short-term quality indicators with survival after gastrectomy in the Netherlands
Best Abstract Presenter: L. Van Der Werf (Netherlands)

Laparoscopic versus open gastrectomy for gastric cancer, results of a multicenter prospectively randomized controlled trial (LOGICA-trial)
Best Abstract Presenter: R. van Hillegersberg (Netherlands)

Chemotherapy versus chemo radiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer: per protocol analysis in the CRITICS trial
Best Abstract Presenter: W.O. De Steur (Netherlands)

The GASTROS study – standardizing the reporting of outcomes in surgical trials for gastric cancer; an update
Best Abstract Presenter: B. Alkhaffaf (United Kingdom)

Multivisceral resections for T4 gastric cancer
Best Abstract Presenter: V. Patsko (Ukraine)

Ten thousand consecutive gastrectomies for gastric cancer by single surgeon: perspectives of a master surgeon
Best Abstract Presenter: S.H. Noh (Republic of Korea)

A comprehensive treatment for peritoneal metastasis with an intent of cure
Best Abstract Presenter: Y. Yonemura (Japan)

Learning curve of minimally invasive gastrectomy: a nationwide analysis
Best Abstract Presenter: H.J.F. Brenkman (Netherlands)

Laparoscopic gastrectomy should be avoided for advanced remnant gastric cancer
Best Abstract Presenter: M. Sasako (Japan)
### Thursday 9 May 2019, 13:15–14:45

**Club B**

**EV02 Endoscopy video session (Part II)**

**Chairs:** O. Urban (Czech Republic); T. Oyama (Japan); H. Messmann (Germany)

- **Early GE junction cancer ESD**  
  Invited Speaker: N. Yahagi (Japan)
- **Early gastric cancer ESD: complication management**  
  Invited Speaker: W. Qi (China)
- **Self-expanding metallic stents in palliative treatment of GE junction cancer**  
  Invited Speaker: Š. Suchánek (Czech Republic)

### Thursday 9 May 2019, 15:00–15:30

**Congress Hall**

**SL01 Jin Pok Kim lecture**

**Chairs:** G. De Manzoni (Italy); T. Sano (Japan)

- **Imaging-guided surgery applied to the digestive system**  
  Invited Speaker: I. Gockel (Germany)

### Thursday 9 May 2019, 15:45–16:45

**North Hall**

**SM01 Radiotherapy as part of multimodal treatment in gastric and EG junction cancer**

**Chairs:** K. Haustermans (Belgium); T. Leong (Australia); M. Vošmik (Czech Republic)

- **What do Surgeons Expects from Radiation Oncologists?**  
  Tutor: M. Nilsson (Sweden)
- **Optimal Treatment Planning for Neoadjuvant Radiotherapy**  
  Tutor: H. Christiansen (Germany)
- **Current studies and perspectives of radiotherapy in gastric and EG junction cancer**  
  Tutor: M. Verheij (Netherlands)
- **Evidence for Immunotherapy Combined with Radiotherapy for Gastric and EG Junction Cancer**  
  Tutor: R.A. De Mello (Brazil)

### Thursday 9 May 2019, 15:45–16:45

**South Hall 1A**

**WS01 Basis of radiology for surgeons and medical oncologists, basis of chemotherapy for young surgeons, and basis of surgery for young medical oncologists**

**Chairs:** E. Smyth (United Kingdom); M. Alsina (Spain)

- **Radiology**  
  Tutor: R. Mast (Spain)
- **Surgery**  
  Tutor: K. Kataoka (Japan)
- **Medical Oncology**  
  Tutor: S. Lorenzen (Germany)
Thursday 9 May 2019, 15:45–16:45  
South Hall 1B

**WS02  Women in visceral surgery**

**How to build a career as a woman in Surgery**  
Tutor: I. Gockel (Germany)  
Tutor: S. Gisbertz (Netherlands)  
Tutor: M. Bencivenga (Italy)

Thursday 9 May 2019, 15:45–16:45  
South Hall 2A

**WS03  Multimodal treatment in stage IV gastric cancer**

* Chairs: E. Wöll (Austria); Y. Kodera (Japan)  

**Case Presentation Liver Metastases**  
Tutor: E. Wöll (Austria)  

**Pro surgery of liver metastases**  
Tutor: Y.W. Kim (Republic of Korea)  

**Contra surgery of liver metastases**  
Tutor: P. Thuss-Patience (Germany)  

**Case presentation metachronous peritoneal carcinomatosis**  
Tutor: Y. Kodera (Japan)  

**Pro localized treatment**  
Tutor: B. Rau (Germany)  

**Contra localized treatment**  
Tutor: M. Möhler (Germany)

Thursday 9 May 2019, 15:45–16:45  
South Hall 2B

**WS04  Towards individualized treatment of localized disease**

* Chairs: K. Ott (Germany); T. Nakajima (Japan); M. Zemanová (Czech Republic)  

**Based on Molecular Subtypes**  
Tutor: M. Ducreux (France)  

**Based on ctDNA**  
Tutor: N. van Grieken (Netherlands)  

**Based on Imaging & Radiomics**  
Tutor: A. Barbour (Australia)

Thursday 9 May 2019, 15:45–16:45  
Club A

**WS05  Margin or not to margin – Controversies and discussion about resection margins**

* Chairs: C. Röcken (Germany); F. Roviello (Italy); T. Yamaguchi (Japan)  

Discussant: T. Kinosita (Japan)  
Discussant: P. Kassab (Brazil)
Thursday 9 May 2019, 15:45–16:45

**PS01 Best Poster Presenters – Genetics and translational research**

*Chairs: M. Shah (USA); P. Tan (Singapore); O. Slaby (Czech Republic)*

- **KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis**
  - Best Poster Presenter: S.S. Yoon (USA)

- **Molecular subtyping of diffuse-type gastric cancer by proteomic analysis using formalin-fixed paraffin-embedded patient samples**
  - Best Poster Presenter: W. Huang (China)

- **Microsatellite instability of gastric cancer: individualized therapy**
  - Best Poster Presenter: A. Dignazio (Italy)

- **Clinical implication of the consensus subtypes of gastric cancer**
  - Best Poster Presenter: J.S. Lee (USA)

- **PD-L1 mRNA expression in resectable gastric or oesophago-gastric junction cancer undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial**
  - Best Poster Presenter: T.O. Götze (Germany)

- **NDRG1 predicts poor prognosis and promotes initiation of gastric cancer stem cells through modulating metabolic reprogramming**
  - Best Poster Presenter: L. Mi (China)

- **Role of RhoA mutations in malignant biological behaviors and chemoradiosensitivity of gastric carcinoma**
  - Best Poster Presenter: M.L. Zhou (China)

- **Dynamic changes of genomic instability based on circulating tumor DNA reflect the therapeutic response in advanced gastric cancer**
  - Best Poster Presenter: Z. Chen (China)

- **Genomic subtyping of gastroesophageal junction and gastric adenocarcinomas from American Hispanic/Latino patients**
  - Best Poster Presenter: S. Wang (USA)

- **Epstein-Barr virus infection and microsatellite instability as potential prognostic and predictive markers in gastric cancer**
  - Best Poster Presenter: G. Keller (Germany)
**PS02 Best Poster Presenters – Genetics and translational research and pathology and biomarkers**

Chairs: G. Prager (Austria); R. Petty (United Kingdom); A. Ryška (Czech Republic)

**Stearoyl-CoA desaturase regulates gastric cancer stemness and tumor metastasis via Hippo/YAP signal pathway**
Best Poster Presenter: Y. Gao (China)

**Molecular characterization and its correlation to clinical outcome in advanced gastric cancer (GC): From bed to benchside**
Best Poster Presenter: M. Di Bartolomeo (Italy)

**Cancer associated fibroblasts enhance migration and invasion of gastric cancer stem cells through p-AKT-JUNB-LAMA3 signal pathway mediated by FN1**
Best Poster Presenter: X.L. Chen (China)

**TGFβ2 inhibits proliferation of gastric cancer stem cells mediated by FOSB**
Best Poster Presenter: X.L. Chen (China)

**Down-regulation of plasma miR-133b is related to sarcopenia and contributes to cancer progression in gastric cancer**
Best Poster Presenter: J. Kiuchi (Japan)

**CD73 induced cytoskeleton remodeling as a possible therapeutic target in peritoneal metastasis of gastric cancer**
Best Poster Presenter: H. Liu (China)

**EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice**
Best Poster Presenter: Z. Chen (China)

**High lymphocyte infiltration as a positive prognostic marker in adenocarcinomas of the stomach and the gastro-esophageal junction**
Best Poster Presenter: M. Berndt (Germany)

**CD4+FOXP3+ and CD8+ T cell synergy in gastric cancer leads to improved clinical outcomes**
Best Poster Presenter: M. Wang (Australia)

**Caveolin-1 is a potential complementary biomarker to select patients for HER2-targeted therapy with trastuzumab**
Best Poster Presenter: P. Pereira (USA)
Thursday 9 May 2019, 15:45–16:45

**PS03  Best Poster Presenters – Diagnosis and staging**

*Chairs: P. Vítek (Czech Republic); H. Hartgrink (Netherlands); V. Válek (Czech Republic)*

- **Gastric cancer with lymph node metastasis more than 15 (N3b): is it really stage III disease?**
  *Best Poster Presenter: S.H. Kim (Republic of Korea)*

- **Impact of tumor-related factors and inter-institutional heterogeneity on preoperative T staging for gastric cancer: an exploratory analysis of JCOG1302A**
  *Best Poster Presenter: T. Hagi (Japan)*

- **Significance of tumor regression after neoadjuvant chemotherapy in lymph node metastases of gastric cancers**
  *Best Poster Presenter: D. Reim (Germany)*

- **European validation of the Yonsei Gastric Cancer Prognosis Prediction Model after gastrectomy: Validation with the Netherlands Cancer Registry**
  *Best Poster Presenter: H.J.F. Brenkman (Netherlands)*

- **Evaluation of the 8th AJCC staging system for gastric cancer based on a single institution in western China**
  *Best Poster Presenter: D.Y. Zhang (China)*

- **Optimization of criteria in diagnosing lymph node metastasis in gastric cancer (JCOG1302AS2)**
  *Best Poster Presenter: Y. Kurokawa (Japan)*

- **The 8th UICC-TNM classification for gastric cancer – Chinese experience**
  *Best Poster Presenter: H. Liang (China)*

- **Usefulness of laparoscopic narrow-band imaging for the evaluation of therapeutic effects on peritoneal metastasis in gastric cancer**
  *Best Poster Presenter: H. Kikuchi (Japan)*

- **Prognostic value of three lymph node staging systems in gastric cancer following D2 lymphadenectomy in a Latin American Cancer Institute**
  *Best Poster Presenter: A. Guevara-Jabiles (Peru)*

Thursday 9 May 2019, 15:45–17:15

**WS06  Surviving gastric cancer – Bridging science and the patient perspective**

*Chairs: P. Tesařová (Czech Republic); T. Tiano (Canada); E. Kosyachkova (Canada)*

- **Introduction**
  *Tutor: C. Brezden-Masley (Canada)*

- **How to find the best physician(s) to guide your treatment**
  *Tutor: D. Gabrielson (Canada)*

- **The challenge of diet and nutrition – before, during and long after treatment**
  *Tutor: A. Mehnert (Germany)*

- **The ever changing journey of the gastric cancer patient – Physical & Psycho-social short and long term side effects and how to manage**
  *Tutor: A. Mehnert (Germany)*

- **Integrating health care – resources, awareness of unique patient needs, etc**
  *Tutor: C. Brezden-Masley (Canada)*
  *Tutor: D. Gabrielson (Canada)*
  *Tutor: A. Mehnert (Germany)*
Thursday 9 May 2019, 15:45–16:45

**SM02 Early gastric cancer**

*Chair: D. Lorenz (Germany)*

**Pro endoscopic resection**
*Tutor: J. Martinek (Czech Republic)*

**Laparoscopic gastrectomy (D2+CME) for EGC**
*Tutor: J. Gong (China)*

Thursday 9 May 2019, 16:45–18:15

**PW01 Poster session with poster walks I**

For the list of posters, see page 62.
Friday 10 May 2019

Friday 10 May 2019, 08:30–10:00

Panorama Hall

SS13  Quality assurance of gastric and EG junction surgery

Chairs: W. Allum (United Kingdom); H.K. Yang (Republic of Korea); D. D’Ugo (Italy)

Surgical standard for gastric cancer – a brief overview
Invited Speaker: M. Degiuli (Italy)

European consensus on standardization of complications
Invited Speaker: G.L. Baiocchi (Italy)

Eastern view on standardization of complications
Invited Speaker: J. Bok Yan So (Singapore)

Centralization – does it lead to better quality of care – the EU perspective
Invited Speaker: J.W. van Sandick (Netherlands)

Centralization – does it lead to better quality of care – the Asian perspective
Invited Speaker: H.J. Lee (Republic of Korea)
### SS14  Current status and future directions of systemic treatment in stage IV gastric cancer

**Chairs:** N. Boku (Japan); E. Segelov (Australia); R. Obermannová (Czech Republic)

- **Questions and Challenges for defining 1st line chemotherapy**
  Invited Speaker: A.D. Wagner (Switzerland)

- **Options and choices in second and later lines of treatment**
  Invited Speaker: S. Lorenzen (Germany)

- **Immunotherapy and targeted therapy: hope or hype**
  Invited Speaker: I. Chau (United Kingdom)

- **Analysis of health-related quality of life (HRQoL) in a phase III clinical trial of trifluridine/tipiracil in metastatic gastric cancer (TAGS)**
  Best Abstract Presenter: M. Alsina (Spain)

- **Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer**
  Best Abstract Presenter: S.Y. Rha (Republic of Korea)

### SS15  Current controversies/debates in the treatment of localized disease

**Chairs:** S.H. Noh (Republic of Korea); M. Verheij (Netherlands); J. Hoch (Czech Republic)

- **Biomarkers to determine individualized risk in early gastric cancer**
  Invited Speaker: V.E. Strong (USA)

- **Pre/peri- vs post-operative radiation strategies**
  Invited Speaker: T. Leong (Australia)

- **Locoregional vs systemic relapse risk — who is needing which treatment?**
  Invited Speaker: D. Ilson (USA)

- **Which is the preferred postoperative treatment? A Japanese perspective**
  Invited Speaker: Y. Kodera (Japan)

- **Quality of life in the CRITICS gastric cancer study**
  Best Abstract Presenter: R. Van Amelsfoort (Netherlands)
Friday 10 May 2019, 08:30–10:00

**South Hall 1B**

**SS16**  Diagnosis and staging – Standards and controversies

*Chairs: L. Lambert (Czech Republic); H. Hartgrink (Netherlands); W. Polkowski (Poland)*

- **Staging and classification of gastric and esophago-gastric junction cancer – The 8th version of TNM**
  *Invited Speaker: C. Wittekind (Germany)*

- **Intraoperative imaging techniques for staging of gastric cancer**
  *Invited Speaker: A. Vahrmeijer (Netherlands)*

- **Staging after neoadjuvant chemo – what information clinicians should get from their pathologist**
  *Invited Speaker: H. Bläker (Germany)*

- **Standardization of endoscopic diagnosis**
  *Invited Speaker: T. Rösch (Germany)*

- **The practical method of photodynamic diagnosis for peritoneal metastasis mediated 5-aminolevlinic acid in advanced gastric carcinoma**
  *Best Abstract Presenter: T. Ishida (Japan)*

- **Limited usefulness of 18f-fdg-pet/ct in predicting tumour regression after preoperative chemotherapy for non-cardia gastric cancer. The GIRCG experience**
  *Best Abstract Presenter: M. Sacco (Italy)*

---

Friday 10 May 2019, 08:30–10:00

**South Hall 2A**

**SS17**  Early detection of gastric cancer – Standard and Future

*Chairs: P. Vítek (Czech Republic); E. Santoro (Italy)*

- **Early detection of gastric cancer: results from an endoscopic surveillance programme (GCEP) in a high-risk population**
  *Invited Speaker: K.G. Yeoh (Singapore)*

- **Emerging biomarkers**
  *Invited Speaker: R. Thieme (Germany)*

- **Plant metabolites – real potential or fiction?**
  *Invited Speaker: N. Arber (Israel)*

- **Identification of volatile organic compounds as a new biomarker in gastric adenocarcinoma through exhaled breath analysis**
  *Best Abstract Presenter: Y.J. Jung (Republic of Korea)*

- **Characteristics of gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan**
  *Best Abstract Presenter: T. Nakamura (Japan)*
Friday 10 May 2019, 08:30–10:00
South Hall 2B

SS18 Economic burden of gastric cancer and treatment in different healthcare systems

Chairs: P. Kassab (Brazil); R. Demlová (Czech Republic)

Is it possible to decrease the costs with prevention in public developed countries?
Invited Speaker: P. Puolakkainen (Finland)

Impact of laparoscopy and robotics in surgery costs: cheaper because of less complications or more expensive due to new technology
Invited Speaker: J.P. Ruurda (Netherlands)

The Epidemiology of Gastric Cancer in Latin America
Invited Speaker: M. Mester (Brazil)

Age and ethnic disparities in newly diagnosed gastric cancer in the United States
Best Abstract Presenter: M. Burch (USA)

Gastric cancer in young: a real world experience
Best Abstract Presenter: R. Chennamaneni (India)

Friday 10 May 2019, 08:30–10:00
Club A

SS19 Perioperative supportive care needs of patients with gastric cancer

Chairs: R. Němeček (Czech Republic); A. Weimann (Germany)

Prehabilitation
Invited Speaker: I. Gockel (Germany)

Nutrition support
Invited Speaker: A. Weimann (Germany)

Endoscopic interventions
Invited Speaker: O. Pech (Germany)

Psychosocial aspects of follow-up and cancer survivorship of young adult cancer survivors
Invited Speaker: A. Sender (Germany)

Glucagon-like peptide 1 is a key factor in dumping syndrome after gastrectomy: a randomised, double-blind, placebo controlled crossover study
Best Abstract Presenter: G. Roberts (United Kingdom)

Impact of remnant stomach volume and anastomosis on nutrition and body composition in gastric cancer patients
Best Abstract Presenter: I.S. Lee (Republic of Korea)
Friday 10 May 2019, 10:15–11:45

**Congress Hall**

### PR02 Building bridges II – Connecting tradition and innovation

*Chairs: M. Sasako (Japan); H. Grabsch (Netherlands); M. Zavoral (Czech Republic)*

**Gastric Cancer, What we Knew 25 Years Ago**
Invited Speaker: M. Brennan (USA)

**From traditional gastric cancer treatment to contemporary strategies**
Invited Speaker: M. Terashima (Japan)

**How to implement quality assurance today into contemporary treatment concepts**
Invited Speaker: W. Allum (United Kingdom)

**The vision of precision surgery**
Invited Speaker: H.K. Yang (Republic of Korea)

**Innovative perioperative treatment – a surgeons perspective how to improve outcomes**
Invited Speaker: P. Mansfield (USA)

Friday 10 May 2019, 12:00–14:45

**South Hall 2B**

### MT02 EGJ cancer, imaging, Gist, Varia

*Chairs: A.C. Weston (Brazil); M.S. Karpeh (USA)*

**Laparoscopic double-flap technique after proximal gastrectomy for gastrointestinal stromal tumor in the esophagogastric junction**
Best Abstract Presenter: W. Wang (China)

**Fluorolaparoscopic distal gastrectomy with D2 lymph nodes dissection for a 44 years old female**
Best Abstract Presenter: Z. Chen (China)

**The lower mediastinal lymphadenectomy and Giraffe reconstruction in laparoscopic proximal gastrectomy for Siewert type II tumor**
Best Abstract Presenter: X. Cheng (China)

**Hand-sewn esophagogastrostomy as an anti-reflux procedure in laparoscopy proximal gastrectomy for gastric cancer**
Best Abstract Presenter: S. Komatsu (Japan)

**Laparoscopic total gastrectomy with transhiatal lower mediastinal lymph node dissection for advanced gastroesophageal junction cancer**
Best Abstract Presenter: A. Kaito (Japan)

**Laparoscopic transhiatal lower mediastinal lymphadenectomy using the infracardiac bursa as a surgical landmark**
Best Abstract Presenter: H. Shinohara (Japan)

**Sentinel Node Navigation Surgery using infrared observation for early gastric cancer**
Best Abstract Presenter: S. Mayanagi (Japan)

**Radical gastrectomy by fluorescence laparoscopy in distal gastric cancer**
Best Abstract Presenter: W. Liang (China)

**Robotic-assisted gastric resection for a posterior wall GIST lesion**
Best Abstract Presenter: C.H. Wassmer (Switzerland)

**Hyperspectral imaging (HSI) in gastro-jejunal anastomosis following gastric cancer resection**
Best Abstract Presenter: I. Gockel (Germany)

**Single-port distal gastrectomy with D2 lymphadenectomy using a novel articulating grasper**
Best Abstract Presenter: S.H. Kang (Republic of Korea)
Minimally invasive Ivor Lewis procedure for gastroesophageal junction cancer: a step by step instructional video for surgeons in training
Best Abstract Presenter: A.M. Oo (Singapore)

Laparoscopic total gastrectomy and D2 limphadenectomy Indocyanine Color Green fluorescence angiography assisted
Best Abstract Presenter: A. Cossu (Italy)

Bleeding gastric lipoma: an unconventional surgery for an infrequent benign gastric tumor
Best Abstract Presenter: F. Calabrese (Italy)

Gastric PEComa: first case of robotic sparing surgery
Best Abstract Presenter: A. Marano (Italy)

The experience of fundoplication with wrapping a half circumference of esophagus during esophagogastrectomy after laparoscopic proximal gastrectomy
Best Abstract Presenter: M. Aizawa (Japan)

Totally laparoscopic distal splenorenal venous anastomosis with distal gastrectomy in patient with locally advanced gastric cancer and complicated liver cirrosis
Best Abstract Presenter: N. Semenov (Russian Federation)

Laparoscopic proximal gastrectomy with double tract reconstruction for GEJ cancer
Best Abstract Presenter: N. Semenov (Russian Federation)

Robotic treatment of cardial lesion
Best Abstract Presenter: A. Marano (Italy)

Laparoscopic-assisted seldinger technique for stomach: a cardinal procedure facilitate percutaneous tunnel gastrostomy
Best Abstract Presenter: Z. Ma (China)

Totally laparoscopic total gastrectomy for the upper third of gastric cancer
Best Abstract Presenter: L. Vo Duy (Viet Nam)

Full-thickness resection by totally laparoscopic intra-gastric surgery method to treat submucosal tumors located near the gastric cardia
Best Abstract Presenter: L. Tianzhou (China)

Use of ICG in laparoscopic lymph node dissection: focus on number 6
Best Abstract Presenter: S. Giacopuzzi (Italy)

Laparoscopic and Endoscopic Cooperative Surgery (LECS) for gastric GIST
Best Abstract Presenter: J. Viganò (Italy)

Dual port laparoscopic distal gastrectomy with D2 lymphadenectomy is safe and feasible
Best Abstract Presenter: G. Li (China)

Usefulness of a 2-point lifting type Internal Organ Retractor in laparoscopic total gastrectomy
Best Abstract Presenter: Y. Matsumoto (Japan)

Double Channel reconstruction after resection of the gastroesophageal junction for subcardial gastric cancer
Best Abstract Presenter: A.H. Hölscher (Germany)

Indocyanine green (ICG) fluorescence image-enhanced laparoscopic distal gastrectomy
Best Abstract Presenter: I.Y.H. Wong (Hong Kong)
Friday 10 May 2019, 13:15–14:45  Panorama Hall

**SS20  Don’t be afraid of new molecular technologies**

*Chairs: T. Zima (Czech Republic); R. Langer (Switzerland); B. Luber (Germany)*

- **Deep tissue imaging: from a preclinical cancer research perspective**
  - Invited Speaker: A. Walch (Germany)
- **NGS to characterize gastric cancer**
  - Invited Speaker: A. Boussioutas (Australia)
- **3D models for gastric cancer studies**
  - Invited Speaker: P. Puolakkainen (Finland)
- **Modelling gastric cancer using CRISPR/Cas9-mediated engineering of organoid for precision medicine**
  - Best Abstract Presenter: Z. Lu (China)
- **Tumor organoid model for gastric cancer (GC) microenvironment and stemness study**
  - Best Abstract Presenter: P. Puolakkainen (Finland)

Friday 10 May 2019, 13:15–14:45  North Hall

**SS21  Gastric cancer – bugs and genes**

*Chairs: F. Carneiro (Portugal); M. Hajdúch (Czech Republic)*

- **H pylori, EBV and the gastric microbiota**
  - Invited Speaker: C. Figueiredo (Portugal)
- **Recent progress in the molecular classification of gastric cancer**
  - Invited Speaker: P. Tan (Singapore)
- **The role of exosomes and microRNAs in gastric cancer progression**
  - Invited Speaker: O. Slabý (Czech Republic)
- **Construction and Comprehensive Analysis of a Competitive Endogenous RNA Network and Potential Regulatory Axis in Gastric Cancer**
  - Best Abstract Presenter: H. Pan (China)
- **Evaluation of exosomal mRNAs from liquid biopsies in gastric cancer patients**
  - Best Abstract Presenter: R. Thiemer (Germany)
**SS22**  Novel drugs (Non-immune therapy)

**Chairs:** B. Melichar (Czech Republic); Y. Yamada (Japan); L.T. Chen (Taiwan, Province of China)

- **Angiogenesis inhibition from metastatic to perioperative setting: new data and novel drugs**
  Invited Speaker: E. Van Cutsem (Belgium)

- **New (pan)HER inhibitors and combinations: Are they better than established standards?**
  Invited Speaker: K. Shitara (Japan)

- **Personalized treatment: How to overcome tumor heterogeneity**
  Invited Speaker: D. Catenacci (USA)

- **Nintedanib, a triple angiokinase inhibitor, augments chemotherapy response in preclinical models of gastric cancer**
  Best Abstract Presenter: N. Awasthi (USA)

- **Nuclear exporter protein XPO1 as a novel therapeutic target in gastric cancer**
  Best Abstract Presenter: R. Sexton (USA)

**SS23**  Multimodal treatment concepts in stage IV disease

**Chairs:** Y.K. Kang (Republic of Korea); A. Stier (Germany); V. Jedlička (Czech Republic)

- **The concept of oligometastatic disease: completed and ongoing randomized trials**
  Invited Speaker: S. Mönig (Switzerland)

- **Liver metastasis: is there a role for surgery?**
  Invited Speaker: K. Yoshida (Japan)

- **Peritoneal metastases from gastric cancer: evidence for peritoneectomy, HIPEC and systemic chemotherapy**
  Invited Speaker: P. Piso (Germany)

- **Secondary gastrectomy significantly improve survival in stage IV gastric cancer: a comparison of current treatment strategies from the SEER database**
  Best Abstract Presenter: J. Desiderio (Italy)

- **The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis**
  Best Abstract Presenter: A. Brandl (Germany)
Friday 10 May 2019, 13:15–14:45

**SS24 Pathology of gastric cancer: Past, present and future**

*Chairs: R. Gürlich (Czech Republic); T. Yoshikawa (Japan); C. Röcken (Germany)*

- **The many faces of signet ring cell cancer**
  *Invited Speaker: H. Grabsch (Netherlands)*

- **Signet Ring and Diffuse Type Gastric Cancer – Molecular Alterations, Clinical Impact**
  *Invited Speaker: M. Möhler (Germany)*

- **Implications for clinical trials**
  *Invited Speaker: G. Piessen (France)*

- **A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 – 2015**
  *Best Abstract Presenter: R. Van Der Kaaij (Netherlands)*

- **The amount of signet ring cells significantly impacts on tumour stage in poorly cohesive tumours**
  *Best Abstract Presenter: M. Bencivenga (Italy)*

Friday 10 May 2019, 13:15–14:45

**SS25 Endoscopic treatment**

*Chairs: O. Urban (Czech Republic); K.G. Yeah (Singapore)*

- **What are the indications for endoscopic treatment in gastric cancer?**
  *Invited Speaker: H. Messmann (Germany)*

- **What are the long-term results of endoscopic treatment in early gastric cancer?**
  *Invited Speaker: T. Oyama (Japan)*

- **How to manage complications during and after endoscopic treatment?**
  *Invited Speaker: N. Yahagi (Japan)*

- **The feasibility and efficacy of intraoperative endoscopy for tumor localization in totally laparoscopic gastrectomy**
  *Best Abstract Presenter: S.H. Park (Republic of Korea)*

- **Non-exposure simple suturing endoscopic full-thickness resection (NESS-EFTR) with sentinel basin dissection in patients with early gastric cancer**
  *Best Abstract Presenter: B.W. Eom (Republic of Korea)*

Friday 10 May 2019, 15:00–15:30

**SL02 Nishi-Takashi lecture**

*Chairs: C. Wittekind (Germany); F. Carneiro (Portugal)*

- **Heterogeneity and Evolution – What Cancer Physicians can Learn from Evolutionary Biology**
  *Invited Speaker: F. Thomas (France)*
## SM03  Challenges and innovation of laparoscopic surgery

*Chairs: S. Gisbertz (Netherlands); K. Kojima (Japan); D. Lorenz (Germany)*

- **Splenic hilar lymph node dissection**  
  Tutor: C. Huang (China)

- **Laparoscopic endoscopic cooperative surgery (LECS) for the gastrointestinal tract: updated indications**  
  Tutor: N. Hiki (Japan)

- **Novel reconstruction methods in MIS**  
  Tutor: A. Parisi (Italy)

Friday 10 May 2019, 15:45–16:45

### South Hall 1A

## WS07  Reconstruction after laparoscopic total gastrectomy

*Chairs: H.H. Kim (Republic of Korea); T. Kinoshita (Japan); B. Wijnhoven (Netherlands)*

Lecture and video and discussion. Target: young audience

Friday 10 May 2019, 15:45–16:45

### South Hall 1B

## WS08  Signet ring cell cancer

*Chairs: F. Carneiro (Portugal); H. Grabsch (Netherlands)*

- **Case Presentation – Poorly Cohesive and Poorly differentiated tumours – Interactive discussion**  
  Tutor: F. Renaud (France)

- **Case Presentation – Pure SCR and Poorly cohesive tumours: do they have a transitional relationship?**  
  Tutor: T. Arai (Japan)

- **Case Presentation – Stromal features in pure SCR and Poorly cohesive tumours**  
  Tutor: A. Tomezzoli (Italy)
**Friday 10 May 2019, 15:45–16:45**

**South Hall 2A**

**SM04**  **How to deal with challenging cases: a cT2N0, an N+ Siewert I, and with a questionable milimetric M1 lymph nodes**

- **Surgery**
  - Panellist: S. Castro Boix (Spain)

- **Surgery**
  - Panellist: K. Polom (Poland)

- **Surgery**
  - Panellist: O. Lyros (Germany)

- **Medical Oncology**
  - Panellist: L. Wyrwicz (Poland)

- **Medical Oncology**
  - Panellist: M. Ng (Singapore)

- **Medical Oncology**
  - Panellist: E. Baba (Japan)

- **Gastroenterology**
  - Panellist: M. Venerito (Germany)

**Friday 10 May 2019, 15:45–16:45**

**South Hall 2B**

**WS09**  **Delivering serious news in oncology: Evidence-based recommendations for practice**

- **Chair**: R. Němeček (Czech Republic)
- **Tutor**: M. Loučka (Czech Republic)
- **Tutor**: A. Houska (Czech Republic)

**Friday 10 May 2019, 15:45–16:45**

**Club A**

**SM05**  **Where molecular pathology meets clinical practice**

- **Chairs**: D. Valík (Czech Republic); M. Mester (Brazil)

- **HER2 resistance mechanisms and how to explore them**
  - **Tutor**: B. Luber (Germany)

- **Impact of molecular biology on surgical concepts today**
  - **Tutor**: F. Roviello (Italy)

- **From GC molecular classification to novel clinical study concepts**
  - **Tutor**: E. Smyth (United Kingdom)
**PS04  Best Poster Presenters – Surgery and quality assurance**

*Chairs: P. Morgagni (Italy); M. Sasako (Japan); K. Ott (Germany)*

<table>
<thead>
<tr>
<th>Title</th>
<th>Best Poster Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relationship between Clavien–Dindo classification and long-term survival outcomes after curative resection for gastric cancer</td>
<td>Z. Li (China)</td>
</tr>
<tr>
<td>Histological findings of the non-tumoral gastric mucosa in patients operated by gastric cancer</td>
<td>C. García (Chile)</td>
</tr>
<tr>
<td>Decreasing resection rates for gastric cancer in Europe and USA in the early 21st century: A large international population-based study</td>
<td>L. Huang (Germany)</td>
</tr>
<tr>
<td>Effect of hospital and surgeon volume on postoperative outcomes after total gastrectomy for gastric cancer based on Japanese nationwide database</td>
<td>H. Baba (Japan)</td>
</tr>
<tr>
<td>Cancer surgery centre designation and the clinical and economic outcomes of patients with gastric cancer</td>
<td>Y. Jeong (Canada)</td>
</tr>
<tr>
<td>Modified gastroesophageal anastomosis in proximal gastrectomy</td>
<td>N. Chorna (Ukraine)</td>
</tr>
<tr>
<td>Prediction of intraabdominal infectious complications after laparoscopic gastrectomy and effectiveness of postoperative management without drainage</td>
<td>M. Saji (Japan)</td>
</tr>
<tr>
<td>Survival outcomes of Siewert-II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches: joint analysis of thoracic and gastrointestinal surgery</td>
<td>X.Z. Chen (China)</td>
</tr>
<tr>
<td>Identification of the clinically most relevant postoperative complications after gastrectomy: a population-based cohort study</td>
<td>E.C. Gertsen (Netherlands)</td>
</tr>
<tr>
<td>Does non-compliance in lymph node dissection affect oncological efficacy in gastric cancer patients undergoing radical gastrectomy?</td>
<td>Q.Y. Chen (China)</td>
</tr>
</tbody>
</table>
Friday 10 May 2019, 15:45–16:45

**Club C**

**PS05 Best Poster Presenters – Minimally-invasive and robot-assisted surgery**

*Chairs: D.L. van der Peet (Netherlands); I. Gockel (Germany); M. Terashima (Japan)*

- **Impact of fluorescent lymphography guided lymphadenectomy on gastric cancer**
  Best Poster Presenter: M.K. Jung (Switzerland)

- **Comparison of anastomotic complications after laparoscopic total gastrectomy with esophagojejunostomy using circular stapler versus linear stapler**
  Best Poster Presenter: X. Jiang (China)

- **Analysis of factors which affect direction of lymphatic drainage in the stomach**
  Best Poster Presenter: A. Shida (Japan)

- **Safety and clinical value of laparoscopic gastrectomy for elderly patients with gastric cancer**
  Best Poster Presenter: T. Yamada (Japan)

- **Laparoscopic distal gastrectomy with complete mesogastrium excision (D2+CME) can reduce surgery induced intraperitoneal free cancer cells in advanced gastric cancer**
  Best Poster Presenter: J. Gong (China)

- **Laparoscopic gastrectomy and D2 lymphadenectomy for gastric cancer: a single center experience at University Medical Center, Hochiminh city, Vietnam**
  Best Poster Presenter: L. Vo Duy (Viet Nam)

- **Is minimally invasive surgery the better choice? Short-term and long-term outcomes of laparoscopic gastrectomy for elderly gastric cancer patients**
  Best Poster Presenter: K. Xu (China)

- **Laparoscopic partial gastrectomy with sentinel node mapping for early gastric cancer**
  Best Poster Presenter: H. Takeuchi (Japan)

- **Risk factors for atypical metastasis in gastric cancer were analyzed**
  Best Poster Presenter: J. Jung (Republic of Korea)

- **Surgical and long-term oncologic outcomes of laparoscopic and open gastrectomy for serosa-positive (pT4a) gastric cancer: a propensity score-matched analysis**
  Best Poster Presenter: Z. Li (China)

---

Friday 10 May 2019, 15:45–16:45

**Club D**

**PS06 Best Poster Presenters – Young investigators**

*Chairs: M. Alsina (Spain); J. Varas (Chile)*

- **A case matched analysis from the IMIGASTRIC database to compare robotic, laparoscopic and open gastrectomy with D2 lymphadenectomy**
  Best Poster Presenter: J. Desiderio (Italy)

- **Morphological and transcriptomic insights into gastric cancer with Epstein-Barr virus infection and microsatellite instability as potential candidates for targeted immunotherapies**
  Best Poster Presenter: I. Gullo (Portugal)

- **Upper GI training of young surgeons. An international survey**
  Best Poster Presenter: R. Reddavid (Italy)

- **Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit**
  Best Poster Presenter: Y. Jiang (China)
Surgeon assessment of gastric cancer lymph node specimens with a video of technique
Best Poster Presenter: N. Ikoma (USA)

A prospective trial comparing minimally invasive approaches and open surgery is needed in gastric cancer. Methodology from a study protocol
Best Poster Presenter: D. Di Nardo (Italy)

Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO): a multicentre clinical and pathological database including over 25,000 patients
Best Poster Presenter: V. Gupta (Canada)

Diffusion-weighted MR Imaging can predict pathological non-responders after neoadjuvant chemotherapy in locally advanced gastric cancer-early result of clinical trial NCT03413514
Best Poster Presenter: Y. Wang (China)

C-reactive protein is an early marker of major complication after gastrectomy for gastric cancer
Best Poster Presenter: A.R. Dias (Brazil)

Adjuvant chemoradiotherapy is beneficial in margin positive patients following neo-adjuvant chemotherapy and surgery for lower oesophageal and GOJ adenocarcinoma
Best Poster Presenter: R. Bott (United Kingdom)

Friday 10 May 2019, 15:45–17:45

WS10 Endoscopic resection techniques (hands-on training)

Chairs: Š. Suchánek (Czech Republic); J. Martínek (Czech Republic); H. Messmann (Germany)
Tutor: T. Oyama (Japan)
Tutor: N. Yahagi (Japan)
Tutor: O. Pech (Germany)

Friday 10 May 2019, 16:45–18:15

PW02 Poster session with poster walks II

For the list of posters, see page 103.
Saturday 11 May 2019

Saturday 11 May 2019, 08:30–10:00

PR03  Building bridges III – Connecting science and treatment

Chairs: F. Lordick (Germany); G. De Manzoni (Italy); P. Puolakkainen (Finland)

The genetic features behind hereditary gastric cancer
Invited Speaker: F. Carneiro (Portugal)

Molecular classification of gastric and esophageal cancer – a basis for new treatments?
Invited Speaker: A. Bass (USA)

The vision of molecularly personalized drug treatment of gastric cancer
Invited Speaker: Y. Janjigian (USA)

How to translate new knowledge into clinical studies on medical treatment of gastric cancer
Invited Speaker: K. Shitara (Japan)

Will molecular knowledge change the surgical approach to gastric cancer?
Invited Speaker: Y. Kitagawa (Japan)

Saturday 11 May 2019, 10:15–11:00

SL03  Highlights of the congress

Chairs: S. Mönig (Switzerland); P. Tesařová (Czech Republic); H.K. Yang (Republic of Korea)

Highlights from Cancer Biology
Invited Speaker: I. Ben-Aharon (Israel)

Highlights from Surgery
Invited Speaker: M. Nilsson (Sweden)

Highlights from Multimodal Treatment
Invited Speaker: R. Obermannová (Czech Republic)

Building Bridges – Mission Accomplished?
Invited Speaker: F. Lordick (Germany)

Saturday 11 May 2019, 11:15–12:00

PL02  IGCA General Assembly and IGCC Closing Ceremony
OPTIMIZING EVIDENCE-BASED SEQUENCING AND SURVIVAL IN ADVANCED GASTRIC AND GEJ CANCER – CASE-BASED DISCUSSIONS

Thursday 9 May 2019 | 12:00-13:00
Congress Hall | Prague Congress Centre, Prague, Czech Republic

AGENDA

12:00 Welcome and introduction
Co-Chairs: Ian Chau (UK) and Christine Brezden-Masley (Canada)

Clinical case study discussions – practical examples of managing common challenges in advanced gastric and GEJ cancer

12:05 Case study 1 – Radka Obermannová (Czech Republic)
Case study 2 – Sylvie Lorenzen (Germany)
Case study 3 – Sun Young Rha (South Korea)

12:50 Questions and closing remarks
Co-Chairs: Ian Chau (UK) and Christine Brezden-Masley (Canada)

13:00 Symposium closes
You’re Invited
to experience
INTRAOPERATIVE FLUORESCENCE IMAGING

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker / Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Introduction and Overview of Fluorescence</td>
<td>Isaac LAI Clinical Marketing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stryker</td>
</tr>
<tr>
<td>12:15</td>
<td>Fluorescence in Upper Gastrointestinal Surgery</td>
<td>Professor Do Joong PARK</td>
</tr>
<tr>
<td></td>
<td>- D2 lymphatic mapping</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- SLN biopsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Perfusion assessment in esophagectomy</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>Question &amp; Answer</td>
<td>Professor Han Kwang YANG</td>
</tr>
<tr>
<td>13:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Professor Han Kwang YANG**  
Director, Gastric Cancer Centre  
Seoul National University Hospital  
College of Medicine  

**Professor Do Joong PARK**  
Seoul National University Hospital  
College of Medicine  

See more. Do more.

LUNCH SYMPOSIUM  
9th May 2019  
12:00 - 13:00  
Panorama Hall  
Prague Congress Center  

Visit us at Booth 6
Lunch Symposium

CONVERSION Surgery and NEOADJUVANT Chemotherapy for GC
− How Much Have We Achieved? −

Date: 10 May, 2019 (Friday)
Time: 12:00 - 13:00
Venue: Congress Hall

OPENING REMARKS
Masaki Kitajima, M.D., FACS(hon), FRCS(hon), FISS(hon)
International University of Health and Welfare, Tokyo, Japan

CHAIRS

Masaki Kitajima, M.D., FACS(hon), FRCS(hon), FISS(hon)
International University of Health and Welfare, Tokyo, Japan

Takeshi Sano, M.D., Ph.D., FRCS
Cancer Institute Hospital Of JFCR, Tokyo, Japan

Giovanni de Manzoni, M.D., Ph.D.
University of Verona, Verona, Italy

SPEAKERS

Kazuhiro Yoshida, M.D., Ph.D., FACS
Gifu University Graduate School of Medicine, Gifu, Japan

Masanori Terashima, M.D., Ph.D., FACS
Shizuoka Cancer Center, Shizuoka, Japan

Salah-Eddin Al-Batran, M.D., Ph.D.
Krankenhaus Nordwest, Frankfurt, Germany

Jiafu Ji, M.D., Ph.D., FACS
Peking University Cancer Hospital & Institute, Peking, China

Q&A Session
“How to implement the adoption of mini-invasive gastrectomy in the West?”

Olympus - ESSO Satellite Symposium
8 - 11 May 2019
Prague, Czech Republic

Friday 10 May 2019 | 12:00 - 13:00 in Panorama Hall

Chair Domenico D’Ugo - ESSO President Elect

Intro D.D’Ugo (10 min)

The Utrecht Course Richard Van Hillegensberg (10 min)

How we teach in the West Jelle Ruurda (20 min)

How I teach in the East Woo-Jin Hyung (20 min)
Lunch Symposia

Thursday 9 May 2019, 12:00–13:00

Lunch Symposium sponsored by LILLY

CONGRESS HALL
OPTIMIZING EVIDENCE-BASE SEQUENCING AND SURVIVAL IN ADVANCED GASTRIC AND GAEH CANCER – CASE-BASED DISCUSSIONS

Chairs: Ian Chau (United Kingdom), Christine Brezden-Masley (Canada)
Speakers: Radka Obermannová (Czech Republic), Sylvie Lorenzen (Germany), Sun Young Rha (South Korea)

Friday 10 May 2019, 12:00–13:00

Lunch Symposium sponsored by TAIHO

CONGRESS HALL
CONVERSION SURGERY AND NEOADJUVANT CHEMOTHERAPY FOR GC – HOW MUCH HAVE WE ACHIEVED?

Chairs: Masaki Kitajima (Japan), Takeshi Sano (Japan), Giovanni de Manzoni (Italy)
Speakers: Kazuhiro Yoshida (Japan), Masanori Terashima (Japan), Salah-Eddin Al-Batran (Germany), Jiafu Ji (China)

Lunch Symposium sponsored by OLYMPUS – ESSO Satellite Symposium

PANORAMA HALL
HOW TO IMPLEMENT THE ADOPTION OF MINI-INVASIVE GASTRECTOMY IN THE WEST?

Chair: Domenico D’Ugo (Italy)
Speakers: Domenico D’Ugo (Italy), Richard Van Hillegersberg (Netherlands), Jelle Ruurda (Netherlands), Woo-Jin Hyung (South Korea)

PANORAMA HALL
FLUORESCENCE IMAGING IN UPPER GI SURGERY

Chair: Han Kwang Yang (South Korea)
Speakers: Isaac Lai (China), Do Joong Park, (South Korea)
Social Program

Opening Ceremony

Wednesday 8 May 2019 (17:00 – 18:30),
Prague Congress Centre, Main Congress Hall

The IGCC 2019 Congress will be officially opened on 8 May 2019 with the Ceremony held in the Congress Hall where we will be welcomed by our hosts and hosting institution representatives. We sincerely invite all our participants to take part and listen to our opening speaker Vivian Strong talking about Gastric cancer etiology and management in Asia and in the West as well as enjoy the Light Art show prepared especially for this purpose. We will also recognize our Young Investigator Award winners.

Tickets: Included in the registration fees for participants and accompanying persons.

Welcome Reception

Wednesday 8 May 2019 (18:30 – 20:00),
Prague Congress Centre, 2nd floor, exhibition foyer

The IGCC 2019 Exhibition will be officially opened with the drinks and a buffet dinner reception whilst catching up with old acquaintances and networking with your colleagues. This is an informal evening prior to the serious scientific discussions.

Tickets: Included in the registration fees for participants and accompanying persons.

Congress Dinner

Friday 10 May 2019 (19:00 – 23:00),
Zofin Palace - Slovansky ostrov 226, Prague 1

Something is always going on at Slovansky Island on the Vltava river. It is a green oasis of comfort and excellent gastronomy in the heart of Prague. Slovansky Island has always been the centre of the Prague social scene and culture.

Take some time to relax, reconnect with friends and meet new colleagues during this unforgettable cultural event. Experience the city of Prague while enjoying dinner and entertainment, showcasing Prague’s cuisine and arts.

Tickets: NOT INCLUDED in the delegates’ registrations
Extra ticket: 80 EUR (subject to availability)
Dress code: Smart causal
Transportation provided from the venue at 19:00. Meeting point at the Registration Desk.
**Posters**

**Poster Session I, Thursday 9 May 2019, 16:45—18:15**

**P.02 Pathology and biomarkers**

**P.02-034-Thu | Reprimo-like: A potential tumor suppressor and biomarker in gastric cancer**

M.A. Alarcon\(^1\), W. Olives\(^2\), A. Rodriguez\(^2\), I. Wichmann\(^2\), G. Carrasco-Avino\(^3\), A. Corvalan\(^2\)

\(^1\) Faculty of Medicine Pontificia Universidad Catolica de Chile, Oncology and Hematology, Santiago, Chile
\(^2\) Pontificia Universidad Catolica de Chile, Advanced Center for Chronic Diseases ACCDOS, Santiago, Chile
\(^3\) Clínica Las Condes, Pathology, Santiago, Chile

**P.02-035-Thu | Clinicopathological diversity of solid-type poorly differentiated adenocarcinoma of the stomach**

T. Saj\(^i\), Y. Matsuda\(^i\), T. Wang\(^j\), J. Aida\(^j\), T. Ishiwata\(^j\)

\(^i\) Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Pathology, Tokyo, Japan

**P.02-036-Thu | PD-1 and PD-L-1 expression in gastric cancer lymph nodes**

P. Assumpção\(^1\), E. Canales\(^1\), A. Anaisi\(^1\), C. Assumpção\(^2\), A. Ramos\(^1\), J.F. Acioli\(^1\), W. Barra\(^1\), G. Ishak\(^3\), P. Assumpção\(^1\)

\(^1\) Universidade Federal do Pará, Oncologia, Belém, Brazil
\(^2\) Universidade Federal do Pará- HA Oswaldo Cruz- HGG, Oncologia, Belém, Brazil
\(^3\) Universidade Federal do Pará, Oncologia- Surgery, Belém, Brazil

**P.02-037-Thu | Molecular subtyping of EBV and Microsatellite Instability along metastatic course of Gastric Cancers**

N. Blaser\(^1\), B. Dislich\(^1\), M. Berger\(^1\), B. Gloo\(^1\), R. Lunger\(^1\)

\(^1\) University of Bern, Pathology, Bern, Switzerland

**P.02-038-Thu | Stromal component significantly impacts on clinico-pathological features of gastric poorly cohesive tumors**

M. Bencivenga\(^1\), C. Castelli\(^2\), G. Verlato\(^1\), L. Torroni\(^3\), A. Tomezzoli\(^1\), A. Scarpa\(^2\), G. de Manzoni\(^1\)

\(^1\) University of Verona, Upper GI Surgery, Verona, Italy
\(^2\) University of Verona Hospital Pathology, Verona, Italy
\(^3\) University of Verona, Public Health and Medical Statistics, Verona, Italy

**P.02-039-Thu | Prognostic impact of tubular-papillary/poorly cohesive-Signet Ring Cell ratio in WHO mixed gastric adenocarcinomas**

C. Castelli\(^1\), M. Bencivenga\(^1\), A. Tomezzoli\(^1\), L. Sanagogni\(^1\), G.A.M. Tiberio\(^1\), L. Alessandrini\(^1\), C. Belluco\(^1\)

\(^1\) Verona University Hospital, Pathology, Verona, Italy

**P.02-040-Thu | Malignant ascites-derived exosomes promote peritoneal metastasis and reveal a distinct miRNA signature in advanced gastric cancer**

Q. Changsong\(^1\), Y. Hu\(^1\), X. Wang\(^1\), L. Shen\(^1\)

\(^1\) Peking University Cancer Hospital & Institute, Department of Gastrointestinal Oncology, Beijing, China

**P.02-041-Thu | ANGPTL6-mediated angiogenesis promotes alpha-fetoprotein-producing gastric cancer progression**

F. Chen\(^1\), Y. Yu\(^1\), Q. Li\(^1\), Y. Wang\(^1\), X. Guo\(^1\), T. Liu\(^1\)

\(^1\) Department of Medical Oncology Zhongshan Hospital-, Fudan University, Shanghai, China

**P.02-042-Thu | Prognostic value of TYMS, ERCC1, BRCA1 and TUBB3 in Chinese patients with resectable advanced gastric cancer**

X. Chen\(^1\)

\(^1\) Sichuan Cancer Hospital, Department of Gastrointestinal Surgery, Chengdu, China
P.02-043-Thu | CDH11 promotes gastric cancer progression and predicts an unfavorable prognosis
Y. Chen1, W. Zhao2, L. Teng3, X. Rao4, D. Guo5, Y. Ding6, H. Wang7, Y. Liu8, Y. Huang9, T. Zhou1
1 School of Medicine, Zhejiang University, Department of Cell Biology and Program in Molecular Cell Biology, Hangzhou, China
2 First Affiliated Hospital, School of Medicine, Zhejiang University, Department of Surgical Oncology, Hangzhou, China
3 First Affiliated Hospital, School of Medicine, Zhejiang University, Department of Medical Oncology, Hangzhou, China

P.02-044-Thu | The prognostic significance of lymphovascular, venous and perineural invasion after neoadjuvant chemotherapy in patients with gastric adenocarcinoma
B.L. Woodham1, L. Chen1, C. Donohoe1, B. Disep1, S.M. Griffin1, A.W. Phillips1
1 Royal Victoria Infirmary, Northern Oesophago Gastric Unit, Newcastle upon Tyne, United Kingdom

P.02-045-Thu | Outcomes of diffuse type versus intestinal type gastric cancer in patients receiving neoadjuvant chemotherapy
J. Chen1, B.L. Woodham1, A. Madhavan1, M. Navidi1, A. Immanuels1, S.M. Griffin1, A.W. Phillips1
1 Royal Victoria Infirmary, Northern Oesophago Gastric Unit, Newcastle upon Tyne, United Kingdom

P.02-046-Thu | Clinical implication of Cyclin D1 expression in stage II/III gastric cancer: Results from the CLASSIC randomized controlled trial
S.J. Shin1, Y.Y. Choi1, E. Jang1, T. San1, H.I. Kim1, W.J. Hyung2, Y.M. Huh2, S.H. Noh3, J.H. Cheong4
1 Hanyang University College of Medicine, Pathology, Seoul, Republic of Korea
2 Yonsei University Health System, Surgery, Seoul, Republic of Korea
3 MedBio-Informatics Research Center, Novomics Co., Ltd, MediBio-Informatics Research Center, Novomics Co., Ltd, Seoul, Republic of Korea
4 Yonsei University Health System, Seoul, Republic of Korea

P.02-047-Thu | The complementary role of microsatellite instability and single patient classifier for stage II/III gastric cancer: Results from randomized controlled trial
Y.Y. Choi1, E. Jang1, T. San1, H.I. Kim1, W.J. Hyung2, Y.M. Huh2, S.H. Noh3, J.H. Cheong4
1 Yonsei University Health System, Surgery, Seoul, Republic of Korea
2 MedBio-Informatics Research Center, Novomics Co., Ltd, MediBio-Informatics Research Center, Novomics Co., Ltd, Seoul, Republic of Korea
3 Yonsei University Health System, Seoul, Republic of Korea

P.02-048-Thu | The impact of nerve involvement on the prognosis of gastric cancer patients with curative gastrectomy
K. Yang1, Y.Q. Dan2, S.H. Noh3, J.K. Hu4
1 West China Hospital, Sichuan University, Department of Gastrointestinal Surgery, Chengdu, China
2 Sichuan University, West China School of Medicine, Chengdu, China
3 Yonsei University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.02-049-Thu | PD-L1 as a prognostic factor in gastric cancer patients
A. Dignazio1, K. Polom2, S. Qiujin3, C. Williams4, M. Guergova-Kuras2, M. Kamali-Moghaddam3, L. Marano1, D. Marrelli1, F. Roviello1
1 University of Siena, General Surgery and Surgical Oncology, Siena, Italy
2 Medical University of Gdańsk, General Surgery and Surgical Oncology, Gdańsk, Poland
3 University of Uppsala, Immunology - Genetics and Pathology - Science for Life Laboratory, Uppsala, Sweden
4 Ariana Pharmaceuticals, Ariana Pharmaceuticals, Paris, France

P.02-050-Thu | Analysis of immune status in gastric adenocarcinoma with different origin sites and infiltrating patterns
Y. Duan1, W. Yi1
1 Xi'an Jiaotong University, Health Science Center, Xi'an, China

P.02-051-Thu | Putative stem cells markers in gastric cancer and their correlation with therapy responses
A. Freim Grafe1, C. Haake1, H.M. Behrens1, S. Krüger1, J.H. Egberts1, C. Röcken1
1 Institute of Pathology, Christian-Albrechts-University, Kiel, Germany
2 Department of General Surgery and Thoracic Surgery, Christian-Albrechts-University, Kiel, Germany

P.02-052-Thu | The Value of Circulating Tumor Cells (CTC) in Neoadjuvant Chemotherapy for Local Advanced Gastric Cancer (NCT03425058)
T. Fei1, Z. Bu1, S. Guo2, S. Jia2, G. Xu1, J. Ji1
1 Beijing Cancer Hospital, Gastrointestinal Department, Beijing, China
2 Peking Union Medical College, Institute of Medical Biology, Kunming, China
P.02-053-Thu | Monitoring patient-specific mutation in circulating tumor DNA for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma
T. Fu1, Z. Bu1, J. Ji1
1 Beijing Cancer Hospital, Gastrointestinal Department, Beijing, China

P.02-054-Thu | Identification of long non-coding RNA biomarkers for gastric adenocarcinoma
T. Fu1, Z. Bu1, J. Ji1
1 Beijing Cancer Hospital, Gastrointestinal Department, Beijing, China

P.02-055-Thu | Comparison of signet ring and non-signet-ring gastric adenocarcinomas in a 20-year period
R.D.M. Cordts1, D.K. Fukuhara1, O.A.P. Castro1, F. Thuler1, W. Freitas Jr1, E. Lima1, P. Brito1, L. Gannem1, M. Marinho1, L. Claro1, M. Carvalho1, E. Ilia3, C.A. Malheiros2, P. Kassab3
1 Santa Casa Medical School, Department of Surgery, São Paulo, Brazil
2 Santa Casa Medical School, Department of Pathology, São Paulo, Brazil
3 Santa Casa Medical School, Department of Oncology, São Paulo, Brazil

P.02-056-Thu | Gastric polyps with dysplasia in Portuguese patients with familial adenomatous polyposis: higher frequency of intestinal-type adenomas than previously reported
M. Garrido1, I. Gullo2,3,4,5, F. Sousa6, M. Baptista6, F. Carneiro2,3,4,5
1 Centro Hospitalar do Porto, Gastroenterology, Porto, Portugal
2 Centro Hospitalar de São João, Pathology, Porto, Portugal
3 University of Porto, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
4 University of Porto, Institute of Molecular Pathology and Immunology, Porto, Portugal
5 Faculty of Medicine of the University of Porto, Pathology, Porto, Portugal
6 Centro Hospitalar de São João, Surgery, Porto, Portugal

P.02-057-Thu | PNI as indicator of survival in gastric cancer resected patients
L. Graziosi1, E. Marino1, M.C. Vannoni1, A. Donini2
1 University of Perugia, General and Emergency Surgery, Perugia, Italy
2 Santa Maria della Misericordia Hospital of Perugia, General and Emergency Surgery, Perugia, Italy

P.02-058-Thu | Prognostic factor affecting gastric cancer patients that underwent a curative surgery: a single Western study
L. Graziosi1, E. Marino1, M.C. Vannoni1, A. Donini2
1 University of Perugia, General and Emergency Surgery, Perugia, Italy
2 Santa Maria della Misericordia Hospital of Perugia, General and Emergency Surgery, Perugia, Italy

P.02-059-Thu | Application of computer based diagnosis of metastasis based on deep learning to sentinel lymph node navigation for gastric cancer
H. Hayashi1, J. Matsushima1, T. Ohnishi1, T. Sato1, S. Kato1, H. Mizutani1, M. Kano1, H. Matsubara1
1 Chiba University, Center for Frontier Medical Engineering, Chiba, Japan
2 Graduate School of Medicine- Chiba University, Diagnostic Pathology, Chiba, Japan
3 Toshiba Digital Solutions Corporation, Software and AI Technology Center, Kawasaki, Japan
4 Graduate School of Medicine- Chiba University, Department of Frontier Surgery, Chiba, Japan

P.02-060-Thu | KRAS mutation, not KRAS amplification is related to histological phenotype in gastric cancer
1 GROW School for Oncology and Developmental Biology- Maastricht University Medical Center+, Department of Pathology, Maastricht, Netherlands
2 Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Department of Pathology, Tokyo, Japan
3 Leiden University Medical Center, Department of Pathology, Leiden, Netherlands
4 University of Leeds, Pathology and Data Analytics - School of Medicine, Leeds, United Kingdom
5 Duke-NUS Medical School, Duke-NUS Medical School, Singapore, Singapore
6 National Cancer Center Hospital, Department Director of Gastric Surgery, Tokyo, Japan

P.02-061-Thu | Perineural invasion independently affects survival for stage II/III gastric cancer patients undergoing radical surgery
J.T. Hsu1, K.H. Liu1, C.N. Yeh1, T.S. Yeh1, T.L. Hwang1, Y.Y. Jan1
1 Chang Gung Memorial Hospital at Linkou - Chang Gung University College of Medicine, Surgery, Taoyuan, Taiwan
P.02-062-Thu | PD-L1 and HER2 expression in gastroesophageal cancer: a matched case control study
A. Beer1, H. Taghiadeh1, A.I. Schiefer1, A. Karner1, G. Jomrich1, S. Schoppmann1, R. Kain1, M. Preusser1, A. Ilhan-Mutlu1
1 Medical University of Vienna, Department of Pathology, Vienna, Austria
2 Medical University of Vienna, Department of Oncology, Vienna, Austria
3 Medical University of Vienna, Department of Surgery, Vienna, Austria

P.02-063-Thu | Radiomic Signature of 18F Fluorodeoxyglucose PET/CT for Prediction of Gastric Cancer Survival and Chemotherapeutic Benefits
Y. Jiang1, G. Li1, W. Huang1, H. Zhen1
1 Nanfang Hospital-Southern Medical University, Surgery, Guangzhou, China

P.02-064-Thu | Higher preoperative CRP-to-Transthyretin ratio predicts poor survival following curative resection of gastric carcinoma
Y.K. Park1, M.R. Jung1, S.Y. Ryu1, J. Oh1
1 Chonnam National University Hwasun Hospital, Department of Surgery, Hwasun-eup, Republic of Korea

P.02-065-Thu | The Helicobacter pylori Resistance Rate to Carithromycin in gastric samples
S. Jung1, K.J. Lee1, K.H. Noh1
1 Seegene Medical Foundation, Molecular Diagnostics Testing Center, Seoul, Republic of Korea
2 Kangwon National University, Department of Physics, Chuncheon, Republic of Korea

P.02-066-Thu | Clinicopathological features and prognosis of gastric carcinoma with a micropapillary component
M. Kang1, J. Hihara1, N. Tokumoto1, N. Hirabayashi1
1 Hiroshima City Asa Citizens Hospital, Surgery, Hiroshima, Japan

P.02-067-Thu | Na+-activated K+ channel in the regulation of vascular and gastric smooth muscle contraction
Y. Hye Yung1, D.H. Kim1, K. Young Chul2
1 Chungbuk National University College of Medicine, Department of Surgery, Cheongju, Republic of Korea
2 Chungbuk National University College of Medicine, Department of Physiology, Cheongju, Republic of Korea

P.02-068-Thu | Inter-observer reproducibility in the diagnosis of gastric intraepithelial neoplasia in ESD specimens: A multi-center study in Korea
1 Inha University School of Medicine, Pathology, Incheon, Republic of Korea
2 Kangbuk Samsung Hospital-Sungkyunkwan University School of Medicine, Pathology, Seoul, Republic of Korea
3 Yonsei University Wonju Christian Hospital, Pathology, Wonju, Republic of Korea
4 Seoul National University College of Medicine, Pathology, Seoul, Republic of Korea
5 Kasan University College of Medicine, Pathology, Busan, Republic of Korea
6 The Catholic University of Korea- College of Medicine- Seoul St. Mary’s Hospital, Pathology, Seoul, Republic of Korea
7 National Cancer Center- Center for Gastric Cancer, Pathology, Goyang-si, Republic of Korea
8 Soonchunhyang University Hospital, Pathology, Seoul, Republic of Korea
9 Korea University College of Medicine, Pathology, Seoul, Republic of Korea
10 University of Ulsan College of Medicine Asan Medical Center, Pathology, Seoul, Republic of Korea
11 Inje University Busan Paik Hospital, Pathology, Busan, Republic of Korea
12 Yonsei University College of Medicine, Pathology, Seoul, Republic of Korea
13 Chonnam National University Hwasun Hospital, Pathology, Hwasun, Republic of Korea
14 Pusan National University College of Medicine, Pathology, Busan, Republic of Korea
15 Sunyangkwan University Samsung Medical Center, Pathology, Busan, Republic of Korea
16 Department of Biomedical Sciences- Inha University School of Medicine, Pathology, Incheon, Republic of Korea
17 Pusan Paik Hospital-Inje University College of Medicine, Pathology, Busan, Republic of Korea
18 University of Ulsan College of Medicine- Asan Medical Center- Asan Digestive Disease Research Institute, Gastroenterology, Seoul, Republic of Korea
19 Department of Statistics- Inha University, Pathology, Incheon, Republic of Korea

P.02-069-Thu | Molecular subtypes of gastric cancer based on immunohistochemical profile
M.F. Kodama Pertiile Ramos1, M.A. Pereira1, S.F. Faragi1, C.D.S. Cirqueira1, A.R. Dias1, O.K. Yagi1, A.Z. Charruf1, L.C. Barchi1, V.A.F. Alves1, B. Zillbertein1, I. Cecconello1, E.S. Mello1, U. Ribeiro-Júnior1
1 University of São Paulo Medical School, Cancer Institute, São Paulo, Brazil
2 Adolfo Lutz, Pathology, São Paulo, Brazil
3 University of São Paulo Medical School, Pathology, São Paulo, Brazil
P.02-070-Thu | Development of novel prognostic score using preoperative values of hemoglobin and albumin for gastric cancer patients

T. Konishi1, T. Kosuga1, T. Kubota1, A. Shisakiz1, K. Okamoto1, K. Shoda1, H. Konishi1, H. Fujiiwa1, Y. Matsumoto1, M. Kudou1, T. Arita1, R. Morimura1, Y. Murayama1, Y. Kuni1, H. Koma1, M. Nakanishi1, T. Otsuji1

1 Kyoto Prefectural University of Medicine, Division of Digestive Surgery- Department of Surgery, Kyoto, Japan

P.02-071-Thu | Prognostic value of tesmin expression in gastric cancer

K. Kurnol1,2, A. Diakun2, J. Rudno-Rudzinska1, E. Frejlich1, W. Hap1, P. Dzierzek2, M. Zawadzki1, A. Piotrowska1, A. Gomulkiewicz1, J. Grzegzółka1, A. Halori1, M. Podhorska-Okołow1, W. Kielan2, P. Dzierżek1

1 Wrocław Medical University, Department of Histology and Embryology, Wrocław, Poland
2 Wrocław Medical University, 2nd Department of General and Oncological Surgery, Wrocław, Poland

P.02-072-Thu | Expression loss of major histocompatibility complex I and PD-L1 in microsatellite instability high gastric cancer


1 Seoul National University Hospital, Department of Pathology, Seoul, Republic of Korea
2 Seoul National University Bundang Hospital, Department of Laboratory Medicine, Seongnam, Republic of Korea
3 Seoul National University Bundang Hospital, Department of Pathology, Seongnam, Republic of Korea
4 Seoul National University Bundang Hospital, Department of Surgery, Seongnam, Republic of Korea

P.02-073-Thu | A case of serially metastatic gastric and jejunal cancer originating from colon cancer

W.Y. Lee1

1 Seoul Paik Hospital- Inje University College of Medicine, Departments of Surgery, Seoul, Republic of Korea

P.02-074-Thu | Increased MEK Activity Predicts Worse Prognosis in CD44 Positive Gastric Cancer Patients Undergoing Radical Gastrectomy

J. Lin1, C. Yoon2, P.U. C.H. Zheng1, C. Huang1, S.S. Yoon2

1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
2 Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, USA

P.02-075-Thu | Relationship of CD10, MUC2, MUC5AC, and MUC6 with prognosis and histological phenotype in a cohort of western gastric cancer

D. Liu1, L. Thomas2, H. Grabisch3

1 Maastricht University Medical Center+, Pathology, Maastricht, Netherlands
2 Leeds Institute of Medical Research at St. James’s- School of Medicine- University of Leeds, Pathology of Data Analytics, Leeds, United Kingdom

P.02-076-Thu | High frequency of co-overexpression of cMet and VEGF in AFP-producing gastric cancer: a rationale for dual inhibition therapy

J. Liu1, H. Wang1, Y. Ding2, L. Teng1

1 First Affiliated Hospital of Zhejiang University School of Medicine, Surgical Oncology, Hangzhou, China
2 First Affiliated Hospital of Zhejiang University School of Medical Oncology, Hangzhou, China

P.02-077-Thu | SPARC Secreted by Gastric Cancer Associated Fibroblasts (GCAFs) Contributes to Cancer Stemness and 5-fluorouracil Resistance in Gastric Cancer

Y. Ma1, J. Ma1, J. Hu1, G. Chen1, Y. Liu1

1 Peking University First Hospital, General Surgery, Beijing, China

P.02-078-Thu | Utilization of Phage Display Peptide Library to Screening Specific Peptides Specifically Targeting Gastric Cancer Cells

Z. Ma1, S. Zhao1, X. wang1

1 The second hospital of Jin University, Gastrointestinal Nutrition and Hernia Surgery, Changchun, China

P.02-079-Thu | Prognostic and predictive biomarker evaluation of HER3 in metastatic gastric cancer: results of the phase III of chemotherapy+/−-EGFR1 blockade (EXPAND)

A. Maderer1, K. Knoch1, A. Schaaf1, H. Zimmer-Zachmann2, T. Thomaisic1, F. Lendick1, M. Moehler1

1 Universitätshochschule Mainz, I. Med. Klinik und Poliklinik, Mainz, Germany
2 Universitätshochschule Mainz, Institut für Pathologie, Mainz, Germany
3 Universitätssklinikum Leipzig, Universitätsklinikum Leipzig, Leipzig, Germany
P.02-080-Thu | Prognostic factor affecting N0 gastric cancer patients that underwent a curative surgery: a single Western study
E. Marino1, L. Graziosi1, A. Donini1
1 University of Perugia, General and Emergency Surgery, Perugia, Italy

P.02-081-Thu | Loss of Rnf43 function aggravates Helicobacter pylori-induced gastric pathology
V. Neumann1, R. Mejias-Luque1, M. Gerhard1
1 Technische Universität München, Institut für medizinische Mikrobiologie-Immunologie und Hygiene, Munich, Germany

P.02-082-Thu | High expression of RNF126 indicates a poor prognosis and promotes the proliferation of gastric cancer
K. Matsumoto1, S. Matsumoto1, K. Wakatsuki2, T. Kunishige2, H. Nakade2, S. Miyao3, M. Sha1
2 Nara Medical University, Surgery, Kashihara, Japan

P.02-083-Thu | Early gastric cancer: identification of molecular markers able to distinguish penetrating lesions with different prognosis (on behalf of GIRC)
C. Molinaro1, L. Capelli1, P. Morgagni2, P. Uulvi1, S. Ravaiali1, M.M. Tumedi1, G. Tedaldi1, R. Abou Khouzam1, E. Scarp1, D. Calistr1, M. Bonafe1, A. Tommazzoli1, C. Castelli1, M.R. Ambrosio1, A. D'Ignazio1, L. Saragoni1
1 Istituto Scientifico Romagnolo per le Studi e la Cura dei Tumori IRST IRCCS, Biosciences Laboratory, Meldola, Italy
2 Morgagni-Pierantoni Hospital, Department of General Surgery, Forlì, Italy
3 University of Pavia, Department of Biology and Biotechnology, Pavia, Italy
4 University of Verona, Department of Pathology, Verona, Italy
5 University of Siena, Pathology Unit, Siena, Italy
6 University of Siena, Department Of Medicine- Surgery and Neurosciences, Siena, Italy
7 Morgagni-Pierantoni Hospital, Department of Pathology, Forlì, Italy

P.02-084-Thu | Pattern of PD-1 and PD-L1 expression and their expression on CD4+ and CD8+ T cells in gastric cancer
J.Y. Mun1, K.H. Jun1
1 The Catholic University of Korea- St. Vincent’s Hospital, General surgery, Suwon, Republic of Korea

P.02-085-Thu | Pathological tumor infiltrative pattern predicts sites of initial recurrence in stage II/III gastric cancer
1 Nagoya University, Gastroenterological Surgery, Nagoya, Japan
2 Aichi Cancer Center, Gastroenterological Surgery, Nagoya, Japan
3 Kamaki Municipal Hospital, Surgery, Komaki, Japan
4 Yokkaichi Municipal Hospital, Surgery, Yokkaichi, Japan
5 Kanon Kosei Hospital, Surgery, Kenan, Japan
6 Ichinomiya Municipal Hospital, Surgery, Ichinomiya, Japan
7 Gifu Prefectural Tajimi Hospital, Surgery, Tajimi, Japan
8 Okazaki City Hospital, Surgery, Okazaki, Japan
9 Toei General Hospital, Surgery, Seto, Japan

P.02-086-Thu | Tale of deceit: A case of gastric leiomyosarcoma masquerading as mucormycosis
Y.L.A. Ng1, J. Lee1, S.S. Ching1, S.Y.A. Wong1
1 Changi General Hospital, Upper Gastrointestinal Surgery, Singapore, Singapore

P.02-087-Thu | Prognostic impact of increased perioperative platelet count in gastric cancer patients
S. Oh1, J.E. Seo1, J.Y. Ahn1, S.H. Ahn1, T.S. Sohn1, J.M. Bae1, S. Kim1, M.G. Choi1
1 Samsung Medical Center, Surgery, Seoul, Republic of Korea

P.02-088-Thu | A comprehensive study of microsatellite instability testing and its comparison with immunohistochemistry in gastric cancer
1 Seoul National University Bundang Hospital, Department of Pathology, Seongnam-si, Republic of Korea
2 Seoul National University Bundang Hospital, Department of Surgery, Seongnam-si, Republic of Korea
3 Seoul National University College of Medicine, Department of Pathology, Seoul, Republic of Korea
4 Seoul National University Bundang Hospital, Department of Laboratory Medicine, Seongnam-si, Republic of Korea
P.02-089-Thu | Evaluation of the concentration and presence of CEA, CA 19-9 and CA 72-4 in homogenates of gastric cancer tissue

R. Partyka¹, P. Jałowiecki²

¹ Department of Emergency Medicine of the Department of Anaesthesiology- Intensive Treatment and Emergency Medicine- Independent Public Clinical Hospital in Katowice, Department of Anaesthesiology- Intensive Treatment and Emergency Medicine Medical University of Silesia in Katowice, Sosnowiec, Poland
² Department of Emergency Medicine of the Department of Anaesthesiology- Intensive Treatment and Emergency Medicine Medical University of Silesia in Katowice, Katowice, Poland

P.02-090-Thu | Assessment of presence of VEGF in the serum and the tissue in patients with gastric cancer

R. Partyka¹, D. Kokocińska¹

¹ Department of Emergency Medicine of the Department of Anaesthesiology- Intensive Treatment and Emergency Medicine- Independent Public Clinical Hospital in Katowice, Department of Anaesthesiology- Intensive Treatment and Emergency Medicine Medical University of Silesia in Katowice, Sosnowiec, Poland

P.02-091-Thu | Prognostic value of Epstein-Barr virus infection, mismatch repair-deficiency and high lymphoid infiltration in submucosa-penetrating early gastric cancers

M. Pellilli¹, A.M. Chiaravalli², M. Berselli³, V. Quintodei², R. D’Amato², E. Cocazzi², F. Sessa¹

¹ Unit of Pathology, Department of Medicine and Surgery-University of Insubria, Varese, Italy
² ASST Sette Laghi, Department of Pathology, Varese, Italy
³ ASST Sette Laghi, Department of Surgery, Varese, Italy

P.02-092-Thu | Controlling Nutritional Status (CONUT) score is a prognostic factor for gastric cancer patients after radical resection from a Chinese hospital

B.Q. Peng¹, S. Chen¹, K. Liu¹, X.L. Chen¹, W.H. Zhang¹, J.K. Hu¹

¹ State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy, Department of Gastrointestinal Surgery and Laboratory of Gastroenteric Cancer, Chengdu, China

P.02-093-Thu | Clinicopathological characteristics and prognosis of gastric cancer patients based on the therapeutic profile

M.A. Pereira¹, M.F.K.P. Ramos¹, A.R. Dias¹, S.F. Farag¹, C.D.S. Criqueira¹, O.K. Yogi¹, E.S. Mello¹, V.A.F. Alves¹, B. Zilberstein¹, I. Ceconello¹, U. Ribeiro-Júnior¹

¹ Cancer Institute- Hospital das Clínicas- University of São Paulo Medical School, Department of Gastroenterology, São Paulo, Brazil
² Cancer Institute- Hospital das Clínicas- University of São Paulo Medical School, Department of Pathology, São Paulo, Brazil
³ Instituto Adolfo Lutz, Department of Pathology, São Paulo, Brazil

P.02-094-Thu | A clinically meaningful molecular classification of gastric cancer in Chilean patients

M. Pinto¹, M. Muñoz-Medel¹, M. Cordova-Delgado¹, J.N. Retamal¹, M.L. Bravo¹, D. Romero¹, N. De La Jara¹, J. Torres¹, M. Espinoza¹, C. Balmaceda¹, F. Crovari⁵, A.H. Corvalan¹, M. Garrido¹

¹ Pontificia Universidad Catolica de Chile, Hematology & Oncology, Santiago, Chile
² Pontificia Universidad Catolica de Chile, Physiology, Santiago, Chile
³ Pontificia Universidad Catolica de Chile, Pathology, Santiago, Chile
⁴ Pontificia Universidad Catolica de Chile, Centre of Clinical Research-Health Technology Assessment Unit, Santiago, Chile
⁵ Pontificia Universidad Catolica de Chile, Gastrointestinal Surgery, Santiago, Chile

P.02-095-Thu | Any amount of poorly cohesive carcinoma (PCC) has a negative impact on survival in resected gastric adenocarcinoma (GA)

F. Renaud¹, A. Gandori¹, S. Humez¹, H. Béthel¹, A. Chau¹, C. Dejeante¹, G. Dubreuil¹, C. Brès¹, A. Lintis¹, A. Adenis¹, E. Leteurtre¹, C. Mariette¹, C. Eveno¹, G. Piessen¹

¹ Lille University Hospital, Institute of Pathology, Lille, France
² Lille University Hospital, Digestive and Oncological Surgery, Lille, France
³ Department of Methodology- Biostatistics and Data Management, Lille, France
⁴ Montpellier Cancer Center, Medical Oncology, Montpellier, France

P.02-096-Thu | The complementary role of microsatellite instability and single patient classifier for stage II/III gastric cancer: Results from the CLASSIC trial

C. Roh¹, C. Yoon Young¹, C. Joe-Ho¹

¹ Yonsei University College of Medicine, Surgery, Seoul, Republic of Korea

P.02-097-Thu | Mixed histology is a risk factor for lymph node metastasis in early gastric cancer

H.S. Seo¹, G.E. Lee¹, M.G. Kang¹, K.H. Han¹, E.S. Jung¹, K.Y. Song¹

¹ The Catholic University of Korea, Gastrointestinal Surgery, 222- Banpodae-Ro- Seocho-Gu, Republic of Korea
² The Catholic University of Korea, Surgery, 222- Banpodae-Ro- Seocho-Gu, Republic of Korea
³ The Catholic University of Korea, Clinical Pathology, 222- Banpodae-Ro- Seocho-Gu, Republic of Korea
P.02-098-Thu | Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer
X. Xue1, Y. Huang1, X. Shen1
1 Wenzhou Medical University, Basic Medical College, Wenzhou, China
2 Second Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China

P.02-099-Thu | Human cytomegalovirus detection in gastric cancer and its possible association with lymphatic metastasis
X. Shen1, A. Chando1, X. Xue1, Y. Huang1
1 Wenzhou Medical University, Department of Microbiology and Immunology- Institute of Molecular Virology and Immunology- Institute of tropical medicine, Wenzhou, China

P.02-100-Thu | Clinical manifestations and prognostic characteristics of alpha-fetoprotein producing gastric cancer in single medical center
D. Shi1, L. Lin1, C. Chen1, Y. Huang1, J. Chen1
1 The Second Affiliated hospital of Zhejiang University School of Medicine, Department of General Surgery, Hangzhou, China

P.02-101-Thu | Correlation of gastric cancer pathologic factors and recurrence after radical surgery
I. Jelovskis1, A. Savins2, S. Isajevs3, M. Lej3, G. Ancans2, V. Krumins2, A. Pcholkins3
1 Riga East University Hospital- Latvian Oncological center, Department of abdominal and soft tissue oncological surgery, Riga, Latvia
2 Riga East University Hospital- Oncology Centre of Latvia, Department of abdominal and soft tissue oncological surgery, Riga, Latvia
3 Riga East University Hospital, Pathology Centre, Riga, Latvia
4 University of Latvia, Department of medical research, Riga, Latvia

P.02-102-Thu | Characterization of biomarkers in Canadian gastric cancer patients
D. Skubleny1, E. Boivin1, S. Bhavanam1, S. Gang1, D. Schiller1, G.R. Rayat1
1 University of Alberta, Department of Surgery, Edmonton, Canada

P.02-103-Thu | Multicentric comparative analysis of the analytical performance of five different PD-L1 assays in gastric carcinoma
U. Sommer1, G. Baretton1, W. Weichert1, M. Boxberg1, K. Schwamborn1, R. Böttner1, O. Alexander1, S. Andreas1, P. Schirmacher1, F. Lasitschka1, M. Tiemann1, U. Tschiesner1
1 Universitätsklinikum Carl Gustav Carus, Institute of Pathology, Dresden, Germany
2 Technical University Munich, Institute of Pathology, Munich, Germany
3 Universitätsklinik Köln, Institute of Pathology, Cologne, Germany
4 University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany
5 Institut für Hämostopatologie, Institut für Hämostopatologie, Hamburg, Germany
6 MSD Sharp & Dohme GmbH, MSD Sharp & Dohme GmbH, Haar, Germany
7 Charité – Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Institute of Pathology, Berlin, Germany

P.02-104-Thu | Oncostatin M Receptor promotes gastric cancer progression via STAT3/FAK/Src signaling upon treatment with Oncostatin M
Z. Yu1, X. Wu1, B. Liu1, Z. Zhu1, L. Su1
1 Shanghai Key Laboratory of Gastric Neoplasms- Shanghai Institute of Digestive Surgery- Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Surgery, Shanghai, China

P.02-105-Thu | Alterations of the gut microbiome in gastric carcinogenesis in rats
Z. Su1, C. Yu1, Y. Li1, Y. Li1, W. Cao1, Q. Zhang1, Y. Zhang1, Z. Ding2
1 Beijing University of Chinese Medicine, Institute of Traditional Chinese Medicine, Beijing, China
2 Beijing University Hospital, Department of gastroenterology, Beijing, China
3 Beijing University of Chinese Medicine, School of Chinese Medicine, Beijing, China
4 China Academy of Chinese Medical Sciences, Institute of Basic Research in Clinical Medicine, Beijing, China

P.02-106-Thu | Clinicopathological features of MSI-H gastric cancer
Y. Sun1, X. Wang1, Z. Lin1
1 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education- Department of Pathology- Peking University Cancer Hospital & Institute-, Department of Pathology, Beijing, China
P.02-107-Thu | Comparison of prognostic values of pre- and post-operative neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio in gastric cancer with positive peritoneal cytology
M. Takahashi1, K. Hiroki2, K. Sato2, W. Sato2, H. Miyamoto2, T. Kosaka2, H. Akiyama1, C. Kunisaki2
1 Yokohama Municipal Citizen’s Hospital, Division of Gastroenterological Surgery, Yokohama, Japan
2 Yokohama City University, Department of Surgical Oncology, Yokohama, Japan

P.02-108-Thu | Extra-Perigastric Extranodal Metastasis is a Significant Prognostic Factor in Node-Positive Gastric Cancer
A. Tonouchi1, M. Sugano1, M. Tokunaga1, S. Sugita1, M. Watanabe1, R. Sato1, A. Kaito1, T. Kuwata1, T. Kinoshita1
1 National Cancer Center Hospital East, Department of Gastric Surgery, Kashiwa, Japan
2 National Cancer Center Hospital East, Department of Pathology and Clinical Laboratories, Kashiwa, Japan

P.02-109-Thu | Prognostic value of the fibrinogen – to – platelet ratio as an inflammatory and coagulative index in patients with gastric cancer
K. Wakatsuki1, S. Matsumoto1, K. Migita1, H. Nakade1, T. Kunishige1, S. Miyao2, M. Sho1
1 Nara Medical University, Surgery, Nara, Japan
2 First Hospital of Jilin University, Department of Gastrointestinal Surgery, Changchun, China

P.02-110-Thu | Study on the relationship between serum small molecular metabolites and lymph node metastasis in gastric cancer
D. Wang1, Y. Guo1
1 First Hospital of Jilin University, Department of Gastrointestinal Surgery, Changchun, China

P.02-111-Thu | LncRNA MIR4435-2HG promotes growth and metastasis of gastric cancer by targeting desmoplakin via activating Wnt/β-catenin signaling pathway
H. Wang1, M. Wu1, Y. Lu1, X. Cai1, X. Yu2, K. He1, L. Teng1
1 1St Affiliated Hospital- Zhejiang University- College of Medicine-, Surgical oncology, Hangzhou, China
2 Graduate school of Biomedical & Health Sciences- Hiroshima University, Department of Molecular Pathology, Hiroshima, Japan

P.02-112-Thu | High expression of TRIM36 is associated with radiosensitivity in gastric cancer
Y. Wang1, Z. Tang1, J. Zhou1
1 The First Affiliated Hospital of Soochow University, Department of General Surgery, Suzhou, China
2 Medical College of Soochow University, Department of Biostatistics - School of Public Health, Suzhou, China
3 The First Affiliated Hospital of Soochow University, Department of General Surgery, Suzhou, China

P.02-113-Thu | Identification of the biomarkers for evaluating the clinical efficacy of bevacizumab in the treatment of gastric cancer
S. Wu1
1 The first affiliated hospital of Sun-Yet-Sun university, Zhanshan second street, Guangzhou, China

P.02-114-Thu | Pathological Features of Different Tumor Regression Grades in Gastric Cancer with Neoadjuvant Chemotherapy
Z. Xue1, J. Yu1, W. Kang1, Z. Ma1, X. Ye1
1 Peking Union Medical College Hospital - Chinese Academy of Medical Sciences, General Surgery, Beijing, China

P.02-115-Thu | Changes in clinicopathological features of resectable gastric cancer for about 3 decades
S. Yagi1, S. Nunobe1, R. Otoke1, J. Tajima1, M. Isazaki1, R. Takahashi1, T. Ohashi1, M. RY1, Y. Imamura1, S. Mine1, S. Ida1, K. Kumagai1, M. Ohashi1, M. Watanabe1, N. Hiki1, T. Sano1
1 Cancer Institute Hospital, Department of Gastrointestinal Surgery, Koto-ka, Japan

P.02-116-Thu | DSG1(Despomiglein 1) is involved in spheroid formation of gastric cancer cells
Y. Yamamoto1,2, N. Oue1, T. Imai1, R. Asai1, K. Tanabe1, H. Ohdani1, N. Sakamoto1, K. Sentani1, W. Yasu1
1 Graduate school of Biomedical & Health Sciences - Hiroshima University, Department of Molecular Pathology, Hiroshima, Japan
2 Graduate school of Biomedical & Health Sciences - Hiroshima University, Department of Gastroenterological and Transplant Surgery, Hiroshima, Japan

P.02-117-Thu | Prognostic value of tumor deposits in resectable gastric cancer
J. Yang1, M.L. Zhou1, W. Yang1, R. Hu1, G.C. Li1, Z. Zhang1
1 Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Shanghai, China

P.02-118-Thu | Prognostic value of Immunoscore in gastric cancer (GC) with adjuvant chemoradiation (CRT)
J. Yang1, M.L. Zhou1, R. Hu1, W. Yang1, G.C. Li1, Z. Zhang1
1 Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Shanghai, China
P.02-119-Thu | Clinicopathological characterization of gastric cancer with deficient mismatch repair proteins – implication to adjuvant chemotherapy
T.S. Yeh1
1 Chang Gung Memorial Hospital- Chang Gung University, General Surgery, Taoyuan, Taiwan

P.02-120-Thu | Correlation between hMLH1 methylation and clinicopathological characteristics in Chinese gastric cancer patients
Q. Wei1, Q. Xu1, J. Ying1
1 Zhejiang Cancer Hospital, Department of Medical Oncology, Hangzhou, China

P.02-121-Thu | UBE2C is a potential biomarker of intestinal-type gastric cancer with chromosomal instability
Y. Yu1, F. Yuan2, Z. Zhu1
1 Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Surgery, Shanghai, China
2 Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Pathology, Shanghai, China

P.02-122-Thu | Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, HER2 and PD-L1 expression in 2504 Chinese gastric cancer patients
L. Zhang1, J. Ji2, D. Lin1, Y. Sun1, Z. Li1
1 Peking University Cancer Hospital, Pathology, Beijing, China
2 Peking University Cancer Hospital, Gastrointestinal tumor surgery, Beijing, China

P.02-123-Thu | The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma
N. Zhang1, Y. Wang1
1 Institute of cancer research, Xi'an Jiaotong University Health Science Center, Xi'an, China

P.02-124-Thu | Prognostic meaning of preoperative alpha-fetoprotein (AFP) of gastric cancer patients, results of single institute center in western area of China
W.H. Zhang1, L. Kai1, C. Xin-Zu1, Y. Kun1, H. Jian-Kun1
1 West China Hospital- Sichuan University, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy, Chengdu- Sichuan, China

P.02-125-Thu | Difference between signet ring cell gastric cancers and non-signet ring cell gastric cancers: A systematic review and meta-analysis
W.H. Zhang1, C. Xin-Zu1, Y. Kun1, H. Jian-Kun1
1 West China Hospital- Sichuan University, 1. Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy, Chengdu- Sichuan, China

P.02-126-Thu | The prognostic significance of LNC IDH2 in gastric cancer patients with gastrectomy
L.Y. Zhao1, J.K. Hu2
1 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China
2 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China

P.02-127-Thu | Is preoperative fibrinogen associated with the prognosis of gastric cancer patients? A multi-centered, propensity score-matched retrospective study
L.Y. Zhao1, J.K. Hu1
1 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China
**P03 Gastric cancer genetics and translational research**

**P.03-128-Thu | Gastric field cancerization: microRNAs as promising biomarkers**

1 Universidade Federal do Pará, Oncologia, Belém, Brazil
2 Universidade Federal do Pará, Laboratory of Human and Medical Genetics-Institute of Biological Sciences, Belém, Brazil
3 Universidade Federal do Pará, Endoscopy, Belém, Brazil
4 Universidade Federal do Pará, Laboratory of Human and Medical Genetics-Institute of Biological Sciences, Belém, Brazil
5 Universidade Federal do Pará, Oncology-Pathology, Belém, Brazil
6 Universidade Federal do Pará-Hospital Ofir Loloa, Oncologia, Belém, Brazil
7 São Camilo and São Luis Hospital, biology, Macapa, Brazil
8 Universidade Federal do Pará, Laboratory of Human and Medical Genetics-Institute of Biological Sciences, Belém, Brazil

**P.03-129-Thu | New insights into the molecular biology of gastric field cancerization**

1 Universidade Federal do Pará, Oncologia, Belém, Brazil

**P.03-130-Thu | Integrated Analysis of Human and Microbiome transcripts in Gastric Cancer**

1 Universidade Federal do Pará, Oncologia, Belém, Brazil

**P.03-131-Thu | Immunogenetic analysis for gastric cancers identifies novel humoral cancer antigens and therapeutic human antibodies**
S. Atsumi, H. Kato, D. Komura, Y. Seto, S. Ishikawa

1 The University of Tokyo, Department of Gastrointestinal Surgery-Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
2 The University of Tokyo, Department of Molecular Preventive Medicine-Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
3 Tokyo Medical and Dental University, Department of Genomic Pathology-Medical Research Institute, Bunkyo-ku, Tokyo, Japan

**P.03-132-Thu | [18F]FDG PET/MRI in gastric cancer patient-derived xenografts**

1 Seoul National University Hospital, Department of Surgery-Division of Gastrointestinal Surgery, Seoul, Republic of Korea
2 Seoul National University College of Medicine, Department of Nuclear Medicine, Seoul, Republic of Korea

**P.03-133-Thu | Extra-capsular growth of lymph node metastases in gastric cancer: Association with markers of epithelial-to-mesenchymal transition**

1 Department of General-Visceral- and Transplant Surgery-Ludwig-Maximilians-University Munich-Munich, Germany, Department of General-Visceral- and Transplant Surgery, Munich, Germany
2 Heidelberg University Hospital-Heidelberg-Germany, Department of Obstetrics and Gynecology, Heidelberg, Germany
3 Institute of Pathology-Ludwig-Maximilians-University LMU Munich-Munich, Germany, Institute of Pathology-Ludwig-Maximilians-University LMU Munich-Munich, Germany
4 Bundeswehr Medical Academy, Bundeswehr Institute of Pharmacology and Toxicology, München, Germany

**P.03-134-Thu | HER3 activation regulates cellular adhesion and invasiveness in gastric cancer cells**
T. Buech, M. Reim, S. Müller, H. Kahava, R. Jenke, A. Tsoutsoulopoulos, D. Steinritz, F. Lordick, A. Aigner

1 University Leipzig, Rudolf-Buehmer Institute of Pharmacology and Toxicology-Clinical Pharmacology, Leipzig, Germany
2 University Medicine Leipzig, University Cancer Center Leipzig UCC, Leipzig, Germany
3 University Leipzig, Rudolf-Buehmer Institute of Pharmacology and Toxicology, Leipzig, Germany
4 Bundeswehr Medical Academy, Bundeswehr Institute of Pharmacology and Toxicology, München, Germany

**P.03-135-Thu | Effects of alcaline water in gastritis patients and correlation with epigenetics targets miR-7, miR-155, miR135b and miR-29c**

1 Universidade Federal do Pará, Núcleo De Pesquisa em Oncologia, Belém, Brazil
2 Universidade Federal do Pará, Núcleo De Pesquisa em Oncologia, Belém, Brazil
P.03-136-Thu | Arsenic and Topoisomerase inhibitors Synergistically inhibit Gastric cancer cells through NFAT-RAG-DSB Pathway

T. Kang1, M. Ge1, X. Zhang1, R. Wang1, L. Zhang1, Z. Tan1, H. Liu1, M. Pan3, S. Chen1

1 Xin Hua Hospital- School of Medicine- Shanghai Jiao Tong University, Department of Oncology, Shanghai, China
2 Rui Jin Hospital School of Medicine- Shanghai Jiao Tong University, Shanghai Institute of Hematology and State Key Laboratory of Medical Genomic, Shanghai, China
3 Kaiser Permanente Medical Center, Department of Oncology and Hematology, Santa Clara- CA, USA

P.03-137-Thu | Apatinib promotes sensitivity of gastric cancer cells to paclitaxel by inhibiting EMT

X. Cheng1

1 The First Affiliate Hospital of Zhejiang Chinese Medical University, department of gastrointestinal Surgery, Zhejiang, China

P.03-138-Thu | The relationship between metastasis with the immunological microenvironment after radical resection in locally advanced gastric cancer

Y. Cui1, X. Cheng1, C. Tang1, Y. Yu1, Z. Tang2, Z. Shen1, F. Liu1, C. Xu1, J. Hou1, X. Hou1, T. Liu1

1 Zhanghan Hospital, Medical oncology department, Shanghai, China
2 Zhanghan Hospital, Surgical department, Shanghai, China
3 Zhanghan Hospital, Pathological department, Shanghai, China

P.03-139-Thu | Response Prediction using NanoString nCounter Technology and NGS Panel Sequencing in Neoadjuvant Chemotherapy in Patients with Gastric/esophageal Adenocarcinoma

S. Daum1, C. Treece1, A. Arnold1, H. Harloff1, H. Lammert1, F. Mairinger3, M. Hummel1, K. Klee1

1 Gastroenterology- Rheumatology and Infectious Diseases, Charité - Campus Benjamin Franklin, Berlin, Germany
2 Institute of Pathology, Charité - Campus Mitte, Berlin, Germany
3 Institute of Pathology, University Clinic Essen, Essen, Germany

P.03-140-Thu | Genetic landscape of gastric cancer in the Chinese population

Y. Ding1, H. Wang1, J. Li1, K. Luo1, F. Mo1, W. Zheng1, Z. Ma1, Y. Chen1, S. Chen1, L. Tang1

1 The First Affiliated Hospital- College of Medicine- Zhejiang University, Cancer Center, Hangzhou, China
2 Neantigen Therapeutics Ltd. ca, Neantigen Therapeutics Ltd. ca, Hangzhou, China
3 College of Pharmaceutical Sciences- Zhejiang University, Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou, China

P.03-141-Thu | MET as resistance factor for afatinib therapy in gastric cancer cells

K. Ebert1, T. Kunzke1, S. Keller1, G. Zwingenberger1, B. Luber1

1 Technical University of Munich, Institute of Pathology, Munich, Germany

P.03-142-Thu | Laparoscopic versus open total gastrectomy for advanced gastric cancer: a retrospective study of short-term outcomes

Z. Xu1, W. Wang1, F. Li1

1 First affiliated hospital of Nanjing medical university, General surgery, Nanjing, China

P.03-143-Thu | RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer

D. Fujimoto1, Y. Hirono1, J. Takashima1, T. Goi1, K. Taniguchi1

1 Surgery, Teikyo University Hospital- Mizonokuchi, Kawasaki-city, Japan
2 Surgery 1, University of Fukuoka, Fukuoka, Japan

P.03-144-Thu | PYLOTUM: A reference laboratory for upper Gl cancer

R. Mejias-Luque1, Y. Zhang1, M. Vieth1, M. Bajbouj1, Q. Michael1, R. Schmidt1, S. Stepans1, W.C. You2, K.F. Pan1, M. Gerhard5

1 Technische Universität München, Institut für medizinische Mikrobiologie- Immunologie und Hygiene, Munich, Germany
2 Peking University Cancer Hospital & Institute, Department of Cancer Epidemiology, Beijing, China
3 Klinikum Bayreuth, Institute of Pathology, Bayreuth, Germany
4 Technische Universität München, Department of Medicine II- Klinikum rechts der Isar, Munich, Germany
5 Charles University- Military University Hospital, Department of Internal Medicine- 1st Faculty of Medicine, Prague, Czechia

---
P.03-145-Thu | Management of stage IV gastric cancer: Chemotherapy followed by surgery in oligometastatic gastric cancer. FLOT-5 trial and current data in literature
1 Krankenhaus Nordwest-UCL-University Cancer Center, Institute of Clinical Cancer Research IKF, Frankfurt am Main, Germany
2 Hôpitaux Universitaires de Genève, Service de Chirurgie viscérale, Geneva, Switzerland
3 Medizinische Hochschule Hannover, Klinik für Gastroenterologie- Hepatologie & Endokrinologie, Hannover, Germany
4 Klinikum Wolfsburg, Med. Klinik II, Wolfsburg, Germany
5 Universitätsklinikum Goettingen and Marburg GmbH, Klinik für Hämatologie, Marburg, Germany
6 Universitätsklinik Köln, Gastrointestinal Cancer Group Cologne, Cologne, Germany
7 Justus-Liebig-Universität Giessen, Klinik für Hämatologie und Onkologie, Giessen, Germany
8 Klinikum Ludwigshburg, Med. Klinik I, Ludwigshburg, Germany
9 Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Viszeral- Thorax- und Gefäßchirurgie, Dresden, Germany
10 Universitätsmedizin Mannheim, Tagestherapiezentrum am ITM- III. Medizinische Klinik, Mannheim, Germany
11 Frankfurt University Hospital and Clinics, Department of General and Visceral Surgery, Frankfurt, Germany
12 Frankfurt University Hospital and Clinics, Department of Internal Medicine, Frankfurt, Germany
13 Universitätsmedizin Mainz, Klinik für Allgemein- Visceral- and Transplantationschirurgie, Mainz, Germany

P.03-146-Thu | C12orf48 facilitated gastric cancer metastasis and formation via Poly r(C)-Binding Protein (PCBP) 1
Q. Guo1, D. Wu1, L. Lele1
1 Second Affiliated Hospital-Zhejiang University College of Medicine, Department of Gastrointestinal Surgery, Hangzhou, China

P.03-147-Thu | Sericin regulates proliferation of human gastric cancer MKN45 cells through autophagic pathway
W. Guo1, G. Li1
1 Nanfang Hospital, Department of General Surgery, Guangzhou, China

P.03-148-Thu | Sericin nanomicelles with enhanced cellular uptake and pH-triggered release of doxorubicin reverse cancer drug resistance
W. Guo1, G. Li1
1 Nanfang Hospital, Department of General Surgery, Guangzhou, China

P.03-149-Thu | Analysis of presence of viral DNA in sporadic gastric tumors (This is the title of my abstract)
P. Żebrowska1, P. Karpiński1, W. Hap2, K. Kurnol2, A. Diakun2, P. Dzierżek2, M. Zawadzki2, E. Frejlich2, K. Kotaszk1, J. Rudno-Rudzińska2, W. Kielan2
1 Wroclaw Medical University, Department of Genetics, Wroclaw, Poland
2 Wroclaw Medical University, 2nd Department of General and Oncological Surgery, Wroclaw, Poland

P.03-150-Thu | Endoscopic samples of gastric cancer for individual drug susceptibility testing
L. Hennig1, A. Tenne mann1, J. Kö rter1, R. Thiem1, A. Kö rter1, J. Tenne mann2, J. Gockel2, A. Hoffmeister2, I. Bechmann2, S. Kallendrusch1, F. Lordick2
1 University Medicine Leipzig, Institute for Anatomy, Leipzig, Germany
2 University Medicine Leipzig, University Cancer Center, Leipzig, Germany
3 University Medicine Leipzig, Department of Visceral- Thoracic and Vascular Surgery, Leipzig, Germany
4 Medical center for oncolgy and internal medicine, Medical center for oncolgy and internal medicine, Peine, Germany
5 University Medicine Leipzig, Department of Gastroenterology and Rheumatology- Interdisciplinary Endoscopy and Sonography, Leipzig, Germany

P.03-151-Thu | Molecular mechanism of the anti-cancer effects of Chinese herbal formula Modified Liang-Fu Granules in gastric cancer
Y. Li1, P. Lv1, F. Shi1, X. Chen1, L. Hou1
1 Dongzhimen Hospital- Beijing University of Chinese Medicine, Department of Oncology and Hematology, Beijing, China

P.03-152-Thu | Vitamin B12 (VB12)-conjugated sericin micelles for targeting gastric cancer and reversing drug resistance
Y. Hu1, G. Li1
1 Nanfang Hospital, Department of General Surgery, Guangzhou, China

P.03-153-Thu | LncRNA_SLC16A1-AS1/microRNA-532-3p/Rab31P promotes cell proliferation through inhibiting cell autophagy signaling pathway in gastric cancer
Y. Hu1, G. Li1
1 Nanfang Hospital, Department of General Surgery, Guangzhou, China
P.03-154-Thu | **NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway**

Y.K. Huang

1 Fudan University Shanghai Cancer Center- Shanghai- 200032- PR China, Department of Gastric Surgery, Shanghai, China

P.03-155-Thu | **Regulation of HER and MET receptors in gastric cancer cells via histone deacetylases and SATB1: Implications for targeted therapies**

R. Jenke1,2, T. Büch3, J. Körfer1, F. Lordick1, A. Aigner2

1 University Cancer Center Leipzig UCCL, University Hospital Leipzig, D-04103 Leipzig, Germany
2 Rudolf Boehm Institute for Pharmacology and Toxicology- Clinical Pharmacology, Leipzig University, D-04107 Leipzig, Germany

P.03-156-Thu | **TET1 acts a tumor suppressor in gastric cancer by up-regulating PTEN**

L. Jiang1, B. Liu1

1 Fujin Hospital- Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Surgery, Shanghai, China

P.03-157-Thu | **Leptin stimulates migration and invasion and maintains cancer stem-like properties in gastric cancer cells**

K.H. Jun

2 St. Vincent’s Hospital- The Catholic University of Korea, Surgery, Suwon, Republic of Korea

P.03-158-Thu | **Mouse xenopatient (PDX) and ex vivo models of gastric cancer for studying tumor heterogeneity, molecular alterations and therapeutic effects**

T. Kahl1, R. Jenke1,2, T. Büch1,2, F. Lordick1, A. Aigner1

1 University Medicine Leipzig, University Cancer Center Leipzig UCCL, Leipzig, Germany
2 University of Leipzig, Clinical Pharmacology / Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig, Germany

P.03-159-Thu | **The clinical significance of glycoprotein non-metastatic melanoma B (GPNMB) expression in gastric cancer**

M. Khalid

1 Kagoshima University Hospital, Department of Digestive Surgery, Kagoshima, Japan

P.03-160-Thu | **Protective Effects of Female Hormone Exposing Factors on Lauren Intestinal-Type Gastric Adenocarcinoma**

H.K. Kim1, Y.J. Jung2, H.S. Seo1, C.H. Park1, H.H. Lee2

1 Seoul St. Mary’s Hospital- The Catholic Medical Collage- The Catholic University of Korea, Department of Nursing, Seoul, Republic of Korea
2 Seoul St. Mary's Hospital- The Catholic Medical Collage- The Catholic University of Korea, Division of Gastrointestinal Surgery- Department of Surgery, Seoul, Republic of Korea

P.03-161-Thu | **Epigenetic inactivation of the candidate tumor suppressor gene NDRG4 in gastric carcinoma and its role as a potential therapeutic target**

J. Kim1,2, S.J. Byeon1, M.A. Kim1, W.H. Kim1,2

1 Seoul National University College of Medicine, Cancer Research Institute, Seoul, Republic of Korea
2 Seoul National University College of Medicine, Department of Pathology, Seoul, Republic of Korea

P.03-162-Thu | **Diffuse and intestinal type spheroid forming gastric cancer cells differ in their gene expressions**

Y.H. Kim1, J.W. Lee1, Y.S. Park1, S.H. Park1, S. Chung1

1 Korea University College of Medicine, Medical Oncology, Seoul, Republic of Korea
2 Korea University College of Medicine, Surgery, Seoul, Republic of Korea
3 School of mechanical engineering- Korea University, Scalefree integrative discovery laboratory, Seoul, Republic of Korea

P.03-163-Thu | **The Chilean Gastric Cancer Task Force: A First Report of Results**

E. Koch1, J.N. Retama1, M. Cordova-Delgado1, M. Muñoz-Medel1, M.L. Bravo1, M.J. Maturana1, D. Romero1, N. De la Jara1, J. Torres1, M. Espinoza1, C. Balmaceda1, F. Covarruvia1, A. Corvalán1, G. Owen1, M. Garrido1

1 Faculty of Medicine- Pontificia Universidad Católica de Chile, Hematology and Oncology, Santiago, Chile
2 Faculty of Biological Sciences- Pontificia Universidad Católica de Chile, Department of Physiology, Santiago, Chile
3 Faculty of Medicine- Pontificia Universidad Católica de Chile, Pathology, Santiago, Chile
4 Faculty of Medicine- Pontificia Universidad Católica de Chile- Centre of Clinical Research- Health Technology Assessment Unit, Public Health, Santiago, Chile
5 Faculty of Medicine- Pontificia Universidad Católica de Chile, Gastrointestinal Surgery, Santiago, Chile
6 Faculty of Medicine- Pontificia Universidad Católica de Chile- Advanced Center for Chronic Diseases ACCDiS, Hematology and Oncology, Santiago, Chile
7 Faculty of Biological Sciences- Pontificia Universidad Católica de Chile- Millennium Institute on Immunology and Immunotherapy, Department of Physiology, Santiago, Chile
P.03-164-Thu | A microsatellite based multiplex PCR method for the detection of chromosomal instability in gastric cancer

M. Kohlruss1, M. Reiche1, M. Jesinghaus1, B. Grosser1, J. Sлотта-Huspenina1, A. Hapfelmeier1, L. Bauer1, A. Novotny2, W. Weichert1*, G. Keller1
1 Technical University of Munich, Institute of Pathology, Munich, Germany
2 Technical University of Munich, Department of Medical Informatics - Statistics and Epidemiology, Munich, Germany
3 Technical University of Munich, Department of Surgery, Munich, Germany
4 Technical University of Munich, German Cancer Consortium DKTK - Partner Site Munich, Munich, Germany

P.03-165-Thu | Immunoprofiling of patient-derived slice cultures (PDSC) of gastroesophageal-junction (GEJ) and gastric cancer (GC) as a model to study immunotherapy

J. Körfer1, S. Prill2, A. Tennemann1, J. Rebstock1, J. Gockel1, R. Thieme1, C. Wittkeind1, A. Manecke1, R. Jenke1, G. Schumacher2, N. Gassler1, K. Winter2, A. Weimann1, V. Wiechmann1, A. Aigner3, J. Beckmann1, S. Kallendrusch3, F. Lordick3
1 University of Leipzig, Institute of Anatomy, Leipzig, Germany
2 University Medicine Leipzig, Department for General and Visceral Surgery, Braunschweig, Germany
3 University Medicine Leipzig, Institute of Pathology, Leipzig, Germany
4 Hospital Braunschweig, Department for General and Visceral Surgery, Braunschweig, Germany
5 Hospital St. Georg, Department for General and Visceral Surgery, Leipzig, Germany
6 Hospital St. Georg, Institute of Pathology, Leipzig, Germany
7 University Medicine Leipzig, Rudolf-Boehm-Institute for Pharmacology and Toxicology - Clinical Pharmacology, Leipzig, Germany

P.03-166-Thu | Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases

H.H. Lee1, T.M. Kim2
1 Seoul St. Mary's Hospital - College of Medicine - The Catholic University of Korea, Division of Gastrointestinal Surgery - Department of Surgery, Seoul, Republic of Korea
2 College of Medicine - The Catholic University of Korea, Department of Medical Informatics, Seoul, Republic of Korea

P.03-167-Thu | Highly water-soluble zinc phthalocyanine nanowires for cancer phototherapy

S.H. Lee1, H.K. Moon2, H.C. Choi1
1 Kogin University College of Medicine, Surgery, Busan, Republic of Korea
2 Pohang University of Science and Technology, Department of Chemistry and Division of Advanced Materials Science, Pohang, Republic of Korea

P.03-168-Thu | The Role of Microsatellite Instability with hMLH1 Methylation in Expanding Indications for Endoscopic Submucosal Dissection of Undifferentiated Early Gastric Cancer

H. Li1, H. Zhang1, C. Shuo2, L. Dengxiang1, Z. Tongshuan1, H. Qiongqiang3
1 Affiliated Xing Tai People Hospital of Hebei Medial University, Department of Surgical Oncology, Xingtai, China

P.03-169-Thu | Luteolin induces EMT in gastric cancer by suppressing Notch signaling pathway

J. Li1, M. Zang4, L. Su5, Z. Zhu1, B. Liu1
1 Ruijin Hospital - Shanghai Jiaotong University School of Medicine, Surgery, Shanghai, China

P.03-170-Thu | Overexpression of IC53d promotes the proliferation of gastric cancer cells by activating the AKT/GSK3β/cyclinD1 signaling pathways

J.X. Lin1, Y.S. Xie1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou - Fujian Province, China

P.03-171-Thu | THBS2 combining with PTEN subcellular translocation regulates liver metastases from gastric cancer

J. Li1, G. Yunhe1, Z. Chao1, L. Wenquan1, X. Hongqing1, P. Heng2, Z. Kecheng1, C. Jianxin1, Q. Zhi1, W. Bo1, C. Lin1
1 Chinese People's Liberation Army General Hospital, Department of General Surgery, Beijing, China
2 Weill Cornell Medicine, Institute for Computational Biomedicine, New York, USA

P.03-172-Thu | ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via Par-1/Rho GTPases signaling pathway

B. Liu1, L. Pan1, J. Li1, L. Su1
1 Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Surgery, Shanghai, China

P.03-173-Thu | MicroRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer

K. Liu1, Z. Long1, H. Ca1, H. Huang1, Y. Wang1
1 Fudan University Shanghai Cancer Center, Department of Gastric Surgery, Shanghai, China
P.03-174-Thu | Endothelial-mesenchymal transition in esophagogastric cancer progression and peritoneal metastasis
O. Lyros1, M. Mehdorn1, K. Schierle1, T. Thomaidis1, M. Moehler2, I. Gockel3, R. Thieme3
1 University Hospital Leipzig, Department of Surgery, Leipzig, Germany
2 University Hospital Leipzig, Institute of Pathology, Leipzig, Germany
3 University Hospital Mainz, Department of Gastroenterology, Mainz, Germany

P.03-175-Thu | Development of a Mouse Model of Entero gastric Reflux
Y. Tian1, F. Ma2, Y. Li3, W. Li4, W. Kang5, H. Liu6, S. Ma7
1 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital- Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Pancreatic and Gastric Surgery, Beijing, China

P.03-176-Thu | Investigation of the specific microRNAs in alpha-fetoprotein(AFP)-producing gastric cancer
1 Faculty of Medicine University of Yamanashi, First Department of Surgery, Chuo- Yamanashi, Japan

P.03-177-Thu | Evaluating epi-/genomic profile in gastric cancer, microsatellite unstable and Epstein-Barr subtypes
R. Mengual1, S. S. Oltra2, C. Martinez-Carpaglini1, M. LLorca1, M. Ibarrola-Villalba2, A. Gill1, V. Gambardella1, T. Fleitas3, C. Mongart3, S. Navarro4, A. Cervantes5, G. Ribas6
1 Biomedical Research Institute INCLIVA, Department of Medical Oncology, Valencia, Spain

P.03-178-Thu | Update of an operated giant periampullary duodenal hamartoma with carcinoma transformation in Peutz-Jeghers Syndrome
M. Mester1, B. V. H. Mattos1, B. Zilberstein1, J. Evangelista1, A.V. Safatle-Ribeiro1, V. A. Alves1, P. Hoff, J. Ceconello2
1 University of São Paulo Medical School, Gastroenterology, São Paulo, Brazil
2 University of São Paulo Medical School, Clinical Oncology, São Paulo, Brazil

P.03-179-Thu | Multigene panel testing increases the number of loci associated with gastric cancer predisposition
1 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Biosciences Laboratory, Meldola, Italy
2 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Ramagna Cancer Registry, Meldola, Italy
3 Ospedale Infantino, Department of General Medicine, Rimini, Italy
4 University of Pavia, Department of Biology and Biotecnology, Pavia, Italy
5 Morgagni-Pierantoni Hospital, Department of General Surgery, Forlì, Italy
6 Morgagni-Pierantoni Hospital, Pathology Unit, Forlì, Italy
7 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Department of Medical Oncology, Meldola, Italy

P.03-180-Thu | Immune profiles in relation to PD-L1 expression and tumor mutation burden in gastric cancer
K. Nakamura1, K. Hatakeyama2, T. Toriumi1, M. Nagata1, Y. Koseki1, Y. Waki1, K. Furukawa1, H. Omori1, K. Fujiya1, S. Kamiya1, R. Makucuchi1, Y. Tanizawa1, E. Bando1, M. Terashima1
1 Gastric Surgery, Shizuoka Cancer Center, Sunto-gun, Japan
2 Medical Genetics Division, Shizuoka Cancer Center, Sunto-gun, Japan

P.03-181-Thu | Prognostic impact of circERBB2 in gastric cancer
K. Nanishi1, K. Shoda1, H. Konishi1, K. Takao1, D. Matsubara1, S. Ogino1, M. Kudo1, T. Arita1, T. Kasuga1, R. Morimura2, Y. Murayama1, S. Komatsu1, A. Shiozaki1, Y. Kuriu1, H. Ikoma1, T. Kubota1, M. Nakaniishi1, K. Okamoto1, H. Fujiwara1, E. Otsuji1
1 Kyoto Prefectural University of Medicine- Graduate School of Medical Science, Division of Digestive Surgery- Department of Surgery, Kyoto, Japan

P.03-182-Thu | Long noncoding RNA SDCBP2-AS1 inhibits gastric cancer progression throug SDCBP2-AS1/hnRNPK/β-catenin axis
M. Nie1, J. Ji2, X. Wei3, J. Han4, X. Li5
1 Peking University Cancer Hospital & Institute, Department of Gastrointestinal Surgery- Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Beijing, China

P.03-183-Thu | Plasma microRNA profiles: identification of novel microRNA as a biomarker for chemoresistance in gastric cancer
K. Nichibeppu1, S. Komatsu1, J. Kiuchi1, T. Kishimoto1, T. Kasuga2, K. Okamoto1, H. Konishi1, T. Kubota1, A. Shiozaki1, H. Fujiwara1, E. Otsuji1
1 Kyoto Prefectural University of Medicine, Division of Digestive Surgery, Kyoto, Japan
2 Kyoto Prefectural University of Medicine- Graduate School of Medical Science, Division of Digestive Surgery- Department of Surgery, Kyoto, Japan
P.03-184-Thu | EBV-associated gastric cancer evades T cell immunity by PD-1/PD-L1 interactions  
J. Nishikawa1, S. Sasaki2, I. Sakaoda*  
1 Yamaguchi University Graduate School of Medicine, Faculty of Laboratory Science, Ube, Japan  
2 Yamaguchi University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Ube, Japan

P.03-185-Thu | Identification of rare and aggressive CDH1 germline mutation in hereditary gastric cancer: assessment of a Latin American family registry  
E. Noreño1, A. Alançon2, C. Hakkaraia1, T. de Mayo1, C. Mellado1, M. Garrido1, G. Aguyao1, J. Torres1, A. Calvo1, M. Lagos1, P. Guifford1, A.H. Corvalan1  
1 Esophagogastrectomy Surgery Unit, Surgery Department, Hospital Dr. Sotero del Río, Pontificia Universidad Católica de Chile, Digestive Surgery Department, Santiago, Chile  
2 Hospital de la Santa Cruz, Atenas, Guatemala

P.03-186-Thu | Clinical significance of altering epithelial-mesenchymal transition (EMT) in metastatic lymph nodes of gastric cancer  
K. Okubo1, Y. Uenosono1, T. Arigami2, S. Yanagita2, D. Matushita2, S. Hokita1, S. Natsugoe2  
1 Imamura general hospital, digestive surgery, Kagoshima, Japan  
2 Kagoshima university, digestive surgery, Kagoshima, Japan

P.03-187-Thu | VEGF-C induced by TGF- β1 signaling in gastric cancer enhances tumor-induced lymphangiogenesis  
K.H. Pak1, J.H. Cheong2  
1 Hallym University Dongtan Sacred Heart Hospital, Surgery, Hwaseong, Republic of Korea  
2 Yonsei University Severance Hospital, Surgery, Seoul, Republic of Korea

P.03-188-Thu | EXOSC5 as a novel prognostic marker promotes gastric cancer proliferation by activating the AKT and MAPK signaling pathways  
H. Pan1, D. Xu1, Y. Wang1  
1 Fudan University Shanghai Cancer Center, Department of Gastroscary, Shanghai, China

P.03-189-Thu | The abundance of unsaturated glycerophospholipids in Gastro-Oesophageal junctional adenocarcinoma  
P. Patel1, S. Kumar2, L. Doría1, R. Soares1, M. Adam1, N. Abbassi-Ghadi1, Z. Takats1, G. Hanna1  
1 Imperial College London, Surgery and Cancer, London, United Kingdom  
2 The Royal Marsden NHS Foundation Trust, Esophago-gastric Surgery, London, United Kingdom

P.03-190-Thu | Mitochondrial somatic mutations impact in gastric cancer  
A. Ribeiro-Dos-Santos1, G. Gavalcante1, G. Araújo1, A.M. Ribeiro-dos-Santos1, A. Marinho2, T. Vinasco-Sandoval1, A. Vide1, A. Anaissi1, P. Assumpção1, S. Demachki1  
1 Federal University of Pará- Belém- Pará- Brazil, Center of Oncology Researches Núcleo de Pesquisas Oncológica, Belém, Brazil  
2 Federal University of Pará- Belém- Pará- Brazil, Laboratotoy of Human and Medical Genetics- Biological Sciences Institute, Belém, Brazil

P.03-191-Thu | ONECUT2, encoding one cut homeobox 2, is a putative oncogene in gastric cancer and trigger ACS5L  
E.H. Seo1,2, H.J. Kim1, J.L. Park1, D.H. Bae1, Y.S. Kim1  
1 Korea Research Institute of Bioscience and Biotechnology, Genome Editing Research Center, Daejeon, Republic of Korea  
2 University of Science and Technology, Functional Genomics, Daejeon, Korea

P.03-192-Thu | Presence of serum autoantibodies against Ras-like GTPases, RaLA, in patients with gastric cancer  
H. Shimada1, T. Nanami1, S. Yajima1, O. Ishim1, M. Ito1, T. Suzuki1, K. Funahashi1, Y. Nabey1, M. Tagawa1, M. Katsushita1, K. Yoshino2  
1 Toho University Graduate School of Medicine, Gastroenterological Surgery and Clinical Oncology, Tokyo, Japan  
2 Chiba Cancer Center, Division of Gastroenterological Surgery, Chiba, Japan

P.03-193-Thu | Molecular mechanism of peritoneal metastasis via adipocytes in gastric cancer  
K. Shoda1, T. Kubota1, T. Kosuga1, H. Korishi1, S. Komatsu1, A. Shizakai1, K. Okamoto1, H. Fujitani1, E. Otsuji1  
1 Kyoto Prefectural University of Medicine, Division of Digestive Surgery- Department of Surgery, Kyoto, Japan
P.03-194-Thu | Comprehensive phosphoproteomics using gastric cancer biopsy specimens
Y. Abe1, H. Shoji2, H. Hirano3, J. Adachi4, M. Aoki2, K. Honda5, N. Boku2, T. Tomonaga1
1 National Institute of Biomedical Innovation - Health and Nutrition, Laboratory of Proteome Research, Osaka, Japan
2 National Cancer Center Hospital, Gastrointestinal Medical Oncology Division, Tokyo, Japan
3 National Cancer Center Research Institute, Department of Biomarker for Early Detection of Cancer, Tokyo, Japan

P.03-195-Thu | RUNX3 drives metastasis in gastric cancer by upregulating angiogenesis and EMT
K. Suda1, N. N. Man1, Y. Ito1
1 National University of Singapore, Cancer Science Institute of Singapore, Singapore, Singapore

P.03-196-Thu | The role of Her2 in self-renewal, invasion and tumorigenicity of gastric cancer stem cells
L. Sun1, X. L. Chen1, K. Yang1, J. K. Hu1
1 Department of Gastrointestinal Surgery - Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy - West China Hospital - Sichuan University - and Collaborative Innovation Center for Biotherapy - Chengdu - China, Department of Gastrointestinal Surgery - Laboratory of Gastric Cancer, Chengdu, China

P.03-197-Thu | Pharmacodynamic markers in metastatic gastric cancer during second-line treatment with paclitaxel plus ramucirumab: potential prognostic and predictive role
C. Vivaldi1, G. Mussettini1, P. Orlandi1, I. Pecora1, E. Vasile1, T. Di Desidero1, D. Gentile1, M. Lencioni1, L. Fornaro1, G. Pasquini1, S. Catanesi1, F. Salani1, I. Petrini1, A. Falcone1, G. Bocci1
1 Azienda Ospedaliero-Universitaria Pisana, Unit of Medical Oncology, Pisa, Italy
2 University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy

P.03-198-Thu | The molecular characteristics of multiple gastric cancer with MSH2 predisposing mutations
A. Wang1, Z. Li1, M. Wang1, S. Jia1, X. Ji1, T. Fu1, Z. Jia1, K. Ji1, X. Zong1, X. Wu1, J. Zhang1, Y. Hu1, L. Zhang1, Z. Li1, Z. Bu1, Q. Zheng1, J. Ji1
1 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education - Peking University Cancer Hospital & Institute, Department of Gastrointestinal Surgery, Beijing, China
2 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education - Peking University Cancer Hospital & Institute, Department of Pathology, Beijing, China
3 Novogene Bioinformatics Technology, Novogene Bioinformatics Technology, Beijing, China
4 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education - Peking University Cancer Hospital & Institute, Center for Molecular Diagnostics, Beijing, China
5 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education - Peking University Cancer Hospital & Institute, Department of Biobank, Beijing, China

P.03-199-Thu | CircRNA_0082836 promotes proliferation, migration and invasion of gastric cancer cells by regulating EMT
J. Xia Zeng1, H. Qi1, Y. Chen Gang1, T. Shan1, N. Wang1, Y. Chen1, H. Wang1
1 The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, General surgery, Wuxi, China

P.03-200-Thu | The expression of ERBB2, TP53, STAT4, and HOTAIR in gastric adenocarcinoma determined by cancer genome atlas: a bioinformatics analysis
Z. Wei-Dong1, J. Xiao1
1 Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Department of Gastrointestinal Surgery, Fuzhou, China

P.03-201-Thu | Effects of vascular endothelial growth factor and epidermal growth factor on biological properties of gastric cancer cells
C. Li1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.03-202-Thu | Clinicopathological features and survival analysis of patients with stage T4b gastric cancer invading different organs
R. Wang1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.03-203-Thu | Succinate dehydrogenase deficiency in gastrointestinal stromal tumors
K. Yamashita1, K. Mitsushashi1, G. Sudo1, H. Igarashi1, Y. Shibata1, Y. Kazama1, H. Yamano1, H. Nakase1
1 Sapporo Medical University, Department of Gastroenterology and Hepatology, Sapporo, Japan

P.03-204-Thu | GLI2-ABCG2 signaling axis is responsible for 5Fu resistance in gastric cancer
B. Yu1, D. Gu1, X. Zhang1, J. Xie1, B. Liu1
1 Shanghai Key Laboratory of Gastric Neoplasms - Shanghai Institute of Digestive Surgery, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 The Wells Center for Pediatrics Research and IU Simon Cancer Center, Departments of Pediatrics - Biochemistry and Molecular Biology - Indiana University School of Medicine, Indianapolis, USA
P.03-205-Thu | Tivantinib inhibits VEGFA signaling pathways and its induce apoptosis in gastric cancer positive or negative for c-MET amplification
D.Y. Zang1, S.H. Sohn1, B. Kim1, H.J. Suh1, H.S. Kim2
1 Hallym University Medical Center- Hallym University College of Medicine; Hallym Translational Research Institute, Hematology-Oncology-Internal Medicine, Anyang-si, Republic of Korea
2 Hallym University Medical Center- Hallym University College of Medicine, Hallym Translational Research Institute, Anyang-si, Republic of Korea

P.03-206-Thu | Diallyl trisulfide inhibits gastric cancer stem cells through suppression of Sonic Hedgehog pathway
C. Zhong1,2, M. Ge1, X. Li1, S. Geng1
1 Nanjing Medical University- School of Public Health, Department of Nutrition and Food Safety, Nanjing, China
2 Nanjing Medical University- School of Public Health, Center for Global Health, Nanjing, China

P.04 Prevention and early detection
P.04-207-Thu | The Suicide journey of Helicobacter pylori: A new interpretation from the current data on gastric microbiota carcinogenesis
P. Assumpção1, T. Araújo1, A. Khayat1, P. Assumpção2, W. Barra1, B. Khayat1, C. Assumpção1, G. Ishak1, M. Assumpção1, Â. Santos1, E. Dias-Neto1, D. Nunes1, S. Santos1
1 Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Brazil
2 Universidade Federal do Pará, Programa de Pós-graduação em Genética e Biologia Molecular, Belém, Brazil

P.04-208-Thu | Prevalence difference of Helicobacter pylori infection between Tibetan and Han ethnics: A meta-analysis on epidemiologic studies
D. Bai1, X.Z. Chen1, J.K. Hu1
1 Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy, Chengdu, China

P.04-209-Thu | Usefulness of regular arrangement collecting venules to rule out Helicobacter Pylori infection
M.A. Herrera Servin1, M.C. Galindo Orozco1, K. Picazo Ferrera1, A. Hernández Guerrero1, A.M. Leon Takahashi1
1 National Cancer Center, Gastrointestinal Endoscopy, Mexico, Mexico

P.04-210-Thu | Japanese revolutionary endoscopic screening method. Diagnosis of Helicobacter pylori gastritis with endoscopic screening test and induction to the eradication therapy
S. Ikeda1, H. Okamura2, M. Ino1, M. Ikeda1, S. Fukunaga1
1 Ikeda Hospital, Surgery, Shizuoka, Japan
2 Ikeda Hospital, Internal medicine, Shizuoka, Japan

P.04-211-Thu | Hereditary Diffuse Gastric Cancer: four generation family history and prophylactic laparoscopic total gastrectomy as prevention for advanced diffuse gastric cancer
J. Khurralde-Argerich1, F. Cuerva-Abente1, C. Duque-Seguro1, L. Rosner1, A. Faerberg1, M. Kujaruk2
1 Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Upper GI Surgery Unit, Digestive Surgery Department, Ciudad Autónoma de Buenos Aires, Argentina
2 Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Pathology Department, Ciudad Autónoma de Buenos Aires, Argentina

P.04-212-Thu | Young age increases risk for lymph node positivity in gastric cancer: a Chinese multi-institutional database and US SEER database study
Y. Jiang1, G. Li1, W. Huang1, Z. Han1
1 Nanfang Hospital- Southern Medical University, Surgery, Guangzhou, China

P.04-213-Thu | Incidental pathological findings in sleeve gastric resections – is the incidence higher in obese patients?
T. Louro1, I. Estalagem2, C. Marques1, R. Martelo1, N. Gonçalves3, A. Rabago1, M. Brilliant1, C. Fonseca1, J. Morais1, F. Rodrigues1
1 Hospital Vila Franca de Xira, General Surgery Department, Vila Franca de Xira, Portugal
**P.04-214-Thu | Prognostic value of preoperative immunonutritional parameters in patients with gastric cancer**

Y. Matsumoto1, I. Kosuga1, T. Kubota1, A. Shiozaki1, K. Okamoto1, K. Shoda1, H. Konishi1, H. Fujiwara1, T. Konishi1, M. Kudou1, T. Arita1, R. Morimura1, Y. Murayama1, Y. Kurui1, H. Ikoma1, M. Nakashima1, E. Otsuji1

1 Kyoto Prefectural University of Medicine, Division of Digestive Surgery - Department of Surgery, Kyoto, Japan

**P.04-215-Thu | Timing of initiation of adjuvant S-1 monotherapy after curative gastrectomy for gastric cancer: Analysis of a multi-institutional dataset**

K. Nakasone1, M. Kanda1, S. Ita1, Y. Morishita1, H. Teramoto1, K. Ishigure1, T. Mura1, T. Asada1, A. Ishiyama1, H. Matsushita1, C. Tanaka1, D. Kobayashi1, M. Fujiwara1, K. Murotani1, Y. Kodera1

1 Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery Surgery II, Nagoya, Japan
2 Aichi Cancer Center Hospital, Department of Gastroenterological Surgery, Nagoya, Japan
3 Kamaki Municipal Hospital, Department of Surgery, Kamaki, Japan
4 Yokkaichi Municipal Hospital, Department of Surgery, Yokkaichi, Japan
5 Kanazawa Kosei Hospital, Department of Surgery, Kanazawa, Japan
6 Ichinomiya Municipal Hospital, Department of Surgery, Ichinomiya, Japan
7 Gifu Prefectural Tajimi Hospital, Department of Surgery, Tajimi, Japan
8 Okayama City Hospital, Department of Surgery, Okayama, Japan
9 Toa General Hospital, Department of Surgery, Toa, Japan
10 Kurume University - Graduate School of Medicine, Biostatistics Center, Kurume, Japan

**P.04-216-Thu | Gastric carcinoma arising from the remnant stomach after curative distal gastrectomy**

Y. Park1, S. Kim1

1 Yeungnam University Medical Center, Gastrointestinal Surgery, Daegu, Republic of Korea

**P.04-217-Thu | Predictive efficacy of C-reactive protein in early detection of postoperative complications after gastric cancer surgery**

J. Shi1, Z. Wu1, Z. Li1, J. Ji1

1 Peking University Cancer Hospital & Institute, Department of Gastrointestinal Surgery - Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Beijing, China

**P.04-218-Thu | Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations: ABC Method for Gastric Cancer Screening**

C. Xianzhe1,2, X. Yao1,2

1 Southern Medical University, The Second School of Clinical Medicine, Guangzhou- Guangdong, China
2 Guangdong General Hospital- Guangdong Academy of Medical Sciences, Department of General Surgery, Guangzhou- Guangdong, China

**P.04-219-Thu | Prognostic Significance of Tumor Size in 1,370 Patients With Early Gastric Cancer: a result from SEER Database**

J. Xiao1, Z. Wei-Dong1

1 Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Department of Gastrointestinal Surgery, Fuzhou, China

**P.04-220-Thu | Non-genetic risk factors for gastric cancer: an exposure-wise umbrella review of meta-analyses**

X. Ying1, F. Shan1, X. Lei1, Z. Li1, J. Ji1

1 Peking University Cancer Hospital, Gastrointestinal Cancer Center, Beijing, China

**P.04-221-Thu | Local Experience of Gastric and Gastroesophageal Junction Cancers in a Single Center of Huai’an in China**

X. Zhang1, H. Zhao1, H. Zhuang1, Y. Zhao1, X. Wang1

1 Huai’an Second People’s Hospital and the Affiliated Huai’an Hospital of Xuzhou Medical University, Department of General Surgery, Huai’an, China
2 University Hospital of Cologne, Department of General - Visceral and Cancer Surgery-, Cologne, Germany
3 Huai’an Second People’s Hospital and the Affiliated Huai’an Hospital of Xuzhou Medical University, Medical Informatic Center, Huai’an, China

**P.04-222-Thu | Wnt/β-catenin pathway mediates chronic 1-methyl-3-nitro-1-nitrosoguanidine exposure-induced acquisition of gastric cancer stem cells properties and sulforaphane intervention**

C. Zhang1,2, Y. Meng1, C. Xie1, X. Li1, Y. Chen1, J. Zhu1

1 Nanjing Medical University - School of Public Health, Department of Nutrition and Food Safety, Nanjing, China
2 Nanjing Medical University - School of Public Health, Center for Global Health, Nanjing, China
P05-223-Thu | Investigation of clinicopathologic factors associated with lymph node metastasis in gastric cancer
O. Ureyen1, E. Ilhan1, D. Alay1, H. Fenercioglu1
1 University of Health Sciences Izmir Boyazoka Training and Research Hospital, General Surgery, Izmir, Turkey

P05-224-Thu | Predictive value of magnetic resonance in pre-operative gastric cancer T staging: An initial experience
V. Molinelli1, V. Quintodesi2, G. Angeretti2, M. Berselli2, G. Borroni2, A.M. Chiaravalli3, E. Coccozza2
1 ASST Sette Laghi, Department of Radiology, Varese, Italy
2 ASST Sette Laghi, Department of Surgery, Varese, Italy
3 ASST Sette Laghi, Department of Pathology, Varese, Italy

P05-225-Thu | Development and external validation of web-based prediction models to predict the prognosis of remnant gastric cancer: A multicenter study
Q.Y. Chen1, Q. Zhong1, J.W. Xie1, P. Li1, C. Huang1, C.H. Zheng1
1 Fujian Medical University Union Hospital, Department of Gastrointestinal Surgery, Fuzhou, China

P05-226-Thu | Maximum SUV of PET-CT for Predicts Perigastric and Distant Occult Lymph Node Metastasis in Gastric Carcinoma
F. Chen1,2, G. Chen1, X. Dou1, L. Wang1,2, L. Chen1
1 The Second Affiliated hospital of Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China
2 Zhejiang University, Institute of Gastroenterology, Hangzhou, China

P05-227-Thu | A Preoperative Prediction Model of Lymph Node Metastasis for Patients with Gastric Cancer based on Machine Learning
T. Chen1, Z. Gao1, L. Chen1, J. Cai1, Y. Hu1, J. Yu1, G. Li1
1 Nanfang Hospital- Southern Medical University, Department of General Surgery, Guangzhou, China

P05-228-Thu | CT versus DOTANAC in gastric carcinoid
K. Manickavasagam1, C. S N2, M. Chinnathamby2, K. Bhargav2, A. Kuriar2, A. Chandramahar2, A. Madhugin2
1 St. Isabel Hospital, General Surgery, Chennai, India
2 St. Isabel hospital, General Surgery, Chennai, India
3 Esoindia, Surgery, Chennai, India
4 Kilpauk medical college, Medical student, Chennai, India
5 Sri Ramachandran medical college, Medical student, Chennai, India

P05-229-Thu | Gastric Cancer: Extent of Lymphadenectomy at our Institution
M. Correia Fragata1, N. Monteiro1, A. Batista1, F. Almeida1, V. Praedez1, J. Santos1, R. Baia1, J. Almeida1, A. Pinto1, R. Garcia1, L. Cortez1
1 Hospital de Sao Bernardo, General Surgery, Setubal, Portugal

P05-230-Thu | Necessity of staging laparoscopy in gastric cancer
O. Dobzhanskiy1, Y. Kondratskyi2, R. Fridel2, A. Kolesnik2, A. Minich2, A. Minich1, Y. Shudrak1
1 National Cancer Institute, Upper Gastrointestinal Tumors Department, Kiev, Ukraine

P05-231-Thu | Accuracy and role of endoscopic ultrasound in preoperative staging of early gastric cancer at an University hospital in Brazil
F. Ponce Leon1, G. Bravo Neto Pinto2, N. Santos Barros de Oliveira1, B. Figueiredo Nogueira Lima1
1 General Surgeon, Department of Surgery at Clementino Fraga Filho University Hospital at Universidade Federal do Rio de Janeiro UFRJ, Rio de Janeiro, Brazil
2 Adjunct Professor, Department of Surgery of Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
3 Resident, Department of Surgery of Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

P05-232-Thu | Comparison of Asiatic and non-Asiatic patients with gastric cancer in Brazil
D.K. Fukuhara1, R.D.M. Corrêa1, O.A.P. Castro1, F. Thuler2, W. Freitas Jr1, E. Lima1, P. Brito1, L. Ganem2, M. Marinho2, L. Claro2, M. Carvalho2, E. Ilias1, C.A. Malheiros1, P. Kassab1
1 Santa Casa Medical School, Department of Surgery, Sao Paulo, Brazil
2 Santa Casa Medical School, Medical School, Sao Paulo, Brazil
3 Santa Casa Medical School, Department of Pathology, Sao Paulo, Brazil
4 Santa Casa Medical School, Department of Oncology, Sao Paulo, Brazil
P.05-233-Thu | The role of staging laparoscopy in gastric cancer. A population-based cohort study
A. Borgstein¹, M.I. van Berge Henegouwen¹, S. Gisbertz², W. Eshuis³
¹ Academic Medical Centre Amsterdam, Upper GI Surgery, Amsterdam, Netherlands

P.05-234-Thu | Survival Comparison in Gastric cancer patients between 7th and 8th edition of the AJCC TNM Staging System
L. Grassi¹, E. Marino¹, M.C. Vannoni¹, A. Donini¹
¹ University of Perugia, General and Emergency Surgery, Perugia, Italy

P.05-235-Thu | Primary gastric choriocarcinoma, experience in a national cancer institute
K. Picazo Ferrera¹, M.A. Herrera Servin¹, A. Hernandez Guerrero¹, M.C. Galindo Orozco¹, T.M. Cesá Fernando¹, L.T. Alberto Mitzao¹
¹ National Cancer Institute of México, Gastrointestinal endoscopy, Mexico City, Mexico

P.05-236-Thu | Comparison between Gastric and Esophageal Classification system among Adenocarcinomas of Esophagogastric Junction According to AJCC 8th edition
J.K. Hu¹, K. Liu², F. Feng³, H.W. Zhang³
¹ Department of Gastrointestinal Surgery- Institute of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China. ² Department of Gastrointestinal Surgery, Chengdu, China. ³ The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, USA

P.05-237-Thu | The Optimal Selection of Patients with Gastric Cancer for Staging Laparoscopy
M. Kwatsuki¹, K. Harada¹, S. Inagami¹, K. Eto¹, B. Badgewell², N. Ikoma², K. Yamashita², Y. Koga², T. Ishimoto², Y. Baba², N. Yoshida², H. Baba², J. Aijani³
¹ The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, USA. ² Department of Gastrointestinal Surgical Oncology, Shizuoka, Japan. ³ The University of Texas MD Anderson Cancer Center, Department of General Medical Oncology, Houston, USA

P.05-238-Thu | Validation of clinical staging system in the 8th AJCC/UICC TNM Classification of gastric cancer and proposal of new classification
Q. Jeong¹, S.Y. Ryu¹, M.R. Jung¹, J.H. Kang¹
¹ Chonnam National University Hwasun Hospital, Department of Surgery, Hwasun-eup, Republic of Korea

P.05-239-Thu | Gastric cancer patients who have preoperative nutritional risk have worse postoperative clinical outcomes
L. Jiang¹
¹ Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, General Surgery, Beijing, China

P.05-240-Thu | Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen with Outcome and Chemotherapy in Gastric Cancer
Y. Jiang¹, G. Li¹, T. Li²
¹ Nanfang Hospital- Southern Medical University, Surgery, Guangzhou, China. ² Georgetown University Medical Center, Surgery, Washington DC, USA

P.05-241-Thu | Overtreatment of Younger Adults with Gastric Cancer: More Chemotherapy Use with Unmatched Survival Gains
Y. Jiang¹, G. Li¹, T. Li²
¹ Nanfang Hospital- Southern Medical University, Surgery, Guangzhou, China. ² Georgetown University Medical Center, Surgery, Washington DC, USA

P.05-242-Thu | A Preoperative Nomogram to Predict Splenic Hilar Lymph Node Metastasis in Proximal Gastric Cancer
G. Jeong¹, M.R. Jung¹, S.Y. Ryu¹, Y.K. Park¹, M.C. Kim¹, S.W. Ryu¹, Y.G. Sori¹
¹ Chonnam National University Hwasun Hospital, Department of Surgery, Hwasun-eup, Republic of Korea. ² Dong-A University Medical Center, Department of Surgery, Busan, Republic of Korea. ³ Keimyung University Dongsan Medical Center, Department of Surgery, Dongsan, Republic of Korea

P.05-243-Thu | The relevance of serosal exposure without nodal metastasis in resectional gastric cancer
Y.J. Jung¹, H.S. Seo¹, J.H. Kim¹, C.H. Park¹, H.H. Lee¹
¹ Seoul St. Mary's Hospital- The Catholic Medical College- The Catholic University of Korea, Division of Gastrointestinal Surgery, Department of Surgery, Seoul, Republic of Korea
P.05-244-Thu | A case of protein-losing hyperplastic polyposis of the stomach with autoimmune gastritis

D. Kajiyama1, T. Tei1, M. Iida1, A. Fukuda2, M. Ando1
1 Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, General Surgery, Tokyo, Japan
2 Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, Pathology, Tokyo, Japan

P.05-245-Thu | The implication of early recurrence and symptoms after curative gastrectomy for gastric cancer

S. Kamay1, R. Makucki1, K. Fukukawa1, K. Fujita1, Y. Tanizawa1, E. Bando1, A. Shiomi2, T. Sugiu1, M. Terasima1
1 Shizuoka Cancer Center, Division of Gastric Surgery, Shizuoka, Japan
2 Shizuoka Cancer Center, Division of Gastrointestinal Surgery, Shizuoka, Japan

P.05-246-Thu | Clinicopathological features of Borrmann type 1 gastric cancer

K. Kawahara1, H. Takiguchi1, H. Guro1, T. Horino1, H. Sako1, A. Ikeda1, Y. Nabeya1
1 Chiba cancer center, Surgery, Chiba city, Japan

P.05-247-Thu | D-dimer as a prognostic marker after gastrectomy for gastric cancer

E.Y. Kim1, K.Y. Song1, H.M. Jeon1
1 Uljeongbu St. Mary Hospital - College of Medicine - The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

P.05-248-Thu | Not only preoperative but also postoperative Neutrophil-to-lymphocyte ratio predict prognosis of gastric cancer

E.Y. Kim1, K.Y. Song1, H.M. Jeon1
1 Uljeongbu St. Mary Hospital - College of Medicine - The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

P.05-249-Thu | Significance of Preoperative Immunonutritional Parameters in the Prediction of Lymph Node Metastasis of Gastric Cancer

T. Kosugi1, T. Kubota1, A. Shizaki1, T. Konishi1, K. Okamoto1, K. Shoda1, H. Konishi1, H. Fujisawa1, Y. Matsumoto1, M. Kudou1, T. Arita1, R. Morimura1, Y. Muramaya1, Y. Kuri1, H. Koma1, M. Nakamishi1, E. Otsuji1
1 Kyoto Prefectural University of Medicine, Division of Digestive Surgery - Department of Surgery, Kyoto, Japan

P.05-250-Thu | A case of gastric mixed adenoneruoendocrine carcinoma with diffuse distribution of neuroendocrine cells in the submucosa

A. Kusano-Kitazume1, A. Katsunori2, S. Tei3, M. Kondo1, A. Tamura1, Y. Karakama1, M. Kitamura1, N. Oi1, J. Yamazaki1, K. Motoyama1, S. Ooka1
1 Tokyo Metropolitan Health and Hospitals Corporation Toshima Hospital, Gastrointestinal Medicine, Tokyo, Japan
2 Tokyo Metropolitan Health and Hospitals Corporation Toshima Hospital, Surgery, Tokyo, Japan
3 Tokyo Metropolitan Health and Hospitals Corporation Toshima Hospital, Diagnostic Pathology, Tokyo, Japan

P.05-251-Thu | How to improve the accuracy of discrimination between T1 and T2-4 gastric cancers using preoperative EUS and stomach protocol CT

K.G. Lee1, H.K. Yang2
1 Myongji Hospital - Hanyang University College of Medicine, Department of Surgery, Goyang-si, Republic of Korea
2 Seoul National University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.05-252-Thu | Current epidemiology of gastric cancer in Mexico: Review of the last 8 years in a National Reference Hospital for Cancer

A.M. Leon Takahashi1, H.N. Lopez-Basave1, G. Calderillo Ruíz1, L.S. Lino-Silva1, M. Herrera Servin1, E. Sosa1, A. Alfaro Godaracena1, C. Diaz Romero1, A. Herrera Gomez2
1 National Cancer Institute, Gastrointestinal Surgery, Mexico City, Mexico
2 National Cancer Institute, Gastrointestinal Oncology, Mexico City, Mexico

P.05-253-Thu | Tumor deposits counted as positive lymph nodes in stage III gastric cancer: a novel N category in TNM staging

W. Liang1, K. Zhang1, H. Xi1, J. Cai1, A. Cai1, J. Li1, Y. Gao1, B. Wei1, L. Chen1
1 Chinese People’s Liberation Army General Hospital, Department of General Surgery, Beijing, China

P.05-254-Thu | “Four-Step Procedure” of Laparoscopic Exploration for Gastric Cancer in West China Hospital

K. Liu1, X.Z. Chen1, W.H. Zhang1, J.K. Hu1
1 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer - State Key Laboratory of Biotherapy - West China Hospital - Sichuan University - Collaborative Innovation Center for Biotherapy - Chengdu-China, Department of Gastrointestinal Surgery, Chengdu, China
P.05-255-Thu | The association of surgical specimen dissection with the number of harvested lymph nodes in gastric cancer
J. Louhimo1, P. Puolakkainen1, A. Kokkola1
1 University of Helsinki, Department of Surgery, Helsinki, Finland
2 Helsinki University Hospital, Department of Abdominal Surgery, Helsinki, Finland

P.05-256-Thu | A Novel TNM Staging System for Gastric Cancer Based on the “Metro-ticket” Paradigm: Comparative Study with the AJCC-TNM Staging System
J. Lu1, Z.F. Zheng1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, Fujian Province, China

P.05-257-Thu | Combination of Lymphovascular Invasion and the AJCC TNM Staging System Improves Prediction of Prognosis in N0 Stage Gastric Cancer
J. Lu1, Y. Dai1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, Fujian Province, China

P.05-258-Thu | The impact on survival of harvested Non-pathologic Lymph Nodes in pN+ patients following radical gastrectomy for cancer
P. Matos Da Costa1, P. Lages2, S. Onofre2, R. M. Ribeiro2
1 Serviço de Cirurgia Gastro-Hospital Garcia de Orta, Faculdade de Medicina da Universidade Lisboa, Lisbon, Portugal
2 Serviço de Cirurgia Gastro-Hospital Garcia de Orta, Faculdade de Medicina da Universidade Lisboa, Lisbon, Portugal

P.05-259-Thu | A case of mixed adenoneuroendocrine carcinoma (MANEC) of the stomach
Y. Matsui1, T. Morii1, T. Itami1, H. Koike1, Y. Kudose1, T. Shoji1, N. Hirooka1, Y. Takaya1, M. Ogawa1, A. Ogawa1, Y. Uemura1, T. Nishi1, H. Niwa1
1 TANE General Hospital, Surgery, Osaka, Japan

P.05-260-Thu | Incidence and clinico-pathological risk factors of peritoneal carcinomatosis detected during staging laparoscopy in patients with esophagogastric cancer
M. Melkonyan1, H. Hamadeh1, K. Schiesel1, R. Thieme1, S. Niebisch1, Y. Moula1, B. Jansen-Winkeln1, I. Gockel1, O. Lyros1
1 University Hospital Leipzig, Department of Surgery, Leipzig, Germany
2 University Hospital Leipzig, Department of Pathology, Leipzig, Germany

P.05-261-Thu | Prognostic Value of the TNM-Classification After Neoadjuvant Therapy
A. Novotny1, R. Schirren1, N. Sammler1, H. Friess1, D. Reim1
1 Klinikum rechts der Isar der TU München, Surgery, Munich, Germany

P.05-262-Thu | Borrmann type I is associated with high recurrence rate in locally advanced gastric cancer
K.B. Park1, J.H. Kim1, H.S. Soo1, Y.J. Jung1, H.H. Lee1, C.H. Park1
1 Seoul St. Mary’s Hospital-The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

P.05-263-Thu | Staging Laparoscopy in Gastric Cancer – 6-Year Retrospective Analysis of a Service
V.S. Pereira Praxedes1, N. Monteiro1, A. Batista1, F. Almeida1, I. Santos1, R. Baia1, J. Almeida1, R. Pinto1, R. Garcia1, M. Correia1, L. Cortez1
1 Hospital São Bernardo, General Surgery, Setúbal, Portugal

P.05-264-Thu | Endomicroscopy and endocytoscopy for early gastric cancer diagnostics: proposal of new classification
S. Pirogov1, I. Perfiliev1, D. Sukhin1, A. Vodoleev1, M. Belyakov1, V. Khomyakov1, A. Kaprin1
1 PA. Herzen Moscow Cancer Research Institute, Endoscopy, Moscow, Russian Federation
2 PA. Herzen Moscow Cancer Research Institute, Pathology, Moscow, Russian Federation
3 PA. Herzen Moscow Cancer Research Institute, Thoracic and abdominal surgery, Moscow, Russian Federation
4 PA. Herzen Moscow Cancer Research Institute, Oncological surgery, Moscow, Russian Federation

P.05-265-Thu | The value of laparoscopy with narrow band imaging in the assessment of tumor staging in gastric cancer
K. Pudlo1, T. Skoczylas1, B. Młynarski1, K. Nuczynski1, J. Krzak-Bachankiewicz1, W. Krupska1, J. Sierocińska-Sowa1, G. Wallner1
1 Medical University of Lublin, Second Department of General and Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Lublin, Poland
2 Medical University of Lublin, Department of Radiology, Lublin, Poland
3 University Hospital 1 in Lublin, Department of Pathology, Lublin, Poland

WWW.IGCC2019-PRAGUE.ORG
P.05-266-Thu | Yield of staging laparoscopy and peritoneal cytology for intestinal versus diffuse (Laurén) type of gastric cancer
K. Rawicz-Pruszyński1, K. Pudło2, R. Lisiecki3, J. Mielko1, T. Skoczylas2, D. Murawa4, G. Wallner2, W. Polkowski1
1 Medical University of Lublin, Department of General Surgery and Surgical Oncology, Lublin, Poland
2 Pleszew Medical Center, Department of General Surgery and Oncological Surgery, Pleszew, Poland
3 Pleszew Medical Center, Department of General Surgery and Surgical Oncology, Lublin, Poland
4 University of Medical Science, Chair of Surgery and Oncology, Zielona Góra, Poland

P.05-267-Thu | The frequency of criteria in patients with familial gastric cancer and adenocarcinoma of gastro-esophageal junction in Berlin
J. Schölzchen1, C. Treese1, P. Thuss-Patience2, A. Mrózek3, B. Rau4, F. von Weizsäcker5, H. Seeliger6, D. Hartmann7, L. Estevéz-Schwarz8, B. Siegmund1, D. Horn9, M. Nassir1, S. Daum1
1 Charité - Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie-Infektiologie und Rheumatologie, Berlin, Germany
2 Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Hämatologie-Onkologie und Tumorimmunologie, Berlin, Germany
3 Onkologisches Zentrum Prenzlauer Berg, Onkologische Schwerpunktpraxis, Berlin, Germany
4 Charité - Universitätsmedizin Berlin, Chirurgische Klinik, Berlin, Germany
5 Schlosspark Klinik Berlin, Innere Medizin I – Gastroenterologie-Hepatologie-Onkologie-Infektiologie, Berlin, Germany
6 Charité – Universitätsmedizin Berlin, Klinik für Allgemein – Viszeral – und Gefäßchirurgie, Berlin, Germany
7 Katholischen Kliniken Mainz, Klinik für Innere Medizin II, Mainz, Germany
8 St. Joseph Krankenhaus Berlin Tempelhof, Klinik für Allgemein – Viszeral – und Gefäßchirurgie, Berlin, Germany
9 Charité – Universitätsmedizin Berlin, Ambulantes Gesundheitszentrum der Charité GmbH Humangenetik, Berlin, Germany

P.05-268-Thur | The patterns and factors associated with recurrence after curative resection for gastric cancer in stage IIIB
J.E. Seo1
1 Samsung medical Center, Department of surgery, Seoul, Republic of Korea

P.05-269-Thur | A nomogram to predict lymph node metastasis in gastric cancer patients
Y. Huang1, R. Wu2, X. Shen1
1 Second Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China
2 First Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China

P.05-270-Thur | Gastric cancer with intestinal malrotation; a case report
M.W. Son1, G.J. Song1, M.S. Lee1
1 Soonchunhyang University Cheonan Hospital, Department of Surgery, Cheonan, Republic of Korea

P.05-271-Thur | Tumor deposit indicates more worse prognosis than metastatic lymph node in gastric cancer: a propensity score matching study
J. Tan1, F. Hans1, Y. Yang1, S. Chou1
1 Sun Yat-Sun Memorial Hospital, Department of gastrointestinal surgery, Guangzhou, China

P.05-272-Thur | Implementation of diagnostic staging laparoscopy in gastric cancer treatment: A retrospective analysis in tertiary center of Eastern Europe
S. Uzeli1, V. Lipnickas1, E. Pisku1, A. Strupas1
1 Vilnius University Hospital Santaros Clinics, Centre of Abdominal Surgery, Vilnius, Lithuania

P.05-273-Thur | Feasibility of Sentinel Node Navigation Surgery after eCura in Patients with Early Gastric Cancer Treated with Endoscopic Treatment
M. Wada1, T. Ariigami1, S. Yanagita1, D. Matsushita1, T. Kijima1, M. Shimonoasono1, M. Amatsu1, K. Okubo1, Y. Uenosono1, S. Natsugoe1
1 Kagoshima University Graduate School of Medical and Dental Sciences, Department of Digestive Surgery- Breast and Thyroid Surgery, Kagoshima, Japan
2 Kagoshima University Graduate School of Medical and Dental Sciences, Department of Oncology-Surgical Oncology, Kagoshima, Japan

P.05-274-Thur | A preliminary study on White Eye Imaging Health Care System in 11 cases of gastric cancer
Y. Xu1, W. Zhang1, H. Sun1, F. Gu1, X. Liu1, D. Yue1, P. Li2, J. Li2
1 Beijing Cancer Hospital, Department of Integrated Traditional Chinese and Western Medicine, Beijing, China
2 Beijing Cancer Hospital, Department of Geriatric Oncology, Beijing, China
P.05-275-Thu | Development and validation of a staging system for gastric adenocarcinoma following neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy

J. Lin1, C. Yoon1, J. Desiderio1, P. Li1, C.H. Zheng1, A. Parisi3, C. Huang1, V.E. Strong3, S.S. Yoon1

1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
2 Memorial Sloan Kettering Cancer Center, Surgery, New York, USA
3 St. Mary's Hospital-University of Perugia, Department of Digestive Surgery, Terni, Italy

P.05-276-Thu | Feasibility and usefulness of staging laparoscopy for peritoneal recurrences of gastric cancer after gastrectomy

Y. Yukawa1, A. Takeno1, K. Kawai1, T. Sakamoto1, A. Naito1, K. Murakami1, Y. Katsura1, Y. Kagawa1, Y. Omura1, T. Masuzawa1, Y. Takeda1, K. Murata1

1 Kansai Rosai Hospital, Surgery, Amagasaki, Japan

P.05-277-Thu | ypT0 gastric carcinoma after preoperative chemotherapy and radical surgery: an orphan status according to AJCC 8th edition cancer staging system

J. Yu1, K. Zhu1, Y. Gao1, Q. Shen1, Z. Zhao1, Q. Zhang1, X. Liu1, W. Yang1, X. Shi2, C. Shou1

1 The First Affiliated Hospital- Zhejiang University School of Medicine, Department of Gastrointestinal Surgery, Hangzhou, China

---

P.06 Endoscopic treatment

P.06-278-Thu | C-reactive protein increase after gastric endoscopic submucosal dissection: Is it clinically significant?

S.H. Ko1, M.K. Bong2, S.H. Jeong2, Y. Myung2

1 Haernadae Paik Hospital- College of Medicine- Inje University, Internal Medicine, Busan, Republic of Korea
2 International St. Mary’s Hospital- Catholic Kwandong University, Gastroenterology, Incheon, Republic of Korea

P.06-279-Thu | Long-term outcome comparisons between endoscopic submucosal dissection and surgery for early gastric cancer with undifferentiated histologic types

Y.I. Kim1, M.C. Kook1, J.Y. Lee1, C.G. Kim1, B.W. Eom1, H.M. Yoon1, K.W. Ryu1, Y.W. Kim1, I.J. Choi1

1 National Cancer Center, Center for Gastric Cancer, Goyang, Republic of Korea

P.06-280-Thu | Predictive model of non-neoplastic pathology result after endoscopic resection for gastric epithelial neoplasia

T.G. Gwown1, C.H. Lim1

1 Incheon St. Mary’s Hospital- The Catholic University of Korea- College of Medicine, Internal medicine, Incheon, Republic of Korea

P.06-281-Thu | Endoscopic approach assisted by laparoscopy in the management of Gastric Non Epithelial Neoplasms: Experience in an Oncology Reference Center

F. Robles1, M.A. Herreno1, M.C. Galindo1, A.M. Leon1

1 National Institute of Oncology, Endoscopy, Mexico City, Mexico

P.06-282-Thu | Risk factors for lymph node metastasis and the feasibility of LLND after ESD for treating signet ring cell of EGC

L. Hua1, Z. Hua1, C. Shuba1, L. Dengxiang1, Z. Tongshan1, H. Qingqiang1, Z. Xiaofeng1, G. Tianhua1

1 Affiliated Xing Tai People Hospital of Hebei Medical University, Department of Surgical Oncology, Xingtai, China

P.06-283-Thu | Comparison of non-exposure simple suturing endoscopic full-thickness resection (NESS-EFTR) and LECS for gastric subepithelial tumors

C.G. Kim1, D.I. Choi1, H.M. Yoon1, B.W. Eom1, K.W. Ryu1, Y.W. Kim1, Y.I. Kim1, J.Y. Lee1, I.J. Choi1

1 National Cancer Center, Center for Gastric Cancer, Goyang, Republic of Korea

P.06-284-Thu | Endoscopic submucosal dissection in the treatment of esophageal and gastric cancer

J. Krajcova1, Z. Vackova1, M. Kollar1, J. Maluskova2, J. Spicak1, J. Martinek1

1 Institute for Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czechia
2 Institute for Clinical and Experimental Medicine, Clinical and Transplant Pathology Centre, Prague, Czechia

P.06-285-Thu | Establishment of a scoring system predicting the lymph node metastasis in undifferentiated EGC and a preliminary exploration of ESD feasibility

H. Li1, H. Zhbin1, C. Shuba1, L. Dengxiang1, Z. Tongshan1, H. Qingqiang1, Z. Xiaofeng1, G. Tianhua1

1 Affiliated Xing Tai People Hospital of Hebei Medical University, department of Surgical Oncology, Xingtai, China

---

WWW.IGCC2019-PRAGUE.ORG 87
P.06-286-Thu | Endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) treatment: ten years of experience at a single center in Chile
R. Mejía1, J. Sáez1, F. Aranda1, A. Sharp1, E. Norero1, M. Ceroni1, R. Muñoz1, C. Martínez1, C. Godoy1, A. Calvo1, P. Gonzalez1, A. Díaz1
1 Digestive Surgery, Hospital Dr. Sotero del Río - Esophagogastric Surgery Unit - Digestive Surgery Department - Division of Surgery - Faculty of Medicine - Pontificia Universidad Católica de Chile, Santiago, Chile
2 General Surgery Resident, Division of Surgery - Faculty of Medicine - Pontificia Universidad Católica de Chile, Santiago, Chile
3 Medical Intern, Faculty of Medicine - Pontificia Universidad Católica de Chile, Santiago, Chile
4 Digestive Surgery, Digestive Surgery Department - Division of Surgery - Faculty of Medicine - Pontificia Universidad Católica de Chile, Santiago, Chile
5 Endoscopy Unit, Hospital Dr. Sotero del Río - Esophagogastric Surgery Unit - Digestive Surgery Department - Division of Surgery - Faculty of Medicine - Pontificia Universidad Católica de Chile, Santiago, Chile

P.06-287-Thu | Incidence of esophago-gastric junctional adenocarcinoma
A. Takahashi1, O. Tsuneo1
1 Saku Central Hospital Advanced Care Center, Department of Endoscopy, Nagano, Japan

P.06-288-Thu | Polysomnographic assessment of respiratory disturbance during deep propofol sedation for endoscopic submucosal dissection of gastric tumors
M. Uesato1, R. Urahama1, M. Aikawa1, K. Hayano1, H. Matsuhashi2
1 Chiba University Graduate School of Medicine, Frontier Surgery, Chiba, Japan

P.09 Multidisciplinary treatment of localized gastric cancer

P.09-587-Thu | Peri-operative versus post-operative chemotherapy in gastric cancer: a propensity score matched analysis
R. Seshadri1, G. Surendra Kumar1, G. Trivadi1
1 Cancer Institute WIA, Dept. of Surgical Oncology, Chennai, India
2 Cancer Institute WIA, Dept. of Medical Oncology, Chennai, India

P.09-588-Thu | Long-term survival rates with preoperative chemoradiotherapy and gastrectomy in patients with gastric adenocarcinoma
B. Badgwell1, N. Ilioma1, P. Das1, B. Minsky1, M. Blum1, P. Mansfield1, J. Ajani1
1 MD Anderson Cancer Center, Surgical Oncology, Houston, USA
2 MD Anderson Cancer Center, Radiation Oncology, Houston, USA
3 MD Anderson Cancer Center, Medical Oncology, Houston, USA

P.09-589-Thu | Neoadjuvant Laparoscopic HIPEC plus chemotherapy followed by surgery plus intraoperative HIPEC: A more comprehensive feasible approach for advanced Gastric cancer
M.K. Beeharry1, X.F. Wang1, W.T. Liu1, X.Y. Yao1, M. Yan1, Z.G. Zhu2
1 Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, GastroIntestinal Surgery, Shanghai, China

P.09-590-Thu | Neoadjuvant chemotherapy for resectable gastric cancer
A. Boiko1, A. Lukaschenko1, O. Kolesnik2, M. Zubarev2
1 National Cancer Institute, Department of minimal invasive and endoscopic surgery - interventional radiology, Kyiv, Ukraine
2 National Cancer Institute, Abdominal surgery, Kyiv, Ukraine

P.09-591-Thu | Ideal indications of laparoscopic and endoscopic cooperative surgery (LECS) for gastric submucosal tumors from a case series in Taiwan
W. Chang1, K.H. Lin1
1 Changhua Christian Hospital, General Surgery, Changhua City - Changhua County, Taiwan

P.09-592-Thu | Nomograms for pre- and postoperative prediction of long-term survival for proximal gastric cancer patients: A large-scale, single-center retrospective study
Q.Y. Chen1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou - Fujian Province - China, China
P.09-593-Thu | The correlation between computed tomography volumetry and prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy
C. Chen1, C. Shou1, X. Shi1, Q. Zhang1, J. Yu1
1 The First Affiliated Hospital- Zhejiang University School of Medicine, Department of Gastrointestinal Surgery, Hangzhou, China

P.09-594-Thu | The influence of No.8p dissection on the prognosis of advanced gastric cancer with different total number of lymph node metastasis
Y. Zaisheng1, Z. Yi1, W. Shenghong1, W. Yi1, L. Zhitao1, C. Luchuan1
1 Fujian cancer hospital, Gastrointestinal Surgical Department, Fuzhou, China

P.09-595-Thu | Multidisciplinary treatment of malignant gastrointestinal stromal tumor: a case report and systematic review
J. Yang1, T.H.J. Chong1, J. Peng1
1 The first affiliated hospital of Anan University, Gastrointestinal Surgery Department, Guangzhou, China

P.09-596-Thu | Multidisciplinary treatment of malignant gastrointestinal stromal tumor: a case report and systematic review
J. Yang1, T.H.J. Chong1, J. Peng1
1 The first affiliated hospital of Anan University, Gastrointestinal Surgery Department, Guangzhou, China

P.09-597-Thu | Comparison of survival prognosis of pure and mixed signet ring cell carcinoma of gastric cancer
T. Fu1, Z. Bu1, J. Ji1
1 Beijing Cancer Hospital, Gastrointestinal Department, Beijing, China

P.09-598-Thu | The value and prognosis of neoadjuvant chemotherapy for undifferentiated gastric cancer
T. Fu1, Z. Bu1, J. Ji1
1 Beijing Cancer Hospital, Gastrointestinal Department, Beijing, China

P.09-599-Thu | The association of interval time with postoperative morbidity and pathological response in esophagogastric cancer receiving neoadjuvant chemoradiotherapy
C. Gao1, S. Li1, X. Ying1, F. Shani1, Y. Jiao1, K. Xue1, R. Miao1, Z. Wu1, X. Li1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital, department of gastroenterology surgery, Beijing, China

P.09-600-Thu | Prognostic factors associated with survival in a cohort of Italian gastric cancer patients resected over a decade: the Cremona experience
M. Ghidini1, B.M. Donida1, L. Totaro1, M. Ratti1, C. Pizzol1, I. Benzoni1, D. Lomiento1, F. Aldighieri1, L. Toppo1, V. Ranieri1, C. Centi1, G. Tanzi4, M. Martinotti4, R. Passalacqua1, M. Rovatti2, G. Tomassello1
1 Operative Unit of Oncology- ASST of Cremona- Hospital of Cremona- Cremona- IT, Department of Oncology, Cremona, Italy
2 Operative Unit of Oncology- ASST of Cremona- Hospital of Cremona- Cremona- IT, Department of Surgery, Cremona, Italy
3 Operative Unit of Oncology- ASST of Pavia- Hospital of Voghiera- Voghiera- IT, Department of Medicine, Voghiera, Italy
4 Operative Unit of Pathology- ASST of Cremona- Hospital of Cremona- Cremona- IT, Department of Oncology, Cremona, Italy

P.09-601-Thu | The prognostic value of FDG-PET/CT early in the course of neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction
T. Hanzlík1, M. Zemanová1, P. Fendl1, L. Horňáková1, A. Pazdro1, M. Šnajdauf1, E. Šalíková2, A. Staš1, R. Lischke1
1 Masaryk University Hospital and First Faculty of Medicine- Charles University in Prague, 3rd Department of Surgery, Prague, Czechia
2 First Faculty of Medicine- Charles University in Prague and General University Hospital, Department of Oncology, Praha, Czechia
3 Na Homolce Hospital, Department of Nuclear Medicine and PET Centre, Prague, Czechia
4 Second Faculty of Medicine- Charles University in Prague and Motol University Hospital, Department of Pathology and Molecular Medicine, Prague, Czechia

P.09-602-Thu | What about the forgotten ones? Analysis of esophageal cancer patients treated with neoadjuvant therapy who never made it to surgery
M. Thomas2, L. Deypere1, J. Moons1, W. Coosemans3,4, T. Lerat1, H. Preenen1, K. Haustermans1, H. Van Veer1, P. Nafteux1,2
1 KU Leuven – University of Leuven, Department of Oncology – Laboratory of Experimental Radiotherapy, B- 3000 Leuven, Belgium
2 UZ Leuven – University Hospitals Leuven, Department of Radiation Oncology, B- 3000 Leuven, Belgium
3 KU Leuven – University of Leuven, Department of Chroma, B-3000 Leuven, Belgium
4 UZ Leuven – University Hospitals Leuven, Department of Thoracic Surgery, B- 3000 Leuven, Belgium
5 UZA – University Hospital Antwerp, Department of Oncology, B-2650 Edegem, Belgium
P.09-603-Thu | Dose response relationship in esophageal cancer after neoadjuvant treatment: a multi-institutional analysis
M. Thomas1,2, A.S. Borggreve1,3, P.S. van Rossum1, C. Penne1, J. Moons1, E. Van Daele1, R. van Hillelsgersberg1, W. Deng1, P. Pattyn1, S. Mook1, T. Boterberg1, J.P. Ruanda2, P. Nafteux3, S.H. Lint1, K. Haustermans1,2
1 KU Leuven – University of Leuven, Department of Oncology – Laboratory of Experimental Radiotherapy, B-3000 Leuven, Belgium
2 UZ Leuven – University Hospitals Leuven, Department of Radiation Oncology, B-3000 Leuven, Belgium
3 University Medical Center Utrecht, Department of Radiation Oncology, 3584CX Utrecht, Netherlands
4 University Medical Center Utrecht, Department of Radiation Oncology, 3584CX Utrecht, Netherlands
5 Royal Military Academy, Department of Applied Mathematics, B-1000 Brussels, Belgium
6 UZ Leuven – University Hospitals Leuven, Department of Thoracic Surgery, B-3000 Leuven, Belgium
7 UZ Gent – Ghent University Hospital, Department of Pediatric and Gastrointestinal Surgery, B-9000 Ghent, Belgium
8 The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston – Texas, USA
9 UZ Gent – Ghent University Hospital, Department of Radiation Oncology, B-9000 Ghent, Belgium

P.09-604-Thu | Prognostic impact of perioperative treatment for the patient with postoperative complications after radical gastrectomy for gastric cancer
M. Hayami1, S. Kamiya1, F. Klevenbro1,2, M. Nilsson1,2, M. Lindblad1,2, A. Tsekrekos1,2, I. Rouvelas1,2
1 Karolinska University Hospital, Department of Upper Abdominal Surgery- Centre for Digestive Diseases, Stockholm, Sweden
2 Karolinska Instituted, Division of Surgery- Department of Clinical Science- Intervention and Technology CLINTEC, Stockholm, Sweden

P.09-605-Thu | FLOT in the preoperative treatment of resectable advanced gastric cancer in combination with D2 gastrectomy
S. Zhang1, D. Yan1, T. Du1, Y. Jiang1, C. Song1
1 Shanghai East Hospital East Hospital Affiliated to Tongji University, Department of Gastroenterology Surgery, Shanghai, China

P.09-606-Thu | Neoadjuvant chemotherapy and paraaortic lymphnode dissection for gastric cancer with bulky N2/N3
Y. Kawashima1, T. Yamada1, K. Ehara1, H. Hara1, H. Sakamoto1
1 Saitama Cancer Center, Gastroenterological Surgery, Ina-Machi- Kita-Adachi gun, Japan
2 Saitama Cancer Center, Gastrointestinal Medicine, Ina-Machi- Kita-Adachi gun, Japan

P.09-607-Thu | Efficacy of adjuvant S-1 versus XELOX chemotherapy for patients with gastric cancer after D2 lymph node dissection
J.H. Kim1, H.D. Chae1
1 Daegu Catholic University School of Medicine, Department of Surgery, Daegu, Republic of Korea

P.09-608-Thu | Pathological and Surgical outcomes after neoadjuvant chemotherapy in resected gastric cancer patients: a case-control study
A.Z. Charruf1, M. Ramos1, M. Pereira1, A.R. Dias1, R. Oliveira1, L. Cardili1, E.S. Mello1, O. Yaggy1, B. Zilberstein1, I. Ceccinello1, R. Ulysses1
1 University of Sao Paulo, Clinics Hospital/Cancer Institute, Sao Paulo, Brazil

P.09-609-Thu | Twenty years of gastric cancer surgery in Cologne - pre- and post-MAGIC era
M. Koremekci1, A.H. Hoelscher1, S.P. Moening1, E. Bollschweiler1, A. Quass1,2, T. Zander1,2, S.H. Chon1, Y. Zhao1, P.S. Plum1, C. Bruns1, H. Alakus1,2
1 University of Cologne, Department of General- Visceral and Cancer Surgery, Cologne, Germany
2 University of Cologne, Gastrointestinal Cancer Group Cologne GCGC, Cologne, Germany
3 University of Cologne, Gastrointestinal Cancer Group Cologne GCGC, Cologne, Germany
4 University of Cologne, Department I of Internal Medicine, Cologne, Germany

P.09-610-Thu | Outcomes of neoadjuvant 5-FU and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
T. Kosaka1, H. Akiyama1, H. Miyamoto2, S. Sato2, Y. Tanaka1, K. Sato2, C. Kunisaki1, I. Endo1
1 Yokohama-city university, Gastroenterological Surgery, Yokohama, Japan
2 Yokohama-city university, Department of Surgery- Gastroenterological Center, Yokohama, Japan

P.09-611-Thu | What are the prognostic factor in T2N0 gastric cancer?
S. Lee1, J.H. Song1, S. Choi1, C. Minah1, C. Yoon Young1, S. Taell1, K. Hyung-Wil1, C. Jae-Ho1, N. Sung Hoon1, H. Woo Jin1
1 Yonsei University College of Medicine, Surgery, Seoul, Republic of Korea
P.09-612-Thu | The survival and recurrence of gastric adenocarcinoma patients following radical gastrectomy after neoadjuvant chemotherapy or chemoradiation
J. Lin¹, C. Yoon², P. Li¹, C. Zheng¹, C. Huang¹, V.E. Strong², S.S. Yoon¹
¹ Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
² Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, USA

P.09-613-Thu | The impact of neoadjuvant therapy on survival for Lauren diffuse gastric adenocarcinoma patients following by radical gastrectomy
J. Lin¹, C. Yoon², P. Li¹, C. Zheng¹, V.E. Strong², C. Huang¹, S.S. Yoon¹
¹ Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
² Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, USA

P.09-614-Thu | Clinicopathological Features and Impact of Adjuvant Chemotherapy on Long-term Survival of Patients with Multiple Gastric Cancers: Propensity Score Matching Analysis
J.K. Lin¹, Z.K. Wang¹, J.W. Xie², P. Li¹, C.H. Zheng¹, C. Huang¹
¹ Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
² Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, USA

P.09-615-Thu | Preoperative chemoradiation improves median overall survival in stage III gastric adenocarcinoma compared with perioperative chemotherapy
J. Lin¹, M. Shi¹, G. Chen¹, Y. Huang¹, Y. Zhang¹, D. Shi¹, K. Chen¹, Q. Guo¹, D. Wu¹, J. Chen¹
¹ The Second Affiliated hospital of Zhejiang University School of Medicine, Department of General Surgery, Hangzhou, China

P.09-616-Thu | Comparison of preoperative chemotherapy and preoperative radiochemotherapy in patients with locally advanced gastric cancer
X. Liu², Z. Long¹, H. Cai¹, G. Li², H. Huang¹, Y. Wang¹
¹ Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China
² Fujian Medical University Union Hospital, Department of Radiotherapy, Fuzhou, China

P.09-617-Thu | Efficacy and safety of perioperative chemotherapy in patients with advanced gastric cancer: a multicenter randomized clinical trial
Q. Zhao¹, C. Liang¹, Z. Huo¹, M. Li¹, Y. Liu¹, H. Guo¹, Y. Tian¹, P. Yang¹, L. Fan¹, B. Tan¹, Z. Zhang¹, D. Wang¹, X. Zhai¹, Y. Liu¹, Y. Li¹
¹ Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, General surgery three wards, Shijiazhuang, China
² Changzh Medical College Affiliated Peace Hospital, Surgical Oncology, Changzhi- Shanxi, China
³ Xingtai People's Hospital, Gastrointestinal tumor surgery, Xingtai, China
⁴ The first hospital of Shijiazhuang, General surgery, Shijiazhuang, China

P.09-618-Thu | TOPGEAR: A phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer: Comparison of FLOT versus ECX/F
M. Michael¹, F. Lordick², B.M. Smithers¹, J. Zalckberg¹, J. Simes³, M. Fidjela³, V. Gebaké³, R. O'Connell¹, D. Miller¹, C. Aiken¹, S. York³, R. Wong⁵, K. Haustermans⁶, C. Swallow³, G. Darling¹, A. Strickland¹, M. Lee¹, J. Ringash⁵, M. Thomas³, T. Leong¹
¹ Peter MacCallum Cancer Centre, Medical Oncology, Melbourne, Australia
² University Cancer Centre – Leipzig, Medical Oncology, Leipzig, Germany
³ University of Queensland / Princess Alexandra Hospital, Surgery, Brisbane, Australia
⁴ Monash University, Public Health and Preventative Medicine, Melbourne, Australia
⁵ University of Sydney, NHMRC Clinical Trials Centre, Sydney, Australia
⁶ University of Auckland, Medical Oncology, Auckland, New Zealand
⁷ Princess Margaret Cancer Centre, Radiation Oncology, Toronto, Canada
⁸ U.Z. Leuven – Leuven Cancer Institute, Radiation Oncology, Leuven, Belgium
⁹ Princess Margaret Cancer Centre / Mt Sinai Hospital, Radiation Oncology, Toronto, Canada
¹⁰ University of Toronto / Toronto General Hospital, Surgery, Toronto, Canada
¹¹ Monash Health, Medical Oncology, Melbourne, Australia
¹² Liverpool Hospital, Radiation Oncology, Sydney, Australia
¹³ Princess Margaret Cancer Centre / University of Toronto, Radiation Oncology, Toronto, Canada
P.09-619-Thu  | Cancer cells disseminated during gastric cancer surgery are associated with recurrence and can be effectively treated with hyperthermic intraperitoneal chemotherapy
S. Murata1,2, K. Takebayashi1, Y. Yamaguchi1, S. Kaida1, H. Kodama1, M. Shimoji1, A.M. Sihombing1, H. Iida1, T. Shimizu1, E. Mekata1, Y. Daigo1, M. Tani1
1 Shiga University of Medical Science, Department of Surgery, Otsu, Japan
2 Shiga University of Medical Science Hospital, Cancer Center, Otsu, Japan

P.09-620-Thu  | Paraaortic lymph node (No.16LN) dissection as multidisciplinary treatment for advanced gastric cancer with No.16LN metastasis
N. Nakagawa1, T. Mizutani1, Y. Fujita1, K. Soga1, M. Nishio1, T. Kahi1, J. Fujiyama1, A. Oguro1, T. Yamane1, M. Yasukawa2
1 JCHO Kobe Central Hospital, Surgery, Kobe, Japan
2 Shiga University of Medical Science, Department of Comprehensive Surgery, Otsu, Japan

P.09-621-Thu  | Neoadjuvant chemoradiotherapy for advanced gastric cancer with bulky lymph node metastasis shows promise
E. Nomura1, M. Takashi2, Y. Yamasaki1, K. Haji1, Y. Sato2
1 Tokai University Hachiouji Hospital, Gastroenterological and General Surgery, Hachiouji, Japan
2 Shiga University of Medical Science, Department of Surgery Upper G.I. Division, Otsu, Japan

P.09-622-Thu  | The eCura system as a novel indicator for the necessity of salvage surgery after non-curative ESD for gastric cancer
R. Ozawa1, H. Niiwai1, O. Koichi1, K. Tsutsumi1, N. Yasutaka2, K. Yasunori1, J. Yoshinori1, S. Hisashi1
1 Hyogo College of Medicine, Department of Surgery of University of Japan, Nishinomiya, Japan
2 The Catholic University of America, Obstetric and Gynecological Surgery, Nishinomiya, Japan

P.09-623-Thu  | The effect of metformin on prognosis in patients with locally advanced gastric cancer associated with type 2 diabetes mellitus
H.S. Seo1, Y.J. Jung1, H.H. Kim1, H.H. Lee1, C.H. Park1
1 The Catholic University of Korea, Gastrointestinal Surgery, 222- Banpodae-Ro- Seocho-Gu, Republic of Korea

P.09-624-Thu  | Which are the implementation rates and prognostic implications of perioperative chemotherapy in locally advanced gastric cancer? A population-based analysis
J. Osorio1, M. Miro2, S. Castro3, M. Puigadas1, E. Garrosa1, M. Santamaria1, A. Luna1, A. Aldeano1, M. Pere1, J. Molinas3, J. Feliu1, J.J. Sanchez-Cano1, D. Salazar1, J. Rodriguez-Santiago1
1 Hospital Universitari Mutua Terrassa, Oesophagogastric Surgery, Terrassa, Spain
2 Hospital de Bellvitge, Oesophagogastric Surgery, L’Hospitalet de Llobregat, Spain
3 Hospital General de Girona, Oesophagogastric Surgery, Girona, Spain

P.09-625-Thu  | Selecting the optimal multimodality treatment for gastric cancer patients using decision analysis models
W.L. Da Costa Junior1, V.H.F. de Jesus1, H.S. Ribeiro1, A.L. Diniz1, A.L. de Godoy1, J.C. Farias1, T. Felisminho1, O.A.P. Castro1, R. Riechmann1, F.J.F. Coimbra1
1 A.C. Camargo Cancer Center, Abdominal Surgery, Sao Paulo, Brazil
2 A.C. Camargo Cancer Center, Clinical Oncology, Sao Paulo, Brazil
3 Santa Casa Medical School, Surgery, Sao Paulo, Brazil

P.09-626-Thu  | Short term outcomes of laparoscopic near-total (95 %) gastrectomy for gastric cancer
D. Ramos1, R. Aranzaz1, A. Puerta1, J. Barquin1, A. Centeno1, M. Cuadrado1, S. Sanchez1, L. Bilbao1, P. Priege1, J. Galindo1
1 Ramon y Cajal University Hospital, General and Gastrointestinal Surgery, Madrid, Spain

P.09-627-Thu  | Resting energy expenditure (REE) and body composition in gastric cancer patients: validation of a novel predictive equation
U. Ribeiro-Junior1, M.T. Pires de Souza1, G.A. Ozorio2, M.M.F. Alves de Almeida1, D.L. Wachtberg1
1 Sao Paulo State Cancer Institute- University of Sao Paulo School of Medicine - IESP-HCFMUSP, Gastroenterology, Sao Paulo, Brazil
2 Instituto do Cancer do Estado de Sao Paulo, Nutrition, Sao Paulo, Brazil
3 Faculdade de Medicina da Universidade de Sao Paulo, Gastroenterology, Sao Paulo, Brazil
P.09-628-Thu | A comparison of epirubicin/cisplatin/capecitabine and epirubicin/oxaliplatin/capecitabine in the CRITICS gastric cancer trial
A. Slagter1, P. Lind1, E. Meershoek-Klein Kranenbarg1, K. Sikorska2, J.W. van Sandick2, C. van de Velde2, N. van Grieken3, J. Braak3, C. Grootscholten3, M. Nordsmark4, H. van Laarhoven5, H. Putter6, E. Jansen7, M. Verheij8, A. Cats9
1 Netherlands Cancer Institute/Antoni van Leeuwenhoek, Radiation Oncology, Amsterdam, Netherlands
2 Karolinska Institutet, Oncology, Huddinge, Sweden
3 Leiden University Medical Center, Surgery, Leiden, Netherlands
4 Netherlands Cancer Institute/Antoni van Leeuwenhoek, Statistics, Amsterdam, Netherlands
5 Netherlands Cancer Institute/Antoni van Leeuwenhoek, Surgery, Amsterdam, Netherlands
6 VU University Medical Center, Pathology, Amsterdam, Netherlands
7 Netherlands Cancer Institute/Antoni van Leeuwenhoek, Medical Oncology, Amsterdam, Netherlands
8 Aarhus University Hospital, Oncology, Aarhus, Denmark
9 Academic Medical Center Amsterdam, Medical Oncology, Amsterdam, Netherlands
10 Leiden University Medical Center, Statistics, Leiden, Netherlands
11 Radboud University Medical Center, Radiation Oncology, Nijmegen, Netherlands
12 Netherlands Cancer Institute/Antoni van Leeuwenhoek, Gastrointestinal Oncology, Amsterdam, Netherlands

P.09-629-Thu | XELOX chemotherapy compliance after gastrectomy in elderly gastric cancer patients
G.J. Song1, Y.K. Kim1, H.S. Shin1, M.W. Son1, M.S. Lee1
1 Soonchunhyang University Cheonan Hospital, Department of Surgery, Cheonan, Republic of Korea

P.09-630-Thu | Neoadjuvant chemotherapy for advanced gastric cancer
H. Sugita1, S. Sakuramoto1, S. Ito1, M. Kasaya1, S. Ishii1, K. Watanabe1, N. Fujiiwara1, Y. Miyawaki1, H. Sato1, K. Okamoto1, S. Yamaguchi1, I. Koyama1
1 Saitama Medical University International Medical Center, Gastroenterological Surgery, Hidaka, Japan

P.09-631-Thu | Short-term efficacy and safety of the neoadjuvant chemotherapy with S-1 and oxaliplatin in locally advanced gastric cancer
T. Suzuki1, T. Hiroyama1, I. Ryuta1, I. Hirotaka1
1 department of Surgery, National Hospital Organization- Kure Medical Center- Chu-goku Cancer Center, Kure City- Hiroshima Pref., Japan

P.09-632-Thu | The safety of using shared decision making in determination of neoadjuvant chemotherapy cycles for gastric cancer-preliminary results of trial NCT03413514
Y Wang1, L. Tang2, F. Shan3, Q. Xiao4, J. Xing5, L. Zhang1, S. Li1, Y. Jia1, X. Ying1, K. Xue1, R. Miao1, Z. Li1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital, Gastrointestinal cancer center, Beijing, China
2 Peking University Cancer Hospital, Radiology Department, Beijing, China

P.09-633-Thu | Perioperative chemotherapy versus adjuvant chemotherapy for resectable gastric cancer: Comparison of toxicity in a prospective cohort study
Y. Wang1, F. Pang1, F. Shan1, X. Ying1, L. Zhang1, S. Li1, Y. Jia1, R. Miao1, K. Xue1, Z. Li1, X. Lei1, Q. Xiao1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital, gastrointestinal cancer center, Beijing, China

P.09-634-Thu | Preliminary study of clinical efficacy of neoadjuvant interventional chemotherapy for locally advanced gastric cancer
Z. Xu1, D. Zhang1
1 First affiliated hospital of Nanjing medical university, general surgery, Nanjing, China

P.09-635-Thu | Phase II trial of neoadjuvant chemotherapy using Apatinib plus SOX regimen for locally advanced gastric cancer: updated results
Y. Zheng1, X. Yang1, C. Li1, M. Yan1, Z. Zhu1
1 Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Department of Gastrointestinal Surgery, Shanghai, China

P.09-636-Thu | Adjuvant chemoradiotherapy versus chemotherapy for patients with pN3 gastric cancer after R0 resection: a study based on propensity score analysis
M.L. Zhou1, Y.Q. Wang1, W. Yang1, L.P. Liang1, M. Mo1, R. Hu1, Y. Wang1, J.K. Yang1, G.C. Li1, Z. Lang2, X.W. Liu2, Y.N. Wang2, Z. Zhang1
1 Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Shanghai, China
2 Fudan University Shanghai Cancer Center, Department of Cancer Prevention, Shanghai, China
3 Fudan University Shanghai Cancer Center, Department of Gastro Surgery, Shanghai, China
P.10 Management of stage IV gastric cancer

P.10-637-Thu | Comparison of PIPAC and intravenous chemotherapy with intravenous chemotherapy only in patients with synchronous peritoneal metastases of gastric cancer
A. Brandl1, M. Alberto2, A. Arnold2, M. Schomaker3, M. Jara1, M. Biebl1, J. Pratschke1, P. Thuss-Patience4, B. Rau1
1 Charité - Universitätsmedizin Berlin, Department of Surgery, Berlin, Germany
2 Charité - Universitätsmedizin Berlin, Department of Pathology, Berlin, Germany
3 Charité - Universitätsmedizin Berlin, Medical Clinic for Hematology-Oncology and Tumor-Immunology, Berlin, Germany

P.10-638-Thu | Efficacy of Apatinib dose increase and combination with Irinotecan in patient-derived gastric cancer xenografts after Apatinib resistance
X. Chen1, Y. Chen1, Y. Zhang1, Y. Xie1
1 First Affiliated Hospital- School of Medicine- Zhejiang University, Department of Surgical Oncology-, Hangzhou, China

P.10-640-Thu | Chemotherapy alone (Docetaxel, Oxaliplatin and S-1, DOS regimen) versus chemotherapy followed by radical resection in stomach adenocarcinoma with single non-curable factor
Y. Cui1, S. Zheng1, Y. Du1, Y. Lu1, X. Wang1, Z. Shen1, F. Liu1, Y. Yu1, Y. Wang1, J. Xiang1, L. Zhao1, X. Wang1, Y. Zhao1, Z. Zheng1, Y. Sun1, T. Liu1
1 Zhongshan Hospital, medical oncology department, Shanghai, China
2 Hangzhou first people’s hospital, medical oncology department, Hangzhou, China
3 Zhejiang Cancer hospital, medical oncology department, Hangzhou, China
4 Peking Union Medical college hospital, medical oncology department, Beijing, China
5 Shanxi Provincial people’s hospital, surgical department, Xi’an, China
6 Liaoning Cancer hospital, surgical department, Shenyang, China

P.10-641-Thu | Nab-Paclitaxel as first-line Chemotherapy for unresectable or recurrent gastric cancer
M. Gou1, H. Si1, Y. Zhang1, G. Dai1
1 Chinese general PLA hospital, oncology, Beijing, China

P.10-642-Thu | Impact of body weight loss on survival in patients with advanced gastric cancer receiving second-line treatment
A. Du1, T. Mizukami1, K. Hamaj1, R. Onuki1, A. Yokomizo1, Y. Nagashima1, H. Arat1, M. Hirakawa1, Y. Horie1, N. Iwai1, T. Ogura1, T. Tsuda1, Y. Tanaka1, S. Mikami1, T. Tanaka1, M. Shibata1, T.E. Nakajima1
1 St. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan
2 St. Marianna University School of Medicine Hospital, Department of Pharmacy, Kawasaki, Japan
3 St. Marianna University School of Medicine Hospital, Department of Nutrition, Kawasaki, Japan
4 St. Marianna University School of Medicine, Division of Gastroenterological and General Surgery, Kawasaki, Japan

P.10-643-Thu | Comparison of survival outcomes according to the addition of Trastuzumab in patients who received systemic chemotherapy for metastatic gastric cancer
G.Y. He1, Y.J. Kim1, J. Kim1, H.L. Lee1, H.J. Kang1, S.H. Yang1, H.J. Yu1, J.J. Lee1, S.H. Jin1
1 Korea Cancer Center Hospital- Korea Institute of Radiological and Medical Sciences, Surgery, Seoul, Republic of Korea
2 Korea Cancer Center Hospital- Korea Institute of Radiological and Medical Sciences, Gastroenterology, Seoul, Republic of Korea
3 Korea Cancer Center Hospital- Korea Institute of Radiological and Medical Sciences, Hemato-Oncology, Seoul, Republic of Korea

P.10-644-Thu | The abdominal wall recurrence 4-years after laparoscopic gastrectomy for early gastric cancer. -A case report-
K. Hakoda1, N. Fujikuni1, R. Hirotota1, T. Bekki1, F. Hirata1, T. Yaho1, H. Okuda1, T. Abe1, T. Sasada1, M. Yamaki1, H. Amano1, M. Nakahara1, T. Noriyuki1
1 Onomichi general hospital, surgery, Onomichi city, Japan
P.10-645-Thu | The role of liver-directed therapy for liver metastasis of gastric cancer
I. Hamano1, S. Ikuta1, T. Aihara1, H. Yanagi1, Y. Naoki1
1 Meiwa Hospital, Department of Surgery, Hyogo Nishinomiya, Japan

P.10-646-Thu | Prognostic factors in advanced gastric cancer with peritoneal dissemination (P1cy0/1) and intraperitoneal free cancer cells (P0cy1)
H. Hanayama1, S. Ohki1, T. Sato1, D. Ujiié1, A. Nirei1, T. Kikuchi1, T. Tada1, Y. Watanabe1, K. Gonda1, T. Momma1, Z. Saze1, K. Kono1
1 Fukushima Medical University, Gastrointestinal Tract Surgery, Fukushima city, Japan

P.10-647-Thu | Multidisciplinary therapeutic strategy for advanced gastric cancer with peritoneal dissemination
S. Hisamori1, K. Obama1, S. Tsumoda1, T. Nishigori1, Y. Sakai1
1 Kyoto University, Department of Surgery, Kyoto, Japan

P.10-648-Thu | Clinical implication of periodic staging laparoscopy for assessment of chemotherapeutic effects on gastric cancer with CT-negative peritoneal dissemination
S. Hori1,2, M. Honda1,2, H. Kobayashi1,2, H. Kawamura1,2, Y. Nakayama1,2, A. Kaneta1, Y. Todate1,2, M. Waragai1, Y. Takano1
1 Southern Tohoku Research Institute for Neuroscience - Southern TENAGI General Hospital, Surgery, Miyagi, Japan
2 Fukushima Medical University, Minimally Invasive Surgical and Medical Oncology, Fukushima - Fukushima prefecture, Japan

P.10-649-Thu | HIPEC in the treatment of gastric cancer – first experience
D. Hoskovec1, P. Dytrych1, M. Vocka2, Z. Kriska1, L. Petruzela1, P. Klobusicky1, E. Konecna1
1 General University Hospital, 1st Department of Surgery, Prague, Czechia
2 General University Hospital, Deparment of Oncology, Prague, Czechia
3 Charles University, 1st Medical Faculty, Prague, Czechia

P.10-650-Thu | Cell-free and concentrated ascites reinfusion therapy for management of massive malignant ascites in gastric cancer may have survival benefit
T. Ichimura1, K. Chiri1, D. Takahara1, M. Ogura1, E. Shinozaki1, M. Suenaga1, A. Ooki1, T. Wakatsuki1, I. Nakayama1, H. Osumi1, Y. Ota1, T. Suzuki1, K. Yamaguchi1
1 Cancer Institute hospital of JFCR, Gastroenterological Chemotherapy Department, Tokyo, Japan

P.10-651-Thu | Conversion therapy for stage IV gastric cancer
T. Imai1, K. Yamaguchi1, A. Goto1, J. Yasuhuku1, T. Tanahashi1, S. Matsu1, H. Ima1, Y. Tanaka1, N. Matsuhashi1, T. Takahashi1, M. Futamura1, K. Yoshida1
1 Gifu University Graduate School of Medicine, Department of Surgical Oncology, Gifu, Japan

P.10-652-Thu | Long-term normothermic intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis: Results from clinical trials in Japan
H. Ishigami1, T. Omori1, Y. Kodera1, H. Yahasaki1, R. Fukushima1, M. Imano1, S. Kadowaki1, H. Niwa1, A. Hidemura1, T. Arigami1, Y. Hirono1, K. Amagai1, Y. Tsuba1, M. Ota1, T. Kusumoto1, K. Kishi1, Y. Fushida1, S. Ueda1, H. Yamaguchi1, J. Kitayama1
1 The University of Tokyo, Department of Chemotherapy, Tokyo, Japan
2 Osaka International Cancer Institute, Department of Gastroenterological Surgery, Osaka, Japan
3 Nagoya University, Department of Gastroenterological Surgery, Nagoya, Japan
4 Niigata Cancer Center Hospital, Department of Gastroenterological Surgery, Niigata, Japan
5 Teikyo University, Department of Surgery, Tokyo, Japan
6 Kinki University, Department of Surgery, Osaka-Sayama, Japan
7 Aichi Cancer Center Hospital, Department of Clinical Oncology, Nagoya, Japan
8 Hyogo College of Medicine, Division of Gastroenterology - Department of Internal Medicine, Nishinomiya, Japan
9 Kanto Rosai Hospital, Department of Surgery, Kawasaki, Japan
10 Kagoshima University, Department of Obstetric-Biologic Surgery, Kagoshima, Japan
11 University of Fukui, Department of Gastroenterological Surgery, Fukui, Japan
12 Ibaraki Prefectural Central Hospital, Department of Gastroenterology, Kasama, Japan
13 Tanabe Hospital, Department of Medical Oncology, Sapporo, Japan
14 National Kyushu Cancer Center, Department of Gastroenterological Surgery, Fukuoka, Japan
15 National Kyushu Medical Center, Department of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, Fukuoka, Japan
16 Osaka Police Hospital, Department of Surgery, Osaka, Japan
17 Kagawa University, Department of Gastroenterological Surgery, Kagawa, Japan
18 Kitano Hospital - Tazuke Kofuki Medical Research Institute, Department of Gastroenterological Surgery and Oncology, Osaka, Japan
19 Sichi Medical University, Department of Clinical Oncology, Shimotsuke, Japan
20 Sichi Medical University, Support Center for Clinical Investigation, Shimotsuke, Japan
P.10-653-Thu | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as treatment options for peritoneal metastasis of advanced gastric cancer

D.W. Kim1, Y.S. Jee2

1 Dankook University Hospital, Surgery, Cheonan, Republic of Korea
2 Dankook University Hospital, Surgery, Cheonan, Republic of Korea

P.10-654-Thu | Multicenter phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX)

S. Kadowaki1, K. Chi1, H. Shoji1, K. Minashi1, T. Nishida1, T.E. Nakajima3, K. Amagari1, N. Machida4, M. Goto4, K. Taku5, N. Ishizuka1, D. Takahari1

1 Aichi cancer center hospital, Clinical oncology, Nagoya, Japan
2 The cancer institute hospital of JFCR, Gastroenterology, Tokyo, Japan
3 National cancer center hospital, Gastrointenstinal medical oncology, Tokyo, Japan
4 Chiba cancer center, Clinical trial promotion, Chiba, Japan
5 Shikuken cancer center, Gastroenterology, Matsuyama, Japan
6 St Marianna university school of medicine, Clinical oncology, Kawasaki, Japan
7 Ibaraki prefectural central hospital, Gastroenterology, Kama, Japan
8 Shizukau cancer center, Gastrointestinal oncology, Shizuoka, Japan
9 Osaka medical college, Cancer chemotherapy center, Takatsuki, Japan
10 Shizuka general hospital, Medical oncology, Shizuoka, Japan
11 The cancer institute hospital of JFCR, Clinical trial planning and management, Tokyo, Japan

P.10-655-Thu | Surgical and oncological outcomes of conversion surgery for Stage IV gastric cancer patients

A. Kameyama1, A. Kaito1, M. Tokunaga1, Y. Tanaka1, A. Tonouchi1, R. Sato1, E. Akimoto1, T. Ono1, H. Daika1, T. Fujita1, H. Fujivara1, T. Kinoshita1

1 National Cancer Center Hospital East, Gastric Surgery Division, Kashiwa, Japan
2 National Cancer Center Hospital East, Esophageal Surgery Division, Kashiwa, Japan

P.10-656-Thu | Combination versus single-agent as palliative chemotherapy for gastric cancer: significance of age and platelet-to-lymphocyte ratio

S.Y. Kang1, H.Y. Kim2

1 Ajou University School of Medicine, Hematology-Oncology, Suwon, Republic of Korea
2 Hallym University College of Medicine, Hematology-Oncology, Anyang, Republic of Korea

P.10-657-Thu | Pressurized intraperitoneal aerosol chemotherapy (PIPAC) combining with standard systemic chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC)

V. Khomiakov1, A. Ryabov1, L. Bolotina2, A. Utkina2, D. Sobolev1, A. Chayka1, O. Kuznetsova1

1 P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Center of Radiology- Moscow- Russia, Thoracoabdominal Surgery Department, Moscow, Russian Federation
2 P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Center of Radiology- Moscow- Russia, Department of Chemotherapy, Moscow, Russian Federation
3 P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Center of Radiology- Moscow- Russia, Department of Pathology, Moscow, Russian Federation

P.10-658-Thu | Neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and intraperitoneal / systemic chemotherapy in advanced gastric cancer with severe peritoneal metastasis

D.W. Kim1, Y.S. Jee2

1 Dankook University Hospital, Surgery, Cheonan, Republic of Korea

P.10-659-Thu | Phase 1 study of pressurized intraperitoneal aerosol chemotherapy oxaliplatin for peritoneal metastasis

G. Kim1, H.L. Tan1, L. Wang1, K.M. Chue1, C.H. Tai1, S.C. Teo1, C.J.M. Jang1, A. Shabbir1, W.P. Yong1, J. So1

1 National University Health System, Division of General Surgery- University Surgical Cluster, Singapore, Singapore
2 National University Health System, National University Cancer Institute- Singapore, Singapore, Singapore
3 National University of Singapore, Cancer Science Institute, Singapore, Singapore
4 National University of Singapore, Department of Surgery, Singapore, Singapore

P.10-660-Thu | Comparison of the nephrotoxicity with SOX versus SP with short hydration in outpatient setting for gastric cancer patients

K. Kishi1, T. Sato1, M. Mikamori1, M. Ohtsuka1, K. Furukawa1, Y. Suzuki1, M. Tanemura1, H. Akamatsu1

1 Osaka Police Hospital, Surgery, Osaka, Japan
P.10-661-Thu | Multidisciplinary treatment combining gastrectomy after intraperitoneal plus systemic chemotherapy for gastric cancer patients with peritoneal metastasis or positive peritoneal cytology


1 Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery, Nagoya, Japan
2 The University of Tokyo, Department of Chemotherapy, Tokyo, Japan
3 Niigata Cancer Center Hospital, Department of Gastroenterological Surgery, Niigata, Japan
4 Osaka International Cancer Institute, Department of Gastroenterological Surgery, Osaka, Japan
5 Tokyo University, Department of Surgery, Tokyo, Japan
6 Kindai University, Department of Surgical Oncology, Osaka, Japan
7 Kagoshima University, Department of Oncology, Kagoshima, Japan
8 Hyogo College of Medicine, Division of Gastroenterology, Interior Medicine, Nishinomiya, Japan
9 Osaka Police Hospital, Department of Surgery, Osaka, Japan
10 Aichi Medical University, Department of Gastroenterological Surgery, Nagakute, Japan
11 Aichi Cancer Center Hospital, Department of Gastroenterological Surgery, Nagoya, Japan
12 University of Fukui, Department of Gastroenterological Surgery, Fukui, Japan
13 Tokyo Metropolitan Tama Medical Center, Department of Surgery, Fuchu, Japan
14 Tanan Hospital, Department of Medical Oncology, Sapporo, Japan
15 Kansai Rosai Hospital, Department of Surgery, Amagasaki, Japan
16 National Hospital Organization Kyoto Medical Center, Department of Surgery, Kyoto, Japan
17 Toho University, Department of Surgery, Tokyo, Japan
18 Jichi Medical University, Department of Clinical Oncology, Shimotsuma, Japan
19 Jichi Medical University, Support Center for Clinical Investigation, Shimotsuma, Japan

P.10-662-Thu | Long term survival of metastasising gastric cancer under maintenance capecitabine – possible role of thymidine phosphorylase (TP) expressing cells

B. Koch1, L. Uflacker1, A. Tannapfel2

1 St. Vincenz-Hospital, Internal Medicine, Datteln, Germany
2 Ruhr-University Bochum, Institute for Pathology, Bochum, Germany

P.10-663-Thu | Can curative gastrectomy be justified for gastric cancer with only cytology positive Stage IV factor?

S. Komatsu1, S. Nasuhiro1, F. Hirotaka1, O. Atsuki1, T. Sachi2, K. Tatsuya3, I. Ken-ichiro4, S. Katsumi5, I. Juni5, T. Fumihiro5, O. Eigo6

1 Kyoto First Red Cross Hospital, Department of Surgery, Kyoto, Japan
2 Kyoto Prefectural University of Medicine, Division of Digestive Surgery, Department of Surgery, Kyoto, Japan

P.10-664-Thu | ‘Real world practices of sequential palliative chemotherapy in Taiwan: single institute experience’

Y. Kuo1

1 Chang-Gung Medical Foundation- Linkou Branch- No5- Fu-Shin Street- Guei-shan Distric- Taoyuan City- TAIWAN-R.O.C., Department of Oncology, Taoyuan, Taiwan

P.10-665-Thu | Challenging the odds

M. Laureano1, J. Nobre2, J. Gonçalves2, N. Ventura2, T. Valente1, S. Hildário1, J. Pais1, M. Coelho dos Santos1

1 Centro Hospitalar de Leiria, General Surgery, Leiria, Portugal

P.10-666-Thu | The effectiveness of gastrectomy with chemoradiotherapy among stage IV gastric adenocarcinoma: a population-based analysis

J. Ma1, Z. Li1, L. Zang1

1 Ruijin Hospital Shanghai Jiao tong University School of Medicine, Department of Surgery, Shanghai, China
2 Ruijin Hospital Shanghai Jiao tong University School of Medicine, Shanghai Minimally Invasive Surgery Center, Shanghai, China

P.10-667-Thu | Tailored approach to peritoneal metastasis in gastric cancer patients: who can benefit from intensive surgical treatment

E. Marinelli1, F. Roviello1, L. Graziosi1, D. Marrelli1, S. Ministri1, M. Benvenuto1, L. Solaini1, S. Sofi1, B. Molteni1, M.S. Alfano1, C. Cipollari1, K. Polom1, M. Degiuli1, P. Mongiari1, G. Mura1, G.A.M. Tiberio1, G. De Marchi1, R. D’Ignazio1

1 University of Perugia, General and Emergency Surgery, Perugia, Italy
2 University of Siena, General Surgery, Siena, Italy
3 University of Brescia, General Surgery, Brescia, Italy
4 University of Verona, General Surgery, Verona, Italy
5 Hospital of Forlì, General Surgery, Forlì, Italy
6 University of Torino, General Surgery, Torino, Italy
7 Hospital of Arezzo, General Surgery, Arezzo, Italy

WWW.IGCC2019-PRAGUE.ORG
**P.10-668-Thu**  | HER2 reassessment in primary tumor and metastatic LN in advanced Gastric Cancer with initially HER2-positive tumor treated by trastuzumab-containing chemotherapy

J. Matsuyama1, S. Tamura1, R. Kato1, T. Sakai1, G. Sato1, Y. Chinen1, H. Itakura1, K. Ide1, Y. Tsuda1, M. Ueda1, S. Nakashima1, K. Ohta1, M. Ikenaga1, T. Yamada1

1 Higashiosaka City Medical Center, Department of Gastroenterological Surgery, Higashiosaka City- Osaka, Japan

**P.10-669-Thu**  | A phase II study of modified FOLFOX-6 for gastric cancer refractory to standard therapies

S. Mitani1, S. Kadowaki1, A. Komori1, C. Kondoh1, I. Oe1, K. Kato1, T. Masuishi1, K. Honda1, Y. Naria1, H. Taniguchi1, M. Ando1, T. Tanaka1, M. Tajika1, K. Muro1

1 Aichi Cancer Center Hospital, Department of Clinical Oncology, Nagoya, Japan

**P.10-670-Thu**  | Surgery for stage IV Gastric Cancer: an Italian perspective

B. Molteni1, S. Ministrini1, M. Bencivenga2, E. Marino1, A. D’Ignazio1, L. Solaini1, G. Mur1, S. Sofia1, C. Cipollari1, M.S. Alfano1, M.C. Vannoni1, M. Deiuli1, K. Poloni1, P. Morgagni1, D. Marrelli1, A. Donini1, F. Rosiglione1, G. De Manzoni1, G.A.M. Tiberio1

1 Brescia University, General Surgery, Brescia, Italy

**P.10-671-Thu**  | Association between estimated glomerular filtration rate and the prognosis in patients with unresectable advanced gastric cancer

Y. Nagata1, R. Sawada1, M. Ishikawa1, T. Kano1, U. Ishimoto1, T. Nishimura1, M. Noguchi1, K. Amano1, M. Saruta1

1 The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan

**P.10-672-Thu**  | Serum CEA level and nutritional parameters predict successful conversion gastrectomy for stage IV gastric cancer

N. Nakamura1, S. Kinami1, T. Kosaka1

1 Kanazawa Medical University Hospital, Surgery, Ishikawa, Japan

**P.10-673-Thu**  | The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer: multicenter retrospective study

S. Nakano1, Y. Komatsu1, S. Yuki1, K. Sawada1, T. Muranaka1, Y. Kawamoto1, H. Nakatsumi1, H. Yoshida1, T. Ando1, K. Harada1, Y. Kobayashi1, T. Miyagishima1, T. Sasa1, K. Hatanaka1, A. Tanimoto1, A. Ishiguro1, T. Handa1, M. Dazai1, N. Sakamoto1

1 Hokkaido University Hospital, Department of Gastroenterology and Hepatology, Sapporo, Japan

**P.10-674-Thu**  | Systemic chemotherapy for the advanced esophagogastric junction cancer

I. Nakayama1, T. Datsoke1, C. Kiesho1, W. Takera1, I. Takashi1, O. Maniko1, O. Hiroki1, O. Yumiko1, O. Akira1, S. Mitsukuni1, S. Yoji1, Y. Kensei1

1 Cancer Institute Hospital of Japanese Foundation for Cancer Research, Gastroenterological Chemotherapy, Koto-ku, Japan
P.10-675-Thu | Second-line irinotecan plus cisplatin versus irinotecan alone in patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy
1 National Hospital Organization Osaka National Hospital, Surgery, Osaka, Japan
2 Graduate School of Medicine, Kurume University, Biostatistics Center, Kurume, Japan
3 Osaka General Medical Center, Surgery, Osaka, Japan
4 Inagaki Clinic, Surgery, Osaka, Japan
5 Ikeda Municipal Hospital, Surgery, Ikeda, Japan
6 Osaka City General Hospital, Medical Oncology, Osaka, Japan
7 Shizuoka General Hospital, Surgery, Shizuoka, Japan
8 Yao Municipal Hospital, Surgery, Yao, Japan
9 Osaka International Cancer Institute, Medical Oncology, Osaka, Japan
10 Saiseikai Shiga Prefectural Hospital, Gastroenterology, Ritto, Japan
11 National Hospital Organization National Cancer Center Hospital, Gastric Surgery, Tokyo, Japan
12 Saitama Medical Center, Digestive Tract and General Surgery, Saitama, Japan
13 Aizuwa Hospital, Comprehensive Cancer Center, Matsumoto, Japan
14 National Hospital Organization Osaka National Hospital, Gastroenterology, Osaka, Japan
15 Kyoto University Graduate School of Medicine, Biomedical Statistics and Bioinformatics, Kyoto, Japan
16 Epidemiological & Clinical Research Information Network, Data center, Kyoto, Japan
17 Ozawa Hospital, Surgery, Odawara, Japan
18 Tokai Central Hospital, Surgery, Kamaishi, Japan
19 Kajikawa City Hospital, Surgery, Kajikawa, Japan

P.10-676-Thu | A phase II study of induction DCS chemotherapy for gastric cancer with peritoneal metastasis
1 New Tokyo Hospital, Department of Gastroenterological Surgery, Matsudo, Japan
2 Kyoto Medical Center, Department of Surgery, Kyoto, Japan
3 Kitano Hospital, Department of Surgery, Osaka, Japan
4 Kyoto City Hospital, Department of Surgery, Kyoto, Japan
5 Saiseikai Noe Hospital, Department of Surgery, Osaka, Japan
6 Himeji Medical Center, Department of Surgery, Himeji, Japan
7 Kyoto University, Department of Surgery, Kyoto, Japan

P.10-677-Thu | Evaluation of surgically treated stage IV gastric cancer: a retrospective monocentric analysis
E. Orsenigo1, M. Carlucci1
1 San Raffaele Hospital, Department of General and Emergency Surgery, Milan, Italy

P.10-678-Thu | Treatment result of conversion surgery for unresectable advanced gastric cancer
M. Ota1, M. Kagaya1, Y. Nakajii1, T. Nakano1, M. Sugiyama1, M. Ikek1, M. Morita1, Y. Toh1
1 National Kyushu Cancer Center, Gastroenterological Surgery, Fukuoka, Japan

P.10-679-Thu | Survival benefit of palliative gastrectomy in patients with incurable gastric cancer
J.Y. Park1, B. Yu1, K.B. Park1, O.K. Kwon1, S.S. Lee1, H.Y. Chung1
1 Kyungpook National University, Department of Surgery, Daegu, Republic of Korea

P.10-680-Thu | Effect of conversion surgery in advanced gastric cancer
S.H. Park1, J.H. Choi1, Y.S. Suh1, S.H. Kang1, H.J. Lee1, H.K. Yang1
1 Seoul National University Hospital, Department of Surgery, Seoul, Republic of Korea

P.10-681-Thu | Creatinine clearance as a predictor of dosage modification and discontinuation in S-1 plus cisplatin chemotherapy for advanced gastric cancer
Y. Sasaki1, J. Hirota3, J. Koim1
1 Hakodate Central General Hospital, Division of Medical Oncology, Hokkaido, Japan
2 Hakodate Central General Hospital, Division of Gastroenterology, Hokkaido, Japan

P.10-682-Thu | Role of surgery and systemic chemotherapy in combined treatment of gastric cancer with peritoneal free cancer cells
N. Semenov1, R. Izrailov1, B. Pomortsev1
1 Moscow Clinical Scientific Center, High Technology Surgery, Moscow, Russian Federation
P.10-683-Thu | Result of simultaneous intraperitoneal & systemic chemotherapy for gastric peritoneal carcinomatosis

W. J. Seo1, C. M. Lee1, Y. J. Jang1, J. H. Kim1, S. S. Park1, S. H. Park1, Y. J. Mok1

1 Korea University College of Medicine, Surgery, Korea, Republic of Korea

P.10-684-Thu | A case of isolated metastasis of gastric cancer to skeletal muscle 9 years after the initial surgery

A. Serizawa1, K. Taniguchi1, S. Kotake1, S. Ito1, K. Suzuki1, M. Yamamoto1

1 Tokyo Women’s University, Gastroenterologic surgery, Tokyo, Japan

P.10-685-Thu | Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study

L. Solaini1, S. Ministrini1, M. Bencivenga1, E. Marino1, C. Cipollari1, A. D’Ignazio1, G. Mura1, D. Marrelli1, A. Donini1, F. Roviello1, G. De Manzoni1, G.A.M. Tiberio2, P. Morgagni2

1 Morgagni-Pierantoni Hospital Forlì, Department of Surgery, Forlì, Italy
2 University of Brescia, Department of Experimental and Clinical Sciences, Brescia, Italy
3 University of Verona, General and Upper GI Surgery Division, Verona, Italy
4 Santa Maria della Misericordia Hospital University of Perugia, Department of Surgery, Perugia, Italy
5 Poli clinica le Sotte- University of Siena, Department of Surgery, Siena, Italy
6 Azienda USL Toscana Sud Est – Arezzo, Department of Surgery, Arezzo, Italy

P.10-686-Thu | A Case of Stage IV Gastric Cancer Curative Resection by Conversion Therapy

G. J. Song1, Y. K. Kim1, H. S. Shin1, M. W. Son1, M. S. Lee1

1 Soonchunhyang University Cheonan Hospital, Department of Surgery, Cheonan, Republic of Korea

P.10-687-Thu | Case of Noncuratively Resected Gastric Cancer and Postoperative Chemotherapy with S-1 Monotherapy Resulting in Long-Term Survival for Over 8 Years

B. J. Suh1, S. J. Oh1

1 Haeundae Paik Hospital- Inje University, General surgery/Gastric cancer center, Busan, Republic of Korea

P.10-688-Thu | Efficacy and prognostic factors of apatinib in patients with advanced gastric cancer

G. Sun1, W. Yao1, W. Hu1, P. Gao1, J. Jia1, Z. Yang1, M. Liu1, S. Chen1, C. Zhang1, L. Sun1, X. Yao1, J. Song1, M. Chen1, H. Zhai1, L. Zhang1

1 Tangshan People’s Hospital, Department of Oncology, Tangshan, China

P.10-689-Thu | The predictive roles of HER2 gene amplification and neutrophil-to-lymphocyte ratio on survival in HER2-positive gastric cancer treated with trastuzumab-based chemotherapy

S. J. Sym1, Y. S. Kim1, H. K. Ahn1, J. Park1, D. B. Shin1, W. K. Lee1, J. Y. Yang1, H. S. Kim1

1 Gachon University Gil Medical Center, Division of Medical Oncology - Internal Medicine, Incheon, Republic of Korea
2 Gachon University Gil Medical Center, Surgery, Incheon, Republic of Korea
3 Gachon University Gil Medical Center, Radiology, Incheon, Republic of Korea

P.10-690-Thu | Conversion surgery for gastric cancer with peritoneal metastasis or positive peritoneal cytology

R. Takahashi1, S. Ida1, M. Isazuki1, S. Yagi1, T. Ohashi1, M. R1, K. Kumagai1, S. Nunobe1, M. Ohashi1, T. Sano1, N. Hiki1

1 The Cancer Institute Hospital- Japanese Foundation for Cancer Research, Department of Gastroenterology, Koto-ku, Japan

P.10-691-Thu | Conversion surgery for patients with liver metastasis from gastric cancer

K. Tanabe1, Y. Sasaki1, H. Ohta1, Y. Yamamoto1, R. Saito1, H. Ohdan1

1 Hiroshima University, Department of Gastroenterological and Transplant Surgery, Hiroshima, Japan

P.10-692-Thu | Our experience of the treatment with Nivolumab for advanced gastric cancer

H. Tazawa1, T. Suzuki1, R. Ide1, H. Kubota1, M. Kojima1, N. Hadano1, W. Shimizu1, K. Ishiyama1, T. Onoe1, T. Sudo1, Y. Shimizu1, T. Hinoi1, H. Tashiro1

1 National Hospital Organization Kure Medical Center, Department of Surgery, Kure city, Japan

P.10-693-Thu | Evaluation of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis

R. Thieme1, B. Jansen-Winkel1, L. Haase1, P. Rhode1, M. Mehdorn1, S. Niebisch1, Y. Moulla1, O. Lyros1, F. Lordick1, K. Schierle1, C. Wittekind1, I. Gockel1

1 University Hospital Leipzig, Department of Visceral- Transplant- Thoracic and Vascular Surgery, Leipzig, Germany
2 University Hospital Leipzig, University Cancer Center Leipzig, Leipzig, Germany
3 University Hospital Leipzig, Institute of Pathology, Leipzig, Germany
P.10-694-Thu | Metastasectomy Improves the Survival of Gastric Cancer Patients with Krukenberg Tumors: A Retrospective Analysis of 182 Patients
Y. Tian1, F. Ma1, Y. Li1, W. Kang1, W. Li1, H. Liu1, S. Ma1
1 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital- Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Pancreatic and Gastric Surgery, Beijing, China

P.10-695-Thu | S-1 in patients with advanced esophagogastric adenocarcinoma: Results from the safety compliance observatory on oral fluoropyrimidines (SCOOP)
M. Venerito1
1 Otto-von-Guericke University Hospital, Department of Gastroenterology- Hepatology and Infectious Diseases, Magdeburg, Germany

P.10-696-Thu | The most effective chemotherapy regimen for unresectable gastric cancer: A Bayesian network meta-analysis of 28 chemotherapy regimens
Y. Wang2, X. Jing1, X. Lei2, F. Shan1, L. Zhang1, S. Li1, Y. Jia1, R. Miao1, K. Xue1, Z. Li1, Z. Li1, J. Ji1
2 Peking University Cancer Hospital, gastroenterological cancer center, Beijing, China

P.10-697-Thu | Conversion Therapy For Solitary Polyoid Rectal Metastasis From Gastric Stump Adenocarcinoma — A Case Report
P. Wen1
1 E-Da Cancer Hospital, Surgery Department, Chiayi City, Taiwan

P.10-698-Thu | Laparoscopic gastrectomy with simultaneous intraperitoneal chemotherapy may be considered as a treatment for far advanced gastric cancer
Y. Wen1, Y.S. Cho1, S.H. Min1, Y.S. Park1, S.H. Ahn2, D.J. Park2, H.H. Kim1
2 Seoul National University Bundang Hospital, Department of Surgery, Seongnam, Republic of Korea

P.10-699-Thu | Prognostic Factor and Treatment Strategy for CY1 Gastric Cancer
A. Yago1, H. Akiyama1, K. Sato1, S. Sato1, Y. Tanaka1, H. Miyamoto1, T. Kosaka1, C. Kanisaki1, I. Endo1
1 Yokohama City University, Gastroenterological Surgery, Yokohama, Japan

P.10-700-Thu | Possibility of surgical intervention in Stage IV gastric cancer
S. Yanagita1, T. Arigami1, D. Matsuhashita1, K. Okubo1, T. Kijima1, T. Kijima1, K. Kawagoe3, M. Shimonosono1, Y. Uenosono2, S. Ishigami3, S. Natsugoe1
1 Kagoshima University hospital, Department of Digestive Surgery- Breast and Thyroid Surgery, Kagoshima, Japan
2 Imamura general hospital, Department of Surgery, Kagoshima, Japan
3 Kagoshima Prefectural Oshima hospital, Department of surgery, Amami, Japan

P.10-701-Thu | Utilization and cost-effectiveness analysis for palliative chemotherapy in metastatic gastric adenocarcinoma
Y.H. Yang1, W.S. Chang1, K.P. Hsieh1, L.T. Chen2
1 Kaohsiung Medical University, School of Pharmacy, Kaohsiung, Taiwan
2 National Health Research Institutes, National Institute of Cancer Research-, Tainan, Taiwan

P.10-702-Thu | Hyperthermic intraperitoneal chemotherapy in combined treatment of locally advanced and intraperitoneally disseminated gastric cancer: A retrospective cooperative Central-Eastern European study
B. Yarema1, J. Mielko1, T. Fetsch1, M. Oharchok1, M. Skrzeszevska1, K. Rawicz-Pruszyński1, A. Maszuk2, V. Maksimovsky1, T. Jastrzębski1, P. Grywa1, Y. Kovalchuk1, V. Safyan1, I. Karel1, V. Kopetskiy1, O. Kolesnik1, Y. Kondratskiy1, M. Pakoniś1, W. Polkowicki2
1 Danylo Halytsky Lviv National Medical University, Department of Oncology and Medical Radiology, Lviv, Ukraine
2 Medical University of Lublin, Oncology, Lublin, Poland
3 Lviv State Oncological Regional Treatment and Diagnostic Center, Abdominal Surgery, Lviv, Ukraine
4 Odessa National Medical University, Oncology, Odessa, Ukraine
5 Medical University of Gdansk, Oncology, Gdansk, Poland
6 National Cancer Institute, Uper GI, Kyiv, Ukraine
7 National Cancer Institute, Chief, Kyiv, Ukraine
8 Vilnius University Hospital Santaros klinikos, Oncology, Vilnius, Lithuania

P.10-703-Thu | Conversion therapy for advanced gastric cancer with paraaortic lymph node metastasis or distant lymph node metastasis
I. Yasufuku1
1 Gifu University Graduate school of Medicine, Surgical Oncology, Gifu, Japan
P.10-704-Thu | A single center experience to explore efficacy of intraperitoneal cisplatin in comparison with paclitaxel in gastric cancer with peritoneal metastasis
Q. Wei1, Q. Xu1, Y. Gao1, J. Ying1
1 Zhejiang Cancer Hospital, Department of Medical Oncology, Hangzhou, China

P.10-705-Thu | Ramucirumab plus paclitaxel therapy for unresectable recurrent advanced gastric cancer
K. Yoshimitsu1, S. Yanagita1, T. Arijyama1, D. Matsushita1, K. Okubo1, T. Kijima1, M. Shimonosono1, Y. Uenosono1, S. Ishigami1, S. Hokita1, S. Natsugoe1
1 Graduate School of Medical and Dental Sciences- Kagoshima University-, Department of Digestive Surgery- Breast and Thyroid Surgery- Field of Oncology, Kagoshima, Japan
2 Imamura general hospital-, Department of surgery, Kagoshima, Japan
3 Kagoshima Prefectural Oshima hospital, Department of surgery, Kagoshima, Japan

P.10-706-Thu | Conversion surgery may provide prolonged survival in carefully selected patients with stage IV gastric cancer
B. Yu1, K.B. Park1, J.Y. Park2,3, S.S. Lee2,3, O.K. Kwon1,2, H.Y. Chung2,3
1 Kyungpook National University Chilgok Hospital, Gastric cancer center, Daegu, Republic of Korea
2 Kyungpook National University, Department of Surgery- School of Medicine, Daegu, Republic of Korea
3 Kyungpook National University Hospital, Department of Surgery, Daegu, Republic of Korea
**Poster Session II, Friday 10 May 2019, 16:45–18:15**

**P01 Young investigators**

**P01-Fri |** The effect of perioperative chemotherapy on postoperative morbidity, mortality and overall survival in gastric cancer

J. Back¹, A. Kokkola², V. Sallinen², P. Puolakkainen²

1 Helsinki University and Helsinki University Hospital, Department of abdominal surgery, Helsinki, Finland
2 Helsinki University and Helsinki University Hospital, Department of abdominal surgery Meilahden sairaala, Helsinki, Finland

**P01-002-Fri |** The current role of adjuvant therapy in patients following neo-adjuvant chemotherapy and R0 resection for lower oesophageal and GOJ adenocarcinoma

R. Bott¹, J. Zylstra, M. Wilkins, W. Knight, C. Baker, M. Kelly, N. Maisey, J. Gossage, W. Allum, D. Cunningham, A. Davies

¹ St Thomas’ Hospital, Department of Upper GI and General Surgery, London, United Kingdom
2 The Royal Marsden Hospital, Department of Upper GI Surgery, London, United Kingdom
3 Guy’s Hospital, Department of Medical Oncology, London, United Kingdom
4 The Royal Marsden Hospital, Department of Medical Oncology, London, United Kingdom

**P01-003-Fri |** Robotic gastrectomy compared with open surgery in western centers: a weighted analysis based on sites effect from the Imigastric database

J. Desiderio¹, S. Trastulli², D. Di Nardo³, F. Ricci, A. Parisi

¹ St. Mary’s Hospital - “La Sapienza” University of Rome, Department of Digestive Surgery, Terni, Italy
2 St. Mary’s Hospital, Department of Digestive Surgery, Terni, Italy

**P01-004-Fri |** Fluorescence image-guided lymphadenectomy using indocyanine green and near infrared technology in robotic gastrectomy

J. Desiderio¹, S. Trastulli², F. Ricci, D. Di Nardo³, V. D’Andrea, A. Parisi

¹ St. Mary’s Hospital - “La Sapienza” University of Rome, Department of Digestive Surgery, Terni, Italy
2 St. Mary’s Hospital, Department of Digestive Surgery, Terni, Italy
3 “La Sapienza” University of Rome, Department of Surgical Sciences, Rome, Italy

**P01-005-Fri |** Which size is the best cutoff for primary small gastric gastrointestinal stromal tumors?

X. Feng¹, Z. Yang², P. Zhang, T. Chen, Z. Chen, H. Qiu, J. Yu, X. Sun, Z. Zhou, G. Li³, K. Tao, Y. Li

1 Guangdong General Hospital- Guangdong Academy of Medical Sciences, Department of General Surgery, Guangzhou, China
2 Guangdong General Hospital- Guangdong Academy of Medical Sciences, Department of General Surgery, Guangzhou, China
3 Union Hospital Tongji Medical College Huazhong University of Science and Technology, Department of Gastrointestinal Surgery, Wuhan, China
4 Southern Medical University Nanfang Hospital, Department of General Surgery, Guangzhou, China
5 Sun Yat-sen University Cancer Center- State Key Laboratory of Oncology in South China- Collaborative Innovation Center of Cancer Medicine, Department of Gastric Surgery, Guangzhou, China

**P01-006-Fri |** Sarcopenia in patients undergoing surgery for gastric cancer

M. Ferreira¹, J. Felício Costa², P. Botelho², G. Oliveira², E. Fernandes³, M. Ramalho², P. Matos Da Costa³

¹ Cirurgia Geral - Hospital Garcia de Orta, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
2 Serviço de Radiologia, Hospital Garcia de Orta, Almada, Portugal
3 Serviço de Cirurgia Geral, Hospital Garcia de Orta, Almada, Portugal

**P01-007-Fri |** Adjuvant chemotherapy for gastric cancer in older patients aged over 80 years old

S. Fujishima¹, H. Tsujimoto¹, K. Kouzu¹, S. Hiroki¹, Y. Yaguchi¹, H. Horiguchi¹, S. Nomura¹, N. Ito¹, M. Harada¹, H. Nagata¹, Y. Ishibashi¹, Y. Itazaki¹, S. Tsuchiya¹, K. Hase², H. Ueno

¹ National Defense Medical College, Department of Surgery, 3-2 Namiki Tokorozawa Saitamakken, Japan
² Universidade de Lisboa, Faculdade de Medicina, Lisboa, Portugal

**P01-008-Fri |** Impact of hepatic steatosis on the long-term outcome after potentially curative gastrectomy for gastric cancer

M. Harada¹, H. Tsujimoto¹, M. Nishikawa¹, S. Tsuchiya¹, Y. Ishibashi¹, K. Kouzu¹, Y. Itazaki¹, H. Nagata¹, T. Sugihara¹, K. Nagata¹, N. Ito¹, S. Nomura¹, K. Okamoto¹, I. Kumano¹, Y. Kajiwara¹, Y. Yaguchi¹, S. Hiroki, E. Shimizu¹, K. Hase², H. Ueno

¹ National defence medical college, Department of surgery, Tokorozawa, Japan
P.01-009-Fri | Evaluation of Different Markers as Predictors for Response to Neoadjuvant Radio/Chemotherapy for Gastro/Esophageal Adenocarcinoma
H. Harloff1, C. Treese1, H. Tröger1, S. Sander1, S. Daum1
1 Charité – Universitätsmedizin Berlin - Campus Benjamin Franklin, Medizinische Klinik I m. S. Gastroenterologie-Infektiologie und Rheumatologie, Berlin, Germany
2 Charité - Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany

P.01-010-Fri | A novel prognostic index for patients with resectable gastric cancer: Post-operative Glasgow Prognostic Score (Post-GPS)
T. Hashimoto1, Y. Kurokawa1, T. Takahashi1, Y. Miyazaki1, K. Tanaka1, T. Makino1, M. Yamasaki1, K. Nakajima1, M. Mori1, Y. Doki1
1 Osaka University Graduate School of Medicine, Department of Gastroenterological Surgery, Suita- Osaka, Japan

P.01-011-Fri | A multi-country, multi-center randomized controlled trial comparing the quality of life between LADG and TLDG for gastric cancer
H. Hua1, P. Sungsoo2
1 Fudan University Shanghai Cancer Center, Gastric Surgery, Shanghai, China
2 Korea University Medical Center, Department of Surgery, Seoul, Republic of Korea

P.01-012-Fri | Phase II clinical trial of preoperative chemoradiation and intraoperative radiation therapy for gastric cancer
N. Ikoma1, B. Badgwell1, M. Blum2, Y. J. Chiang1, P. Das1, A. Matamoros4, A. Ajani2, P. Mansfield1
1 University of Texas MD Anderson Cancer Center, Surgical Oncology, Houston, USA
2 University of Texas MD Anderson Cancer Center, Medical Oncology, Houston, USA
3 University of Texas MD Anderson Cancer Center, Radiation Oncology, Houston, USA
4 University of Texas MD Anderson Cancer Center, Diagnostic Radiology, Houston, USA

P.01-013-Fri | Extracellular vesicles from cancer associated fibroblasts induce drug resistance via integrinβ1/FAK signaling in gastric cancer cells
T. Ishimoto1, T. Uchihara1, M. Iwatsuki2, Y. Baba1, N. Yoshida1, H. Baba1
1 Kumamoto University, Department of Gastroenterological Surgery, Kumamoto, Japan
2 Kumamoto University, Department of Gastroenterological Surgery, Kumamoto, Japan

P.01-014-Fri | Secondary carcinoma in upper gastrointestinal tract surgery
1 University of Heidelberg, Department of General- Visceral and Transplant Surgery, Heidelberg, Germany

P.01-015-Fri | Overexpression of RFC3 relates to tumor development and poor outcome of gastric cancer
T. Kishimoto1, S. Komatsu1, M. Miyamae1, S. Higashima1, J. Kikuchi1, K. Nishibeppu1, T. Kosuga1, H. Konishi1, A. Shiozaki1, T. Kubota1, K. Okamoto1, E. Otsuji1
1 Kyoto Prefectural University of Medicine, Digestive Surgery, Kyoto, Japan

P.01-016-Fri | Risk factors for stage underestimation in patients with clinical T1N0 gastric cancer
T. Kunishige1, K. Migita1, S. Matsumoto1, K. Wakatsuki1, H. Nakade1, S. Miyao1, M. Sho1
1 Nara Medical University, Surgery, Kashihara, Japan

P.01-017-Fri | Correlation study between c-kit, ETV1, FOXF1 and clinicopathological data of gastrointestinal stromal tumors
D. Liu1, W. Kang1
1 Peking Union Medical College Hospital- Dongcheng District, General Surgery department- Ward four, Beijing, China

P.01-018-Fri | Clinical application of Trastuzumab therapy for unresectable advanced gastric cancer patients with HER2 positive circulating tumor cells
D. Matushita1
1 Graduate School of Medical and Dental Sciences- Kagoshima University, Digestive Surgery- Breast and Thyroid Surgery, Kagoshima, Japan

P.01-019-Fri | Is enhanced recovery protocol for gastric cancer feasible and safe in the West? A single center experience
V. Mengardi1, J. Weindelmayer1, A. Gasparini1, L. Torroni1, G. Verlato1, G. de Manzoni1
1 University of Verona, Upper G.I. Surgery Division, Verona, Italy
2 University of Verona, Department of Diagnostics and Public Health, Verona, Italy

P.01-020-Fri | A case of ramucirumab-related small intestinal perforation in gastric cancer
H. Murase1, H. Ishii1, A. Ogawa1, K. Kamiuchi1, A. Mitsuoka1, M. Hayashi1, S. Park1
1 Tokyo Shinagawa Hospital, Surgery, Tokyo, Japan
P.01-021-Fri | Impact of infectious complications after laparoscopic gastrectomy on the long-term outcome in gastric cancer patients
H. Nagata1, H. Tsujimoto1, S. Tsuchiya1, K. Kouzu1, Y. Itazaki1, Y. Ishibashi1, T. Sugihara1, M. Harada1, S. Nomura1, K. Okamoto1, E. Kojima1, Y. Kajiwara1, S. Hiraki1, E. Shinto1, K. Hase1, H. Uno1
1 National Defence Medical College, Department of surgery, Tokorozawa- Saitama, Japan

P.01-022-Fri | Effectiveness of 2-week S-1 administration followed by 1-week rest as adjuvant chemotherapy for gastric cancer
K. Ogawa1, Y. Akashi1, M. Honda1, S. Inagawa1, A. Kaneda1, S. Hiroi1, K. Hisakura1, Y. Owada1, Y. Ohara1, T. Enomoto1, Q. Shimomura1, K. Takahashi1, M. Kurata1, T. Oda1
1 Tsukuba University, University, Tsukuba- Ibaraki, Japan
2 Fukushima Medical University, Minimally Invasive Surgical and Medical Oncology, Fukushima, Japan
3 Tsukuba Medical Center Hospital, Gastroenterological Surgery, Ibaraki, Japan
4 Southern TOHOKU General Hospital, Surgery, Fukushima, Japan

P.01-023-Fri | Platelet-lymphocyte ratio (PLR) as an independent prognostic factor in patients with advanced gastrointestinal stromal tumor (GIST) treated with imatinib
J.H. Kim1, M.H. Ryu1, J. Mo1, J. Jeon1, Y.K. Kang1
1 Asan Medical Center, Oncology, Seoul, Republic of Korea

P.01-024-Fri | Is the anatomical localization of the tumor in adenocarcinoma of esophagogastric junction related to prognostic survival? A multivariable analyses
F.R. Takeda1, R.A.A. Sallum1, U. Ribeiro1, I. Ceconello1
1 University of Sao Paulo School of Medicine, Department of Gastroenterology Digestive Surgery Division, Sao Paulo, Brazil

P.01-025-Fri | The risk factor of recurrence in patients with pStage I gastric cancer
N. Wada1, Y. Akamaru1, D. Hakokou1, R. Wada1, R. Ikeshima1, K. Munakata1, D. Takiuchi1, G. Morimoto1, H. Ota1, K. Shibata1
1 Meda City Hospital, Gastroenterological Surgery, Meda, Japan

P.01-026-Fri | Negative enrichment and immune fluorescence in situ hybridization (NEimFISH): a novel intraperitoneal free cancer cell detection modality for gastric cancer
A. Wang1, Z. Li1, Y. Xue1, Y. Bai1, X. Ji1, T. Fu1, Z. Jia1, K. Ji1, X. Zong1, X. Wu1, J. Zhang1, Y. Yang1, Z. Bu1, J. Ji1
1 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education- Peking University Cancer Hospital & Institute, Department of Gastrointestinal Surgery, Beijing, China
2 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education- Peking University Cancer Hospital & Institute, Department of Pathology, Beijing, China
3 Cyttel Biosciences INC, Cyttel Biosciences INC, Beijing, China

P.01-027-Fri | Remnant gastric cancer: A twenty-year single-center retrospective analysis on clinicopathological features and prognosis
L. Wang1, V.S.Y. Ng1, K.K.F. Wong1, S.K. Leung1
1 Tuen Mun Hospital, General Surgery, Hong Kong, Hong Kong

P.01-028-Fri | Hot spot analysis of gastric cancer based on bibliometrics
Q. Yan1
1 Guangdong General Hospital, Department of General Surgery, Guangdong Province, China

P.01-029-Fri | Enhanced recovery protocol for patients receiving 3D laparoscopy-assisted gastrectomy: high compliance rate correlated with a shortened postoperative stay
K. Zhang1, C. Li1, J. Cui1, X. Huang1, L. Chen1
1 Chinese PLA General Hospital, Department of General Surgery, Beijing, China

P.01-030-Fri | Effects and mechanism of dihydroartemisinin on malignant behavior of cisplatin-resistant gastric cancer cells
S. Zhang1, R. Feng1, F. Yuan1, Q. Luo1, X. Chen1, N. Lin1, S. Yang1
1 Fujian Medical University Union Hospital, Department of Medical Oncology, Fuzhou, China
2 Fujian Medical University Union Hospital, Department of Respiratory Medicine, Fuzhou, China
3 Fujian Medical University Union Hospital, Department of Chinese Medicine, Fuzhou, China
P.01-031-Fri | Clinical efficacy of combination intravenous and intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis
S. Zhang1,2, R. Feng1,2, Z. Pan1,2, M. Lin1,2, X. Huang1,2, T. Jiang1,2, Q. Xu2, Q. Chen1,2, S. Yang1,2,3
1 Fujian Medical University Union Hospital, Department of Medical Oncology, Fuzhou, China
2 Union Clinical Medical College of Fujian Medical University, Teaching and Research Department of Oncology, Fuzhou, China
3 Fujian Provincial Key Laboratory of Translational Cancer Medicine, Translational Cancer Medicine, Fuzhou, China

P.01-032-Fri | To evaluate the prognostic factors of primary localized gastrointestinal stromal tumour after radical resection
X. Zhang1, Y. Zhou1, S. Cao1, L. Ning1, Y. Hu1, S. Zhao1, L. Li1, D. Yong1, L. Jiang1, A. Wang1, X. Chu1, M. Li1, D. Yang1, C. Li1, L. Yao1, G. Cai1, H. Lin1, G. Chen1, Q. Cui1, D. Zhang1
1 Affiliated Hospital of Qingdao University, Department of General Surgery, Qingdao, China
2 Shandong Provincial Hospital Affiliated of Shandong University- Jinan- Shandong- China, Department of Gastrointestinal Surgery, Jinan, China
3 Qilu Hospital of Shandong University, Department of General Surgery, Jinan, China
4 Affiliated Yantai Yuwangedong Hospital of Qingdao University, Department of Gastrointestinal- Thyroid Surgery, Yantai, China
5 Affiliated Hospital of Jining Medical College, Department of Gastrointestinal Surgery, Jining, China
6 The First People's Hospital of Jining City, Department of Gastroenterology Surgery, Jining, China
7 Affiliated Hospital of Binzhou Medical College, Department of Gastrointestinal Surgery, Binzhou, China
8 Liasocheng People's Hospital, Department of Gastrointestinal Surgery, Liasacheng, China
9 Department of Laparoscopic Surgery Center, Linyi People's Hospital, Linyi, China
10 Central Hospital of Shengli Oil Field, Department of Gastrointestinal Surgery, Yantai, China
11 Taian City Center Hospital, Department of General Surgery, Taian, China
12 Qingdao Municipal Hospital, Department of Gastric Surgery, Qingdao, China
13 Tengzhou Central People's Hospital, Department of Gastrointestinal Surgery, Tengzhou, China
14 Zibo Central Hospital, Department of General Surgery, Zibo, China
15 Qingdao University Medical College, Department of Epidemiology and Health Statistics, Qingdao, China

P.01-033-Fri | Clinicopathological correlation and prognostic analysis of Ghrelin and gastrointestinal stromal tumors / Study on mechanism of Ghrelin regulating GISTs growth
C. Zhu1, W. Kang2
1 Beijing Tsinghua Chang Gung hospital, Gastroenterological Surgery, Beijing, China
2 Peking Union Medical College Hospital, General surgery, Beijing, China

P.07 Surgery and quality assurance

P.07-289-Fri | Gastric cancer in the young-age onset and disease specific prognosis results
L. Lorenzon1, A. Agnes1, A. Biondi1, A. Laurino1, R. Persiani1, D. D’ugo1
1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Surgical Unit 1, Rome, Italy

P.07-290-Fri | Surgical navigation of laparoscopic gastrectomy using deformable 3D images
Y. Akashi1, K. Ogasawara1, K. Hisakura1, T. Emamoto1, Y. Ohashi1, Y. Owada1, O. Shimomura1, K. Takahashi1, M. Kurata1, T. Od01
1 Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery- Faculty of Medicine, University of Tsukuba, Tsukuba- Ibaraki, Japan

P.07-291-Fri | Risk factors analysis for postoperative complication after total and distal gastrectomy in gastric cancer: results of high-volume tertiary center
A. Al Wusahbie1,2, M. Cho1,2, C.K. Noh1,2, W.J. Seo1,2, Y.Y. Choi1,2, T. Son1,2, H.I. Kim1,2, J.H. Cheong1,2, S.H. Noh1,2, W.J. Hyung1,2
1 Yonsei University College of Medicine, Department of Surgery, Seoul, Republic of Korea
2 Yonsei Cancer Center- Yonsei University Health System, Gastric Cancer Center, Seoul, Republic of Korea

P.07-292-Fri | Centralizing Cancer Services to Improve Patient Outcomes; Early Reflections from the Manchester Experience
B. Alkhaffaf1
1 Salford Royal Foundation Trust, Department of Oesophago-Gastric Surgery, Salford, United Kingdom

P.07-293-Fri | Adjuvant chemoradiotherapy after D2 gastric resection: analysis of 87 cases in a University Hospital
N.A. Andreollo1, V. Tercioti Jr1, J.D.S. Coelho Neto1, J.A.P. Ferrer1, L.R. Lopes1
1 State University of Campinas - UNICAMP - Campinas - Sao Paulo, Surgery, Campinas, Brazil
P.07-294-Fri | Surgical Treatment of the Gastric Neuroendocrine Tumors
N.A. Andreollo¹, I.G.G. Santos¹, V. Tercioti Jr¹, J.D.S. Coelho Neto¹, J.A.P. Ferrer¹, L.R. Lopes¹
¹ State University of Campinas - UNICAMP, Campinas - Sao Paulo, Surgery, Campinas, Brazil

P.07-295-Fri | Comparison of LPG with LTG in Early Cancers of Upper Stomach. Is It Better to Preserve the Distal Stomach?
K. Arishime¹, T. Kamikihara¹, Y. Hosaka¹, M. Kubo¹, T. Arigami², S. Natsugoe²
¹ Saiseikai Sendai Hospital, Surgery, Satsumasendai City, Kagoshima, Japan
² Kagoshima University Graduate School of Medicine, Digestive Surgery and Breast and Thyroid Surgery, Kagoshima, Japan

P.07-296-Fri | Clinical experience of laparoscopy-assisted proximal gastrectomy with partial fundoplication in early gastric cancer
S. Asami³
³ Fukuyama city hospital, Surgery, Fukuyama, Japan

P.07-297-Fri | Gastric GIST: 10 years experience in our hospital
R. Baía¹, I. Santos¹, A. Batista¹, F. Almeida¹, V. Praxedes¹, N. Monteiro¹, J. Almeida¹, R. Garcia¹, A. Pinto¹, M. Correia¹, L. Cortez¹
¹ S. Bernardo Hospital - Setúbal Hospital Centre, General Surgery, Setúbal, Portugal

P.07-298-Fri | Pneumo-pericardium after gastric cancer operation (case report)
Y. Baik⁴
⁴ Dongguk university hospital, general surgery, goyang, Republic of Korea

P.07-299-Fri | Diagnosis and treatment of perforated gastric carcinoma
H.J. Bang¹, H. Ryu¹, I. Shin¹
¹ Yonsei university - Korea, General Surgery, Wonju, Republic of Korea

P.07-300-Fri | Total Omentectomy in Gastric Cancer Surgery: Is it always necessary?
L. Barchi¹, B. Zilberstein¹, M.K. Ramos¹, A.R. Dias¹, O. Yagi¹, U. Ribeiro Jr.¹, I. Cecconello¹, A.Z. Charruf¹, R. Oliveira¹, C. Bresciani¹, M. Mester¹, F. Lopasso¹, M. Donato¹
¹ University of São Paulo - School of Medicine, Digestive Surgery Division, São Paulo, Brazil

P.07-301-Fri | Gastrectomy in elderly cancer patients: a big surgical challenge. A two-decade cancer center experience
G. Barile¹, R. De Luca¹, C. Cosimo¹, R. Lomonaco¹, A. Rucci¹, E. Ruggieri¹, M. Simone¹
¹ IRCCS Istituto Nazionale Tumori “Giovanni Paolo II”- Bari, Italy, Department of oncology surgery, Bari, Italy

P.07-302-Fri | Polyglycolic acid trimethylene carbonate reinforcement in duodenal section during gastrectomy for cancer: analysis of an experience
M. Berselli¹, V. Quintodei¹, G. Borroni¹, A. Marzorati¹, D. Sambucci¹, A. Scorza¹, L. Livraghi¹, E. Coccia¹
¹ ASST Sette Laghi, Department of Surgery, Varese, Italy

P.07-303-Fri | Multidisciplinary treatment of esophagojejunal anastomosis leakage after total gastrectomy for esophagogastric junction adenocarcinoma
F. Carboni¹, M. Vallec¹, O. Federici¹, R. Lapenta¹, A. Daniela¹, M. Giolfi², A. Garofalo¹
¹ IRCCS Regina Elena cancer Institute, Digestive Surgery, Rome, Italy
² IRCCS Regina Elena cancer Institute, Digestive Surgery, Rome, Italy
³ IRCCS Regina Elena cancer Institute, Digestive Endoscopy, Rome, Italy
**P.07-304-Fri** | Patient’s comorbidities and tumour stage have more influence on post-gastrectomy complications and mortality than hospital volume: A population-based analysis


1 Hospital Universitari Mutua Terrassa, Oesophagogastric surgery, Terrassa, Spain
2 Complejo Hospitalario de Navarra, Oesophagogastric Surgery, Pamplona, Spain
3 Hospital Universitario de Donostia, Oesophagogastric Surgery, San Sebastian, Spain
4 Hospital Universitario de Basauri, Oesophagogastric Surgery, Bilbao, Spain
5 Hospital Moises Broggi, Digestive Surgery, Sant Joan d’Espli, Spain
6 Hospital Clinic i Provincial, Gastrointestinal Surgery, Barcelona, Spain
7 Hospital de la Santa Creu i Sant Pau, Gastrointestinal Surgery, Barcelona, Spain
8 Hospital Joan XXIII, Digestive Surgery, Tarragona, Spain
9 Hospital Universitario de Araba, Oesophagogastric Surgery, Vitoria, Spain
10 Hospital de Cruces, Digestive Surgery, Bilbao, Spain
11 Hospital Althaia, Digestive Surgery, Manresa, Spain
12 Hospital Comarcal de Bidassoa, General Surgery, Hondarribia, Spain
13 Hospital Comarcal de Zumárraga, Digestive Surgery, Zumárraga, Spain
14 Hospital Comarcal Debagarrapenea, Digestive Surgery, Mendia, Spain
15 Hospital del Mar, Oesophagogastric Surgery, Barcelona, Spain
16 Hospital Universitari Vall d’Hebron, Barcelona

**P.07-305-Fri** | Identify patients at risk for surgery who benefit from a pre-habilitation program: Preliminary results

R. Castro, A. Fernandes, C. Salome, L. Antunes, R. Costa, A. Abreu Sousa, L. Lara Santos

1 Hospital Divino Espírito Santo, General Surgery, Ponta Delgada, Portugal
2 Hospital Garcia da Horta, Intensive Care Unit, Lisboa, Portugal
3 Instituto Português de Oncologia Francisco Gentil, Statistics, Porto, Portugal
4 Instituto Superior Técnico de Lisboa, Academic, Lisboa, Portugal
5 Instituto Português de Oncologia Francisco Gentil, Surgical Oncology, Porto, Portugal

**P.07-306-Fri** | Is three-dimensional laparoscopic spleen preserving splenic hilar lymphadenectomy better than that of two-dimensional? Analysis of a prospective clinical research study


1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China

**P.07-307-Fri** | Surgical and pathological factors that affect the prognosis of remnant gastric cancer

F. Han, Z. Chen

1 Sun Yat-sen Hospital, Gastrointestinal Surgery, Guangzhou, China

**P.07-308-Fri** | Surgical and pathological factors that affect the prognosis of remnant gastric cancer

F. Han, Z. Chen

1 Sun Yat-sen Hospital, Gastrointestinal Surgery, Guangzhou, China

**P.07-309-Fri** | Trainee involvement is safe and feasible in radical gastrectomy with positive surgical and oncological outcomes


1 Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

**P.07-310-Fri** | Effect of non-curative endoscopic submucosal dissection on short-term outcomes of subsequent surgery for early gastric cancer: a propensity score-matched analysis

I. Cho, B. Cho, G. Cho

1 Soon Chun Hyang University Bucheon Hospital, Surgery, Bucheon, Republic of Korea

**P.07-311-Fri** | Risk of gastric cancer appearance in patients with previous bariatric surgery

G. Christodoulidis, D. Magouliotis, D. Zacharoulis

1 University of Larisa, General Surgery, Larisa, Greece

**P.07-312-Fri** | Risk of gastric adenocarcinoma in patients under treatment for gastric lymphoma


1 University of Larisa, General Surgery, Larisa, Greece
2 Papageorgiou University hospital, General Surgery, Thessaloniki, Greece
P.07-313-Fri | Esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer: Treatment options at a tertiary care center
U. Clemente1, A. Alfaro1, R. Cortés1, H. Medina-Franco1
1 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Surgery, Ciudad de México, Mexico

P.07-314-Fri | Contrast-enhanced swallow sensitivity for detection of esophagojejunostomy leakage
U. Clemente1, A. Alfaro1, H. Medina-Franco1, R. Cortés1
1 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Surgery, Ciudad de México, Mexico

P.07-315-Fri | Teaching D2 lymph node dissection for gastric cancer to practicing surgeons: An evaluation of knowledge and educational needs
V. Palter1, S. Bara1, H. Canaj1, V. Delibasic1, L. Davis1, N. Coburn1
1 St. Michael's Hospital, Surgery, Toronto, Canada
2 Mount Sinai Hospital, Surgery, Toronto, Canada
3 Sunnybrook Health Sciences Centre, Toronto, Canada

P.07-316-Fri | Morbidity in 738 gastrectomies
R.D.M. Cordei1, D.K. Fukahara1, O.A.P. Castro1, F. Thuler1, W. Freitas Jr1, E. Lima1, P. Brito1, L. Ganem1, M. Marinho1, L. Claro1, M. Carvalho1, E. Ilias1, C.A. Malheiro1, P. Kassab1
1 Santa Casa Medical School, Department of Surgery, São Paulo, Brazil
2 Santa Casa Medical School, Medical School, São Paulo, Brazil
3 Santa Casa Medical School, Department of Pathology, São Paulo, Brazil
4 Santa Casa Medical School, Department of Oncology, São Paulo, Brazil

P.07-317-Fri | Analysis of perioperative variables and failed ERAS protocol items associated with delayed discharge after gastrectomy. A predictive scoring system construction
P. Parise1, L. Cinelli1, C. Ferrari1, A. Cassù1, F. Puccetti1, R. Rosati1
1 San Raffaele Hospital, Gastrointestinal Surgery Unit, Milan, Italy
2 Vita-Salute University - San Raffaele Hospital, Gastrointestinal Surgery Unit, Milan, Italy

P.07-318-Fri | The different surgical approach on the prognosis of Siewert II and III adenocarcinomas of the esophagogastric junction
J. Cui1, Z. Wenxing1, S. Zuocheng1
1 Weifang People's Hospital, gastrointestinal surgery, Weifang, China

P.07-319-Fri | The role of super extended lymphadenectomy in advanced gastric cancer: a still open question in specific subgroups
M. Dal Cer1, M. Bencivenga1, G. Verlato1, V. Mengardo1, L. Scorsone1, S. Giacone1, G. de Manzoni1
1 General and Upper GI Surgery Division, Department of surgery - University of Verona, Verona, Italy
2 Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health - University of Verona, Verona, Italy

P.07-320-Fri | Predictive Factors of Recurrence in Early Gastric Cancer
V. Devezas1, J. Nogueiro1, H. Santos-Sousa1, F. Sousa1, C. Fernandes1, A. Pereira1, T. Fonseca1, J. Barbosa1, J. Costa-Maia1
1 Centro Hospitalar Universitário de São João, General Surgery, Porto, Portugal

P.07-321-Fri | Outcomes predictor scores for multivisceral resection in T4 gastric cancer
A.R. Dias1, M. Pereira1, R. Oliveira1, R. Marcus1, D. Soz1, A.Z. Charruf1, U. Ribeiro-Júnior1, J. Ceconello1, B. Zilberstein1
1 Cancer Institute, Gastroenterology, Sao Paulo, Brazil

P.07-322-Fri | The use of Lymph node ratio as a prognostic factor in gastric cancer elderly patients?
T. Louro1, J. Estalagem1, M. Alves1, R. Martelo1, C. Marques1, M. Brilhante1, F. Rodrigues1
1 Hospital Vila Franca de Xira, General Surgery Department, Vila Franca de Xira, Portugal

P.07-323-Fri | The impact of pneumonia death for elderly gastric cancer patients after total gastrectomy
K. Eto1, N. Yoshida1, K. Yamashita1, K. Yuki1, K. Yuki1, I. Masaaki1, I. Shiroy1, B. Yoshitumi1, B. Hideo1
1 Kumamoto University, Department of Gastroenterological Surgery, Kumamoto city, Japan
P.07-324-Fri | Prolonged chemotherapy and surgery for selected patients with advanced adenocarcinoma of the oesophago-gastric junction
D. Foley1, J. Zylstra1, D. Dellaports1, M. Kelly1, C. Baker1, J. Gossage1, N. Maisey2, E. Smyth1, D. Cunningham1, W. Allum1, D. Andrew1
1 St Thomas’ Hospital, Upper GI Surgery, London, United Kingdom
2 St Thomas’ Hospital, Medical Oncology, London, United Kingdom
3 Royal Marsden Hospital, Department of Oncology, London, United Kingdom
4 Royal Marsden Hospital, Department of Surgery, London, United Kingdom

P.07-325-Fri | The frequency of cholelithiasis after laparoscopic gastrectomy and significance of prophylactic cholecystectomy
S. Fujita1, M. Kimata2, N. Futawatari1
1 Toho University Ohashi Medical Center, surgery, Tokyo, Japan
2 Saiseikai Utsunomiya Hospital, surgery, Utsunomiya, Japan

P.07-326-Fri | Technique and outcome of esophagogastric anastomosis for laparoscopic proximal gastrectomy
N. Fujiiwa1, S. Ito1, S. Ishii1, M. Kasuya2, K. Watanabe2, Y. Miyawaki1, H. Sugita1, H. Sato1, K. Okamoto1, S. Sakuramoto1, S. Yamaguchi1, I. Koyama1
1 Saitama Medical University- International Medical Center, Department of Gastroenterological Surgery, Hidaka-Shi, Japan

P.07-327-Fri | The proposal of proximal gastrectomy for small advanced gastric cancer which is located in upper-third of stomach
K. Fujiya1, R. Makuuchi1, K. Nakamura1, S. Kamiya1, Y. Tanizawa1, E. Bando1, M. Terashima1
1 Shizuoka Cancer Center, Gastric Surgery, Shizuoka, Japan

P.07-328-Fri | The changes of outcome of gastrectomy for gastric cancer in patients ≥ 80 years old
N. Fukushima1, T. Nomura1, M. Toda1
1 Yamagata Prefectural Central Hospital, Department of Surgery, Yamagata, Japan

P.07-329-Fri | Prognosis of Early Gastric Cancer with Signet Ring Cell
J. Toledo1, C. García1, T. Rojas1, B. Fernandez1, C. Benavidess1
1 Hospital San Borja Arriaran, Surgery, Santiago, Chile
2 Hospital San Borja Arriaranriaran, Surgery, Santiago, Chile

P.07-330-Fri | Impact of lymphonodal harvest in patients with gastric cancer pN0
C. García1, C. Benavidess1, J. Toledo1, T. Rojas1, C. Esperguel1
1 Hospital San Borja Arriaran, Surgery, Santiago, Chile

P.07-331-Fri | Prognosis of microscopic tumor deposits in omentum without carcinomatosis in gastric cancer
C. García1, J. Toledo1, C. Benavidess1, T. Rojas1, C. Esperguel1
1 Hospital San Borja Arriaran, Surgery, Santiago, Chile

P.07-332-Fri | Palliative gastrectomy for advanced gastric cancer does not result in additional postoperative risks compared to curative gastrectomy
E.C. Gertsen1, H.J.F. Bremkamp1, L. Goense1, N. Haj Mohammads1, B.L.A. Weustens2, R. van Hillegersb1, J.P. Ruurda1
1 University Medical Center Utrecht, Department of Surgery, Utrecht, Netherlands
2 Diakonessenhuis, Department of Surgery, Utrecht, Netherlands
3 Sint Antonius Hospital, Department of Surgery, Nieuwegein, Netherlands
4 University Medical Center Utrecht, Department of Medical Oncology, Utrecht, Netherlands
5 University Medical Center Utrecht, Department of Gastroenterology, Utrecht, Netherlands

P.07-333-Fri | Diaphragmatic hernia after totally laparoscopic total gastrectomy for gastric cancer
C.S. Gong1
1 University of Ulsan College of Medicine- Asan Medical Center, Department of Gastric Surgery, Seoul, Republic of Korea

P.07-334-Fri | Morbidity and mortality of laparoscopic D2+CME versus conventional D2 procedure for locally advanced gastric adenocarcinoma (NCT01978444)
J. Gong1, D. Xie1, J. Shen1
1 Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of GI Surgery, Wuhan, China

P.07-335-Fri | Video grading for laparoscopic distal gastrectomy and its association with survival: a retrospective study
D. Xie1, J. Gong1, B. Cao1
1 Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of GI Surgery, Wuhan, China
P.07-336-Fri | D2 lymphadenectomy without bursectomy provides favorable short-term outcomes in patients with gastric adenocarcinoma
R. Yildirim1, M.S. Bodur1, M. Ulusahin1, S. Turkyilmaz2, A. Guner1,2,3
1 Karadeniz Technical University, Department of General Surgery, Trabzon, Turkey
2 Karadeniz Technical University- Faculty of Medicine, Department of General Surgery- Division of Upper GI Surgery, Trabzon, Turkey
3 Karadeniz Technical University, Institute of Medical Science- Department of Biostatistics and Medical Informatics, Trabzon, Turkey

P.07-337-Fri | Long-Term Nutritional Outcomes of Near-Total Gastrectomy in Gastric Cancer Treatment: a Comparison with Total Gastrectomy Using Propensity Score Matching Analysis
H.S. Seo1, M.S. Gwak1, Y.J. Jung1, J.H. Kim1, C.H. Park1, I.H. Kim2, H.H. Lee1
1 The Catholic University of Korea, Gastrointestinal Surgery, 222- Banpodaegyo-Ro- Seocho-Gu, Republic of Korea
2 The Catholic University of Korea, Medical Oncology, 222- Banpodaegyo-Ro- Seocho-Gu, Republic of Korea

P.07-338-Fri | Specific ERAS problems in gastric cancer based on the observation of colorectal patients
W. Han1, E. Frejlich1, K. Kurnol1, M. Zawadzki1, P. Dzierzek1, A. Diakun1, K. Kotulski1, J. Rudno-Rudzinska1, W. Kielan1
2 Wroclaw Medical University, 2nd Department of General and Oncological Surgery, Wroclaw, Poland

P.07-339-Fri | Gastric and gastroesophageal junction carcinomas: An analysis of the gastrectomy database of an academic Upper GI Unit in Greece
D. Schizas1, N. Hasemaki1, M. Yalon1, E. Mpsili1, V. Ntom1, A. Michalinos1, N. Theochari1, C. Theochari1, M. Mpouna1, S. Kriaras1, A. Bakopoulos1, T. Liakakos1
1 Laikon General Hospital- National and Kapodistrian University of Athens, First Department of Surgery, Athens, Greece
2 Atkinson University Hospital- National and Kapodistrian University of Athens, Third Department of Surgery, Athens, Greece

P.07-340-Fri | Mixed Gastric Carcinoma, a rare condition: Report of 2 cases of Adenoneuroendocrine Carcinoma
J.H. Herrera Kok1, L.M. Alcoba Garcia1, C. Cavilanes1, I. Oliva1, M. De la Haz Riesco2, A. Alvarez Martinez1, J.M. Canga Presa1
1 Complejo Asistencial Universitario de León, General and Digestive Surgery - Upper GI Unit, León, Spain

P.07-341-Fri | The treatment of primary gastric synovial sarcoma by laparoscopic surgery: A case report
Y. Hirayama1, T. Koga1, Y. Kimura1, M. Kai1, K. Kajiyama1
1 Aso Iizuka Hospital, Surgery, Fukuoka, Japan

P.07-342-Fri | The establishment and primary application of tissue response grading system following neoadjuvant chemotherapy
J.K. Hu1, X.Z. Chen1, K. Yang1, X.L. Chen1
2 State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer, Chengdu, China

P.07-343-Fri | Research on resection of GIST (gastrointestinal stromal tumour) in the duodenum and proximal jejunum
Y. Huang1, G. Chen1, L. Lin1, X. Jin1, M. Kang1, Y. Zhang1, D. Shi1, K. Chen1, Q. Guo1, L. Chen1, D. Wu1, P. Huang1, J. Chen1
2 Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Surgery, Hangzhou, China
3 Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Radiology, Hangzhou, China

P.07-344-Fri | Impact of postoperative infection on long-term survival of gastric cancer patients: results from a high-volume institution in China
P. Huayang1, X.L. Chen1, K. Liu1, Y.L. Zhao1, W.H. Zhang1, K. Yang1, X.Z. Chen1, J.K. Hu2
2 State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- Sichuan Province- China, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China
3 State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- Sichuan Province- China, hujkwch@126.com, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China

P.07-345-Fri | Reduced port Distal Subtotal Gastrectomy with Lymphadenectomy-164 Consecutive Cases analysis
K. Ki Hyun1, S.H. Lee1, S.H. Hwang1
1 Pusan National University Yangsan Hospital- Yangsan- Republic of Korea, Surgery, Yangsan, Republic of Korea

P.07-346-Fri | Prognostic significance of hiatal hernia in patients with gastric cancer located at the upper-third of the stomach
D. Ichikawa1, S. Maruyama1, T. Kawaguchi1, R. Saito1, H. Akaike1, K. Shiraiishi1, H. Shimizu1, S. Furuya1, N. Hosomura1, H. Amemiya1, H. Kawaida1, M. Sudoh1, S. Inoue1, H. Kono1
2 University of Yamanashi, First Department of Surgery- Faculty of Medicine, Yamanashi, Japan
P.07-347-Fri | Evaluation of the surgical margin shrinkage after formalin fixation in esophageal or gastric cancer operations to create a correction factor
E. Ilhan1, O.B. Namdaroglu1, A. Aykas1, Y. Sahin2, O. Ureyen1, E. Vardar1, M. Yildirim1, A. Uslu1
1 University Of Health Sciences Izmir Baayaka Training And Research Hospital, General surgery, Izmir, Turkey
2 University Of Health Sciences Izmir Baayaka Training And Research Hospital, Pathology, Izmir, Turkey

P.07-348-Fri | A multicenter retrospective study to evaluate the feasibility of the double-flap technique as anti-reflux esophagogastrectomy after proximal gastrectomy (rD-FLAP Study)
M. Ishida1, S. Kuroda23, Y. Choda1, T. Kubota1, S. Otsuka1, S. Ueyama4, N. Tanaka1, A. Murooka5, S. Hato1, T. Kimura6, K. Tanakaya8, S. Kikuchi9, S. Tanabe7, K. Nomu1, M. Nishizaki21, S.K. Shunsuke Kagawa8, Y. Shirakawa3, Y. Kamikawa21, T. Fujitawa1
1 Hiroshima City Hiroshima Citizens Hospital, Department of Surgery, Hiroshima, Japan
2 Okayama University Graduate School of Medicine- Dentistry and Pharmaceutical Sciences, Department of Gastroenterological Surgery, Okayama, Japan
3 Okayama University Hospital, Center for Innovative Clinical Medicine, Okayama-, Japan
4 Fukuyama Medical Center, Department of Surgery, Fukuyama, Japan
5 Mihana Red Cross Hospital, Department of Surgery, Mihana, Japan
6 Kagawa Prefectural Center Hospital, Department of Surgery, Takamatsu, Japan
7 Kagawa Rosai Hospital, Department of Surgery, Marugame, Japan
8 National Hospital Organization Shikoku Cancer Center, Department of Gastroenterological Surgery, Matsuyama, Japan
9 Okayama Saiseikai General Hospital, Department of Surgery, Okayama, Japan
10 Jswaki Clinical Center, Department of Surgery, Iwakuni, Japan
11 Okayama University Hospital, Minimally Invasive Therapy Center, Okayama, Japan
12 Matsuda Hospital, Department of Surgery, Kurashiki, Japan

P.07-349-Fri | Impact of shape of the resected specimen on delayed gastric emptying after laparoscopy-assisted pylorus-preserving gastrectomy
N. Ito1, H. Tsujimoto1, S. Hiraki1, Y. Yaguchi1, I. Kumano1, S. Nomura1, M. Harada1, H. Nagata1, Y. Itazaki1, K. Kouzu1, S. Tsuchiya1, H. Ueno1
1 National Defence Medical College, Department of Surgery, Tokorozawa-shi, Japan

P.07-350-Fri | Conversion surgery for Stage IV Gastric Cancer
S. Iwagami1
1 Kumamoto University, Department of Gastroenterological Surgery, Kumamoto, Japan

P.07-351-Fri | Early Postoperative Oral Feeding after Total Gastrectomy for Gastric Carcinoma: A Propensity Score Matching Analysis
O. Jeong1, R. Seong Yeob1, J. Mi Ran1, K. Ji Hoon1
1 Chonnam National University Hwasun Hospital, Department of Surgery, Hwasun-eup, Republic of Korea

P.07-352-Fri | Implementation of enhanced recovery after surgery (ERAS) program in perioperative care of gastric cancer surgery: A nationwide survey in Korea
O. Jeong1, K. Ho Goon1, J. Mi Ran1, K. Ji Hoon1, R. Seong Yeob1
1 Chonnam National University Hwasun Hospital, Department of Surgery, Hwasun-eup, Republic of Korea
2 Chonnam National University Hospital, Department of Surgery, Gwangju, Republic of Korea

P.07-353-Fri | Comparison study of laparoscopic and open gastrectomy for the treatment of cT4 gastric cancer patients
Y.K. Park1, K. Ji Hoon1, S.Y. Ryu2, O. Jeong1, M.R. Jung1
1 Chonnam National University Hwasun Hospital- South Korea, Division of Gastroenterologic Surgery- Department of Surgery, Gwangju, Republic of Korea
2 Chonnam National University Hospital- South Korea, Division of Gastroenterologic Surgery- Department of Surgery, Gwangju, Republic of Korea

P.07-354-Fri | Is D2 lymphadenectomy mandatory for all advanced gastric cancer?
S.Y. Ryu1, K. Ji Hoon1, M.R. Jung1, O. Jeong1
1 Chonnam National University Hwasun Hospital- South Korea, Division of Gastroenterologic Surgery- Department of Surgery, Gwangju, Republic of Korea

P.07-355-Fri | Current state of surgical treatment of cancer of the stomach and gastro-esophageal junction in the Czech Republic
A. Jurkovic1, M. Duda1, L. Adamcik1, M. Skrovina1, L. Dusel1
1 Comprehensive Cancer Centre of Hospital Novy Jicin, Surgical department, Novji Jicin, Czechia
2 Institute of biostatistics and analyses, Masaryk University- Faculty of medicine, Brno, Czechia

P.07-356-Fri | Relationship between postoperative liver damage after laparoscopic gastrectomy and overlap of liver and stomach based on preoperative CT
S. Kaidi1, Y. Murakami1, T. Yamaguchi1, K. Takebayashi1, S. Murata1, T. Shimizu1, S. Ohta1, M. Tani1
1 Shiga University of Medical Science, Surgery, Otsu- Shiga, Japan
2 Shiga University of Medical Science, Radiology, Otsu- Shiga, Japan
Efficacy and Safety of Postoperative Intravenous Acetaminophen plus Thoracic Epidural Analgesia after Gastrectomy for Gastric Cancer: a randomized controlled trial
M. Kaji, J. Kinoshita, S. Fushida
1 Toyama Prefectural Central Hospital, Surgery, Toyama, Japan
2 Kanazawa University Hospital, Gastroenterological Surgery, Kanazawa, Japan

Intracorporeal triangular anastomosis for B-I reconstruction after laparoscopic distal gastrectomy
T. Kanazawa
1 Fukuyama City Hospital, Surgery Division, Fukuyama, Japan

The prognostic impact of tumor location on patients with resectable gastric cancer
A. Kaneta, S. Hiroi, M. Waragai, M. Honda, Y. Takano, Y. Teranishi
1 Saiseikai Toho University general hospital, Department of Surgery, Koriyama-City, Japan

Incidence of dumping syndrome after laparoscopic vagus nerve-preserving distal gastrectomy for early gastric cancer
1 Seoul National University Bundang Hospital, Department of Surgery, Seongnam, Republic of Korea
2 Seoul National University College of Medicine, Department of Surgery, Seoul, Republic of Korea

Role of splenectomy for upper and/or middle gastric cancer involving the greater curvature
Y. Kano, O. Matsumoto, H. Naoki, S. Kashi, N. Souya, S. Takeda
1 Cancer Institute Hospital- Japanese Foundation for Cancer Research, Department of Gastroenterological Surgery, Tokyo, Japan

Predicting major morbidity risk in gastric cancer resections
1 A. C. Camargo Cancer Center, Abdominal Surgery, Sao Paulo, Brazil
2 Santa Casa Medical School, Surgery, Sao Paulo, Brazil

A retrospective cohort study of perioperative prognostic factors for gastric cancer
1 National Cancer Center Hospital, Department of Gastric Surgery, Tokyo, Japan
2 Teikyo University School of Medicine, Department of Surgery- Teikyo University School of Medicine, Tokyo, Japan

The current trend of the choice of gastrectomy procedures in Japanese institutions
1 Kawamura Hospital, Surgery, Shizuoka, Japan
2 The Jikei University Daisan Hospital, Department of Laboratory Medicine, Tokyo, Japan

Introduction of modified ab-oral pouch to prevent jejunojejunostomy stricture after total gastrectomy for gastric cancer patients
A. Kim
1 Asan Medical Center, UGI Surgery, Seoul, Republic of Korea

Pancreatic Fistula after Radical Subtotal Gastrectomy for Gastric Cancer Patients
Y. H. Yang, D. H. Kim
1 Chungbuk National University College of Medicine, Department of Surgery, Cheongju, Republic of Korea

Factors that associates hospital costs in gastrectomy for gastric cancer
T. H. Kim, J. H. Park, S. H. Jeong, L. Young-Joon
1 Gyeongsang National University Hospital Changwon Hospital, Department of Surgery, Changwon, Republic of Korea
2 Gyeongsang National University Hospital, Department of Surgery, Jinju, Republic of Korea
**P.07-368-Fri | The relationship between compliance of an oral elemental diet (ELENTAL®) and suppressive effect of body weight loss after gastrectomy**


1 Kindai University Faculty of Medicine, Department of Surgery, Osaka-Sayama, Japan
2 National Hospital Organization Osaka National Hospital, Department of Surgery, Osaka, Japan
3 Osaka Police Hospital, Department of Surgery, Osaka, Japan
4 Kansai Medical University, Department of Surgery, Higashinada, Japan
5 Higashi-Hiroshima City Medical Center, Department of Gastroenterological Surgery, Higashi-Hiroshima, Japan
6 Ikeda Municipal Hospital, Department of Surgery, Ikeda, Japan
7 YAO Municipal Hospital, Department of Surgery, YAO, Japan
8 Osaka Municipal Hospital, Department of Surgery, Osaka, Japan
9 Toyonaka Municipal Hospital, Department of Surgery, Toyonaka, Japan
10 Osaka Rosai Hospital, Department of Surgery, Sakai, Japan

**P.07-369-Fri | Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junction Cancer**


1 Yokohama City University, Gastroenterological Surgery, Yokohama, Japan
2 Gastroenterological Center, Yokohama City University, Surgery, Yokohama, Japan

**P.07-370-Fri | Nutritional evaluation and nutritional support in the perioperative period of oncological patients using bioelectric impedance**

I. Krač1, J. Fila2, Z. Misir3, J. Filipovic Cugura1, J. Benčić1, L. Stefancić1

1 University Hospital for Tumors University Hospital Center Sestre milosrdnice, Surgical Oncology, Zagreb, Croatia
2 University Hospital for Tumors University Hospital Center Sestre milosrdnice, Oncological Radiology, Zagreb, Croatia
3 University Hospital Center Sestre milosrdnice, Department of Upper Gastrointestinal Surgery, Zagreb, Croatia
4 University Hospital for Tumors University Hospital Center Sestre milosrdnice, Intensive Care Unit, Zagreb, Croatia

**P.07-371-Fri | Multivisceral resection for treatment complicated advanced gastric cancer. Results analysis**

N. Kiselev1, V. Zagainov1

1 VDMC FMBA Russia Hospital 1, Oncology, Nizhnii Novgorod, Russian Federation

**P.07-372-Fri | Survival after HIPEC with oxaliplatin and docetaxel for gastric cancer patients with limited peritoneal dissemination**

W. Koemans1, R. van der Kaaij T1, E. Wassenaar C.E.1, K. Sikorska1, G. Grootscholten1, M. Loiz1, K. Hartemink J.1, A. Veenhof A.F.A.1, D. Boerma1, B. Ramshorst2, H. Boot4, J. Sandick W1

1 Netherlands Cancer Institute, Surgical Oncology, Amsterdam, Netherlands
2 Sant Antonius Hospital, Surgery, Nieuwegein, Netherlands
3 Netherlands Cancer Institute, Biometrics, Amsterdam, Netherlands
4 Netherlands Cancer Institute, Gastroenterology/Medical Oncology, Amsterdam, Netherlands
5 Sant Antonius Hospital, Medical Oncology, Nieuwegein, Netherlands

**P.07-373-Fri | Laparoscopic sub-total gastrectomy for patients with cT1 gastric cancer of the upper stomach**

K. Kojima1, T. Tanaka2, H. Shusuke3, Y. Ohkura4, S. Koga5, M. Ueno6, H. Udagawa7

1 Tanononom Hospital, Gastroenterostinal Surgery, Minato Ward, Japan

**P.07-374-Fri | 40 years of the Polish Gastric Cancer Study Group: time trends in combined modality treatment of gastric cancer**

P. Kolodziejczyk1, M. Sierzęga1, A. Szczepaniak1, P. Richter2

1 Jagiellonian University Medical College, 1st Department of Surgery, Krakow, Poland

**P.07-375-Fri | Clinical impact of the closure of the Petersen’s defect after laparoscopic gastrectomy**

K. Kozu1, H. Tsujimoto2, S. Hiraiki3, Y. Yaguchi1, I. Kamano1, R. Takahata1, S. Nomura1, N. Ito1, M. Hanada1, H. Nagata1, Y. Ishibashi1, Y. Itazaki1, S. Tsuchiya1, K. Hase1, H. Ueno1

1 National Defense Medical College, Department of Surgery, Saitama, Japan

**P.07-376-Fri | Significance of continuous glucose monitoring after gastrectomy**

T. Kubota1, K. Shoda2, T. Kasaiga3, A. Shisazaki4, H. Konishi5, H. Fujiiwara6, K. Okamoto7, E. Otsuji8

1 Kyoto Prefectural University of Medicine, Digestive Surgery, Kyoto, Japan
P.07-377-Fri | Comparisons between isoperistaltic and antiperistaltic gastrojejunostomy in laparoscopic distal gastrectomy: Surgical outcomes of prospective randomized study
I. G. Kwon1, C. Seung-Ho1, S. Young-Gil1, R. Seung Wan2
1 Yonsei University Gangnam Severance Hospital, Surgery, Seoul, Republic of Korea
2 Keimyung University Dongsan Hospital, Surgery, Daegu, Republic of Korea

P.07-378-Fri | Short-term outcomes after double tract reconstruction versus double flap technique of laparoscopic proximal gastrectomy in early gastric cancer
O. K. Kwon1, B. Yu1, K. B. Park1, J. Y. Park1, S. S. Lee1, H. Y. Chung2
1 Kyungpook National University Chilgok Hospital, Gastric Cancer Center, Daegu, Republic of Korea
2 Kyungpook National University Hospital, Department of Surgery, Daegu, Republic of Korea

P.07-379-Fri | Laparoscopic palliative gastrectomy can be safely applied to stage IV gastric cancer with outlet obstruction
S. J. Kwon1, M. G. Kim1
1 Hanyang University Hospital, Surgery, Seoul, Republic of Korea

P.07-380-Fri | Feasibility and acceptability of gastric emptying SPECT/CT for evaluation of early anastomosis leakage for upper gastrointestinal surgery
S. Lee1, H. Lee1, E. J. Lee2
1 Seoul Medical Center, General Surgery, Seoul, Republic of Korea
2 Seoul Medical Center, Nuclear Medicine, Seoul, Republic of Korea

P.07-381-Fri | Anatomic variations in the left gastric vein and their clinical significance during laparoscopic gastrectomy
J. Lee1, H. Lee2
1 The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea
2 The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

P.07-382-Fri | Impact of Endoscopic Submucosal Dissection on Short-term Surgical Outcomes in Followed Laparoscopic Distal Gastrectomy for Gastric Cancer: Propensity Score-matched Analysis
H. Lee1, J. Lee2
1 The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea
2 The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

P.07-383-Fri | Surgical outcomes after gastrectomy due to perforated gastric cancer
J. Y. Lee1, K. H. Jun1, H. M. Chin2
1 St. Vincent’s Hospital - The Catholic University of Korea, Department of Surgery, Suwon, Republic of Korea
2 The Catholic University of Korea, Department of Surgery, Suwon, Republic of Korea

P.07-384-Fri | Radical gastrectomy with Japanese D2 lymph node dissection for gastric cancer treatment in México. Initial experience
A. M. Leon Takahashi1, H. M. Lopez-Bazave1, L. S. Lino-Silva2, M. A. Herrera Servin3, C. Díaz Romero4, A. Alfaro Goldaracena2, A. Herrera Gomez2
1 National Cancer Institute, Gastrointestinal Surgery, Mexico City, Mexico
2 National Cancer Institute, Pathology Department, Mexico City, Mexico
3 National Cancer Institute, Endoscopy Department, Mexico City, Mexico
4 National Cancer Institute, Medical Oncology Department, Mexico City, Mexico
5 National Cancer Institute, Medical Director Department, Mexico City, Mexico

P.07-385-Fri | Hospital Gastrectomy Volume Predicts Adequate Lymphadenectomy in Gastric Adenocarcinoma
J. Levy1, V. Gupta1, N. Jivraj1, C. Allen-Ayodabo2, E. Amirazodi2, Q. Li2, A. Mahar1, C. De Mestral1, O. Saarela2, N. Coburn1
1 University of Toronto, Division of General Surgery, Toronto, Canada
2 University of Toronto, Department of Anesthesiology, Toronto, Canada
3 Sunnybrook Research Institute, Institute of Clinical Evaluative Sciences, Toronto, Canada
4 Institute of Clinical Evaluative Sciences, Research & Data, Toronto, Canada
5 University of Manitoba, Community Health Sciences, Winnipeg, Canada
6 University of Toronto, Division of Vascular Surgery, Toronto, Canada
7 Dalla Lana School of Public Health, Biostatistics Division, Toronto, Canada

P.07-386-Fri | Variation in Gastric Cancer Outcomes in North America
J. Levy1, V. Gupta1, N. Jivraj1, E. Amirazodi2, C. Allen-Ayodabo2, Q. Li2, O. Saarela2, N. Coburn1
1 University of Toronto, Division of General Surgery, Toronto, Canada
2 University of Toronto, Department of Anesthesiology, Toronto, Canada
3 Sunnybrook Research Institute, Institute of Clinical Evaluative Sciences, Toronto, Canada
4 Institute of Clinical Evaluative Sciences, Research & Data, Toronto, Canada
5 Dalla Lana School of Public Health, Biostatistics Division, Toronto, Canada
P.07-387-Fri | Influence of enhanced recovery after surgery programs on laparoscopy-assisted gastrectomy for gastric cancer: a systematic review and meta-analysis
Z. Li1, Q. Zhao1
1 Xijing Hospital of Digestive Diseases - The Fourth Military Medical University, Department of Surgery, Xian, China

P.07-388-Fri | Distal versus total gastrectomy for middle and lower-third gastric cancer: A systematic review and meta-analysis
Z. Li
1 Xijing Hospital of Digestive Diseases - The Fourth Military Medical University, Department of Surgery, Xian, China

P.07-389-Fri | Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 lymph node dissection for advanced gastric cancer
Z. Li
1 Xijing Hospital of Digestive Diseases - The Fourth Military Medical University, Department of Surgery, Xian, China

P.07-390-Fri | Enhanced Recovery After Surgery Programs for Laparoscopic Abdominal Surgery: A Systematic Review and Meta-analysis
Z. Li1, Q. Zhao2
1 Xijing Hospital of Digestive Diseases - The Fourth Military Medical University, Department of Surgery, Xian, China
2 Xijing Hospital of Digestive Diseases - The Fourth Military Medical University, Department of Surgery, Xieng, China

P.07-391-Fri | Clinical effect of radical gastrectomy with preservation of greater omentum for gastric cancer
S. Jia1, P. Liang1, L. Cao2
1 The First Affiliated Hospital of Dalian Medical University, Department of gastroenterology, Dalian, China

P.07-392-Fri | Incidence, causes and risk factors for anastomotic leakage after operation of gastric cancer
Z.B. Lin1, D.Q. Wu1, X.Q. Yao1
1 Guangdong general hospital, surgical gastroenterology, Guangzhou, China

P.07-393-Fri | Impact of Drinking Chinese Green Tea on Gastrointestinal Function Recovery after Gastrectomy for Gastric Cancer: A Randomized Controlled Trial
Z. Liu1, Y. Zhou1, S. Cao1, X. Liu1, X. Tan1, H. Jiang1, Z. Niu1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.07-394-Fri | Postoperative complications in elderly patients with gastric cancer
X. Liu1, W. Kang1, J. Yu1
1 Peking Union College Hospital, Surgery, Beijing, China

P.07-395-Fri | The role of proximal gastrectomy in the treatment of esophagogastric junction and gastric carcinomas
P. Lochman1, J. Kovařík1, J. Páral1
1 Faculty of Military Health Sciences - University of Defence, Dept. of Field Surgery, Hradec Králové, Czechia

P.07-396-Fri | Is the time to extend the indications of proximal gastrectomy?
P. Lochman1, J. Páral1
1 Faculty of Military Health Sciences - University of Defence, Dept. of Field Surgery, Hradec Králové, Czechia

P.07-397-Fri | A Novel Abdominal Negative Pressure Lavage—Drainage System for Anastomotic Leakage After R0 Resection for Gastric Cancer
J. Lu1, Z.F. Zheng1, J.W. Xie2, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, Fujian Province, China

P.07-398-Fri | Comparison of recurrence between 3D and 2D laparoscopic radical gastrectomy: using randomized phase III trial data
J. Lu1, B.B. Xu1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, Fujian Province, China

P.07-399-Fri | Completion rates of enhanced recovery after surgery in gastrectomy
Y. Luo1, Y. Li1
1 Guangdong General Hospital - Guangdong Academy of Medical Sciences, Department of General Surgery, Guangzhou, China
P.07-400-Fri | Cost-benefit analysis of an enhanced recovery program for gastrectomy
V. Luzuy-Guarnero1, C. Gronnier2, S. Figueiredo1, S. Mantziari1, M. Schäfer1, N. Demartines1, P. Allemann1
1 University Hospital of Lausanne, Digestive Surgery, Lausanne, Switzerland
2 CHU of Bordeaux, Digestive Surgery, Bordeaux, France

P.07-401-Fri | Application of the operative strategy by symmetric mesogastric excision for stomach cancer based on membrane anatomy
Z. Ma1, H. Liu1, S. Zhao1, X. Wang1
1 The second hospital of Jilin University, Gastrointestinal Nutrition and Hernia Surgery, Changchun, China

P.07-402-Fri | Postoperative functional assessment after distal gastrectomy to treat gastric cancer
T. Marché1, E. Nomura1
1 Tokai University, Gastroenterological and General Surgery, Tokyo, Japan

P.07-403-Fri | The role of omentectomy for open and laparoscopic gastrectomy: A supplementary analysis of multicenter retrospective cohort study
R. Makushio1, T. Kinoshita1, I. Uyama1, M. Honda1, Y. Tamamori2, T. Naba1, H. Noshiro1, S. Hisamori3, E. Naga1, M. Tokunaga4, T. Ogino5, Y. Yoda6, K. Obama7, K. Kikuchi8, K. Ohuchida9, K. Sakurai10, T. Abe11, M. Terashima12
1 Shizuoka Cancer Center, Division of Gastric Surgery, Shizuoka, Japan
2 National Cancer Center Hospital East, Gastric Surgery Division, Chiba, Japan
3 Fujita Health University, Department of Surgery, Aichi, Japan
4 Fukushima Medical University, Department of Minimally Invasive Surgical and Medical Oncology, Fukushima, Japan
5 Osaka City General Hospital, Department of Gastroenterological Surgery, Osaka, Japan
6 JCHO Kyushu Hospital, Division of Surgery, Fukuoka, Japan
7 Saga University Faculty of Medicine, Department of Surgery, Saga, Japan
8 Kyoto University, Department of Surgery-Graduated School of Medicine, Kyoto, Japan
9 Kyushu University, Department of Surgery and Oncology-Graduate School of Medical Sciences, Fukuoka, Japan
10 Keio University School of Medicine, Department of Preventive Medicine and Public Health-Biostatistics at Center for Clinical Research, Tokyo, Japan

P.07-404-Fri | Laparoscopic resection of gastric cancer – results from a Norwegian regional centre
T. Mala1, H.O. Johannessen2, D. Førland2, E. Johnson2
1 Oslo University Hospital- Ullevål, Dep Gastrointestinal Surgery, Oslo, Norway
2 Oslo University Hospital, Dep Gastrointestinal Surgery, Oslo, Norway

P.07-405-Fri | Laparoscopic resection of gastric cancer – results from a Norwegian regional centre
T. Mala1, H.O. Johannessen2, D. Førland2, E. Johnson2
1 Oslo University Hospital- Ullevål, Dep Gastrointestinal Surgery, Oslo, Norway
2 Oslo University Hospital, Dep Gastrointestinal Surgery, Oslo, Norway

P.07-406-Fri | Proximal resection margin as a risk factor for recurrence in gastric carcinoma – first preliminary results
R. Matias1, A. Gomes2, M. Sousa1, V. Nunes2
1 Hospital Prof. Doutor Fernando Fonseca, General Surgery, Amadora, Portugal
2 Hospital Prof. Dr Nuno Fonseca, Surgery, Amadora, Portugal

P.07-407-Fri | Proximal resection margin as a risk factor for recurrence in gastric carcinoma – first preliminary results
A. Gomes1, I. Nicole2, M.L. Gloria3, M. Sousa1, R. Matias1, C. Neves Marques1, S. Loureiro dos Santos1, J. Passos Coelho1, C. Fragata2, S. Ramos3, M.J. Brito3, V. Nunes1, A. Miranda14
1 Hospital Prof. Dr Fernando Fonseca, Surgery, Amadora, Portugal
2 Hospital Prof. Dr Fernando Fonseca, Oncology National Registry, Amadora, Portugal
3 National Oncology Registry- Hospital Beatriz Angoels, National Oncology Registry- Hospital Beatriz Angoels, Loures, Portugal
4 National Oncology Registry- Hospital Vila Franca de Xira, National Oncology Registry- Hospital Vila Franca de Xira, Vila Franca de Xira, Portugal
5 National Oncology Registry- Hospital de Olhão, National Oncology Registry- Hospital de Olhão, Olhão, Portugal
6 National Oncology Registry- Hospital Vila Nova de Gaia, National Oncology Registry- Hospital de Gaia, Gaia, Portugal
7 National Oncology Registry- Hospital do Bispo, National Oncology Registry- Hospital da Luz, Lisbon, Portugal
8 National Oncology Registry-Hospital Garcia d’Orta, National Oncology Registry- Hospital Garcia d’Orta, Almada, Portugal
9 Hospital Prof. Dr. Fernando Fonseca, Surgery Department, Amadora, Portugal
10 National Oncology Registry- Instituto Portugues de Oncologia, National Coordination, Lisbon, Portugal
P.07-408-Fri | Partial stomach-partitioning gastrojejunostomy, a procedure to improve nutritional status in malignant gastric outlet obstruction

R. Matias1, M. Sousa1, A. Gomes1, R. Martins1, N. Pignatelli1, V. Nunes1
1 Hospital Prof. Doutor Fernando Fonseca, General Surgery, Amadora, Portugal

P.07-409-Fri | Giant gastric sarcomas versus giant gastric GISTs

M. Mester1, R. M. Cedro1, A. Morrell1, R. Falzoni1, B. Zilberstein1, V. A. Alves1, I. Cecconello1
1 University of São Paulo Medical School, Gastroenterology, São Paulo, Brazil
2 University of São Paulo Medical School, Pathology, São Paulo, Brazil

P.07-410-Fri | What are the effects of neoadjuvant chemotherapy on gastrectomy with D2 lymph node dissection?

M. Mihmanli1, M. Tanal1, U. Demir1, C. Kay1, E. Kabul Gurbulak1, E. Capkinoglu1
1 Health Sciences University, General Surgery Department, Istanbul, Turkey

P.07-411-Fri | Significance of limited surgery for elderly gastric cancer patients who underwent gastrectomy

H. Miyagaki1, O. Takayama1, T. Fukada1, T. Shingai1, T. Fukusaki1
1 Osaka Saiseikai Semni Hospital, Surgery, Suita, Japan

P.07-412-Fri | Prognosis of surgical resection for liver metastases of gastric cancer

K. Miyata1, M. Fukaya1, J. Kawakami1, K. Tominaga1, K. Ishii1, T. Ebata1, Y. Yokoyama1, N. Masata1
1 Nagoya University Graduate School of Medicine, Division of Surgical Oncology Department of Surgery, Nagoya city, Japan
2 Nagoya University Graduate School of Medicine, Division of Perioperative Medicine Department of Surgery, Nagoya city, Japan

P.07-413-Fri | Fluorescence guided gastric cancer lymphadenectomy: is indocyanine green fluorescence able to detect metastatic lymph nodes?

B. Molteni1, S. Molfino1, S. Benedicenti1, M.S. Alfano1, P. Porsio1, N. Portolani1, G.L. Baiocchi1
1 Brescia University, General Surgery, Brescia, Italy

P.07-414-Fri | Assessment of perforated gastric cancer cases at tane general hospital in Japan

T. Mori1, T. Itami1, Y. Matsui1, H. Koike1, Y. Kudose1, T. Shoji1, Y. Yamaguchi1, N. Hirooka1, T. Shirotai1, M. Ogawa1, A. Ogawa1, Y. Uemura1, T. Nishi1, H. Niwa1
1 Tane General Hospital, Surgery, Osaka, Japan

P.07-415-Fri | Impaired tolerance to volume load may be a cause of small stomach syndrome after gastrectomy

K. Murakami1, K. Nakada1, M. Kawamori1, T. Iwasaki1, A. Shida1, T. Matsuura1, H. Hanyu1, K. Yanag1
1 The Jikei University School of Medicine, Surgery, Tokyo, Japan
2 The Jikei University Daishon Hospital, Laboratory Medicine, Tokyo, Japan
3 Tokyo General Hospital, Surgery, Tokyo, Japan

P.07-416-Fri | Laparoscopic partial gastrectomy (LECS and LECS related procedure) for gastric GIST

K. Nabeshima1, M. Ogimi1, H. Haru1, M. Tomioku1, K. Nakamura1, E. Nomura1, T. Nakagori1, S. Ozawa1
1 Tokai University, Department of Surgery, Isehara, Japan
2 Tokai University Hachioji Hospital, Department of Surgery, Hachioji, Japan

P.07-417-Fri | The usefulness of laparoscopic approach and preservation of celiac branch of vagal nerve on postoperative QOL after distal gastrectomy

K. Nakada1, S. Kimami1, M. Ikeda1, M. Takahashi1, M. Yoshida1, Y. Uenosono1, M. Terashima1, Y. Koder1
1 The Jikei University Daishon Hospital, Laboratory Medicine, Tokyo, Japan
2 Kanazawa Medical University, Surgical Oncology, Kanazawa, Japan
3 Asama General Hospital, Surgery, Sakai, Japan
4 Yokohama Municipal Citizen’s Hospital, Gastroenterological Surgery, Yokohama, Japan
5 International University of Health and Welfare Hospital, Surgery, Tochigi, Japan
6 Iinuma General Hospital, Surgery, Nagashima, Japan
7 Shizuoka Cancer Center, Gastric Surgery, Shizuoka, Japan
8 Nagoya University Graduate School of Medicine, Gastroenterological Surgery, Aichi, Japan

P.07-418-Fri | Conversion surgery for advanced gastric cancer with peritoneal metastasis

M. Nakamura1, M. Nakamori1, T. Ojima1, M. Katsuda1, K. Hayata1, T. Goda1, J. Kitadani1, S. Maruoka1, H. Yamaue1
1 Wokayama Medical University, Second Department of Surgery, Wokayama, Japan
P.07-419-Fri | The infracardiac bursa: a newly identified surgical landmark in esophagogastric junction cancer surgery
T. Nakamura1, H. Shinohara1, T. Okada1, S. Hisamori1, S. Tsunoda1, K. Obana1, Y. Kurahashi1, A. Takai1, T. Takakuwa1, S. Yamada1, Y. Sakai1
1 Kyoto University, Department of Surgery, Kyoto, Japan
2 Hyogo College of Medicine, Department of Surgery, Nishinomiya, Japan
3 Ehime University, Department of HPB and Breast Surgery, Toon, Japan
4 Kyoto University, Human Health Sciences, Kyoto, Japan
5 Kyoto University, Congenital Anomaly Research Center, Kyoto, Japan

P.07-420-Fri | Evaluating the Costs of Laparoscopic versus Open Total Gastrectomy: Is laparoscopic expensive than open technique?
A. Navarrete1, R. Humeres2, K. Werner1, L. Manriquez2, R. Sepulveda2
1 1.- Department of Surgery- Hospital Militar- Santiago- Chile 2.- Department of Surgery- Faculty of Medicine Clinica Alemana- Universidad del Desarrollo- Santiago- Chile, Surgery Department, Santiago, Chile
2 Department of Surgery- Hospital Militar- Santiago- Chile, Surgery Department, Santiago, Chile

P.07-421-Fri | Quality of Life After Laparoscopic Total Gastrectomy versus Open Total Gastrectomy: Evaluation with the EORTC30 - QLQ25 questionnaire
A. Navarrete1, R. Humeres2, K. Werner1, L. Manriquez2, R. Sepulveda2
1 1.- Department of Surgery- Hospital Militar- Santiago- Chile 2.- Department of Surgery- Faculty of Medicine Clinica Alemana- Universidad del Desarrollo- Santiago- Chile, Surgery Department, Santiago, Chile
2 Hospital Militar de Santiago, Surgery, santiago, Chile

P.07-422-Fri | Comparison of post-operative complications following open, laparoscopic and robotic gastrectomy: a propensity-score match analysis of 2914 patients using real-world data
B.C. Navarro1, W.J. Hyung2
1 1. St Lukes Medical Center - Global City, Institute of Surgery, Taguig City, Philippines
2 Yongsei University Health System - Severance Hospital, Department of Surgery, Seoul, Republic of Korea

P.07-423-Fri | GAPPS Syndrome: the Surgical Point of View
L. Nemec1, L. Sirotek1, P. Fabian2, R. Sefr1, V. Jedlicka1
1 Masaryk Memorial Cancer Institute, Department of Surgical Oncology, Brno, Czechia
2 Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology, Brno, Czechia

P.07-424-Fri | Gastric cancer nomogram for predicting postoperative survival in patients aged 80 or older
T. Nishigori1, K. Obana1, H. Shinohara1, H. Kawada1, Y. Kadokawa1, H. Harada1, S. Kairha1, H. Hata1, S. Ueda1, S. Konishi1, H. Okabe1, K. Matsuo1, H. Hosogi1, S. Tsunoda1, S. Hisamori1, Y. Sakai1
1 Kyoto University, Department of Surgery, Kyoto, Japan
2 Osaka Red Cross Hospital, Department of Surgery, Osaka, Japan
3 Tenri Hospital, Department of Surgery, Nara, Japan
4 Shiga General Hospital, Department of Surgery, Shiga, Japan
5 Kobe City Medical Center General Hospital, Department of Surgery, Kobe, Japan
6 Kyoto Medical Center, Department of Surgery, Kyoto, Japan
7 Kitano Hospital, Department of Gastroenterological Surgery, Osaka, Japan
8 Kyoto Katsura Hospital, Department of Surgery, Kyoto, Japan
9 Otsu Municipal Hospital, Department of Surgery, Shiga, Japan
10 Kyoto City Hospital, Department of Surgery, Kyoto, Japan

P.07-425-Fri | Prediction of the risk of laparoscopy-assisted gastrectomy by comparing visceral fat area and body mass index
Z. Niu1, Y. Liu2, D. Gao3, Y. Zhou1, Q. Xue1, X. Jin1, Z. Gang1
1 the Affiliated Hospital of Qingdao University, Gastroenterological Surgery, Qingdao, China

P.07-426-Fri | The safety of laparoscopic gastrectomy in early gastric cancer patients
J. Nogueiro1, V. Devezas1, H. Santos-Sousa1, F. Sousa1, C. Fernandes1, A. Pereira1, T. Fonseca1, J. Barbosa1, J. Costa-Maia1
1 Centro Hospitalar Universitário de São João, General Surgery, Porto, Portugal

P.07-427-Fri | Choosing the optimal surgical approach in advanced gastric cancer: analysis of a series of 237 patients from a tertiary center
J. Nogueiro1, V. Devezas1, H. Santos-Sousa1, F. Sousa1, C. Fernandes1, A. Pereira1, T. Fonseca1, J. Barbosa1, J. Costa-Maia1
1 Centro Hospitalar Universitário de São João, General Surgery, Porto, Portugal
P.07-428-Fri | The Platelet-Lymphocyte ratio as a Prognostic Factor in Gastric Cancer patients

J. Nogueiro¹, V. Devezas¹, H. Santos-Sousa¹, F. Sousa¹, C. Fernandes¹, A. Pereira¹, T. Fonseca¹, J. Barbosa¹, J. Costa-Maia¹

¹ Centro Hospitalar Universitário de São João, General Surgery, Porto, Portugal

P.07-429-Fri | Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: a comparison with conventional open distal gastrectomy

J. Noh¹, B. Yu², K.B. Park², J.Y. Park², S.S. Lee², O.K. Kwan³, H.Y. Chung³

¹ Kyungpook National University Hospital, Department of surgery, Daegu, Republic of Korea
² Kyungpook National University Chilgok Hospital, Gastric cancer center, Daegu, Republic of Korea

P.07-430-Fri | Significance of Lymph node dissection of splenic hilum in upper third gastric cancer located in the greater curvature

T. Nomura¹, N. Fukushima¹, M. Toda¹, H. Iizawa¹

¹ Yamagata Prefectural Central Hospital, Surgery, Yamagata, Japan

P.07-431-Fri | Evaluation by E-PASS system of surgical outcomes after gastrectomy for elderly patients with stage I gastric cancer

S. Nunobe¹, N. Hiki¹, K. Kamagari¹, S. Ida¹, M. Ohashi¹, T. Sano¹

¹ Cancer Institute Hospital, Department of Gastric Surgery, Tokyo, Japan

P.07-432-Fri | Retrospective analysis of Reconstruction time of laparoscopic proximal gastrectomy with double-flap technique

T. Ohashi¹, S. Nunobe¹, S. Ida¹, K. Kamagari¹, M. Ohashi¹, T. Sano¹, T. Yamaguchi¹, N. Hiki¹

¹ The Cancer Institute Hospital, Gastric Surgery- Gastroenterological Surgery, Tokyo, Japan

P.07-433-Fri | Operative results of laparoscopic gastrectomy for gastric cancer in our institution

N. Okumura¹, H. Tsuchiya¹, M. Uehara¹, T. Sakurakatani¹, Y. Sasaki¹, S. Osada¹, M. Yamada¹, Y. Sugiyama¹

¹ Gifu Municipal Hospital, Surgery, Gifu, Japan

P.07-434-Fri | Postoperative fever peak as a tool for predicting postoperative complications in patients who underwent gastrectomy

E.C.A. Orlina¹, B.C. Navarro¹, M. Cho¹, W.J. Hyung¹

¹ Yonsei Cancer Center, Gastrointestinal Surgery, Seoul, Republic of Korea

P.07-435-Fri | Clinicopathological features and disease outcome of complicated gastric cancer with outlet obstruction, perforation or overt bleeding. (Multicenter GIRG retrospective study)

E. Orsenigo¹, M.C. Salandini², L. Graziosi², S. Ministrini², S. Giacopuzzi², L. Scorsone², S. Sofia², A. Coniglio², R. Reddavid³, F. Casella³, M. Degiuli³

¹ San Raffaele Hospital, Department of General and Emergency surgery, Milan, Italy
² Santa Maria della Misericordia Hospital, Perugia, Department of General and Emergency surgery, Perugia, Italy
³ Spedali Civili, Brescia, Department of Surgery, Brescia, Italy
⁴ Ospedale Civile Maggiore, Department of General and Upper GI Surgery, Verona, Italy
⁵ San Luigi University Hospital, Orbassano, Surgical Oncology and Digestive Surgery, Torino, Italy
⁶ Ospedale Mal M. Vannini, Rome- Italy, Department of General Surgery, Rome, Italy

P.07-436-Fri | Short term nutritional status and quality of life after laparoscopic total gastrectomy and laparoscopic sub-total gastrectomy for Stage 1 gastric cancer

H. Ota¹, K. Tanabe¹, Y. Saeki¹, Y. Yamamoto¹, R. Saite¹, H. Ohdani¹

¹ Graduate School of Biomedical & Health Science Hiroshima University, Department of Gastroenterological and Transplant Surgery, Hiroshima, Japan
P.07-437-Fri | Ursodeoxycholic Acid Prevents the Gallstone Formation after Gastrectomy in Patients with Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study (PEGASUS-D)

D.J. Park¹, Y.S. Park¹, D.K. Jang¹, M.W. Yoo¹, S.H. Hwang¹, S.Y. Ryu¹, O.K. Kwon¹, H. Hur¹, H.M. Yoon¹, T. Son¹, H.S. Ahn¹, H.H. Lee¹, M.G. Choi¹, S.I. Lee¹, S.H. Lee¹

¹ Seoul National University Bundang Hospital, Surgery, Seongnam-si, Republic of Korea
2 Dongguk University Ilsan Hospital, Internal Medicine, Goyang-si, Republic of Korea
3 Asan Medical Center, Surgery, Seoul, Republic of Korea
4 Pusan National University Yangsan Hospital, Surgery, Pusan, Republic of Korea
5 Chonnam National University Hwasun Hospital, Surgery, Hwasun, Republic of Korea
6 Kyungpook National University Chilgok Hospital, Surgery, Chilgok, Republic of Korea
7 Ajou University Hospital, Surgery, Suwon, Republic of Korea
8 National Cancer Center, Surgery, Goyang, Republic of Korea
9 Yonsei University Severance Hospital, Surgery, Seoul, Republic of Korea
10 Boramae Medical Center, Surgery, Seoul, Republic of Korea
11 Catholic University Seoul St. Mary's Hospital, Surgery, Seoul, Republic of Korea
12 Samsung Medical Center, Surgery, Seoul, Republic of Korea
13 Chungnam National University Hospital, Surgery, Daejeon, Republic of Korea
14 Seoul National University Hospital, Internal Medicine, Seoul, Republic of Korea

P.07-438-Fri | Does age bother to operate on elderly patients older than 80 years with gastric cancer?

J.Y. Park¹, B. Yu¹, K.B. Park¹, O.K. Kwon¹, S.S. Lee¹, H.Y. Chung¹

¹ Kyungpook National University, Department of Surgery, Daegu, Republic of Korea

P.07-439-Fri | Postoperative pulmonary complication after gastrectomy for gastric cancer

J.H. Park¹, T.H. Kim¹, S.S. Jeong¹, Y.J. Lee¹

¹ Gyeongsang National University Hospital, Surgery, Jinju, Republic of Korea

P.07-440-Fri | Long limb Roux-en-Y subtotal gastrectomy for treatment of severe gastroparesis with type 2 diabetes mellitus

J.M. Park¹, J.W. Kim¹, K.C. Chi¹

¹ Chung-Ang University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.07-441-Fri | Quality of life changes after totally laparoscopic distal gastrectomy: a comparison with laparoscopy-assisted distal gastrectomy

K.B. Park¹, B. Yu¹, J.Y. Park¹, S.S. Lee², O.K. Kwon¹, H.Y. Chung¹

¹ Kyungpook National University Chilgok Hospital, Gastric Cancer Center, Daegu, Republic of Korea
2 Kyungpook National University Hospital, Department of Surgery, Daegu, Republic of Korea

P.07-442-Fri | Intracorporeal hemi-double stapling esophagojejunostomy for upper third gastric cancer

S.H. Park¹, Y.S. Suh¹, F. Berthi¹, J.H. Choi¹, J.H. Park¹, T.H. Kim¹, Y.G. Son¹, Y.J. Huh¹, S.H. Kong¹, H.J. Lee¹, H.K. Yang¹

¹ Seoul National University Hospital, Department of Surgery, Seoul, Republic of Korea
2 Seoul National University College of Medicine, Cancer Research Institute, Seoul, Republic of Korea

P.07-443-Fri | Proximal vs total gastrectomy for advanced gastric cancer in the upper third of the stomach: a propensity score-matched analysis

H. Chen¹, G. Li¹, R. Peng¹, C. Yue¹, W. Wei¹, B. Zhou¹, X. Wen¹, R. Gu¹, X. Ming¹

¹ Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Department of General Surgery, Nanjing, China

P.07-444-Fri | Gastric GIST – surgical resection outcomes

M. Pereira Ferreira¹, G. Luz², R. Garrido³, R. Mário³

¹ Hospital Beatriz Ângelo - Loures - Portugal, Grúngia Geral, Lisboa, Portugal
2 Hospital Beatriz Ângelo, Grúngia Geral, Lisboa, Portugal

P.07-445-Fri | Proximal gastric resection with posterior esophago-gastrostomy and partial neo-fundoplication in the treatment of advanced upper gastric carcinoma

W. Polkowski¹, K. Rawicz-Praszynski¹, J. Mleko²

¹ Medical University of Lublin, Department of Surgical Oncology, Lublin, Poland
2 Medical University of Lublin, Department of Surgical Oncology, Lublin, Poland

P.07-446-Fri | Open vs laparoscopic approach in gastric cancer surgery: could non-inferiority be assumed?

A. Puerta¹, D. Ramos¹, P. Priego¹, J. Galindo¹, A. Villar¹

¹ Hospital Ramon y Cajal, Digestive surgery, Madrid, Spain
P.07-447-Fri | Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients.

R. Reddavid1, P. Strignano2, S. Sofia1, A. Evangelista1, G. Deiro1, G. Cannata1, A. Ferreiro2, M. Minecchia1, R. Leli2, S. Gentilli3, P. Chiare1, R. Polastry1, F. Bonghi1, M. Camandona1, R. Romagnoli1, M. Marin2, M. Degiuli2

1 University of Turin- San Luigi University Hospital S.L.U.H., Department of Oncology- Surgical Oncology and Digestive Surgery Unit, Orbassano, Italy
2 AOU Città della Salute e della Scienza di Torino, University of Turin- Department of Surgical Sciences-, Turin, Italy
3 General Surgery Unit- Ospedale Maggiore della Carità, University of Eastern Piedmont- Department of Health Sciences, Novara, Italy
4 ASO SS Crece e Carlo, Unit of General and Oncological Surgery- Department of Surgery, Cuneo, Italy
5 Ospedale Umberto I di Torino, Department of General and Oncological Surgery, Turin, Italy
6 Ospedale degli Infermi di Bietta, Department of General Surgery, Biella, Italy

P.07-448-Fri | Surgical approach to gastric cancer patients: laparoscopic versus open resection

S. Rodrigues1, J. Nogueiro1, V. Devezas1, H. Santos-Sousa1, F. Sousa1, C. Fernandes1, A. Pereira1, T. Fonseca1, J. Barbosa1, J. Costa-Maia1

1 São João Medical Center - Faculty of Medicine, Department of Surgery, Porto, Portugal
2 São João Medical Center, Department of Surgery, Porto, Portugal
3 São João Medical Center - Faculty of Medicine, Department of Surgery, Porto, Portugal

P.07-449-Fri | The Impact of Preoperative ASA Score on Postoperative Complications and Long-term Survival Outcomes in Gastric Cancer Patients

F. Rosa1, G. Quero1, C. Fiorillo1, S. Alfieri1

1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS- Catholic University, Digestive Surgery, Rome, Italy

P.07-450-Fri | Billroth II Reconstruction In Gastric Cancer Surgery: A Good Option for Western Patients

F. Rosa1, G. Quero1, C. Fiorillo1, G.B. Doglietto1, S. Alfieri1

1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS- Catholic University, Digestive Surgery, Rome, Italy

P.07-451-Fri | Surgery for stage IV gastric cancer with extra-regional lymph node metastases

M. Sacco1, S. Sofia2, L. Torroni1, M. Bencivenga1, G.A.M. Tiberio1, P. Morgagni1, A. D'Ignazio1, G. de Manzoni1

1 University of Verona, Upper GI Surgery, Verona, Italy
2 University of Torino, Surgery, Torino, Italy
3 University of Brescia, Surgery, Brescia, Italy
4 Hospital of Forlì, Surgery, Forlì, Italy
5 University of Siena, University of Siena, Siena, Italy

P.07-452-Fri | Lymph node mapping using endoscopic indocyanine green injection and laser fluorescence during esophageal/gastric resection: preliminary results in a western country

A.V. Safatle-Ribeiro1, M.A.C. Rodriguez1, L. Treska1, M.S. Marcelo Simas1, F. Kawaguti1, M.R. Taconi1, F.R. Tokeda1, R.A.A. Sallum1, J.M. Rocha1, M.K.P. Ramos1, A.R. Dias1, A.Z. Charruf1, E. Zaidan1, F. Kawaguti1, M.R. Taccon1, F. Muller Filho1, B. Zilberstein1, I. Cecconello1, U. Ribeiro-Junior1

1 University of Sao Paulo School of Medicine- ICESP-HCFMUSP, Gastroenterology, Sao Paulo, Brazil


J. Šafínraček1, V. Veselý1, J. Geiger1, V. Třeška1, P. Hošek1, J. Rosendorf1

1 Charles University Hospital in Pilsen, Dept. of Surgery, Pilzen, Czechia
2 Charles University Faculty of Medicine in Pilzen, Biomedicine Centrum, Pilzen, Czechia

P.07-454-Fri | Prognostic impact of lymph node dissection along the upper-third stomach in distal gastrectomy for gastric cancer located in lower-third stomach

R. Saito1, Y. Kawaguchi1, S. Maruyama1, H. Akaike1, K. Shiroya1, H. Shimizu1, S. Furuya1, N. Hosomura1, H. Amemiya1, H. Kawaida1, M. Sudo1, S. Inoue1, H. Kono1, D. Ichikawa1

1 University of Yamanashi, First Department of Surgery, Yamanashi, Japan

P.07-455-Fri | Does perioperative chemotherapy impact on short-term outcomes of gastrectomy patients?

I. Santos1, R. Baia1, A. Batista1, N. Monteiro1, F. Almeida1, V. Praxedes1, J. Almeida1, A. Pinto1, R. Garcia1, M. Correia1, L. Cortez1

1 Hospital de Sao Bernardo - Setubal, Surgery, Setubal, Portugal
2 Instituto Gulbenkian de Ciência, Innate Immunity and Inflammation Laboratory, Oeiras, Portugal
P.07-456-Fri | Necessity of D2 lymph node dissection in older patients ≥80 years with gastric cancer
H.S. Seo1, Y.J. Jung1, J.H. Kim1, C.H. Park1, H.H. Lee1, H.M. Jeon2
1 The Catholic University of Korea, Gastrintestinal Surgery, 222- Banpo-dong–Seocho-Gu, Republic of Korea

P.07-457-Fri | Modularized laparoscopic regional en bloc mesogastrium excision (rEME) based on membrane anatomy for distal gastric cancer
J. Shen1, X. Dong1, Z. Liu1, G. Wang1, J. Yang1, F. Zhou1, M. Lu1, X. Ma1, Y. Li1, C. Tang1, X. Luo1, Q. Zhao1, J. Zhang1
1 The Second Affiliated Hospital of Nanjing Medical University, General Surgery, Nanjing, China

P.07-458-Fri | The short-term outcomes of gastric cancer patients based on a proposal for a novel classification system of peri-gastric arteries
S. Shen1, Y. Zhou1, S. Cao1, X. Liu1, X. Tan1, H. Jiang1, J. Zhang1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.07-459-Fri | Sarcopenic Obesity Is Associated with Severe Postoperative Complications in Gastric Cancer Patients Undergoing Gastrectomy: a Prospective Study
X. Shen1, A. Chandoo1, C. Xiaodong1, Y. Huang1
1 Second Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China

P.07-460-Fri | Enhanced recovery after surgery decreases intestinal recovery time and pain intensity in patients undergoing curative gastrectomy
X. Shen1, W. Ji1, A. Chandoo1, Y. Huang1
1 Second Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China

P.07-461-Fri | Gait speed predicts post-operative medical complications in elderly gastric cancer patients undergoing gastrectomy
Y. Huang1, A. Chandoo1, X. Shen1
1 Second Affiliated Hospital of Wenzhou Medical University, Gastrointestinal Surgery, Wenzhou, China

P.07-462-Fri | Surgical technologies of reconstructive jejunogastroplasty after total gastrectomy
E. Shepetko1, P. Fomin1, D. Garmash1, Y. Kazar1, I. Koshman1, A. Azarenkov1, B. Muzychuk1
1 National Medical University n.a. O.O. Bohomolets, Department of Surgery, Kiev, Ukraine

P.07-463-Fri | Risk factors for postoperative complications and impact of complications on survival after gastric cancer surgery
J. Shi1, Z. Wu1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital & Institute, Department of Gastrointestinal Surgery- Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Beijing, China

P.07-464-Fri | Prognostic factors of conversion surgery for unresectable gastric cancer
Y. Shimoda1, K. Hiro1, S. Nagasawa1, M. Nakazono1, Y. Kumas1, T. Hayashi1, T. Yama1, T. Ogata1, T. Oshima1
1 Kanagawa Cancer Center, Gastrointestinal Surgery, Yokohama, Japan

P.07-465-Fri | Surgical treatment of patients with gastric GIST. Ten-years experience
Y. Shudrak1, Y. Kondratk1, A. Minich1, A. Minich1, A. Kolesnik1, R. Fridel1, O. Dobrzanski1
1 National cancer institute, Department of upper gastrointestinal tumors National Cancer Institute, Kyiv, Ukraine

P.07-466-Fri | Extended limfadenectomy in radical treatment of N positive gastric cancer
I. Jelovsk1, S. Isajev1, G. Ancans1, M. Leja1, V. Krumins1, A. Sirvins1, A. Pchelkin1
1 Riga East University hospital- Oncology Centre of Latvia, Department of soft tissue and abdominal oncosurgery, Riga, Latvia
2 Riga East University hospital- Oncology Centre of Latvia, Department of pathology, Riga, Latvia
3 University of Latvia, Department of medical research, Riga, Latvia

P.07-467-Fri | Clinicopathological Features and Prognostic Significance of Borrmann TYPE IV Gastric Cancer: A Retrospective Study from a Single Institution in China
X. Song1, C. Xin-Zu1, Y. Kun1, H. Jian-Kun1
1 West China Hospital- Sichuan University, Department of Gastrointestinal Surgery, Chengdu, China
P.07-468-Fri | The indication of limited resection in gastric cancer
M. Stašek1, R. Aujeský2, R. Vida1, D. Kloš1, Č. Neoral1
1 University Hospital Olomouc, Department of Surgery I, Olomouc, Czechia

P.07-469-Fri | Comparison of short-and long-term clinical outcomes between laparoscopic and open gastrectomy for elderly patients with gastric cancer
Y. Tokano1, A. Shida1, M. Fujisaki1, M. Kawamura1, H. Aoki1, N. Mitsumori1, K. Yanaga1
1 The Jikei University school of Medicine, Department of Surgery, Tokyo, Japan

P.07-470-Fri | After gastrectomy, psychological symptoms (Depression and Anxiety) improved in spite of deteriorated physical complaints
Y. Tokayama1
1 Ogaki Municipal Hospital, Surgery, Ogaki, Japan

P.07-471-Fri | Validity of subtotal gastrectomy for early stage residual gastric cancer
A. Takeno1, T. Masuzawa1, K. Murakami1, K. Kenji1, T. Sakamoto1, A. Naito1, Y. Katsura1, Y. Ohmura1, Y. Kagawa1, Y. Tokeda1, K. Murata1
1 Kansai Rosai Hospital, Surgery, Amagasaki, Japan

P.07-472-Fri | Postoperative complications of gastric cancer by Clavien-Dindo classification; Impact of reoperation
N. Takiguchi1, Y. Nabeya1, A. Ikeda1, H. Soda1, T. Tonooka1, I. Hoshino1, H. Gunji1, A. Yoshizumi1, K. Kawahara1
1 Chiba Cancer Center, Gastrointestinal Surgery, Chiba, Japan

P.07-473-Fri | The Overlap Method of Esophagojejunostomy in Total Gastrectomy is Safe and Useful
T. Tanahashi1, K. Yamaguchi1, I. Yasufuku1, I. Imai1, K. Yoshida1
1 Gifu University, Surgical Oncology, Gifu, Japan

P.07-474-Fri | Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer
C. Tanaka1, M. Kanda1, T. Yoshikawa1, H. Chi1, Y. Itou1, T. Matsui1, H. Nakayama1, T. Yamada1, D. Kobayashi1, Y. Kodera1
1 Nagoya University Graduate School of Medicine, Department of Gastroenterological Surgery, Nagoya, Japan
2 National Cancer Center Hospital, Department of Gastric Surgery, Tokyo, Japan
3 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Department of Surgery, Tokyo, Japan

P.07-475-Fri | Evaluation of reconstruction methods following proximal gastrectomy
T. Tanaka1, S. Haruta1, S. Koga1, Y. Ohkura1, M. Urao1, M. Ueno1, H. Udawaga1
1 Tanakanmon Hospital, Department of Gastroenterological Surgery, Tokyo, Japan

P.07-476-Fri | Strategy for the remnant gastric cancer
K. Taniguchi1, A. Serizawa1, S. Kato1, S. Itou1, K. Suzuki1, M. Yamamoto2
1 Japanese Gastric Cancer Association, gastroenterologic surgery- Tokyo Women's University, Tokyo, Japan

P.07-477-Fri | Long-term survival after resection of transverse colon cancer metastatic to the stomach
S. Terashima1, S. Watanabe1, M. Kogure1
1 Fujita General Hospital, Surgery, Fukushima, Japan

P.07-478-Fri | Prognostic significance of postoperative complications in Stage II-III gastric cancer
K. Tsuchida1, H. Chot1, M. Yasuaki1, S. Toda1, I. Fujimura1, T. Kamioka1, H. Suematsu1, K. Numata1, A. Higuchi1, H. Saeki1, H. Matsukawa1, Y. Rino1, M. Masuda1
1 Yokohama Minami Kyoai Hospital, Surgery, Yokohama, Japan
2 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Gastroenterological Surgery, Bunkyo-ward- Tokyo, Japan
3 Yokohama City University Hospital, Surgery, Yokohama, Japan
P.07-479-Fri | Clinical outcomes of laparoscopic proximal gastrectomy with long and narrow gastric tube reconstruction for early gastric cancer
Y. Ueda1, H. Takahiro2, S. Kosuke2, A. Tomonori2, S. Tomotaka2, T. Manabu2, S. Hidefumi2, E. Tsuyoshi2, I. Masafumi2, S. Norio1
1 Oita University Faculty of Medicine- Oita- Japan, Department of Comprehensive Surgery for Community Medicine, Yufu, Japan
2 Oita University Faculty of Medicine- Oita- Japan, Department of Gastroenterological and Pediatric Surgery, Yufu, Japan

P.07-480-Fri | Impact of Lymphatic Metastasis for the Recurrence of Adenocarcinoma of the Esophagogastric Junction
N. Uraoka1, S. Suzuki1, S. Kanaji1, T. Ikeda1, M. Yamamoto1, Y. Matsuda1, T. Oshikiri1, T. Nakamura1, Y. Kakeji1
1 Gastrointestinal Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

P.07-481-Fri | Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study
A. Van Der Veen1, M.F.J. Seesing1, B.P.L. Wijnhoven2, W.O. de Steur3, M.I. van Berge Henegouwen4, C. Rosman5, J.W. van Sandick6, S. Mook7, N. Haj Mohammad8, J.P. Ruurda1, R. van Hillegersberg1
1 University Medical Center Utrecht, Surgery, Utrecht, Netherlands
2 Erasmus University Medical Center, Surgery, Rotterdam, Netherlands
3 Leiden University Medical Center, Surgery, Leiden, Netherlands
4 Academic Medical Center and Cancer Center Amsterdam, Surgery, Amsterdam, Netherlands
5 Radboud University Medical Center, Surgery, Nijmegen, Netherlands
6 The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Surgery, Amsterdam, Netherlands
7 University Medical Center Utrecht, Radiation Oncology, Utrecht, Netherlands
8 University Medical Center Utrecht, Medical Oncology, Utrecht, Netherlands
9 University Medical Center Utrecht, Pathology, Utrecht, Netherlands

P.07-482-Fri | Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study
A. Van Der Veen1, M.F.J. Seesing1, B.P.L. Wijnhoven2, W.O. de Steur3, M.I. van Berge Henegouwen4, C. Rosman5, J.W. van Sandick6, S. Mook7, N. Haj Mohammad8, J.P. Ruurda1, R. van Hillegersberg1
1 University Medical Center Utrecht, Surgery, Utrecht, Netherlands
2 Erasmus University Medical Center, Surgery, Rotterdam, Netherlands
3 Leiden University Medical Center, Surgery, Leiden, Netherlands
4 Academic Medical Center and Cancer Center Amsterdam, Surgery, Amsterdam, Netherlands
5 Radboud University Medical Center, Surgery, Nijmegen, Netherlands
6 The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Surgery, Amsterdam, Netherlands
7 University Medical Center Utrecht, Radiation Oncology, Utrecht, Netherlands
8 University Medical Center Utrecht, Medical Oncology, Utrecht, Netherlands
9 University Medical Center Utrecht, Pathology, Utrecht, Netherlands

P.07-483-Fri | Influence of surgical training in a Japanese referral center on lymphadenectomy quality: a European middle volume center experience
J. Viganò1, S. Zonta1, M. Reals Luc2, D. Cusano1, L. Gobianchi1, G. Queirinì1, T. Dominioni1, M. Maestri1, S. Giacopuzzi2, G. De Manzoni1, T. Sano1
1 Fondazione IRCCS Policlinico San Matteo, Department of Surgery, Pavia, Italy
2 Azienda Ospedaliera Universitaria Integrata, Gastro- Esophageal and General Surgery, Verona, Italy
3 Cancer Institute Hospital of JFCR, Gastroenterological Surgery, Tokyo, Japan

P.07-484-Fri | Total-laparoscopic Intragastric Surgery for Cardia Endogenous Gastric Submucosal Tumors: A Single-center Short-term Experience
J. Wang1, X. Yao1, Y. Li1
1 Guangdong General Hospital- Guangdong Academy of Medical Sciences, General Surgery Department, Guangzhou, China

P.07-485-Fri | Risk factors of unplanned reoperation after radical gastrectomy in 3213 gastric cancer patients
M. Wang1, W. Guan2
1 Guangdong General Hospital- Guangdong Academy of Medical Sciences, General Surgery Department, Guangzhou, China
2 Nanjing Drum Tower Hospital, Department of General Surgery, Nanjing, China

P.07-486-Fri | Surgical outcomes of the Laparoscopic Gastrectomy for advanced gastric cancer
M. Watarai1, Y. Takano1, M. Honda1, S. Hori1, Y. Ogawama1, Y. Todate1, Y. Tanishi1
1 7-115-Natsuyamada, Karyama, Fukushima, Japan
P.07-487-Fri | Preoperative conditioning of the high risk patient
M. Wobith1, A. Weimann1
1 Klinikum St. Georg Leipzig gGmbH, Klinik für Allgemein–Viszeral- und Onkologische Chirurgie, Leipzig, Germany

P.07-488-Fri | Development and validation of a nomogram predicting the overall survival of gastric cancer patients received neoadjuvant chemotherapy
Q. Xiao1, W. Yiniku1, W. Yuchen1, S. Fei1, L. Ziyu1, J. Jiafu1
1 Key Laboratory of Carcinogenesis and Translational Research Ministry of Education–Peking University Cancer Hospital and Institute, Department of Gastrointestinal Surgery, Beijing, China

P.07-489-Fri | Comparison of treatment outcomes between laparoscopic and endoscopic surgeries for relatively small gastric gastrointestinal stromal tumors
I. Xu1
1 First Affiliated Hospital of Nanjing Medical University, General Surgery, Nanjing, China

P.07-490-Fri | Perioperative Nutrition-focused Enhanced Recovery after Gastrointestinal Surgery Accelerates Postoperative Rehabilitation
L. Yue1, J. Yu1, W. Kang1, Z. Ma1, X. Ye1, X. Liu1, L. Jiang1
1 Peking Union Medical College Hospital–Chinese Academy of Medical Sciences, General Surgery, Beijing, China

P.07-491-Fri | Clinical status of postoperative candidiasis in patients with gastric cancer
Y. Yoshikawa1, H. Takaoka1, H. Manabu1, I. Hazumi1, N. Shinuike1, K. Isao1, H. Shuichi1, E. Takahiro1, H. Takuji1, O. Koichi1, K. Yoshiko1, T. Risa1, K. Minakazu1, S. Eiji1, A. Suefumi1, T. Hiro11, U. Hideki1
1 National Defense Medical College, Surgery, Tokorozawa–Saitama, Japan

P.07-492-Fri | The feasibility and safety of laparoscopy-assisted distal gastrectomy performed by trainee supervised by a technically qualified surgeon
T. Yamada1, Y. Kamazaki1, M. Nakazono1, K. Harada1, S. Nagasawa1, Y. Shimoda1, T. Hayashi1, Y. Rino1, M. Masuda1, M. Shiozawa1, S. Morinaga1, T. Ogata1, T. Oshima1
1 Kanagawa Cancer Center, Department of Gastrointestinal Surgery, Yokohama, Japan

P.07-493-Fri | Incidence of carcinogenesis at a remnant stomach after proximal gastrectomy, and importance of follow up esophageal examination
H. Yamaguchi1, N. Yoshizawa1, M. Kaminishi1
1 Showa General Hospital, Gastrointestinal Surgery, Tokyo, Japan

P.07-494-Fri | Effect of exercise and nutritional prehabilitation for sarcopenic patients with gastric cancer
K. Yamamoto1, T. Omori1, Y. Yamagami1, N. Shinno1, K. Sugimura1, H. Miyata1, M. Yano1, M. Ohue1, M. Yasui1, H. Takahashi1, H. Wada1, J. Nishimura1, K. Nishikawa1, M. Hira1, K. Fujitani1, T. Tsuchiya1
1 Osaka International Cancer Institute, Gastroenterological Surgery, Osaka, Japan

P.07-495-Fri | The factors associated with postoperative malnutrition after proximal gastrectomy with double tract reconstruction
K. Yamashita1, M. Iwatsuki1, K. Iwasaki1, K. Eto1, Y. Koga1, K. Yoyzumi1, Y. Baba1, N. Yoshida1, H. Baba1
1 Kumamoto University, Gastroenterological Surgery, Kumamoto, Japan

P.07-496-Fri | Impact of obesity on short-term surgical outcomes of gastrectomy for gastric cancer patients: a prospective cohort study
S. Yang1, H.R. Li1, J.K. Hu1
1 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer–State Key Laboratory of Biotherapy–West China Hospital–Sichuan University–and Collaborative Innovation Center for Biotherapy–Chengdu–China, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China
P.07-497-Fri | Impact of obesity on short-term surgical outcomes of gastrectomy for gastric cancer patients: a prospective cohort study
S. Yang1, H.R. Li2, J.K. Hu1
1 Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, Chengdu, China

P.07-498-Fri | Comparison of recovery after laparoscopic radical gastrectomy in patients of different ages
Z. Yao1, M. Cai1, J. Xing1, H. Yang1, C. Zhang1, N. Zhang1, L. Chen1, F. Tan1, K. Xu1, M. Liu1, X. Su1
1 Peking University Cancer Hospital, Gastrointestinal cancer center ward IV, Beijing, China

P.07-499-Fri | Comparison of recovery after laparoscopic radical gastrectomy in patients of different ages
Z. Yao1, M. Cai1, J. Xing1, H. Yang1, C. Zhang1, N. Zhang1, L. Chen1, F. Tan1, K. Xu1, M. Liu1, X. Su1
1 Peking University Cancer Hospital, Gastrointestinal cancer center ward IV, Beijing, China

P.07-500-Fri | Functional evaluation for various methods of gastrectomy and reconstruction for gastric cancer
U. Yasuhiko1
2 Tokai University Hachioji Hospital, Surgery, Hachioji- Tokyo, Japan

P.07-501-Fri | Assessment of muscle strength and physical performance is as important as muscle mass measurement: A prospective study for gastric cancer
R. Yildirim1, Ö. Erkul1, A. Cansu1, S. Turkyilmaz1, A. Guner1
1 Karadeniz Technical University Faculty of Medicine, General Surgery, Trabzon, Turkey
2 Karadeniz Technical University Faculty of Medicine, Radiology, Trabzon, Turkey

P.07-502-Fri | Long-term prognosis of patient with anti-thrombotic therapy who underwent laparoscopic distal gastrectomy for gastric cancer
M. Yoshida1, S. Koga1, S. Kikuchi1, K. Ishimaru1, S. Akita1, Y. Ogii1, Y. Nakagawa1, K. Tanigawa1, H. Matsumoto1, J. Kuwabara1, K. Tatsuta1, Y. Watanabe1
1 Ehime University, Gastrointestinal Surgery and Surgical Oncology, Tohon, Japan

P.07-503-Fri | Current status of post-gastrectomy weight loss in our institution
N. Yoshizawa1, H. Yamaguchi1, M. Kaminishi1
1 Showa General Hospital, Department of Gastroenterological Surgery, Kodaira, Japan

P.07-504-Fri | Comparison of Open and Laparoscopic Gastrectomy in Elderly Patients
H. Youn1, J.Y. An2
1 VHS medical center, Surgery, Seoul, Republic of Korea
2 Samsung medical center, Surgery, Seoul, Republic of Korea

P.07-505-Fri | What has changed after perioperative ERAS pathway management in gastric cancer surgery?
Y Zhou1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.07-506-Fri | The effects of ERAS versus conventional protocol on clinical outcome in gastric cancer patients underwent radical gastrectomy
Y Zhou1, C. Meng1, S. Cao1, L. Lv1, Z. Ni1, J. Zhang1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.08 Minimally-invasive and robot-assisted surgery

P.08-507-Fri | Gastric cancer in Oman – the role of laparoscopy in surgical management
R. Almehdi1, K. AlHarrasi2
1 The Muscat Hospital, Surgery, Muscat, Oman
2 The Royal Hospital, Surgery, Muscat, Oman

P.08-508-Fri | Esophagectomy by linear staplers in laparoscopic total gastrectomy
Y. Asao1, F. Kazuhiro2
1 Hirakataokusi Hospital, Laparoscopic Surgery, Hiratoka, Japan
2 Hirakataokusi Hospital, Surgery, Hiratoka, Japan
P.08-509-Fri | Laparoscopic gastrectomy for gastric cancer: comparison of survival in patients with and without postoperative complications
C. Marino1, C. Azócar1, M. Lemus1, S. Revelo1, P. Achurra1, R. Muñoz1, N. Quezada1, L. Ibañez1, F. Crovari1
1 Pontificia Universidad Católica de Chile, Cirugía Digestiva, Santiago, Chile

P.08-510-Fri | Two-Layer Versus Single-layer Hand-Sewn Esophagojejunostomy in Totally Laparoscopic Total Gastrectomy for Gastric Cancer
C. Azócar1, C. Marino1, S. Revelo1, M. Lemus1, E. Grasset1, R. Muñoz1, N. Quezada1, P. Achurra1, L. Ibañez1, F. Crovari1
1 Pontificia Universidad Católica de Chile, Cirugía Digestiva, Santiago, Chile

P.08-511-Fri | Laparoscopic gastrectomy for gastric cancer: learning curve and evolution in terms of perioperative results in an academic center
C. Marino1, C. Azócar1, M. Lemus1, R. Santiago1, E. Grasset1, M. Rodrigo1, N. Quezada1, L. Ibañez1, E. Norero1, F. Crovari1
1 Pontificia Universidad Católica de Chile, Cirugía Digestiva, Santiago, Chile

P.08-512-Fri | Early Outcome Comparison of Robotic-Assisted and Laparoscopy-Assisted Gastrectomy: Data from a 5-year period in a Korean high-volume gastric cancer center
F. Berlth1, S.H. Kong1, J.H. Choi1, S.H. Park1, Y.S. Suh1, H.J. Lee1, H.K. Yang1
1 Seoul National University Hospital, Department of Surgery- Division of Gastrointestinal Surgery, Seoul, Republic of Korea

P.08-513-Fri | Robotic total gastrectomy for gastric cancer in Italy: clinical and oncological results from the IMIGASTRIC database
D. Di Nardo1, J. Desiderio1, Eberspacher1, F. Ricci1, Trastulli1, A. Gemini1, V. D’Andre1, G. Polazzini1, A. Parisi1
1 St. Mary’s Hospital – “La Sapienza” University of Rome, Department of Digestive Surgery, Iterni, Italy
2 “La Sapienza” University of Rome, Department of Surgical Sciences, Rome, Italy
3 St. Mary’s Hospital, Department of Digestive Surgery, Iterni, Italy

P.08-514-Fri | Frequency of lymph node metastasis around splenic hilum, and the recurrence patterns of proximal advanced cancer
K. Ehara1
1 Saitama Cancer Center, Gastroenterological surgery, Saitama, Japan

P.08-515-Fri | Retrospective analysis of surgical performance and short-term clinical outcomes of 95 patients who experienced Da Vinci robotic distal gastrectomy
J. Feng1, K. Liu1, S. Lei1, B. Cui1, X. Ding1, Z. Zhang1, H. Yao1
1 The second Xiangya hospital of central south university, Gastrointestinal department, Changsha city, China

P.08-516-Fri | Comparison of short-term and long-term outcomes between open and laparoscopic total gastrectomy for gastric cancer: a systematic review and meta-analysis
D. Gallil1l, X.Z. Chen1, X.L. Chen1, K. Liu1, J.K. Hu1
1 State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer- Chengdu- China, Chengdu, China

P.08-517-Fri | Oncologic outcomes of laparoscopic distal gastrectomy (D2+CME) for advanced gastric cancer: a single-center retrospective cohort study from China
D. Xie1, J. Gong1, J. Shen1
1 Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of GI Surgery, Wuhan, China

P.08-518-Fri | Jejunal obstruction due to hiatal hernia after laparoscopic total gastrectomy
A. Goto1, K. Suda1, M. Nakauchi1, K. Kikuchi1, S. Kadoya1, K. Inaba1, I. Uyama1
1 Fuji Health University, Surgery, Toyoka, Japan

P.08-519-Fri | Mininvasive technique in approaching gastric cancer: where are we at?
L. Graziosi1, V. Bartolini1, E. Marino1, M.C. Vannoni1, F. Arteriantini2, A. Donini1
1 Santa Maria della Misericordia Hospital of Perugia, General and Emergency Surgery, Perugia, Italy
2 University of Perugia, General and Emergency Surgery, Perugia, Italy

P.08-520-Fri | Short term outcome of laparoscopic total gastrectomy with functional end-to-end esophago-jejunostomy
Y. Hasegawa1, H. Moro1, M. Kinouchi1, H. Iwasashi1, M. Sato1, K. Miura1, T. Fujiiya1
1 Miyagi Cancer Center, surgical gastroenterology, Natori-Miyagi, Japan
P.08-521-Fri | The impact of laparoscopic gastrectomy on the continuity of adjuvant chemotherapy
M. Honda1, T. Kinoshita1, T. Ogino1, Y. Tamamori1, N. Kubo1, H. Noshiro1, T. Nabae1, M. Tokunaga1, K. Obama1, S. Hisamori1, Y. Yoda1, E. Nagai1, K. Kituchi1, K. Ohuchida1, R. Makuschi1, T. Abe1, M. Terashima1
1 Fukushima Medical University, Minimally Invasive Surgical and Medical Oncology, Fukushima, Japan
2 National Cancer Center Hospital East, Gastric Surgery Division, Kashiwa, Japan
3 Fujita Health University, Surgery, Toyama, Japan
4 JCHO Kyushu Hospital, Surgery, Kitakyushu, Japan
5 Osaka City General Hospital, Gastroenterological Surgery, Osaka, Japan
6 Saga University Faculty of Medicine, Surgery, Saga, Japan
7 JCHO Kyushu Hospital, Surgery, Kitakyushu, Japan
8 National Cancer Center Hospital East, Gastric Surgery, Kashiwa, Japan
9 Graduate School of Medicine- Kyoto University, Surgery, Kyoto, Japan
10 Kyoto University, Surgery, Kyoto, Japan
11 Saga University Faculty of Medicine, Surgery, Saga, Japan
12 Graduate School of Medical Sciences- Kyushu University, Surgery and Oncology, Fukuoka, Japan
13 Fujita Health University, Surgery, Toyama, Japan
14 Shizuoka Cancer Center, Gastric Surgery, Shizuoka, Japan
15 Keio University School of Medicine, Preventive Medicine and Public Health, Tokyo, Japan

P.08-522-Fri | Pancreatic compression during lymph node dissection in laparoscopic gastrectomy; possible cause of pancreatic leakage
S. Ida1, N. Hiki1, K. Kumagai1, S. Nunobe1, M. Ohashi1, T. Sano1, T. Yamaguchi1
1 Cancer Institute Hospital of JFCR, Gastroenterological Surgery, Tokyo, Japan

P.08-523-Fri | Prediction of the dorsal landmark using 3D-CT during laparoscopic lymph node dissection along the proximal splenic artery in gastric cancer
T. Ikeya1, S. Kanaji1, G. Takiguchi1, N. Takase1, H. Hasegawa1, M. Yamamoto1, Y. Matsuda1, K. Yamashita1, T. Matsuda1, T. Oshikiri1, T. Nakamura1, S. Suzuki1, Y. Kakeji1
1 Kobe University Graduate School of Medicine, Division of Gastrointestinal Surgery- Department of Surgery, Kobe, Japan
2 Kobe University Graduate School of Medicine, Division of Minimally Invasive Surgery- Department of Surgery, Kobe, Japan

P.08-524-Fri | Difference of Postoperative Acute Phase Response According to the Type of Ultrasonic Shear in Laparoscopic Distal Gastrectomy
P. Jung1, H.J. Cho2, H.J. Yu1, J.J. Lee1, S.H. Jin1
1 Korea Cancer Center Hospital- Korea Institute of Radiological and Medical Sciences, Surgery, Seoul, Republic of Korea
2 Inje University- Sanggye Paik Hospital, Surgery, Seoul, Republic of Korea

P.08-525-Fri | Current status and future prospects of robotic assisted surgery for gastric cancer in our department
S. Kajiwara1, H. Noshiro1, Y. Yoda1
1 Saga University School of Medicine, General & Gastroenterological surgery, Saga Prefecture, Japan

P.08-526-Fri | Comparison of two- and three-dimensional display for performance of laparoscopic total gastrectomy for gastric cancer
Y. Kakeji1, S. Kanaji1, S. Suzuki1, M. Yamamoto1, Y. Matsuda1
1 Kobe University Graduate School of Medicine, Division of Gastrointestinal Surgery- Department of Surgery, Kobe, Japan

P.08-527-Fri | Esophagogastrectomy with double flap technique after laparoscopic proximal gastrectomy: Comparison with double tract reconstruction
Y. Kamio1, O. Hachiyaj1, T. Suzuki1, T. Sato1, H. Fujimoto1, S. Nozu1, S. Iwasami1, W. Kimura1
1 Yamagata University Faculty of Medicine, First Department of Surgery, Yamagata, Japan

P.08-528-Fri | Three-dimensional (3D) visualization provides better outcome in single-port laparoscopic distal gastrectomy
S.H. Kang1, Y.S. Cho1, S.H. Mir1, Y.S. Park1, S.H. Ahn2, D.J. Park2, H.H. Kim2
1 Seoul National University Bundang Hospital, Department of Surgery, Seongnam, Republic of Korea
2 Seoul National University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.08-529-Fri | Intrathoracic double-flap technique after laparoscopic proximal gastrectomy for junctional cancer
H. Kawakubo1, M. Shuhei1, J. Tomoyuki1, K. Yuko1
1 Keio University School of Medicine, Surgery, Tokyo, Japan

WWW.IGCC2019-PRAGUE.ORG
P.08-530-Fri | Adding a needle grasper makes single incision laparoscopic distal gastrectomy much convenient
J.W. Kim1, J.M. Park1, S.H. Choi2, K.C. Chi3
1 Chung-Ang University Hospital- Chung-Ang University College of Medicine, Department of Surgery, Seoul, Republic of Korea
2 Gangnam Severance Hospital- Yonsei University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.08-531-Fri | A comparison study of Totally laparoscopic pylorus preserving gastrectomy and laparoscopic assisted pylorus preserving gastrectomy
W. Han1, B.W. Eom1, H.M. Yoon1, Y.W. Kim1
1 National Cancer Center- Korea, Center for Gastric Cancer, Kayang, Republic of Korea

P.08-532-Fri | Spade shaped Anastomosis Following Proximal Gastrectomy using Double suture fixing Posterior of Esophagus to Anterior of the stomach (SPADE operation)
W. Han1, B.W. Eom1, H.M. Yoon1, J. Ryu1, Y.W. Kim1
1 National Cancer Center- Korea, Center for Gastric Cancer, Kayang, Republic of Korea

P.08-533-Fri | Laparoscopic Gastrectomy Can Improve Tolerance and Compliance with Adjuvant Chemotherapy and Overall Survival of Elderly Patients with Advanced Gastric Cancer
S.J. Kwon1, M.G. Kim1
1 Hanyang University Hospital, Surgery, Seoul, Republic of Korea

P.08-534-Fri | Long-term Outcomes of Duet Totally Laparoscopic Gastrectomy Using a Three-port for Gastric Cancer. A Large-Scale Comparative Korean Multicenter Study
H.H. Lee1, G. Jeong1, H.S. Seo1, M.G. Choi2, T.S. Sohn1, J.M. Bae1, S. Kim1, J.H. Lee1
1 Seoul St. Mary’s Hospital- College of Medicine- The Catholic University of Korea, Division of Gastrointestinal Surgery- Department of Surgery, Seoul, Republic of Korea
2 Chonnam National University Hwasun Hospital, Division of Gastroenterologic Surgery- Department of Surgery, Hwasun, Republic of Korea
3 Samsung Medical Center- Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Republic of Korea

P.08-535-Fri | Surgical outcomes and over one year follow-up results of 100 consecutive cases of laparoscopic total gastrectomy using double-stapling overlap method
I.S. Lee1
1 University of Ulsan College of Medicine and Asan Medical Center, Surgery, Seoul, Republic of Korea

P.08-536-Fri | Laparoscopy-assisted distal gastrectomy versus laparoscopy-assisted total gastrectomy with D2 lymph node dissection for middle-third advanced gastric cancer
Z. Li1, Q. Zhao1
1 Xijing Hospital of Digestive Diseases- The Fourth Military Medical University, Department of Surgery, Xian, China

P.08-537-Fri | Robotic versus laparoscopic gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched analysis
Z. Li1, Q. Zhao1
1 Xijing Hospital of Digestive Diseases- The Fourth Military Medical University, Department of Surgery, Xian, China

P.08-538-Fri | Surgical and Long-Term Survival Outcomes After Laparoscopic and Open Total Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis
Z. Li1, Q. Zhao1
1 Xijing Hospital of Digestive Diseases- The Fourth Military Medical University, Department of Surgery, Xian, China

P.08-539-Fri | Long-term outcomes of laparoscopic versus open D2 gastrectomy for advanced gastric cancer
Z. Li1, Q. Zhao1
1 Xijing Hospital of Digestive Diseases- The Fourth Military Medical University, Department of Surgery, Xian, China

P.08-540-Fri | Total Da Vinci robotic surgical system in manual suture for Billroth I Reconstruction after distal gastrectomy of gastric cancer
L. Zhang1, L. Han1
1 Tianjin Medical University Cancer Hospital, Department of Gastrointestinal Oncological Surgery, Tianjin, China
P.08-541-Fri | Laparoscopic Gastrectomy with Enhanced Recovery after Surgery (ERAS) Program for Gastric Cancer: A prospective, single arm, phase II clinical trial  
H. Liu
1 Nanfang Hospital- Southern Medical University-, General Surgery, Guangzhou, China

P.08-542-Fri | Lower mediastinal lymph nodes en-bloc dissection by totally laparoscopic transthoracic approach to treat Siewert type II adenocarcinoma  
T. Liu1, Z. Jianming1, M. Zhiming1  
1 The second hospital of Jilin University, Gastrointestinal surgery department, Changchun, China

P.08-543-Fri | Totally laparoscopic versus open gastrectomy for advanced gastric cancer: a match-paired analysis  
K. Ludwig1, S. Schneider-Knoith1, D. Moeller1, S. Uwe1  
Klinikum Sudstadt Rostock, Surgery, Rostock, Germany

P.08-544-Fri | Effect analysis of modified totally laparoscopic intra-gastric surgery for submucosal tumors located near the esophagogastric junction  
Z. Ma1, T. Liu1, J. Wang1, J. Zhu1  
1 The second hospital of Jilin University, Gastrointestinal Nutrition and Hernia Surgery, Changchun, China

P.08-545-Fri | Laparoscopic Surgery for Gastric Submucosal Tumor: A Single Center Experience  
H. Moro1, Y. Hasegawa1, M. Kinouchi1, H. Iwasashi1, S. Masayuki1, K. Miura1, T. Hujya1  
1 Miyagi Cancer Center, Gastroenterological Surgery, Natori, Japan

P.08-546-Fri | 5-year comparison between robotic and laparoscopic gastrectomy for gastric cancer — propensity score analysis —  
M. Nakao1, K. Suda1, K. Kikuchi1, S. Kadoya1, K. Inaba1, J. Uyama1  
1 Fujita Health University, Surgery, Toyoake, Japan

P.08-547-Fri | Feasibility of robotic gastrectomy for clinically node-positive gastric cancer using monopolar electrocautery  
K. Obama1, S. Tsunoda1, S. Hisamori1, T. Nishigori1, K. Matsuo1, Y. Sakai1  
1 Kyoto University Graduate School of Medicine, Department of Surgery, Kyoto, Japan
2 Kyoto City Hospital, Department of Surgery, Kyoto, Japan

P.08-548-Fri | Novel Approach for GIST with oncological risk in the posterior wall of the stomach: LECS-assisted minimally gastrectomy  
W. Okajima1, H. Tajyou1, Y. Sawabe1, H. Konosu1  
1 Ayabe City Hospital, Digestive Surgery, Kyoto, Japan

P.08-549-Fri | Outcomes of Patients with Gastroesophageal Junction Cancers: Experience of A Singapore Tertiary Institution  
A.M. Oo1, S. Goh1, D. Yeo1, K. Sanghvi1, A. Koura1, J. Rao1  
1 Tan Tock Seng Hospital, General Surgery, Singapore, Singapore

P.08-550-Fri | Modified book binding technique for Billroth I gastroduodenostomy in totally laparoscopic distal gastrectomy for gastric cancer; Initial Experience  
D.J. Park1,2, E.Y. Park1, S.S. Yang1,2, Y.C. Im1,2, G.Y. Kim1,2  
1 Ulsan University Hospital, Surgery, Ulsan, Republic of Korea
2 University of Ulsan College of Medicine, Surgery, Ulsan, Republic of Korea

P.08-551-Fri | Tailored-strategy of laparoscopic local resection for submucosal tumor of esophago-gastric junction  
J.H. Park1, T.H. Kim1, S.H. Jeong1, Y.I. Lee1  
1 Gyeongsang National University Hospital, Surgery, Jinju, Republic of Korea

P.08-552-Fri | A role of laparoscopic surgery with enhanced recovery after surgery (ERAS) program for the treatment of advanced gastric cancer patients  
Y.S. Yoo1, Y.K. Park1, S.Y. Ryu1, J. Oh1, M.R. Jung1, J.H. Kang1  
1 Chonnam national university hospital- Hwasun, Department of General surgery, Hwasun, Republic of Korea
2 Chonnam national university hospital- Hwasun, Division of Gastroenterologic Surgery-Department of surgery, Hwasun, Republic of Korea
P.08-553-Fri | Laparoscopic approach for gastric cancer: a technically challenging procedure. Learning process analysis
A. Puerta1, D. Ramos1, P. Priego1, A. Vilar1, M. Cuadrado1, L. Blazquez2, S. Sánchez2
1 Hospital Ramón y Cajal, Digestive surgery, Madrid, Spain

P.08-554-Fri | Changes in nutritional status and skeletal muscle after laparoscopic proximal gastrectomy with double flap technique for early gastric cancer
M. Yi1, S. Numabe1, S. Yagi1, R. Takahashi1, T. Ohashi1, S. Iida1, K. Kamagai1, M. Ohashi1, N. Hiki1, T. Sano1
1 Cancer Institute Hospital, Department of Gastroenterological Surgery, Tokyo, Japan

P.08-555-Fri | Robot-assisted surgery for gastric cancer – from 1st to 22th cases
Y. Rino1, T. Yamada1, T. Aoyama1, M. Numata1, Y. Maezawa1, H. Cho1, T. Oshima1, T. Sato1, H. Tamagawa1, S. Morinaga2, M. Shiozawa3, T. Yoshikawa4, N. Yokawa5, M. Masaeda1
1 Yokohama City University- School of Medicine, Department of Surgery, Yokohama, Japan
2 Kanagawa Cancer Center, Department of Gastrointestinal Surgery, Yokohama, Japan
3 Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Department of Surgery, Tokyo, Japan
4 National Cancer Center Hospital, Department of Gastric Surgery, Tokyo, Japan
5 Medical Center- Yokohama City University, Gastroenterological Center, Yokohama, Japan

P.08-556-Fri | A Comparative Study of Intracorporeal versus Extracorporeal Anastomosis during the Laparoscopic Total Gastrectomy: The Short-Term Operative Outcome
W. Han1, B.W. Eom1, H.M. Yoon1, Y.W. Kim1, K.W. Ryu1
1 National Cancer Center-Korea, Center for Gastric Cancer, Koyang, Republic of Korea

P.08-557-Fri | Efficacy of Double Flaps reconstruction after Proximal gastrectomy - in terms of functional preservation-
Z. Saze1, T. Sato1, D. Ujiie1, T. Kikuchi1, Y. Watanabe1, H. Hanayama1, K. Gonda1, T. Momma1, S. Ohki1, K. Kono1
1 Fukushima Medical University, Department of Gastrointestinal Tract Surgery, Fukushima, Japan

P.08-558-Fri | Right-Side Approach-Duet Totally Laparoscopic Distal Gastrectomy (R-Duet TLDG) Using a Three-Port to Treat Gastric Cancer
H.S. Seo1, K.Y. Song1, Y.J. Jung1, J.H. Kim1, C.H. Park1, H.H. Lee1
1 The Catholic University of Korea, Gastrointestinal Surgery, 222- Banpodae-Ro- Seocho-Gu, Republic of Korea

P.08-559-Fri | Usefulness of additional intraoperative abdominal radiograph for identification of clips during totally laparoscopic or robotic gastrectomy
J.E. Seo1, S.E. Oh1, J.E. Seo1, J.Y. An1, M.G. Choi1, T.S. Sohn1, J.M. Bae1, S. Kim1, J.H. Lee1
1 Samsung Medical Center, Surgery, Seoul, Republic of Korea

P.08-560-Fri | A novel strategy for determining to preserve/shear the aberrant left hepatic artery using a NIR fluorescence image-guided technique during gastrectomy
T. Son1, S. Choi1, M. Cho1, W.J. Hyung1
1 Yonsei University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.08-561-Fri | Intracorporeal Esophagojejunostomy during Reduced-port Totally Robotic Gastrectomy For Proximal Gastric Cancer
S. Choi1, T. Son1, W.J. Seo1, C.K. Roh1, M. Cho1, K. Hyung-II, W.J. Hyung1
1 Yonsei University College of Medicine- Republic of Korea, Department of Surgery, Seoul, Republic of Korea

P.08-562-Fri | The safety and patient satisfaction of preoperative carbohydrate loading and early oral feeding after gastrectomy: preliminary results
Y.G. Son1, J.G. Kwong1, S.W. Ryu1
1 Keimyung University School of Medicine, Department of Surgery, Dangun, Republic of Korea
2 Yonsei University College of Medicine, Department of Surgery, Seoul, Republic of Korea

P.08-563-Fri | Robot-assisted gastrectomy versus laparoscopic-assisted gastrectomy for patients with gastric cancer: A retrospective short-term analysis from a single institution in China
L. Sun1, K. Liu1, K. Yang1, X.Z. Chen1, J.K. Hu1
1 Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer- State Key Laboratory of Biotherapy- West China Hospital- Sichuan University- and Collaborative Innovation Center for Biotherapy- Chengdu- China, Department of Gastrointestinal Surgery- Laboratory of Gastric Cancer, Chengdu, China
P.08-564-Fri | Robotic gastrectomy as a solo surgery: exposure method and tips for using monopolar scissors
H. Sunagawa1, H. Okabe1,2, M. Saji1, M. Atarashi1, T. Bari1, M. Hoshikawa1, H. Matsumoto1, G. Honda1, J. Yamamoto1
1 New Tokyo Hospital, Gastroenterological Surgery, Chiba, Japan
2 Kyoto University Graduate School of Medicine, Department of Surgery, Kyoto, Japan

P.08-565-Fri | The horizontal mattress suture method to close the common entry for intracorporeal esophagojejunostomy after totally laparoscopic total gastrectomy
T. Liu1, Z. Jiaming1, M. Zhiming1
1 The second hospital of Jilin University, Gastrointestinal surgery department, Changchun, China

P.08-566-Fri | A modified intracorporeal Roux-en-Y reconstruction after laparoscopic total gastrectomy for gastric cancer: a safe and feasible technique
T. Liu1, Z. Jiaming1, M. Zhiming1
1 The second hospital of Jilin University, Gastrointestinal surgery department, Changchun, China

P.08-567-Fri | Single-layer suture(Gambee) technique to close the common entry in the treatment of distal gastric cancer by totally laparoscopic surgery
T. Liu1, M. Zhiming1, Z. Jiaming1
1 The second hospital of Jilin University, Gastrointestinal surgery department, Changchun, China

P.08-568-Fri | Implementation of laparoscopic gastrectomy for gastric cancer in a Western tertiary referral centre and comparison of outcomes with open gastrectomy
A. Tsakrekos1, F. Kleverbro1, S. Kamiya2, S. Persson1, M. Lindborg2, M. Nilsson1, L. Lundell1, J. Rouvelas1
1 Department of Clinical Science - Intervention and Technology CLINTEC - Karolinska Institutet, Division of Surgery, Stockholm, Sweden
2 Shizuoka Cancer Center, Division of Surgical Surgery, Shizuoka, Japan

P.08-569-Fri | Feasibility of linear-shaped Billroth I reconstruction in totally robotic distal gastrectomy for gastric cancer
B. Wang1, S.Y. Son1, H.J. Shin1, H. Hur1, S.U. Han1
1 Ajou University Medical Center, Gastrointestinal Department, Suwon, Republic of Korea

P.08-570-Fri | Laparoscopic circular stapling esophagojejunostomy following total gastrectomy: a simple and reliable suture-tied-anvil direct insertion technique
W. Wang1
1 Guangdong Provincial Hospital of Chinese Medicine, Department of Gastrointestinal Surgery, Guangzhou, China

P.08-571-Fri | A novel technique of transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of esophagogastric junction
W. Wang1
1 Guangdong Provincial Hospital of Chinese Medicine, Department of Gastrointestinal Surgery, Guangzhou, China

P.08-572-Fri | A novel technique of single-port thoracic-assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of esophagogastric junction
W. Wang1, X. Wenjun1, W. Jin1
1 Guangdong Provincial Hospital of Chinese Medicine, Department of Gastrointestinal Surgery, Guangzhou, China

P.08-573-Fri | Laparoscopic D2 radical distal gastrectomy with complete mesogastrium excision for advanced gastric cancer
W. Wang1, X. Wenjun1, W. Jin1
1 Guangdong Provincial Hospital of Chinese Medicine, Department of Gastrointestinal Surgery, Guangzhou, China

P.08-574-Fri | The comparison of safety and costs between laparoscopic assisted or totally laparoscopic uncut Roux-en-Y and Bill-Braun reconstruction – a prospective cohort study
Y. Wang1, F. Shari1, L. Zhang1, S. Li1, Y. Jiu1, X. Ying1, K. Xue1, R. Miao1, Z. Li1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital, gastrointestinal cancer center, Beijing, China

P.08-575-Fri | The comparison of costs and outcomes of totally laparoscopic and laparoscopic assisted gastrectomy-propensity score matched analysis
Y. Wang1, F. Shari1, L. Zhang1, Y. Jiu1, S. Li1, X. Ying1, R. Miao1, K. Xue1, Z. Li1, Z. Li1, J. Ji1
1 Peking University Cancer Hospital, Gastrointestinal cancer center, Beijing, China
P08-576-Fri | Robotic-assisted gastric GIST resection: a single center experience
Visceral and Transplant Surgery, Department of Surgery, Geneva, Switzerland

P08-577-Fri | Single incision laparoscopic surgery Plus One Assist Port (SILS+1-AP) gastrectomy with D2 lymph node dissection for distal gastric cancer
J. Xiao, Z. Wei-Dong
Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Department of Gastrointestinal Surgery, Fuzhou, China

P08-578-Fri | A single institution analysis: what is the value of laparoscopic D2 lymph nodes dissection for patients with obesity?
Peking University Cancer Hospital and Institute, Department of Gastrointestinal Surgery IV, Beijing, China

P08-579-Fri | Comparison of short-term outcomes between totally laparoscopic distal gastrectomy (TLDG) and laparoscopy-assisted distal gastrectomy (LADG) for gastric cancer patients
Peking University Cancer Hospital and Institute, Department of Gastrointestinal Surgery IV, Beijing, China

P08-580-Fri | Single-Incision Laparoscopic Surgery for the Intraluminal Gastric Submucosal Tumor of the upper stomach
K. Yamamichi, O. Takashi, M. Takashi, F. Hayato, T. Yoshida
Osaka Saiseikai Izuo Hospital, Surgery and Gastroenterological surgery, Osaka, Japan

P08-581-Fri | Improved surgical outcome of laparoscopic gastrectomy compared to conventional open gastrectomy for gastric adenocarcinoma in obese patients
H.M. Yoo, D.J. Kim, K.Y. Song, C.H. Park, J.G. Kim
The Catholic University of Korea, Surgery, Seoul, Republic of Korea

P08-582-Fri | A modified Billroth II with braun anastomosis in totally laparoscopic distal gastrectomy for gastric cancer: initial experience and short-term outcomes
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Department of Surgery, Shanghai, China

P08-583-Fri | Laparoscopic palliative gastrectomy for gastric cancer symptoms. Short-term outcomes and survival
N. Zanini, M. Giordano, G.M. Palini, F. Paratore, G. Novelli, B. Pirriera, V. Alagna, C. Vallicelli, G. Garulli
Ospedale “Infermi” - AUSL Romagna, Department of Surgery, Rimini, Italy

P08-584-Fri | Advanced age should not be a contraindication for laparoscopic gastrectomy in Western patients
N. Zanini, M. Giordano, C. Vallicelli, F. Paratore, B. Pirriera, G.M. Palini, V. Alagna, G. Novelli, G. Garulli
Ospedale “Infermi” - AUSL Romagna, Department of Surgery, Rimini, Italy

P08-585-Fri | Long-term clinical outcome and survival with laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer: initial experience in a Chinese center
E. Zhao, Z. Gang, C. Hui
Renji Hospital Shanghai Jiaotong University- School of Medicine, GI Surgery, Shanghai, China

P08-586-Fri | Rational choice of minimally invasive treatment for esophagogastric junction carcinoma
S. Zuccheng, C. Jingli, Z. Wenxing
Wenfang People’s Hospital, gastrointestinal surgery, wofang, China

P11 Novel drugs and immunotherapy

P11-707-Fri | Efficacy of chemotherapy after progression on nivolumab
K. Akiyoshi, U. Shinya
Osaka City General Hospital, Medical oncology, Osaka, Japan
P.11-708-Fri | Response Rates to Salvage Chemotherapy after Nivolumab in Patients with Gastric Cancer
T. Arigami1, S. Yanagita2, D. Matsushita2, T. Kijima2, M. Shimonosono2, K. Okubo2, Y. Uenosono2, S. Ishigami2, S. Natsugoe2
1 Kagoshima University Graduate School of Medical and Dental Sciences, Department of Onco-Biological Surgery, Kagoshima, Japan
2 Kagoshima University Graduate School of Medical and Dental Sciences, Department of Digestive Surgery - Breast and Thyroid Surgery, Kagoshima, Japan

P.11-709-Fri | Study of the antitumoral activity of crizotinib associated with mebendazole in vitro models of gastric cancer
A. Sousa1, M. Oliveira1, T. Araújo1, E. Texeira1, K. Silva1, J. Batista1, L. Imbiriba1, D. Maysés2, A. Silva1, J. Paiva1, F. Oliveira1, E. Oliveira1, G.J. Riggins2, P. Assumpção3, A. Khayat4
1 Universidade Federal do Pará, Oncologia, Belém, Brazil
2 Hospital Universitário João de Barros Barreto, Cirurgia Geral e Aparelho Digestivo, Belém, Brazil
3 Johns Hopkins Hospital, Brain Cancer Biology and Therapy Research Laboratory, Baltimore, USA
4 Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém, Brazil

P.11-710-Fri | Evaluation of the antineoplastic activity of metformin combined with the anthelmintic mebendazole in a metastatic gastric cancer cell line
K. Silva1, T. Araújo1, M. Oliveira1, A. Sousa1, E. Texeira1, M. Abreu1, R. Barros1, C. Miranda1, V. Marinho1, G. Ishak1, G.J. Riggins2, R. Burbano3, M. Assumpção4, P. Assumpção5, A. Khayat6
1 Universidade Federal do Pará, Oncologia, Belém, Brazil
2 Centro universitário do estado do Pará, Clinica odontologica, Belém, Brazil
3 Seattle Cancer Care Alliance SCCA, Pharmacokinetics Laboratory, Seattle, USA
4 Johns Hopkins Hospital, Brain Cancer Biology and Therapy Research Laboratory, Baltimore, USA
5 Universidade Federal do Pará, Instituto de Ciências da Saúde, Belém, Brazil
6 Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém, Brazil

P.11-711-Fri | Association of idarubicin and mebendazole enhances cellular death and cell cycle arrest in a metastatic gastric cancer cell line
M. Oliveira1, T. Araújo1, L. Quintana1, A. Sousa1, E. Texeira1, K. Silva1, S. Fonseca1, J. Silva Júnior1, N. Galucio1, F. Oliveira1, A. Lima1, D.J. Avadhut2, G.J. Riggins2, P. Assumpção3, A. Khayat4
1 Universidade Federal do Pará, Oncologia, Belém, Brazil
2 Centro universitário do estado do Pará, Clinica odontologica, Belém, Brazil
3 Johns Hopkins Hospital, Brain Cancer Biology and Therapy Research Laboratory, Baltimore, USA
4 Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém, Brazil

P.11-712-Fri | Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer
C. Hu1, X. Zhiyuan2, X. Cheng2
1 Zhejiang Chinese Medical University, Department of gastrointestinal surgery, Hangzhou, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University, Department of gastrointestinal surgery, Hangzhou, China

P.11-713-Fri | Pharmacokinetic Study and Safety of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Paclitaxel in Swine
1 National University Health System, Department of Surgery, Singapore, Singapore
2 National University Health System, Department of Haematology-Oncology, Singapore, Singapore
3 Yong Loo Lin School of Medicine - National University of Singapore, Department of Surgery, Singapore, Singapore
4 Yong Loo Lin School of Medicine - National University of Singapore, Department of Pharmacology, Singapore, Singapore

P.11-714-Fri | Exploring for effect of tumor regression of neoadjuvant chemotherapy of combined S1 plus oxaliplatin and apatinib for advanced gastric cancer
J. Feng1, K. Liu1, S. Lei1, B. Gui1, X. Ding1, Z. Zhang1, H. Yao1
1 The second xiangya hospital of central south university, Gastrointestinal department, Changsha city, China

P.11-715-Fri | Clinical outcome of nivolumab treatment for metastatic or recurrent gastric cancer patients in our institute
T. Hamakawa1, K. Nishikawa1, M. Hiro1, H. Hasegawa1, S. Maeda1, M. Umemura1, M. Miyake1, N. Ham1, A. Miyamoto2, T. Kato1, M. Sekimoto1
1 National Hospital Organization Osaka National Hospital, Surgery, Osaka, Japan
2 National Hospital Organization Osaka National Hospital, Gastroenterology, Osaka, Japan
136
BUILDING BRIDGES BETWEEN THE MEDICAL COMMUNITIES INVOLVED IN GASTRIC CANCER TREATMENT WORLDWIDE

P.11-716-Fri | Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer
X. Jianfei1, S. Liu1, X. Yang1, S. Cao1, Y. Zhou1
1 Affiliated Hospital of Qingdao University, Department of General Surgery, Qingdao, China

P.11-717-Fri | Effectiveness of nivolumab for gastric cancer
S. Katagiri1, Y. Yokota1, K. Koganesawa1, M. Nakagawa1, K. Hikita1, T. Kobayashi1, H. Kawaihara1, M. Shigaki1, S. Tabuchi1, M. Hisada1, S. Kawachi1
1 Tokyo Medical University Hachioji Medical Center, Digestive and Transplantation Surgery, Tokyo, Japan

P.11-718-Fri | Efficacy of nivolumab and irinotecan for metastatic gastric cancer as third-line chemotherapy: A single institutional retrospective study
K. Ryosuke1, S. Mitani1, S. Kadawaki1, K. Kata1, Y. Naita1, K. Honda1, T. Masuishi1, H. Bando1, M. Ando1, M. Tajika1, K. Muro1
1 Aichi Cancer Center Hospital, Department of Clinical Oncology, Nagoya-Aichi, Japan

P.11-719-Fri | Patterns of immune checkpoint expression by primary tumor cells and tumor infiltrating lymphocytes across different tumor entities
M. Theler1,2, K. Wennhold1,2, P.S. Plum2, A. Lechner4, D. Pfister5, K. Hekmat6, F. Thangarajah7, M. Malter7, D. Ratiu7, J. Klussmann8, F. Doerr6, A. Quaas3, C. Bruns2, M. von Bergwelt-Baildon9, H. Schloesser1
1 University of Cologne, Center for Molecular Medicine Cologne, Cologne, Germany
2 University of Cologne, Department of General- Visceral and Cancer Surgery, Cologne, Germany
3 University of Cologne, Institute of Pathology, Cologne, Germany
4 Ludwig Maximilian University, Department of Head and Neck Surgery, Munich, Germany
5 University of Cologne, Department of Urology, Cologne, Germany
6 University of Cologne, Department of Thoracic Surgery, Cologne, Germany
7 University of Cologne, Department of Gynecology, Cologne, Germany
8 University of Cologne, Department of Head and Neck Surgery, Cologne, Germany
9 Ludwig Maximilian University, Department of Oncology, Munich, Germany

P.11-720-Fri | SHR-1210 plus capecitabine and oxaliplatin or apatinib as first-line therapy in subjects with advanced or metastatic gastric or gastroesophageal adenocarcinoma
L. Shen1,2, Z. Peng1, Y. Zhang1, J. Ying1, F. Wang1, Y. Deng1, Y. Chen1, X. Yuan1, K. Gu1, J. Xiao1, G. Li1, J. Zou1
1 Peking University Cancer Hospital & Institute, Department of Gastrointestinal Oncology, Beijing, China
2 Harbin Tumor Hospital, Department of Gastrointestinal Medical Oncology, Harbin, China

P.11-721-Fri | A porphyrin bridged platinum derivative exerted potential in reversing cisplatin-resistance lung cells by targeting the telomere
L. Xia1, X. Zheng1, G. Chang1, K. Kang1, H. Cao1
1 Shenzhen University, Department of Basic Medicine, Shenzhen, China

P.12 Survivorship, supportive and palliative care

P.12-722-Fri | A gender comparison of changes in bone metabolism after gastric cancer surgery: a prospective observational study
Y. Atsumi1, Y. Rino1, H. Wada1, Y. Kitani1, Y. Ozawa2, Y. Wang1, Y. Deng1, Y. Chen1, X. Yuan1, K. Gu1, J. Xiao1, G. Li1, J. Zou1
1 Yokohama City University, Department of Surgery, Yokohama, Japan
2 Miura City Hospital, Department of Surgery, Miura, Japan
3 Kanagawa Cancer Center, Department of Gastrointestinal Surgery, Yokohama, Japan
4 National Cancer Center Hospital, Department of Gastro Surgery, Tokyo, Japan
P.12-723-Fri | Actual status of calorie support in immediate post-operative period after gastrectomy
J.M. Bae¹, E.K. Kim¹, Y.N. Kim¹, J.Y. An², M.G. Choi³, J.H. Lee³, T.S. Sohn³, S. Kim³, K.D. Ahn³
¹ Samsung Medical Center - Sungkyunkwan University School of Medicine, Surgery, Seoul, Republic of Korea
² Samsung Medical Center, Surgery, Seoul, Republic of Korea

P.12-724-Fri | Treatment and prognosis of gastric carcinoma patients aged 80 years or older
H.J. Bang¹, I. Shin¹, H. Ryu¹
¹ Yonsei University - Korea, General Surgery, Wonju, Republic of Korea

P.12-725-Fri | Intraoperative prophylactic HIPEC improves DFS and peritoneal recurrence for advanced Gastric Cancer: preliminary results from a single center RCT
M.K. Beeharry¹, Y.F. Wang¹, X.X. Yao¹, M. Yan¹, Z.G. Zhu¹
¹ Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Gastrointestinal Surgery, Shanghai, China

P.12-726-Fri | Effect of L-carnitine on Imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
H. Choe¹, M-H. Ryu¹, J. Ma¹, M. Beck¹, Y-K. Kang¹
¹ Asan Medical Center, Oncology, Seoul, Republic of Korea

P.12-727-Fri | Long-term quality of life in patients after total gastrectomy versus Ivor Lewis esophagectomy
E. Jezerkyte¹, L. Noteboom¹, M.J. van Berge Henegouwen¹, S. Gisbertz²
¹ Amsterdam UMC location AMC, Surgery, Amsterdam, Netherlands

P.12-728-Fri | Gastric cancer patients who underwent gastrectomy are high risk for colorectal neoplasia: a case control study
T.G. Gweon¹, C.H. Lim¹, J. Kim¹
¹ Incheon St. Mary's Hospital - The Catholic University of Korea, College of Medicine, Incheon, Republic of Korea
² Seoul St. Mary's Hospital - The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea
³ Incheon St. Mary's Hospital - The Catholic University of Korea, College of Medicine, General Surgery, Incheon, Republic of Korea

P.12-729-Fri | Osteoporosis after gastrectomy: a prospective study for elderly gastric cancer patients
R. Kawaihaïta¹, T. Tsuyoshi¹, S. Yurina¹, I. Hiroshi¹, F. Kazumasa¹, F. Junya¹, T. Atsushi¹, K. Kentaro¹, T. Shuji¹, K. Yukinori¹, Y. Makoto², D. Yuichiro²
¹ Osaka Rosai Hospital, Internal Medicine, Sakai, Osaka, Japan
² Osaka University Hospital, Gastroenterology, Suita, Osaka, Japan
³ Toyonaka municipal hospital, Surgery, Toyonaka, Osaka, Japan
⁴ Tokyo General Hospital, Surgery, Osaka, Japan
⁵ Sakai City Hospital, Surgery, Sakai, Osaka, Japan
⁶ Kawasaki Rosai Hospital, surgery, Amagasaki, Hyogo, Japan
⁷ Osaka Police Hospital, surgery, Osaka, Japan

P.12-730-Fri | Role of palliative surgery for patients with peritoneal dissemination from gastric cancer
H. Kiyozaki¹, T. Obitsu¹, Y. Muto¹, D. Ishioka¹, M. Saito¹, T. Rikiyama¹
¹ Saitama Medical Center - Jichi Medical University, Surgery, Omiya, Japan

P.12-731-Fri | Survival adjusted to life expectancy in elderly patients following gastrectomy for gastric cancer
P. Lages¹, S. Onofre¹, P. Batelheiro¹, V. Santos¹, M. Ferreira¹, C. Pereira¹, P. M do Costa¹
¹ Serviço de Cirurgia - Hospital Garcia de Orta, Faculdade de Medicina - Universidade de Lisboa, Lisboa, Portugal
² Serviço de Cirurgia - Hospital Garcia de Orta, Lisboa, Portugal
³ Departamento de Cirurgia, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

P.12-732-Fri | Prognosis of proximal upper-third gastric cancer excluding esophagogastroduodenal junction origin
J.H. Lee¹, Y. Hong¹, S. Nam¹, Y.J. Choi¹, S.H. Lee¹
¹ National Health Insurance Service Ilsan Hospital, Department of Surgery, Goyang-si, Republic of Korea
² National Health Insurance Service Ilsan Hospital, Department of Pathology, Goyang-si, Republic of Korea

P.12-733-Fri | Incidence, clinicopathological characteristics and survival outcome of rare histological variants of gastric carcinoma: a SEER-population-based study
R. Li¹, L.Y. Wong¹, F.S.Y. Chan¹, K.K. Chan¹, C.L.Y. Wong¹, T.T. Law¹, J.Y.Y. Kwok¹, S. Law¹
¹ The University of Hong Kong, Queen Mary Hospital, Hong Kong, Department of Surgery
Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection

J.X. Lin1, J.P. Lin1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastro Surgery, Fuzhou - Fujian Province, China

Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Gastric Cancer Patients Following Radical Gastrectomy

J.X. Lin1, J.P. Lin1, J.W. Xie1, P. Li1, C.H. Zheng1, C. Huang1
1 Fujian Medical University Union Hospital, Department of Gastro Surgery, Fuzhou - Fujian Province, China

The relationship between oral bacteria and postoperative infectious complications after gastrectomy

N. Mao1
1 Southern TOHOKU Research Institute for Neuroscience - Southern TOHOKU General Hospital, Department of Oral and Maxillofacial Surgery, Koriyama, Japan

Efficacy of preoperative oral nutritional supplements for patients with gastric cancer undergoing gastrectomy

H. Nakade1, K. Migita1, S. Matsumoto1, K. Wakatsuki1, T. Kunishige1, S. Miyao1, M. Shio1
1 Nara Medical University, Department of Surgery, Kashihara, Japan

Oncological follow up after gastrectomy for early gastric cancer should be continued over 5 years

E.Y. Park1, D.J. Park1,2, G.Y. Kim1,2
1 Ulsan University Hospital, Surgery, Ulsan, Republic of Korea
2 University of Ulsan College of Medicine, Surgery, Ulsan, Republic of Korea

Impact of body mass index shift on body composition changes after distal gastrectomy for gastric cancer

K.R. Park1, B. Yu1, J.Y. Park1, S.S. Lee1, O.K. Kwon1, H.Y. Chung2
1 Kyungpook National University Chilgok Hospital, Gastric Cancer Center, Daegu, Republic of Korea
2 Kyungpook National University Hospital, Department of Surgery, Daegu, Republic of Korea

Prognostic significance of postoperative sarcopenia in the long-term survival of gastric cancer patients

Y.S. Park1, S.H. Ahn1, D.J. Park1, H.H. Kim1
1 Seoul National University Bundang Hospital, Surgery, Seongnam, Republic of Korea

Prognostic Impact of Infectious Complications after Curative Gastric Cancer Surgery

W. Han1, B.W. Eom1, H.M. Moon1, Y.W. Kim1, K.W. Ryu1
1 National Cancer Center - Korea, Center for Gastric Cancer, Khayang, Republic of Korea

Risk of second primary cancers after gastrectomy for a primary gastric cancer: A population-based study using the HIRA database

S.Y. Son1, J.A. Seong1, C. Oyeon1, N.O. Kye1, O. Young-Taek1, C. Mison1, S. Ho-Jung1, H. Hoon1, H. Sang-Uk1
1 Ajou University School of Medicine, Department of Surgery, Suwon, Republic of Korea
2 Ajou University School of Medicine, Department of Biomedical Informatics, Suwon, Republic of Korea
3 Ajou University School of Medicine, Department of Radiology, Suwon, Republic of Korea

Stage-specific difference in timing and pattern of initial recurrence after curative surgery for gastric cancer

Y.J. Song1, J.H. Kim1, H.S. Seo1, Y.J. Jung1, H.H. Lee1, C.H. Park1
1 Seoul St. Mary’s Hospital - The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

The long-term impact of postoperative pneumonia after curative gastrectomy for elderly gastric cancer patients

S. Suzuki1, T. Ikeda1, N. Urakawa1, S. Kanaji1, M. Yamamoto1, Y. Matsuda1, Y. Kakeji1
1 Kobe University Graduate School of Medicine, Division of Gastrointestinal Surgery - Department of Surgery, Kobe, Japan
P.12-745-Fri | Proposed update of the EORTC Quality of Life Gastric module QLQ-ST022
M. Terada1, S. Sodergren2, J. Blazeyb, S. Singerc,d, T. Yoshikawaa, M. Terashimaa, F. Lordickd, V. Vassilioua
1 EORTC, Medical department, Brussels, Belgium
2 University of Southampton, Faculty of Health Sciences, Southampton, United Kingdom
3 Bristol Medical School - University of Bristol, Bristol Centre for Surgical Research, Bristol, United Kingdom
4 University Medical Centre Mainz, Institute of Medical Biostatistics - Epidemiology - and Informatics, Mainz, Germany
5 University Medical Centre Mainz, University Cancer Centre, Mainz, Germany
6 National Cancer Center Hospital Japan, Department of Gastric Surgery, Tokyo, Japan
7 Shizuuka Cancer Center, Division of Gastric Surgery, Shizuuka, Japan
8 University Hospital Leipzig, University Cancer Center Leipzig, Leipzig, Germany
9 Bank of Cyprus Oncology Centre, Department of Radiation Oncology, Nicosia, Cyprus

P.12-746-Fri | Incidence of small bowel obstruction requiring surgical treatment after radical gastric cancer surgery
T. Wada1, T. Fukagawa2, M. Yura1, S. Otsuki1, Y. Yamagata1, S. Morita1, T. Yoshikawa1, T. Nishida1, H. Kaita1
1 National Cancer Center Hospital, Gastric Surgery Division, Tokyo, Japan
2 Teikyo University School of Medicine, Department of Surgery, Tokyo, Japan

P.12-747-Fri | The prognostic value of tumor–stroma ratio in gastric cancer combined with TNM staging factors
Y. Zhang1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-748-Fri | The prognostic value of albumin to globulin ratio in gastric cancer patients with peritoneal metastasis: a retrospective study
F. Li1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-749-Fri | The clinical value of prognostic nutritional index in gastric cancer patients with peritoneal metastasis
F. Li1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-750-Fri | Relationship between body mass index and clinicopathological characteristics and prognosis in patients with gastric cancer
B. Han1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-751-Fri | Effect of preoperative systemic immune-inflammation index on the prognosis of gastric cancer
B. Han1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-752-Fri | Prognostic significance of preoperative albumin-to-globulin ratio and prognostic nutritional index combined score in Siewert types 3 adenocarcinoma of esophagogastric junction
Y. Wang1, Z. Zhu1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-753-Fri | Preoperative prognostic nutritional index and platelet-to-lymphocyte ratio combined score as a prognosticator in Siewert types 3 adenocarcinoma of esophagogastric junction
Y. Wang1, Z. Zhu1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-754-Fri | Analysis on prognostic factors of gastric cancer patients with liver metastasis and the efficacy of liver metastases resection
J. Gao1, Y. Xue1
1 Harbin Medical University Cancer Hospital, Department of Gastroenterology Surgery, Harbin, China

P.12-755-Fri | Gastric cancer outcomes after perioperative ERAS pathway management
F. Yang1, Y. Zhou1, S. Cao1, Z. Niu1, H. Jiang1, X. Liu1, L. Lv1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China
P.12-756-Fri | Gastric cancer outcomes after perioperative ERAS pathway management
F. Yang1, Y. Zhou1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.12-757-Fri | Lymphovascular invasion is a risk factor for recurrence after gastrectomy in stage IB gastric cancer
B. Yu1, K.B. Park1, J.Y. Park1,2, S.S. Lee1,2, O.K. Kwon1,2, H.Y. Chung1,3
1 Kyungpook National University Chilgok Hospital, Gastric cancer center, Daegu, Republic of Korea
2 Kyungpook National University, Department of Surgery - School of Medicine, Daegu, Republic of Korea
3 Kyungpook National University Hospital, Department of Surgery, Daegu, Republic of Korea

P.12-758-Fri | Early intervention of Traditional Chinese Herbal Medicine Showed Survival Benefit for Patients with Advanced Gastric Cancer
Z. Li1, A. Zhao1, N. Cao1, Y. Xu1, X. Zhu1, G. Zhao1, T. Liu1, W. Guo1, H. Ding1, O. Li1, J. Liu1, J. Wu1, Y. Gu1, Y. Han1, Q. Wang1
1 Longhua Hospital- Shanghai University of Traditional Chinese Medicine, 1 Department of Oncology, Shanghai, China
2 Renji Hospital- Shanghai Jiao Tong University School of Medicine, Department of General Surgery, Shanghai, China
3 Fudan University Zhongshan Hospital, Department of Medical Oncology, Shanghai, China
4 Fudan University Shanghai Cancer Center, Department of Medical Oncology, Shanghai, China
5 Shanghai General Hospital, Department of Oncology, Shanghai, China
6 Shanghai Hospital- Shanghai University of Traditional Chinese Medicine, Department of Medical Oncology, Shanghai, China
7 Shanri Provincial Hospital of Traditional Chinese Medicine, Department of Oncology, Shanxi, China
8 Yunnan Provincial Hospital of Traditional Chinese Medicine, Department of Oncology, Yunnan, China

P.12-759-Fri | Impact of the evidence-based nursing on prevention of falls in hospitalized patients undergoing gastric cancer surgery
L. Zhen1
1 Nanfang Hospital- Southern Medical University, General Surgery, Guangzhou, China

P.13 Economic burden of GC and treatment in different healthcare systems

P.13-760-Fri | Does untimely chemotherapy after radical gastrectomy affect the prognosis of patients with II/III gastric cancer: can we do better?
Q.Y. Chen1, J.W. Xie1, P.Li1, C. Huang1, C.H. Zheng1
1 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China

P.13-761-Fri | The clearance rate of Helicobacter pylori is variant depend on the type of gastrectomy
N. Fujikuni1, K. Hakoda1, T. Bekki1, H. Amano1
1 Onomichi General Hospital, Surgery, Onomichi, Japan

P.13-762-Fri | The status of gastric cancer in the north of Singapore
K.T. Lim1
1 Khoo Teck Puat Hospital, Department of Surgery, Singapore, Singapore

P.13-763-Fri | Clinicopathological characteristics and prognosis of 217 patients with carcinoma in the remnant stomach in Affiliated hospital of Qingdao University
X. Liu1, Y. Zhou1, S. Cao1, Z. Niu1, H. Jiang1, L. Lu1, J. Zhang1
1 Affiliated Hospital of Qingdao University, Department of Gastrointestinal Surgery, Qingdao, China

P.13-764-Fri | Nature versus nurture: the impact of nativity and site of treatment on survival for gastric cancer
K.Y. Song1, J. Muller1
1 The Catholic University of Korea- Seoul St. Mary’s Hospital, Surgery, Seoul, Republic of Korea
2 Harvard Medical School- Massachusetts General Hospital, Surgery, Boston, USA
Welcome Letter
Practical Information A – Z
Floorplans
Exhibition
Congress Program
Social Program
9 May
10 May
11 May
Posters
Authors Index

Abbassi-Ghadi N. 78
Abe T. 94, 117, 129
Abe Y. 79
Ahou Khouzam R. 67, 77
Abreu M. 135
Abreu Sousa J. 108
Achurra P. 128
Acioli J. F. 62
Adachi J. 79
Adamčík L. 112
Adam M. 78
Adenis A. 27, 68
Agnes A. 106
Aguayo G. 78
Ahn H. K. 100
Ahn H. S. 121
Ahn K. D. 137
Aida J. 62
Aigner A. 72, 75–76
Aikawa M. 88
Aiken C. 91
Aikawa M. 46
Ajani J. 83, 88, 104
Akalike H. 77, 111, 122
Akamaru Y. 99, 105, 114
Akamatsu H. 96
Akashi Y. 105–106
Akimoto E. 96
Akira O. 98
Aki S. 127
Akiyama H. 70, 90, 101, 114
Akiyoshi K. 135
Alagia V. 134
Alakus H. 90
Alarcon A. 78
Alarcon M. A. 62
Alay D. 82
Al-Batran S. E. 74
Alberto M. 94
Alberto Mitzu L. T. 83
Albuquerque P. 72
Alcindor E. 34
Alcoba García L. M. 111
Aldegano A. 92
Aldighieri F. 89
Alessandrini L. 62
Alexander Q. 69
Alfano M. S. 97–98, 118
Alfaro A. 109
Alfaro Galdaracena A. 84, 115
Alfieri S. 122
AlHarasi K. 127
Alkhaffaf B. 34, 106
Allen P. 117
Allen–Ayodabo C. 115
Allen T. 72
Allum W. 45, 103, 110
Almehedi R. 127
Almedia F. 82, 85, 107, 122
Almedia J. 82, 85, 107, 122
Alima M. 42
Amaro K. 98
Amatatsu M. 86
Ambrosio M. R. 67
Amemiya H. 77, 111, 122
Aminazzad E. 115
Anagnostopoulos I. 69
Anaisi A. 62, 72, 78
Ancars G. 69, 123
Ando M. 84, 98, 136
Ando T. 98
Andres S. 69
Andre Conde Modesto A. 72
Andre N. A. 106–107
Andres M. 110
Angele M. 72
Angeretti G. 82
An J. Y. 67, 127, 132, 137
Antunes L. 108
Aoki H. 124
Aoki M. 79
Aoyama T. 132, 137
Arai H. 94
Arai T. 50, 62, 64
Aranda F. 88
Araujo G. 78
Araujo T. 80, 135
Arber N. 43
Arcangeli V. 77
Arigami T. 78, 86, 95, 97, 101–102, 107, 135
Arra K. 66, 77, 81, 84
Arnold A. 73, 94
Arranz R. 92
Arteritano F. 128
Asada T. 67, 81
Asai R. 70
Asami S 107
Asao Y. 127
Assis D. 72
Assumpção C. 62, 80
Assumpção M. 72, 80, 135
Assumpção P. 62, 72, 78, 80, 135
Atarashi M. 133
Atsuki O. 97
Atsumi M. 72
Atsumu Y. 137
Atsuo S. 113
Atushi T. 137
Aujeysky R. 124
Avadhut D. J. 135
Aykas A. 112
Azarenkov A. 123
Azár C. 128
Baba E. 51
Baba H. 52, 83, 104, 126
Baba Y. 83, 104, 126
Back J. 103
Badgwell B. 83, 88, 104
Bae D. H. 78
Baeg M. K. 87
Bae J. M. 67, 130, 132, 137
Bae S. W. 72
Baia R. 85, 122
Baia R. 82, 107
Bai D. 80
Baik Y. 107
Baiocchi G. L. 41, 118
Bai Y. 105
Bajbouj M. 73
Baker C. 103, 110
Bakopoulos A. 111
Balogh C. 108
Balmaceda C. 68, 75
Bando E. 77, 84, 110
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chao Z.</td>
<td>76</td>
</tr>
<tr>
<td>Charles C.</td>
<td>135</td>
</tr>
<tr>
<td>Charruf A. Z.</td>
<td>65, 90, 107, 109, 122</td>
</tr>
<tr>
<td>Chau A.</td>
<td>68</td>
</tr>
<tr>
<td>Chau I.</td>
<td>42</td>
</tr>
<tr>
<td>Chaves J.</td>
<td>72</td>
</tr>
<tr>
<td>Chayka A.</td>
<td>96</td>
</tr>
<tr>
<td>Chen C.</td>
<td>89</td>
</tr>
<tr>
<td>Chen E.</td>
<td>62</td>
</tr>
<tr>
<td>Chen F.</td>
<td>82</td>
</tr>
<tr>
<td>Chen G.</td>
<td>66, 82, 91, 106, 111</td>
</tr>
<tr>
<td>Chen Gang Y.</td>
<td>79</td>
</tr>
<tr>
<td>Cheng X.</td>
<td>31, 45, 73, 135</td>
</tr>
<tr>
<td>Chen H.</td>
<td>121</td>
</tr>
<tr>
<td>Chen J.</td>
<td>69, 82, 91, 111</td>
</tr>
<tr>
<td>Chen K.</td>
<td>69, 91, 111</td>
</tr>
<tr>
<td>Chen L.</td>
<td>82, 84, 105, 111, 127</td>
</tr>
<tr>
<td>Chen L. T.</td>
<td>101</td>
</tr>
<tr>
<td>Chen M.</td>
<td>100</td>
</tr>
<tr>
<td>Chennamaneni R.</td>
<td>44</td>
</tr>
<tr>
<td>Chen Q.</td>
<td>106</td>
</tr>
<tr>
<td>Chen Q. Y.</td>
<td>52, 82, 88, 108, 140</td>
</tr>
<tr>
<td>Chen S.</td>
<td>68, 73, 100</td>
</tr>
<tr>
<td>Chen T.</td>
<td>82, 103</td>
</tr>
<tr>
<td>Chen X.</td>
<td>62, 74, 94, 105</td>
</tr>
<tr>
<td>Chen X. L.</td>
<td>38, 68, 79, 111, 128</td>
</tr>
<tr>
<td>Chen X. Z.</td>
<td>52, 80, 84, 111, 128, 133</td>
</tr>
<tr>
<td>Chen Y.</td>
<td>63, 73, 79, 81, 94, 136</td>
</tr>
<tr>
<td>Chen Z.</td>
<td>37–38, 45, 103, 108</td>
</tr>
<tr>
<td>Cheong J. H.</td>
<td>63, 78, 106</td>
</tr>
<tr>
<td>Chevalley M.</td>
<td>134</td>
</tr>
<tr>
<td>Chiang Y. J.</td>
<td>104</td>
</tr>
<tr>
<td>Chiaravalli A. M.</td>
<td>68, 82</td>
</tr>
<tr>
<td>Chian P.</td>
<td>122</td>
</tr>
<tr>
<td>Chi K. C.</td>
<td>121, 130</td>
</tr>
<tr>
<td>Chinen Y.</td>
<td>98</td>
</tr>
<tr>
<td>Ching S. S.</td>
<td>67</td>
</tr>
<tr>
<td>Chin H. M.</td>
<td>115</td>
</tr>
<tr>
<td>Chin K.</td>
<td>95–96</td>
</tr>
<tr>
<td>Chinnathambi M.</td>
<td>82</td>
</tr>
<tr>
<td>Chmelo J.</td>
<td>63, 108</td>
</tr>
<tr>
<td>Cho B.</td>
<td>108</td>
</tr>
<tr>
<td>Choda Y.</td>
<td>112</td>
</tr>
<tr>
<td>Cho G.</td>
<td>108</td>
</tr>
<tr>
<td>Cho H.</td>
<td>124, 132</td>
</tr>
<tr>
<td>Cho H. J.</td>
<td>129</td>
</tr>
<tr>
<td>Cho I.</td>
<td>108</td>
</tr>
<tr>
<td>Choi D. I.</td>
<td>87</td>
</tr>
<tr>
<td>Choi H. C.</td>
<td>76</td>
</tr>
<tr>
<td>Choi I. J.</td>
<td>87</td>
</tr>
<tr>
<td>Choi J. H.</td>
<td>99, 121, 128</td>
</tr>
<tr>
<td>Choi M. G.</td>
<td>67, 121, 130, 132, 137</td>
</tr>
<tr>
<td>Choi S.</td>
<td>90, 132</td>
</tr>
<tr>
<td>Choi S. H.</td>
<td>130</td>
</tr>
<tr>
<td>Choi Y. J.</td>
<td>138</td>
</tr>
<tr>
<td>Choi Y. Y.</td>
<td>63, 106</td>
</tr>
<tr>
<td>Cho M.</td>
<td>106, 120, 132</td>
</tr>
<tr>
<td>Cho M. Y.</td>
<td>65</td>
</tr>
<tr>
<td>Chong T. H. J.</td>
<td>89</td>
</tr>
<tr>
<td>Chon S. H.</td>
<td>90</td>
</tr>
<tr>
<td>Chorna N.</td>
<td>52</td>
</tr>
<tr>
<td>Chou S.</td>
<td>86</td>
</tr>
<tr>
<td>Cho Y. S.</td>
<td>101, 113, 129</td>
</tr>
<tr>
<td>Christiansen H.</td>
<td>35</td>
</tr>
<tr>
<td>Christodoulidis G.</td>
<td>108</td>
</tr>
<tr>
<td>Chue K. M.</td>
<td>96, 135</td>
</tr>
<tr>
<td>Chu K. M.</td>
<td>32</td>
</tr>
<tr>
<td>Chung H. Y.</td>
<td>99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Chung J. K.</td>
<td>72</td>
</tr>
<tr>
<td>Chung S.</td>
<td>75</td>
</tr>
<tr>
<td>Chu X.</td>
<td>106</td>
</tr>
<tr>
<td>Cigueria C. D. S.</td>
<td>65, 68</td>
</tr>
<tr>
<td>Claro L.</td>
<td>64, 82, 94, 109</td>
</tr>
<tr>
<td>Clemarens M.</td>
<td>108</td>
</tr>
<tr>
<td>Clemente U.</td>
<td>109</td>
</tr>
<tr>
<td>Cobianchi L.</td>
<td>125</td>
</tr>
<tr>
<td>Coburn N.</td>
<td>109, 115</td>
</tr>
<tr>
<td>Coccoza E.</td>
<td>68, 82, 107</td>
</tr>
<tr>
<td>Doelio dos Santos M.</td>
<td>97</td>
</tr>
<tr>
<td>Doelio Neto J. D. S.</td>
<td>106–107</td>
</tr>
<tr>
<td>Coinbra F. J. F.</td>
<td>92, 113</td>
</tr>
<tr>
<td>Colt D.</td>
<td>28</td>
</tr>
<tr>
<td>Colucci N.</td>
<td>134</td>
</tr>
<tr>
<td>Coniglio A.</td>
<td>120</td>
</tr>
<tr>
<td>Coozemans W.</td>
<td>89</td>
</tr>
<tr>
<td>Cordova-Delgado M.</td>
<td>68, 75</td>
</tr>
<tr>
<td>Cordts R. D. M.</td>
<td>64, 82, 94, 109, 113</td>
</tr>
<tr>
<td>Coreia Fragata M.</td>
<td>82</td>
</tr>
<tr>
<td>Coreia Lopes Mesquita A. C.</td>
<td>28</td>
</tr>
<tr>
<td>Coreia M.</td>
<td>85, 107, 122</td>
</tr>
<tr>
<td>Cortés R.</td>
<td>109</td>
</tr>
<tr>
<td>Cortez L.</td>
<td>82, 85, 107, 122</td>
</tr>
<tr>
<td>Corvalan A.</td>
<td>62, 75</td>
</tr>
<tr>
<td>Corvalan A. H.</td>
<td>68, 78</td>
</tr>
<tr>
<td>Cosimo C.</td>
<td>107</td>
</tr>
<tr>
<td>Cassu A.</td>
<td>46, 109</td>
</tr>
<tr>
<td>Costa-Maia J.</td>
<td>109, 119–120, 122</td>
</tr>
<tr>
<td>Costa R.</td>
<td>108</td>
</tr>
<tr>
<td>Croaco A.</td>
<td>107</td>
</tr>
<tr>
<td>Crovari F.</td>
<td>68, 75, 128</td>
</tr>
<tr>
<td>Cruardo M.</td>
<td>92, 132</td>
</tr>
<tr>
<td>Cuenca-Abente F.</td>
<td>80</td>
</tr>
<tr>
<td>Cui B.</td>
<td>128, 135</td>
</tr>
<tr>
<td>Cui G.</td>
<td>106</td>
</tr>
<tr>
<td>Cui J.</td>
<td>84, 105, 109</td>
</tr>
<tr>
<td>Cui M.</td>
<td>127, 134</td>
</tr>
<tr>
<td>Cui Q.</td>
<td>106</td>
</tr>
<tr>
<td>Cui Y.</td>
<td>73, 94</td>
</tr>
<tr>
<td>Gunha A.</td>
<td>72</td>
</tr>
<tr>
<td>Cunningham D.</td>
<td>103, 110</td>
</tr>
<tr>
<td>Casado D.</td>
<td>125</td>
</tr>
<tr>
<td>Da Costa Junior W. L.</td>
<td>92, 113</td>
</tr>
<tr>
<td>Dai G.</td>
<td>94</td>
</tr>
<tr>
<td>Daigo Y.</td>
<td>92</td>
</tr>
<tr>
<td>Dai H.</td>
<td>96</td>
</tr>
<tr>
<td>Daijuke T.</td>
<td>98</td>
</tr>
<tr>
<td>Dal Y.</td>
<td>85</td>
</tr>
<tr>
<td>Dal Cero M.</td>
<td>109</td>
</tr>
<tr>
<td>Danes R.</td>
<td>77</td>
</tr>
<tr>
<td>Daniela A.</td>
<td>107</td>
</tr>
<tr>
<td>Dan Y. Q.</td>
<td>63</td>
</tr>
<tr>
<td>Darling G.</td>
<td>91</td>
</tr>
<tr>
<td>Das P.</td>
<td>88, 104</td>
</tr>
<tr>
<td>Daum S.</td>
<td>73, 86, 104</td>
</tr>
<tr>
<td>Davies A.</td>
<td>103</td>
</tr>
<tr>
<td>Davis L.</td>
<td>109</td>
</tr>
<tr>
<td>Dazai M.</td>
<td>98</td>
</tr>
<tr>
<td>Degiuli M.</td>
<td>41, 97–98, 120, 122</td>
</tr>
<tr>
<td>de Godoy A. L.</td>
<td>92, 113</td>
</tr>
<tr>
<td>Deir G.</td>
<td>122</td>
</tr>
<tr>
<td>Dejeante C.</td>
<td>68</td>
</tr>
<tr>
<td>de Jesus V. H. F.</td>
<td>92</td>
</tr>
<tr>
<td>De la Hoz Riesco M.</td>
<td>111</td>
</tr>
<tr>
<td>De la Jara N.</td>
<td>68, 75</td>
</tr>
<tr>
<td>Delblasic V.</td>
<td>109</td>
</tr>
<tr>
<td>Dellaporta D.</td>
<td>110</td>
</tr>
<tr>
<td>De Luca R.</td>
<td>107</td>
</tr>
<tr>
<td>Demachki S.</td>
<td>72, 78</td>
</tr>
<tr>
<td>De Manzoni G.</td>
<td>32, 62, 97–98, 100, 104, 109, 120, 122, 125</td>
</tr>
<tr>
<td>Demartines N.</td>
<td>de Mayo F.</td>
</tr>
<tr>
<td>de C.</td>
<td>78</td>
</tr>
<tr>
<td>De Mello R. A.</td>
<td>35</td>
</tr>
<tr>
<td>De Mestral C.</td>
<td>115</td>
</tr>
<tr>
<td>Demir U.</td>
<td>118</td>
</tr>
<tr>
<td>Deng W.</td>
<td>90</td>
</tr>
<tr>
<td>Dengxiang L.</td>
<td>76, 87</td>
</tr>
<tr>
<td>Deng Y.</td>
<td>136</td>
</tr>
<tr>
<td>Deppepre L.</td>
<td>89</td>
</tr>
<tr>
<td>Desiderio J.</td>
<td>de Steur W. O.</td>
</tr>
<tr>
<td>Devezas V.</td>
<td>109, 119–120, 122</td>
</tr>
<tr>
<td>Diakun A.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Diamantinis A.</td>
<td>108</td>
</tr>
<tr>
<td>Dias A. R.</td>
<td>54, 65, 68, 90, 107, 109, 113, 122</td>
</tr>
<tr>
<td>Dias-Neto E.</td>
<td>80</td>
</tr>
<tr>
<td>Diaz A.</td>
<td>88</td>
</tr>
<tr>
<td>Diaz Romero C.</td>
<td>84, 115</td>
</tr>
<tr>
<td>Di Bartolomeo M.</td>
<td>38</td>
</tr>
<tr>
<td>Di Desidero T.</td>
<td>79</td>
</tr>
<tr>
<td>Author</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Diener M. K.</td>
<td>104</td>
</tr>
<tr>
<td>Diez del Val I.</td>
<td>108</td>
</tr>
<tr>
<td>Dignazio A.</td>
<td>37, 63</td>
</tr>
<tr>
<td>Di Nardo D.</td>
<td>54, 103, 128</td>
</tr>
<tr>
<td>Ding H.</td>
<td>140</td>
</tr>
<tr>
<td>Ding X.</td>
<td>32, 69, 128, 135</td>
</tr>
<tr>
<td>Ding Y.</td>
<td>63, 66, 73</td>
</tr>
<tr>
<td>Dintz A. L.</td>
<td>92, 113</td>
</tr>
<tr>
<td>Disep B.</td>
<td>63</td>
</tr>
<tr>
<td>Dislich B.</td>
<td>62</td>
</tr>
<tr>
<td>Dobrzhanskiy O.</td>
<td>82, 123</td>
</tr>
<tr>
<td>Doeck F.</td>
<td>136</td>
</tr>
<tr>
<td>Doglietto G. B.</td>
<td>122</td>
</tr>
<tr>
<td>Doi A.</td>
<td>94</td>
</tr>
<tr>
<td>Doki Y.</td>
<td>104</td>
</tr>
<tr>
<td>Dominguez F.</td>
<td>108</td>
</tr>
<tr>
<td>Dominioni T.</td>
<td>125</td>
</tr>
<tr>
<td>Donato M.</td>
<td>107</td>
</tr>
<tr>
<td>Dong F.</td>
<td>134</td>
</tr>
<tr>
<td>Dong X.</td>
<td>123</td>
</tr>
<tr>
<td>Donida B. M.</td>
<td>89</td>
</tr>
<tr>
<td>Donini A.</td>
<td>64, 67, 83, 97–98, 100, 120, 128</td>
</tr>
<tr>
<td>Donohoe C.</td>
<td>63</td>
</tr>
<tr>
<td>Doria L.</td>
<td>78</td>
</tr>
<tr>
<td>Duan Y.</td>
<td>82</td>
</tr>
<tr>
<td>Dubreuil G.</td>
<td>68</td>
</tr>
<tr>
<td>Duxce M.</td>
<td>36</td>
</tr>
<tr>
<td>Duda M.</td>
<td>112</td>
</tr>
<tr>
<td>Duque-Seguro C.</td>
<td>80</td>
</tr>
<tr>
<td>Dulak L.</td>
<td>30, 112</td>
</tr>
<tr>
<td>Du T.</td>
<td>90</td>
</tr>
<tr>
<td>Du Y.</td>
<td>94</td>
</tr>
<tr>
<td>Dytrych P.</td>
<td>95</td>
</tr>
<tr>
<td>Dziegiej P.</td>
<td>66</td>
</tr>
<tr>
<td>Dzierzek P.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Ebata T.</td>
<td>118</td>
</tr>
<tr>
<td>Eberspacher C.</td>
<td>128</td>
</tr>
<tr>
<td>Ebert K.</td>
<td>73</td>
</tr>
<tr>
<td>Egberts J. H.</td>
<td>63</td>
</tr>
<tr>
<td>Ehara K.</td>
<td>90, 128</td>
</tr>
<tr>
<td>Eigo O.</td>
<td>97</td>
</tr>
<tr>
<td>Eiji S.</td>
<td>98, 126</td>
</tr>
<tr>
<td>Eizaguire E.</td>
<td>108</td>
</tr>
<tr>
<td>Endo I.</td>
<td>90, 101, 114</td>
</tr>
<tr>
<td>Enomoto T.</td>
<td>105–106</td>
</tr>
<tr>
<td>Eom B. W.</td>
<td>49, 87, 130, 132, 138</td>
</tr>
<tr>
<td>Erkul O.</td>
<td>127</td>
</tr>
<tr>
<td>Estuhs W.</td>
<td>83</td>
</tr>
<tr>
<td>Esperguel C.</td>
<td>110</td>
</tr>
<tr>
<td>Espinoza M.</td>
<td>68, 75</td>
</tr>
<tr>
<td>Estalagem I.</td>
<td>80, 109</td>
</tr>
<tr>
<td>Estevez-Schwarz L.</td>
<td>86</td>
</tr>
<tr>
<td>Eto K.</td>
<td>83, 109, 126</td>
</tr>
<tr>
<td>Evangelista A.</td>
<td>122</td>
</tr>
<tr>
<td>Evangelista J.</td>
<td>77</td>
</tr>
<tr>
<td>Ewen C.</td>
<td>68</td>
</tr>
<tr>
<td>Fabian P.</td>
<td>119</td>
</tr>
<tr>
<td>Faerberg A.</td>
<td>80</td>
</tr>
<tr>
<td>Falcini F.</td>
<td>77</td>
</tr>
<tr>
<td>Falcone A.</td>
<td>79</td>
</tr>
<tr>
<td>Falzoni R.</td>
<td>118</td>
</tr>
<tr>
<td>Fan L.</td>
<td>91</td>
</tr>
<tr>
<td>Fan Y.</td>
<td>134</td>
</tr>
<tr>
<td>Faraj S. F.</td>
<td>65, 68</td>
</tr>
<tr>
<td>Faras I. C.</td>
<td>92, 113</td>
</tr>
<tr>
<td>Federici O.</td>
<td>107</td>
</tr>
<tr>
<td>Fei S.</td>
<td>126</td>
</tr>
<tr>
<td>Felicino Costa J.</td>
<td>103</td>
</tr>
<tr>
<td>Felismino T.</td>
<td>92</td>
</tr>
<tr>
<td>Feliz J.</td>
<td>92</td>
</tr>
<tr>
<td>Fencl P.</td>
<td>89</td>
</tr>
<tr>
<td>Fenecioglu H.</td>
<td>82</td>
</tr>
<tr>
<td>Feng E.</td>
<td>83</td>
</tr>
<tr>
<td>Feng J.</td>
<td>128, 135</td>
</tr>
<tr>
<td>Feng R.</td>
<td>105–106</td>
</tr>
<tr>
<td>Ferrandes A.</td>
<td>108</td>
</tr>
<tr>
<td>Ferrandes C.</td>
<td>109, 119–120, 122</td>
</tr>
<tr>
<td>Ferrandes E.</td>
<td>103</td>
</tr>
<tr>
<td>Fernandez B.</td>
<td>110</td>
</tr>
<tr>
<td>Ferrari C.</td>
<td>109</td>
</tr>
<tr>
<td>Ferreira M.</td>
<td>103, 137</td>
</tr>
<tr>
<td>Ferrer J. A. P.</td>
<td>106–107</td>
</tr>
<tr>
<td>Ferreiro A.</td>
<td>122</td>
</tr>
<tr>
<td>Ferreiro C.</td>
<td>47</td>
</tr>
<tr>
<td>Ferreiro Nogueira Lima B.</td>
<td>82</td>
</tr>
<tr>
<td>Ferreiro S.</td>
<td>117</td>
</tr>
<tr>
<td>Filipov B.</td>
<td>114</td>
</tr>
<tr>
<td>Filipovic Cugura J.</td>
<td>114</td>
</tr>
<tr>
<td>Findlay M.</td>
<td>91</td>
</tr>
<tr>
<td>Fiorillo C.</td>
<td>122</td>
</tr>
<tr>
<td>Flettas Kanonnikoff T.</td>
<td>30</td>
</tr>
<tr>
<td>Flettas T.</td>
<td>77</td>
</tr>
<tr>
<td>Fletter T.</td>
<td>28</td>
</tr>
<tr>
<td>Foland O.</td>
<td>117</td>
</tr>
<tr>
<td>Fomaro L.</td>
<td>79</td>
</tr>
<tr>
<td>Fraga C.</td>
<td>117</td>
</tr>
<tr>
<td>Frein Grote A.</td>
<td>63</td>
</tr>
<tr>
<td>Frettas Jr W.</td>
<td>64, 82, 94, 109</td>
</tr>
<tr>
<td>Frielich E.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Fridel R.</td>
<td>82, 123</td>
</tr>
<tr>
<td>Fujikuni N.</td>
<td>94, 140</td>
</tr>
<tr>
<td>Fujimoto H.</td>
<td>129</td>
</tr>
<tr>
<td>Fujimoto D.</td>
<td>73</td>
</tr>
<tr>
<td>Fujunuma I.</td>
<td>124</td>
</tr>
<tr>
<td>Fujisaki M.</td>
<td>124</td>
</tr>
<tr>
<td>Fujishima S.</td>
<td>103</td>
</tr>
<tr>
<td>Fujitani K.</td>
<td>99, 126</td>
</tr>
<tr>
<td>Fujita S.</td>
<td>110</td>
</tr>
<tr>
<td>Fujita T.</td>
<td>96</td>
</tr>
<tr>
<td>Fujitani Y.</td>
<td>92</td>
</tr>
<tr>
<td>Fujiwara H.</td>
<td>66, 77–78, 81, 84, 96, 114</td>
</tr>
<tr>
<td>Fujiwara M.</td>
<td>67, 81</td>
</tr>
<tr>
<td>Fujiwara N.</td>
<td>93, 110</td>
</tr>
<tr>
<td>Fujitaya T.</td>
<td>112</td>
</tr>
<tr>
<td>Fujii K.</td>
<td>77, 84, 110</td>
</tr>
<tr>
<td>Fujiyama J.</td>
<td>92</td>
</tr>
<tr>
<td>Fujiyta T.</td>
<td>128</td>
</tr>
<tr>
<td>Fukada T.</td>
<td>118</td>
</tr>
<tr>
<td>Fukagawa T.</td>
<td>113, 139</td>
</tr>
<tr>
<td>Fukaya M.</td>
<td>118</td>
</tr>
<tr>
<td>Fukuda A.</td>
<td>84</td>
</tr>
<tr>
<td>Fukuhara D. K.</td>
<td>64, 82, 94, 109, 113</td>
</tr>
<tr>
<td>Fukunaga S.</td>
<td>80</td>
</tr>
<tr>
<td>Fukusaki T.</td>
<td>118</td>
</tr>
<tr>
<td>Fukushima N.</td>
<td>110, 120</td>
</tr>
<tr>
<td>Fukushima R.</td>
<td>95, 97</td>
</tr>
<tr>
<td>Fumagalli Romario U.</td>
<td>28</td>
</tr>
<tr>
<td>Funahashi K.</td>
<td>78</td>
</tr>
<tr>
<td>Funke R.</td>
<td>29, 32</td>
</tr>
<tr>
<td>Furukawa K.</td>
<td>77, 84, 96</td>
</tr>
<tr>
<td>Furuya S.</td>
<td>77, 111, 122</td>
</tr>
<tr>
<td>Fushida S.</td>
<td>95, 113</td>
</tr>
<tr>
<td>Fu T.</td>
<td>63–64, 79, 89, 105</td>
</tr>
<tr>
<td>Futamura M.</td>
<td>95</td>
</tr>
<tr>
<td>Futawatari N.</td>
<td>110</td>
</tr>
<tr>
<td>Gabrielson D.</td>
<td>39</td>
</tr>
<tr>
<td>Galindo J.</td>
<td>92, 121</td>
</tr>
<tr>
<td>Galindo M. C.</td>
<td>87</td>
</tr>
<tr>
<td>Galindo Orosco M. C.</td>
<td>80, 83</td>
</tr>
<tr>
<td>Gallullin D.</td>
<td>128</td>
</tr>
<tr>
<td>Galofre G.</td>
<td>108</td>
</tr>
<tr>
<td>Galicio N.</td>
<td>135</td>
</tr>
<tr>
<td>Gambardella V.</td>
<td>77</td>
</tr>
<tr>
<td>Gandon A.</td>
<td>68</td>
</tr>
<tr>
<td>Ganem L.</td>
<td>64, 82, 94, 109</td>
</tr>
<tr>
<td>Gang Z.</td>
<td>134</td>
</tr>
<tr>
<td>Ganschow P.</td>
<td>72</td>
</tr>
<tr>
<td>Gao C.</td>
<td>89</td>
</tr>
<tr>
<td>Gao J.</td>
<td>139</td>
</tr>
<tr>
<td>Gao P.</td>
<td>100, 134</td>
</tr>
<tr>
<td>Gao Y.</td>
<td>38, 84, 87, 102</td>
</tr>
<tr>
<td>Garcia C.</td>
<td>52, 110</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------</td>
</tr>
<tr>
<td>Ishizuka N.</td>
<td>96</td>
</tr>
<tr>
<td>Isozaki M.</td>
<td>70, 100</td>
</tr>
<tr>
<td>Itakura H.</td>
<td>98</td>
</tr>
<tr>
<td>Itami T.</td>
<td>85, 118</td>
</tr>
<tr>
<td>Itazaki Y.</td>
<td>103, 105, 112, 114</td>
</tr>
<tr>
<td>Ithurnalde-Argerich J.</td>
<td>80</td>
</tr>
<tr>
<td>Ito M.</td>
<td>78</td>
</tr>
<tr>
<td>Ito N.</td>
<td>103, 112, 114</td>
</tr>
<tr>
<td>Ito S.</td>
<td>67, 81, 93, 100, 110, 124</td>
</tr>
<tr>
<td>Ito Y.</td>
<td>79, 97, 124</td>
</tr>
<tr>
<td>Iwagami S.</td>
<td>83, 112, 126</td>
</tr>
<tr>
<td>Iwamoto S.</td>
<td>129</td>
</tr>
<tr>
<td>Iwasaki T.</td>
<td>118</td>
</tr>
<tr>
<td>Iwasaki H.</td>
<td>128, 131</td>
</tr>
<tr>
<td>Iwasaki M.</td>
<td>83, 104, 126</td>
</tr>
<tr>
<td>Izawa N.</td>
<td>94</td>
</tr>
<tr>
<td>Izraelov R.</td>
<td>99</td>
</tr>
<tr>
<td>Jae-Ho C.</td>
<td>68, 90</td>
</tr>
<tr>
<td>Jae-Ho C.</td>
<td>68, 90</td>
</tr>
<tr>
<td>Jaesung H.</td>
<td>138</td>
</tr>
<tr>
<td>Jarzynski P.</td>
<td>68</td>
</tr>
<tr>
<td>Jang C. J. M.</td>
<td>96, 135</td>
</tr>
<tr>
<td>Jang D. K.</td>
<td>121</td>
</tr>
<tr>
<td>Jang E.</td>
<td>63</td>
</tr>
<tr>
<td>Jang Y. J.</td>
<td>100</td>
</tr>
<tr>
<td>Janigian Y.</td>
<td>34, 55</td>
</tr>
<tr>
<td>Jansen E.</td>
<td>93</td>
</tr>
<tr>
<td>Jansen-Winkel B.</td>
<td>85, 100</td>
</tr>
<tr>
<td>Januszewicz W.</td>
<td>33</td>
</tr>
<tr>
<td>Jan Y. Y.</td>
<td>64</td>
</tr>
<tr>
<td>Jara M.</td>
<td>94</td>
</tr>
<tr>
<td>Jastrzębski T.</td>
<td>101</td>
</tr>
<tr>
<td>Jedlicka V.</td>
<td>119</td>
</tr>
<tr>
<td>Jee Y. S.</td>
<td>96</td>
</tr>
<tr>
<td>Jelovskis I.</td>
<td>69, 123</td>
</tr>
<tr>
<td>Jenke R.</td>
<td>72, 75–76</td>
</tr>
<tr>
<td>Jeong K. Y.</td>
<td>72</td>
</tr>
<tr>
<td>Jeong O.</td>
<td>83, 112, 130</td>
</tr>
<tr>
<td>Jeong S. H.</td>
<td>87, 113, 121, 131</td>
</tr>
<tr>
<td>Jeong Y.</td>
<td>52</td>
</tr>
<tr>
<td>Jeon H. M.</td>
<td>84, 123</td>
</tr>
<tr>
<td>Jeon J.</td>
<td>105</td>
</tr>
<tr>
<td>Jesinghaus M.</td>
<td>76</td>
</tr>
<tr>
<td>Jezersek E.</td>
<td>137</td>
</tr>
<tr>
<td>Jiafu J.</td>
<td>126</td>
</tr>
<tr>
<td>Jia J.</td>
<td>100</td>
</tr>
<tr>
<td>Jiaming Z.</td>
<td>131, 133</td>
</tr>
<tr>
<td>Jianfi X.</td>
<td>136</td>
</tr>
<tr>
<td>Jiang H.</td>
<td>116, 123, 140</td>
</tr>
<tr>
<td>Jiang L.</td>
<td>75, 83, 106, 126</td>
</tr>
<tr>
<td>Jiang T.</td>
<td>106</td>
</tr>
<tr>
<td>Jiang X.</td>
<td>53, 90</td>
</tr>
<tr>
<td>Jiang Y.</td>
<td>53, 65, 80, 83</td>
</tr>
<tr>
<td>Jian-Kun H.</td>
<td>71, 123</td>
</tr>
<tr>
<td>Jianxun C.</td>
<td>76</td>
</tr>
<tr>
<td>Jia S.</td>
<td>63, 79, 116</td>
</tr>
<tr>
<td>Jia Y.</td>
<td>89, 93, 101, 134</td>
</tr>
<tr>
<td>Jia Z.</td>
<td>79, 105</td>
</tr>
<tr>
<td>Ji Hoon K.</td>
<td>112</td>
</tr>
<tr>
<td>J.J.</td>
<td>26, 30, 63–64, 71, 77, 81, 86, 89, 93, 101, 105, 123, 134</td>
</tr>
<tr>
<td>J.K.</td>
<td>79, 105</td>
</tr>
<tr>
<td>Jingli C.</td>
<td>134</td>
</tr>
<tr>
<td>Jin S. H.</td>
<td>94, 129</td>
</tr>
<tr>
<td>Jin S. Y.</td>
<td>65</td>
</tr>
<tr>
<td>Jin W.</td>
<td>133</td>
</tr>
<tr>
<td>Jin X.</td>
<td>111, 119</td>
</tr>
<tr>
<td>Jivraj N.</td>
<td>115</td>
</tr>
<tr>
<td>J.J.</td>
<td>123</td>
</tr>
<tr>
<td>Jwong K.</td>
<td>66</td>
</tr>
<tr>
<td>J.X.</td>
<td>79, 105</td>
</tr>
<tr>
<td>Johannessen H. O.</td>
<td>117</td>
</tr>
<tr>
<td>Johnson E.</td>
<td>117</td>
</tr>
<tr>
<td>Johrens K.</td>
<td>69</td>
</tr>
<tr>
<td>Jomrich G.</td>
<td>65</td>
</tr>
<tr>
<td>Jung E. S.</td>
<td>65, 68</td>
</tr>
<tr>
<td>Jung H. Y.</td>
<td>65</td>
</tr>
<tr>
<td>Jung J.</td>
<td>53</td>
</tr>
<tr>
<td>Jung J. O.</td>
<td>104</td>
</tr>
<tr>
<td>Jung M. K.</td>
<td>31, 33, 134</td>
</tr>
<tr>
<td>Jung M. R.</td>
<td>65, 83, 112, 132</td>
</tr>
<tr>
<td>Jung P.</td>
<td>129</td>
</tr>
<tr>
<td>Jung S.</td>
<td>65</td>
</tr>
<tr>
<td>Jung Y. J.</td>
<td>43, 75, 83, 85, 92, 111, 123, 132, 138</td>
</tr>
<tr>
<td>Jun L.</td>
<td>97</td>
</tr>
<tr>
<td>Jun K. H.</td>
<td>67, 75, 115</td>
</tr>
<tr>
<td>Junya F.</td>
<td>137</td>
</tr>
<tr>
<td>Jurkovic A.</td>
<td>112</td>
</tr>
<tr>
<td>Kabul Gurbulak E.</td>
<td>118</td>
</tr>
<tr>
<td>Kadokawa Y.</td>
<td>119</td>
</tr>
<tr>
<td>Kadomatsuki S.</td>
<td>95–96, 98, 136</td>
</tr>
<tr>
<td>Kadoya S.</td>
<td>128, 131</td>
</tr>
<tr>
<td>Kagawa M.</td>
<td>99</td>
</tr>
<tr>
<td>Kagawa Y.</td>
<td>87, 124</td>
</tr>
<tr>
<td>Kahl T.</td>
<td>75</td>
</tr>
<tr>
<td>Kaid S.</td>
<td>92, 112</td>
</tr>
<tr>
<td>Kajihara S.</td>
<td>119</td>
</tr>
<tr>
<td>Kal L.</td>
<td>71</td>
</tr>
<tr>
<td>Kal M.</td>
<td>111</td>
</tr>
<tr>
<td>Kain R.</td>
<td>65</td>
</tr>
<tr>
<td>Kaito A.</td>
<td>45, 70, 96</td>
</tr>
<tr>
<td>Kaji M.</td>
<td>113</td>
</tr>
<tr>
<td>Kaji S.</td>
<td>32</td>
</tr>
<tr>
<td>Kajiwara S.</td>
<td>129</td>
</tr>
<tr>
<td>Kajiwara Y.</td>
<td>103, 105</td>
</tr>
<tr>
<td>Kajiyama D.</td>
<td>84</td>
</tr>
<tr>
<td>Kajiyama K.</td>
<td>111</td>
</tr>
<tr>
<td>Kakiji Y.</td>
<td>125, 129, 139</td>
</tr>
<tr>
<td>Kallendrusch S.</td>
<td>74, 76</td>
</tr>
<tr>
<td>Kallwe H.</td>
<td>72</td>
</tr>
<tr>
<td>Kamachi K.</td>
<td>104</td>
</tr>
<tr>
<td>Kamali-Moghaddam M.</td>
<td>63</td>
</tr>
<tr>
<td>Kameyama A.</td>
<td>96</td>
</tr>
<tr>
<td>Kamikawa Y.</td>
<td>112</td>
</tr>
<tr>
<td>Kamikihara T.</td>
<td>107</td>
</tr>
<tr>
<td>Kaminishi M.</td>
<td>126–127</td>
</tr>
<tr>
<td>Kamio Y.</td>
<td>124</td>
</tr>
<tr>
<td>Kamiyama M.</td>
<td>129</td>
</tr>
<tr>
<td>Kaneeda A.</td>
<td>105</td>
</tr>
<tr>
<td>Kanet A.</td>
<td>95, 113</td>
</tr>
<tr>
<td>Kang H. J.</td>
<td>94</td>
</tr>
<tr>
<td>Kang J. H.</td>
<td>83, 132</td>
</tr>
<tr>
<td>Kang K.</td>
<td>136</td>
</tr>
<tr>
<td>Kang M.</td>
<td>111</td>
</tr>
<tr>
<td>Kang M. G.</td>
<td>68</td>
</tr>
<tr>
<td>Kang M. S.</td>
<td>65</td>
</tr>
<tr>
<td>Kang S. H.</td>
<td>45, 113, 129</td>
</tr>
<tr>
<td>Kang S. Y.</td>
<td>96</td>
</tr>
<tr>
<td>Kang T.</td>
<td>73</td>
</tr>
<tr>
<td>Kang W.</td>
<td>70, 77, 101, 104, 106, 116, 126</td>
</tr>
<tr>
<td>Kang Y. K.</td>
<td>105</td>
</tr>
<tr>
<td>Kano M.</td>
<td>64–65</td>
</tr>
<tr>
<td>Kano T.</td>
<td>98</td>
</tr>
<tr>
<td>Kano Y.</td>
<td>113</td>
</tr>
<tr>
<td>Kapsn A.</td>
<td>85</td>
</tr>
<tr>
<td>Karakama Y.</td>
<td>84</td>
</tr>
<tr>
<td>Kanell L.</td>
<td>101</td>
</tr>
<tr>
<td>Kamer A.</td>
<td>65</td>
</tr>
<tr>
<td>Karpiński P.</td>
<td>74</td>
</tr>
<tr>
<td>Kassab P.</td>
<td>32, 36, 64, 82, 94, 109, 113</td>
</tr>
<tr>
<td>Kasuya M.</td>
<td>93, 110</td>
</tr>
<tr>
<td>Kato H.</td>
<td>113, 139</td>
</tr>
<tr>
<td>Kataoka K.</td>
<td>35</td>
</tr>
<tr>
<td>Katayama S.</td>
<td>136</td>
</tr>
<tr>
<td>Katoh H.</td>
<td>72</td>
</tr>
<tr>
<td>Kato R.</td>
<td>98</td>
</tr>
<tr>
<td>Kato T.</td>
<td>136</td>
</tr>
<tr>
<td>Katsumi S.</td>
<td>97</td>
</tr>
<tr>
<td>Katsumori A.</td>
<td>84</td>
</tr>
<tr>
<td>Katsuno Y.</td>
<td>113</td>
</tr>
<tr>
<td>Kawabata R.</td>
<td>114, 137</td>
</tr>
<tr>
<td>Kawachi S.</td>
<td>136</td>
</tr>
<tr>
<td>Kawada H.</td>
<td>119</td>
</tr>
<tr>
<td>Kawada J.</td>
<td>114</td>
</tr>
<tr>
<td>Kawage K.</td>
<td>101</td>
</tr>
<tr>
<td>Kawaguchi Y.</td>
<td>77, 111, 122</td>
</tr>
<tr>
<td>Kawaguti F.</td>
<td>122</td>
</tr>
<tr>
<td>Kawahara K.</td>
<td>84, 124</td>
</tr>
<tr>
<td>Kawaida H.</td>
<td>77, 111, 122</td>
</tr>
<tr>
<td>Kawai K.</td>
<td>87</td>
</tr>
<tr>
<td>Kawakami J.</td>
<td>118</td>
</tr>
<tr>
<td>Kawakubo H.</td>
<td>129</td>
</tr>
<tr>
<td>Kawamoto Y.</td>
<td>98</td>
</tr>
<tr>
<td>Kawamura H.</td>
<td>95</td>
</tr>
<tr>
<td>Kawamura M.</td>
<td>113, 118, 124</td>
</tr>
<tr>
<td>Kawase T.</td>
<td>114</td>
</tr>
<tr>
<td>Kawashima Y.</td>
<td>90</td>
</tr>
<tr>
<td>Kaya C.</td>
<td>118</td>
</tr>
<tr>
<td>Kazama T.</td>
<td>79</td>
</tr>
<tr>
<td>Kazuhiro F.</td>
<td>127</td>
</tr>
<tr>
<td>Kazumasa F.</td>
<td>137</td>
</tr>
<tr>
<td>Kecheng Z.</td>
<td>76</td>
</tr>
<tr>
<td>Keishiro M.</td>
<td>113</td>
</tr>
<tr>
<td>Keicho C.</td>
<td>98</td>
</tr>
<tr>
<td>Keller G.</td>
<td>37, 76</td>
</tr>
<tr>
<td>Keller S.</td>
<td>73</td>
</tr>
<tr>
<td>Kelly M.</td>
<td>101, 110</td>
</tr>
<tr>
<td>Ken-ichiro I.</td>
<td>97</td>
</tr>
<tr>
<td>Kenji K.</td>
<td>124</td>
</tr>
<tr>
<td>Kensei Y.</td>
<td>98</td>
</tr>
<tr>
<td>Kentaro K.</td>
<td>137</td>
</tr>
<tr>
<td>Khalid M.</td>
<td>75</td>
</tr>
<tr>
<td>Khayat A.</td>
<td>72, 80, 135</td>
</tr>
<tr>
<td>Khayat B.</td>
<td>80</td>
</tr>
<tr>
<td>Khomiakov V.</td>
<td>96</td>
</tr>
<tr>
<td>Khomyakov V.</td>
<td>85</td>
</tr>
<tr>
<td>Kielan W.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Ki Hyun K.</td>
<td>111</td>
</tr>
<tr>
<td>Kikuchi H.</td>
<td>39</td>
</tr>
<tr>
<td>Kikuchi S.</td>
<td>112, 127</td>
</tr>
<tr>
<td>Kikuchi T.</td>
<td>95, 132</td>
</tr>
<tr>
<td>Kim A.</td>
<td>113</td>
</tr>
<tr>
<td>Kimata M.</td>
<td>110</td>
</tr>
<tr>
<td>Kim B.</td>
<td>80</td>
</tr>
<tr>
<td>Kim C. G.</td>
<td>87</td>
</tr>
<tr>
<td>Kim D.</td>
<td>65</td>
</tr>
<tr>
<td>Kim D. H.</td>
<td>65, 113</td>
</tr>
<tr>
<td>Kim D. J.</td>
<td>134</td>
</tr>
<tr>
<td>Kim D. W.</td>
<td>96</td>
</tr>
<tr>
<td>Kim E. K.</td>
<td>137</td>
</tr>
<tr>
<td>Kim E. Y.</td>
<td>84</td>
</tr>
<tr>
<td>Kim G.</td>
<td>96</td>
</tr>
<tr>
<td>Kim G. W.</td>
<td>135</td>
</tr>
<tr>
<td>Kim G. Y.</td>
<td>131, 138</td>
</tr>
<tr>
<td>Kim H.</td>
<td>65</td>
</tr>
<tr>
<td>Kim H. I.</td>
<td>63, 106</td>
</tr>
<tr>
<td>Kim H. J.</td>
<td>78</td>
</tr>
<tr>
<td>Author</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Ko S. H.</td>
<td>87</td>
</tr>
<tr>
<td>Koshi K.</td>
<td>113</td>
</tr>
<tr>
<td>Kosihman I.</td>
<td>123</td>
</tr>
<tr>
<td>Kosuga T.</td>
<td>66, 77–78, 81, 84, 104, 114</td>
</tr>
<tr>
<td>Kosuke S.</td>
<td>125</td>
</tr>
<tr>
<td>Kotake S.</td>
<td>100, 124</td>
</tr>
<tr>
<td>Koto S.</td>
<td>64</td>
</tr>
<tr>
<td>Kotsuki K.</td>
<td>74, 111</td>
</tr>
<tr>
<td>Koura A.</td>
<td>131</td>
</tr>
<tr>
<td>Kozu K.</td>
<td>103, 105, 112, 114</td>
</tr>
<tr>
<td>Kovalchik Y.</td>
<td>101</td>
</tr>
<tr>
<td>Koyama I.</td>
<td>93, 110</td>
</tr>
<tr>
<td>Kozak Y.</td>
<td>123</td>
</tr>
<tr>
<td>Koz K.</td>
<td>103</td>
</tr>
<tr>
<td>Krajcova J.</td>
<td>87</td>
</tr>
<tr>
<td>Krivan S.</td>
<td>111</td>
</tr>
<tr>
<td>Kriska Z.</td>
<td>95</td>
</tr>
<tr>
<td>Krüger S.</td>
<td>63</td>
</tr>
<tr>
<td>Kruk-Bachonko J.</td>
<td>85</td>
</tr>
<tr>
<td>Krumins V.</td>
<td>69, 123</td>
</tr>
<tr>
<td>Kudou M.</td>
<td>85</td>
</tr>
<tr>
<td>Kubo M.</td>
<td>107</td>
</tr>
<tr>
<td>Kubo N.</td>
<td>129</td>
</tr>
<tr>
<td>Kubota H.</td>
<td>100</td>
</tr>
<tr>
<td>Kubota T.</td>
<td>66, 77–78, 81, 84, 104, 112, 114</td>
</tr>
<tr>
<td>Kudo M.</td>
<td>77</td>
</tr>
<tr>
<td>Kudose Y.</td>
<td>85, 118</td>
</tr>
<tr>
<td>Kudoushi M.</td>
<td>66, 81, 84</td>
</tr>
<tr>
<td>Kujarek M.</td>
<td>80</td>
</tr>
<tr>
<td>Kumagai K.</td>
<td>70, 100, 120, 129, 132</td>
</tr>
<tr>
<td>Kumano I.</td>
<td>103, 105, 112, 114</td>
</tr>
<tr>
<td>Kumar S.</td>
<td>78</td>
</tr>
<tr>
<td>Kumazu Y.</td>
<td>123, 126</td>
</tr>
<tr>
<td>Kunisaki C.</td>
<td>70, 90, 101, 114</td>
</tr>
<tr>
<td>Kunishige T.</td>
<td>67, 70, 104, 138</td>
</tr>
<tr>
<td>Kun Y.</td>
<td>71, 123</td>
</tr>
<tr>
<td>Kunzhi T.</td>
<td>73</td>
</tr>
<tr>
<td>Kuo Y.</td>
<td>97</td>
</tr>
<tr>
<td>Kurahashi Y.</td>
<td>119</td>
</tr>
<tr>
<td>Kurata M.</td>
<td>105–106</td>
</tr>
<tr>
<td>Kurian A.</td>
<td>82</td>
</tr>
<tr>
<td>Kurizumi Y.</td>
<td>66, 77, 81, 84</td>
</tr>
<tr>
<td>Kumol K.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Kuruda S.</td>
<td>112</td>
</tr>
<tr>
<td>Kurikawa Y.</td>
<td>39, 104</td>
</tr>
<tr>
<td>Kusano-Kitazume A.</td>
<td>84</td>
</tr>
<tr>
<td>Kusumoto T.</td>
<td>95</td>
</tr>
<tr>
<td>Kusunoki T.</td>
<td>127</td>
</tr>
<tr>
<td>Kusumoto H.</td>
<td>136</td>
</tr>
<tr>
<td>Kusuta T.</td>
<td>70</td>
</tr>
<tr>
<td>Kuznetsova O.</td>
<td>96</td>
</tr>
<tr>
<td>Kwak Y.</td>
<td>66</td>
</tr>
<tr>
<td>Kwok J. Y. Y.</td>
<td>138</td>
</tr>
<tr>
<td>Kwon I. G.</td>
<td>115, 132</td>
</tr>
<tr>
<td>Kwon O. K.</td>
<td>99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Kwon S. J.</td>
<td>115, 130</td>
</tr>
<tr>
<td>Kyu G.</td>
<td>138</td>
</tr>
<tr>
<td>Lacle M.</td>
<td>125</td>
</tr>
<tr>
<td>Lages P.</td>
<td>85, 137</td>
</tr>
<tr>
<td>Lagos M.</td>
<td>78</td>
</tr>
<tr>
<td>Lammert H.</td>
<td>73</td>
</tr>
<tr>
<td>Langer R.</td>
<td>29, 62</td>
</tr>
<tr>
<td>Lang H.</td>
<td>74</td>
</tr>
<tr>
<td>Lapenta R.</td>
<td>107</td>
</tr>
<tr>
<td>Lara Santos L.</td>
<td>108</td>
</tr>
<tr>
<td>Lasitschka F.</td>
<td>69</td>
</tr>
<tr>
<td>Laureano M.</td>
<td>97</td>
</tr>
<tr>
<td>Laurino A.</td>
<td>106</td>
</tr>
<tr>
<td>Law S.</td>
<td>138</td>
</tr>
<tr>
<td>Law T.</td>
<td>138</td>
</tr>
<tr>
<td>Lechner A.</td>
<td>136</td>
</tr>
<tr>
<td>Lee C. M.</td>
<td>100</td>
</tr>
<tr>
<td>Lee E. J.</td>
<td>68</td>
</tr>
<tr>
<td>Lee G. E.</td>
<td>115</td>
</tr>
<tr>
<td>Lee H.</td>
<td>75–76, 83, 85, 92, 99, 111, 121, 123, 130, 132, 138</td>
</tr>
<tr>
<td>Lee H. J.</td>
<td>32, 41, 72, 99, 121, 128</td>
</tr>
<tr>
<td>Lee H. L.</td>
<td>94</td>
</tr>
<tr>
<td>Lee H. S.</td>
<td>66–67</td>
</tr>
<tr>
<td>Lee I. S.</td>
<td>44, 130</td>
</tr>
<tr>
<td>Lee J.</td>
<td>67, 115</td>
</tr>
<tr>
<td>Lee J. H.</td>
<td>65, 67, 130, 132, 137–138</td>
</tr>
<tr>
<td>Lee J. I.</td>
<td>94, 129</td>
</tr>
<tr>
<td>Lee J. S.</td>
<td>37, 72</td>
</tr>
<tr>
<td>Lee J. W.</td>
<td>75</td>
</tr>
<tr>
<td>Lee J. Y.</td>
<td>87, 115</td>
</tr>
<tr>
<td>Lee K. G.</td>
<td>84</td>
</tr>
<tr>
<td>Lee K. I.</td>
<td>65</td>
</tr>
<tr>
<td>Lee M.</td>
<td>91</td>
</tr>
<tr>
<td>Lee M. S.</td>
<td>86, 93, 100</td>
</tr>
<tr>
<td>Lee S.</td>
<td>90, 115</td>
</tr>
<tr>
<td>Lee S. H.</td>
<td>76, 111, 121, 138</td>
</tr>
<tr>
<td>Lee S. I.</td>
<td>121</td>
</tr>
<tr>
<td>Lee S. S.</td>
<td>99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Lee W. K.</td>
<td>100</td>
</tr>
<tr>
<td>Lee W. Y.</td>
<td>66</td>
</tr>
<tr>
<td>Lee Y. J.</td>
<td>121, 131</td>
</tr>
<tr>
<td>Lei S.</td>
<td>128, 135</td>
</tr>
<tr>
<td>Lei X.</td>
<td>81, 93, 101</td>
</tr>
<tr>
<td>Leja M.</td>
<td>69, 123</td>
</tr>
<tr>
<td>Lele L.</td>
<td>74</td>
</tr>
<tr>
<td>Leli R.</td>
<td>122</td>
</tr>
<tr>
<td>Lemus M.</td>
<td>128</td>
</tr>
<tr>
<td>Lencioni M.</td>
<td>79</td>
</tr>
<tr>
<td>Lenz L.</td>
<td>122</td>
</tr>
<tr>
<td>Leon A. M.</td>
<td>87</td>
</tr>
<tr>
<td>Leong T.</td>
<td>42, 91</td>
</tr>
<tr>
<td>Lenut T.</td>
<td>80, 84, 115</td>
</tr>
<tr>
<td>Leteutre E.</td>
<td>68</td>
</tr>
<tr>
<td>Leung S. K.</td>
<td>105</td>
</tr>
<tr>
<td>Levy J.</td>
<td>115</td>
</tr>
<tr>
<td>Liakakos T.</td>
<td>111</td>
</tr>
<tr>
<td>Lian C.</td>
<td>91</td>
</tr>
<tr>
<td>Lian H.</td>
<td>28, 39</td>
</tr>
<tr>
<td>Lian L. P.</td>
<td>93</td>
</tr>
<tr>
<td>Lian P.</td>
<td>116</td>
</tr>
<tr>
<td>Lian W.</td>
<td>45, 84</td>
</tr>
<tr>
<td>Li B.</td>
<td>138</td>
</tr>
<tr>
<td>Li C.</td>
<td>79, 93</td>
</tr>
<tr>
<td>Li F.</td>
<td>73, 139</td>
</tr>
<tr>
<td>Li G.</td>
<td>29, 46, 65, 74, 80, 82–83, 91, 103, 121, 136</td>
</tr>
<tr>
<td>Li G. C.</td>
<td>70, 93</td>
</tr>
<tr>
<td>Li H.</td>
<td>76, 87</td>
</tr>
<tr>
<td>Li H. R.</td>
<td>126–127</td>
</tr>
<tr>
<td>Li J.</td>
<td>76, 84</td>
</tr>
<tr>
<td>Li L.</td>
<td>106</td>
</tr>
<tr>
<td>Li M.</td>
<td>91, 106</td>
</tr>
<tr>
<td>Lima A.</td>
<td>135</td>
</tr>
<tr>
<td>Lima E.</td>
<td>64, 82, 94, 109</td>
</tr>
<tr>
<td>Lim C. H.</td>
<td>87, 137</td>
</tr>
<tr>
<td>Lim K. T.</td>
<td>140</td>
</tr>
<tr>
<td>Lin C.</td>
<td>76</td>
</tr>
<tr>
<td>Lin D.</td>
<td>71</td>
</tr>
<tr>
<td>Lindblad M.</td>
<td>90, 133</td>
</tr>
<tr>
<td>Lind P.</td>
<td>93</td>
</tr>
<tr>
<td>Lin H.</td>
<td>106</td>
</tr>
<tr>
<td>Lin J.</td>
<td>66, 87, 91</td>
</tr>
<tr>
<td>Lin J. P.</td>
<td>138</td>
</tr>
<tr>
<td>Lin J. X.</td>
<td>76, 91, 138</td>
</tr>
<tr>
<td>Lin K. H.</td>
<td>88</td>
</tr>
<tr>
<td>Lin L.</td>
<td>69, 91, 111</td>
</tr>
<tr>
<td>Lin M.</td>
<td>106</td>
</tr>
<tr>
<td>Lin N.</td>
<td>105</td>
</tr>
<tr>
<td>Linho-Silva L. S.</td>
<td>84, 115</td>
</tr>
<tr>
<td>Lin S. H.</td>
<td>90</td>
</tr>
<tr>
<td>Lin S. H.</td>
<td>90</td>
</tr>
<tr>
<td>Lin T.</td>
<td>68</td>
</tr>
<tr>
<td>Lin Z. B.</td>
<td>116</td>
</tr>
<tr>
<td>Lipnickas V.</td>
<td>86</td>
</tr>
<tr>
<td>Li Q.</td>
<td>62, 115, 140</td>
</tr>
<tr>
<td>Li R. L.</td>
<td>135</td>
</tr>
<tr>
<td>Li S.</td>
<td>89, 93, 97, 101, 134</td>
</tr>
<tr>
<td>Lischke R.</td>
<td>89</td>
</tr>
<tr>
<td>Lisiereck R.</td>
<td>86</td>
</tr>
<tr>
<td>Li T.</td>
<td>83</td>
</tr>
<tr>
<td>Liu B.</td>
<td>69, 75–76, 79</td>
</tr>
<tr>
<td>Liu D.</td>
<td>66, 104, 116</td>
</tr>
<tr>
<td>Liu F.</td>
<td>73, 94</td>
</tr>
<tr>
<td>Liu H.</td>
<td>38, 73, 77, 101, 117, 131</td>
</tr>
<tr>
<td>Liu K.</td>
<td>68, 83–84, 111, 128, 133, 135</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Owada Y.</td>
<td>105–106</td>
</tr>
<tr>
<td>Owen G.</td>
<td>75</td>
</tr>
<tr>
<td>Oyama T.</td>
<td>30, 49, 54</td>
</tr>
<tr>
<td>Oyeon C.</td>
<td>138</td>
</tr>
<tr>
<td>Ozawa R.</td>
<td>92</td>
</tr>
<tr>
<td>Ozawa S.</td>
<td>118</td>
</tr>
<tr>
<td>Ozawa Y.</td>
<td>137</td>
</tr>
<tr>
<td>Oze I.</td>
<td>98</td>
</tr>
<tr>
<td>Ozorio G. A.</td>
<td>92</td>
</tr>
<tr>
<td>Pais J.</td>
<td>97</td>
</tr>
<tr>
<td>Paiva I.</td>
<td>135</td>
</tr>
<tr>
<td>Pak K. H.</td>
<td>78</td>
</tr>
<tr>
<td>Palazzini G.</td>
<td>128</td>
</tr>
<tr>
<td>Palini G. M.</td>
<td>134</td>
</tr>
<tr>
<td>Palter V.</td>
<td>109</td>
</tr>
<tr>
<td>Pang F.</td>
<td>93</td>
</tr>
<tr>
<td>Pan H.</td>
<td>47, 78</td>
</tr>
<tr>
<td>Pan K. F.</td>
<td>73</td>
</tr>
<tr>
<td>Pan L.</td>
<td>76</td>
</tr>
<tr>
<td>Pan M.</td>
<td>73</td>
</tr>
<tr>
<td>Pan Z.</td>
<td>106</td>
</tr>
<tr>
<td>Pánal J.</td>
<td>116</td>
</tr>
<tr>
<td>Paratore F.</td>
<td>134</td>
</tr>
<tr>
<td>Parise P.</td>
<td>109</td>
</tr>
<tr>
<td>Parisi A.</td>
<td>50, 87, 103, 128</td>
</tr>
<tr>
<td>Park C. H.</td>
<td>75, 83, 85, 92, 111, 123, 132, 134, 138</td>
</tr>
<tr>
<td>Park D. Y.</td>
<td>65</td>
</tr>
<tr>
<td>Park E. Y.</td>
<td>131, 138</td>
</tr>
<tr>
<td>Park I.</td>
<td>100</td>
</tr>
<tr>
<td>Park J. H.</td>
<td>113, 121, 131</td>
</tr>
<tr>
<td>Park J. L.</td>
<td>78</td>
</tr>
<tr>
<td>Park J. M.</td>
<td>121, 130</td>
</tr>
<tr>
<td>Park J. Y.</td>
<td>99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Park K. B.</td>
<td>85, 99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Park K. U.</td>
<td>66–67</td>
</tr>
<tr>
<td>Park S.</td>
<td>104</td>
</tr>
<tr>
<td>Park S. H.</td>
<td>49, 75, 99–100, 121, 128</td>
</tr>
<tr>
<td>Park S. S.</td>
<td>100</td>
</tr>
<tr>
<td>Park Y.</td>
<td>66–67, 81</td>
</tr>
<tr>
<td>Park Y. K.</td>
<td>65, 83, 112, 132</td>
</tr>
<tr>
<td>Park Y. S.</td>
<td>65, 75, 101, 113, 121, 129, 138</td>
</tr>
<tr>
<td>Partyka R.</td>
<td>68</td>
</tr>
<tr>
<td>Paskonis M.</td>
<td>101</td>
</tr>
<tr>
<td>Pasquini G.</td>
<td>79</td>
</tr>
<tr>
<td>Passalacqua R.</td>
<td>89</td>
</tr>
<tr>
<td>Passos Coelho J.</td>
<td>117</td>
</tr>
<tr>
<td>Patel P.</td>
<td>78</td>
</tr>
<tr>
<td>Patsko V.</td>
<td>34</td>
</tr>
<tr>
<td>Pattyn P.</td>
<td>90</td>
</tr>
<tr>
<td>Pauligk C.</td>
<td>74</td>
</tr>
<tr>
<td>Pazdro A.</td>
<td>89</td>
</tr>
<tr>
<td>Pcholkin A.</td>
<td>69, 123</td>
</tr>
<tr>
<td>Pech O.</td>
<td>44, 54</td>
</tr>
<tr>
<td>Pecora I.</td>
<td>79</td>
</tr>
<tr>
<td>Pellizzl M.</td>
<td>68</td>
</tr>
<tr>
<td>Peng B. Q.</td>
<td>68</td>
</tr>
<tr>
<td>Peng J.</td>
<td>89</td>
</tr>
<tr>
<td>Peng R.</td>
<td>121</td>
</tr>
<tr>
<td>Peng Z.</td>
<td>136</td>
</tr>
<tr>
<td>Peralta Ferreira M.</td>
<td>121</td>
</tr>
<tr>
<td>Pera M.</td>
<td>28, 92, 108</td>
</tr>
<tr>
<td>Pereira A.</td>
<td>72, 109, 119–120, 122</td>
</tr>
<tr>
<td>Pereira C.</td>
<td>137</td>
</tr>
<tr>
<td>Pereira M.</td>
<td>90, 109</td>
</tr>
<tr>
<td>Pereira M. A.</td>
<td>65, 68</td>
</tr>
<tr>
<td>Pereira P.</td>
<td>38</td>
</tr>
<tr>
<td>Pereira Praxedes V. S.</td>
<td>85</td>
</tr>
<tr>
<td>Perfi liev.</td>
<td>85</td>
</tr>
<tr>
<td>Perneel C.</td>
<td>90</td>
</tr>
<tr>
<td>Persiani R.</td>
<td>106</td>
</tr>
<tr>
<td>Persson S.</td>
<td>133</td>
</tr>
<tr>
<td>Peters L.</td>
<td>104</td>
</tr>
<tr>
<td>Petreni I.</td>
<td>79</td>
</tr>
<tr>
<td>Petruzelka L.</td>
<td>95</td>
</tr>
<tr>
<td>Pfister D.</td>
<td>136</td>
</tr>
<tr>
<td>Phillips A.</td>
<td>108</td>
</tr>
<tr>
<td>Phillips A. W.</td>
<td>63</td>
</tr>
<tr>
<td>Picazo Ferrera K.</td>
<td>80, 83</td>
</tr>
<tr>
<td>Piessen G.</td>
<td>27, 49, 68</td>
</tr>
<tr>
<td>Pignatelli N.</td>
<td>118</td>
</tr>
<tr>
<td>Pinto A.</td>
<td>82, 85, 107, 122</td>
</tr>
<tr>
<td>Pinto M.</td>
<td>68</td>
</tr>
<tr>
<td>Pinto P.</td>
<td>72</td>
</tr>
<tr>
<td>Piotrowska A.</td>
<td>66</td>
</tr>
<tr>
<td>Pires de Souza M.  T.</td>
<td>92</td>
</tr>
<tr>
<td>Pirin F.</td>
<td>77</td>
</tr>
<tr>
<td>Pirgov S.</td>
<td>85</td>
</tr>
<tr>
<td>Pirrera B.</td>
<td>134</td>
</tr>
<tr>
<td>Piso P.</td>
<td>48</td>
</tr>
<tr>
<td>Pizc C.</td>
<td>89</td>
</tr>
<tr>
<td>Plum P. S.</td>
<td>90, 136</td>
</tr>
<tr>
<td>Podhorska-Okolow M.</td>
<td>66</td>
</tr>
<tr>
<td>Pola stri R.</td>
<td>122</td>
</tr>
<tr>
<td>Polkowski W.</td>
<td>86, 101, 121</td>
</tr>
<tr>
<td>Polon K.</td>
<td>51, 63, 97–98</td>
</tr>
<tr>
<td>Pomortsev B.</td>
<td>99</td>
</tr>
<tr>
<td>Ponce Leon F.</td>
<td>82</td>
</tr>
<tr>
<td>Persio P.</td>
<td>118</td>
</tr>
<tr>
<td>Portalani N.</td>
<td>118</td>
</tr>
<tr>
<td>Poskus E.</td>
<td>86</td>
</tr>
<tr>
<td>Prado Castro G. A.</td>
<td>28</td>
</tr>
<tr>
<td>Pratschke J.</td>
<td>94</td>
</tr>
<tr>
<td>Praxedes V.</td>
<td>82, 107, 122</td>
</tr>
<tr>
<td>Preten H.</td>
<td>89</td>
</tr>
<tr>
<td>Preussner M.</td>
<td>65</td>
</tr>
<tr>
<td>Priego P.</td>
<td>92, 121, 132</td>
</tr>
<tr>
<td>Prill S.</td>
<td>76</td>
</tr>
<tr>
<td>Pucetti F.</td>
<td>109</td>
</tr>
<tr>
<td>Pudlo K.</td>
<td>85–86</td>
</tr>
<tr>
<td>Puerta A.</td>
<td>92, 121, 132</td>
</tr>
<tr>
<td>Puja das M.</td>
<td>92</td>
</tr>
<tr>
<td>Puolakkainen P.</td>
<td>44, 47, 85, 103</td>
</tr>
<tr>
<td>Putter H.</td>
<td>93</td>
</tr>
<tr>
<td>Qingqiang H.</td>
<td>76, 87</td>
</tr>
<tr>
<td>Qu J. H.</td>
<td>103</td>
</tr>
<tr>
<td>Quinj S.</td>
<td>63</td>
</tr>
<tr>
<td>Qi W.</td>
<td>35</td>
</tr>
<tr>
<td>Quua A.</td>
<td>90, 136</td>
</tr>
<tr>
<td>Quaresma M.</td>
<td>72</td>
</tr>
<tr>
<td>Querini G.</td>
<td>125</td>
</tr>
<tr>
<td>Quero G.</td>
<td>122</td>
</tr>
<tr>
<td>Quezada N.</td>
<td>128</td>
</tr>
<tr>
<td>Qu H.</td>
<td>79</td>
</tr>
<tr>
<td>Quintana L.</td>
<td>135</td>
</tr>
<tr>
<td>Quintero Garzón L.</td>
<td>30</td>
</tr>
<tr>
<td>Quintodel V.</td>
<td>68, 82, 107</td>
</tr>
<tr>
<td>Rabago A.</td>
<td>80</td>
</tr>
<tr>
<td>Ramalho M.</td>
<td>103</td>
</tr>
<tr>
<td>Ramos A.</td>
<td>62</td>
</tr>
<tr>
<td>Ramos D.</td>
<td>92, 121, 132</td>
</tr>
<tr>
<td>Ramos F. K. P.</td>
<td>68, 113</td>
</tr>
<tr>
<td>Ramos M.</td>
<td>90</td>
</tr>
<tr>
<td>Ramos M. K.</td>
<td>107</td>
</tr>
<tr>
<td>Ramos M. K. P.</td>
<td>122</td>
</tr>
<tr>
<td>Ramos S.</td>
<td>117</td>
</tr>
<tr>
<td>Ramshorot B.</td>
<td>114</td>
</tr>
<tr>
<td>Ranieri V.</td>
<td>89</td>
</tr>
<tr>
<td>Ranzani G. N.</td>
<td>77</td>
</tr>
<tr>
<td>Rao J.</td>
<td>131</td>
</tr>
<tr>
<td>Rao X.</td>
<td>63</td>
</tr>
<tr>
<td>Rati D.</td>
<td>136</td>
</tr>
<tr>
<td>Ratti M.</td>
<td>89</td>
</tr>
<tr>
<td>Rau B.</td>
<td>36, 86, 94</td>
</tr>
<tr>
<td>Ravaioli S.</td>
<td>67</td>
</tr>
<tr>
<td>Rayezvnani M.</td>
<td>77</td>
</tr>
<tr>
<td>Raziewicz-Przysski K.</td>
<td>86, 101, 121</td>
</tr>
<tr>
<td>Rayat G. R.</td>
<td>69</td>
</tr>
<tr>
<td>Realis Luc M.</td>
<td>125</td>
</tr>
<tr>
<td>Rebstock J.</td>
<td>76</td>
</tr>
<tr>
<td>Reddavid R.</td>
<td>53, 120, 122</td>
</tr>
<tr>
<td>Reiche M.</td>
<td>76</td>
</tr>
<tr>
<td>Reim D.</td>
<td>28, 39, 85</td>
</tr>
<tr>
<td>Rein M.</td>
<td>72</td>
</tr>
<tr>
<td>Reis-das-Mercês L.</td>
<td>72</td>
</tr>
<tr>
<td>Reka L.</td>
<td>108</td>
</tr>
<tr>
<td>Renaud F.</td>
<td>50, 68</td>
</tr>
<tr>
<td>Retamal I. N.</td>
<td>68, 75</td>
</tr>
<tr>
<td>Revelo S.</td>
<td>128</td>
</tr>
<tr>
<td>Rha S. Y.</td>
<td>34, 42</td>
</tr>
<tr>
<td>Rhode P.</td>
<td>100</td>
</tr>
<tr>
<td>Ribas G.</td>
<td>77</td>
</tr>
<tr>
<td>Name</td>
<td>Block</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Sugita S.</td>
<td>70</td>
</tr>
<tr>
<td>Sugiuara T.</td>
<td>84</td>
</tr>
<tr>
<td>Sugiyama M.</td>
<td>99</td>
</tr>
<tr>
<td>Sugiyama Y.</td>
<td>120</td>
</tr>
<tr>
<td>Suh B. J.</td>
<td>100</td>
</tr>
<tr>
<td>Suh Y. J.</td>
<td>65</td>
</tr>
<tr>
<td>Suh Y. S.</td>
<td>99, 121, 128</td>
</tr>
<tr>
<td>Sukhin D.</td>
<td>85</td>
</tr>
<tr>
<td>Su L.</td>
<td>69, 76</td>
</tr>
<tr>
<td>Sul H. J.</td>
<td>80</td>
</tr>
<tr>
<td>Sunagawa H.</td>
<td>133</td>
</tr>
<tr>
<td>Sunakawa Y.</td>
<td>94</td>
</tr>
<tr>
<td>Sun G.</td>
<td>100</td>
</tr>
<tr>
<td>Sung Hoon N.</td>
<td>90</td>
</tr>
<tr>
<td>Sungsoo P.</td>
<td>104</td>
</tr>
<tr>
<td>Sun H.</td>
<td>86</td>
</tr>
<tr>
<td>Sun L.</td>
<td>79, 100, 133</td>
</tr>
<tr>
<td>Sun X.</td>
<td>103</td>
</tr>
<tr>
<td>Sun Y.</td>
<td>69, 71, 94</td>
</tr>
<tr>
<td>Surendra Kumar G.</td>
<td>88</td>
</tr>
<tr>
<td>Su X.</td>
<td>29, 127, 134</td>
</tr>
<tr>
<td>Su Z.</td>
<td>69</td>
</tr>
<tr>
<td>Suzuki K.</td>
<td>100, 124</td>
</tr>
<tr>
<td>Suzuki S.</td>
<td>125, 129, 139</td>
</tr>
<tr>
<td>Suzuki T.</td>
<td>78, 93, 95, 100, 129</td>
</tr>
<tr>
<td>Suzuki Y.</td>
<td>96</td>
</tr>
<tr>
<td>Swallow C.</td>
<td>91</td>
</tr>
<tr>
<td>Sym S. J.</td>
<td>100</td>
</tr>
<tr>
<td>Szczepanik A.</td>
<td>114</td>
</tr>
<tr>
<td>Szőr D.</td>
<td>109</td>
</tr>
<tr>
<td>Tabuchi S.</td>
<td>136</td>
</tr>
<tr>
<td>Tacconi M. R.</td>
<td>122</td>
</tr>
<tr>
<td>Tada T.</td>
<td>95, 132</td>
</tr>
<tr>
<td>Taef S.</td>
<td>90</td>
</tr>
<tr>
<td>Tagawa M.</td>
<td>78</td>
</tr>
<tr>
<td>Taghizadeh H.</td>
<td>65</td>
</tr>
<tr>
<td>Tagkalos E.</td>
<td>31</td>
</tr>
<tr>
<td>Tai C. H.</td>
<td>96, 135</td>
</tr>
<tr>
<td>Taijou H.</td>
<td>131</td>
</tr>
<tr>
<td>Tajika M.</td>
<td>98, 136</td>
</tr>
<tr>
<td>Tajima J.</td>
<td>70</td>
</tr>
<tr>
<td>Takaaki H.</td>
<td>126</td>
</tr>
<tr>
<td>Takagi M.</td>
<td>99</td>
</tr>
<tr>
<td>Takahari D.</td>
<td>95–96</td>
</tr>
<tr>
<td>Takahashi A.</td>
<td>88</td>
</tr>
<tr>
<td>Takahashi H.</td>
<td>126</td>
</tr>
<tr>
<td>Takahashi K.</td>
<td>105–106</td>
</tr>
<tr>
<td>Takahashi M.</td>
<td>70, 118</td>
</tr>
<tr>
<td>Takahashi R.</td>
<td>70, 100, 132</td>
</tr>
<tr>
<td>Takahashi T.</td>
<td>95, 104</td>
</tr>
<tr>
<td>Takahata R.</td>
<td>114</td>
</tr>
<tr>
<td>Takahiro E.</td>
<td>126</td>
</tr>
<tr>
<td>Takahiro H.</td>
<td>125</td>
</tr>
<tr>
<td>Takai A.</td>
<td>119</td>
</tr>
<tr>
<td>Takakawa T.</td>
<td>119</td>
</tr>
<tr>
<td>Takano Y.</td>
<td>95, 113, 124–125</td>
</tr>
<tr>
<td>Takao K.</td>
<td>77</td>
</tr>
<tr>
<td>Takase N.</td>
<td>129</td>
</tr>
<tr>
<td>Takashi I.</td>
<td>98</td>
</tr>
<tr>
<td>Takashi M.</td>
<td>92, 134</td>
</tr>
<tr>
<td>Takashima J.</td>
<td>73</td>
</tr>
<tr>
<td>Takashima O.</td>
<td>134</td>
</tr>
<tr>
<td>Takats Z.</td>
<td>78</td>
</tr>
<tr>
<td>Takayama O.</td>
<td>118</td>
</tr>
<tr>
<td>Takebayashi K.</td>
<td>124</td>
</tr>
<tr>
<td>Takechi T.</td>
<td>84, 124</td>
</tr>
<tr>
<td>Takeuchi D.</td>
<td>105</td>
</tr>
<tr>
<td>Takiguchi N.</td>
<td>129</td>
</tr>
<tr>
<td>Takiguchi T.</td>
<td>112</td>
</tr>
<tr>
<td>Tanabe K.</td>
<td>70, 100, 120</td>
</tr>
<tr>
<td>Tanabe S.</td>
<td>112</td>
</tr>
<tr>
<td>Tanahashi T.</td>
<td>95, 124</td>
</tr>
<tr>
<td>Tanaka C.</td>
<td>67, 81, 124</td>
</tr>
<tr>
<td>Tanaka K.</td>
<td>104</td>
</tr>
<tr>
<td>Tanaka N.</td>
<td>112</td>
</tr>
<tr>
<td>Tanaka T.</td>
<td>94, 98, 114, 124</td>
</tr>
<tr>
<td>Tanaka Y.</td>
<td>90, 95–96, 101, 114</td>
</tr>
<tr>
<td>Tanakaya K.</td>
<td>112</td>
</tr>
<tr>
<td>Tanai M.</td>
<td>118</td>
</tr>
<tr>
<td>Tan B.</td>
<td>91</td>
</tr>
<tr>
<td>Tanemura M.</td>
<td>96</td>
</tr>
<tr>
<td>Tan F.</td>
<td>127, 134</td>
</tr>
<tr>
<td>Tang C.</td>
<td>73, 123</td>
</tr>
<tr>
<td>Tang L.</td>
<td>93</td>
</tr>
<tr>
<td>Tang Z</td>
<td>70, 73</td>
</tr>
<tr>
<td>Tan H. L.</td>
<td>96, 135</td>
</tr>
<tr>
<td>Tanigawa K.</td>
<td>127</td>
</tr>
<tr>
<td>Taniguchi H.</td>
<td>98</td>
</tr>
<tr>
<td>Taniguchi K.</td>
<td>73, 100, 124</td>
</tr>
<tr>
<td>Tan M.</td>
<td>92, 112</td>
</tr>
<tr>
<td>Tanimoto A.</td>
<td>98</td>
</tr>
<tr>
<td>Tanizawa Y.</td>
<td>77, 84, 110</td>
</tr>
<tr>
<td>Tan J.</td>
<td>86</td>
</tr>
<tr>
<td>Tanmapfel A.</td>
<td>97</td>
</tr>
<tr>
<td>Tan P.</td>
<td>47, 64</td>
</tr>
<tr>
<td>Tan X.</td>
<td>116, 123</td>
</tr>
<tr>
<td>Tan Z.</td>
<td>73</td>
</tr>
<tr>
<td>Taniz G.</td>
<td>89</td>
</tr>
<tr>
<td>Tao K.</td>
<td>103</td>
</tr>
<tr>
<td>Tashiro H.</td>
<td>100</td>
</tr>
<tr>
<td>Tatsuta K.</td>
<td>127</td>
</tr>
<tr>
<td>Tatsuya K.</td>
<td>97</td>
</tr>
<tr>
<td>Tazawa H.</td>
<td>100</td>
</tr>
<tr>
<td>Tebaldi M.</td>
<td>77</td>
</tr>
<tr>
<td>Tedaldi G.</td>
<td>67, 77</td>
</tr>
<tr>
<td>Tei S.</td>
<td>84</td>
</tr>
<tr>
<td>Teng L.</td>
<td>63, 66, 70, 73, 94</td>
</tr>
<tr>
<td>Tennemann A.</td>
<td>74, 76</td>
</tr>
<tr>
<td>Teo S. C.</td>
<td>96</td>
</tr>
<tr>
<td>Terada M.</td>
<td>139</td>
</tr>
<tr>
<td>Teramoto H.</td>
<td>67, 81</td>
</tr>
<tr>
<td>Teranishi Y.</td>
<td>113, 125</td>
</tr>
<tr>
<td>Terashima M.</td>
<td>45, 77, 84, 110, 117–118, 129, 139</td>
</tr>
<tr>
<td>Terashima S.</td>
<td>124</td>
</tr>
<tr>
<td>Terziotti Jr Y.</td>
<td>106–107</td>
</tr>
<tr>
<td>Tesářová P.</td>
<td>26</td>
</tr>
<tr>
<td>Texeira E.</td>
<td>135</td>
</tr>
<tr>
<td>Thangarajah F.</td>
<td>136</td>
</tr>
<tr>
<td>Theilen M.</td>
<td>136</td>
</tr>
<tr>
<td>Theochori C.</td>
<td>111</td>
</tr>
<tr>
<td>Theochori N.</td>
<td>111</td>
</tr>
<tr>
<td>Thieme R.</td>
<td>43, 47, 74, 76–77, 85, 100</td>
</tr>
<tr>
<td>Thomaidis T.</td>
<td>66, 77</td>
</tr>
<tr>
<td>Thomas F.</td>
<td>49</td>
</tr>
<tr>
<td>Thomas L.</td>
<td>66</td>
</tr>
<tr>
<td>Thomas M.</td>
<td>89–91</td>
</tr>
<tr>
<td>Thomaz T.</td>
<td>72</td>
</tr>
<tr>
<td>Thuiller F.</td>
<td>64, 82, 94, 109</td>
</tr>
<tr>
<td>Thuss-Patience P.</td>
<td>36, 86, 94</td>
</tr>
<tr>
<td>Tianhua G.</td>
<td>87</td>
</tr>
<tr>
<td>Tian Y.</td>
<td>77, 91, 101</td>
</tr>
<tr>
<td>Tianzhou L.</td>
<td>46</td>
</tr>
<tr>
<td>Tiberio G. A. M.</td>
<td>62, 97–98, 100, 120, 122</td>
</tr>
<tr>
<td>Tiemann M.</td>
<td>69</td>
</tr>
<tr>
<td>Tienken M.</td>
<td>30</td>
</tr>
<tr>
<td>Tinoco A.</td>
<td>31</td>
</tr>
<tr>
<td>Toda M.</td>
<td>110, 120</td>
</tr>
<tr>
<td>Toda S.</td>
<td>124</td>
</tr>
<tr>
<td>Todate Y.</td>
<td>95, 125</td>
</tr>
<tr>
<td>Toh Y.</td>
<td>99</td>
</tr>
<tr>
<td>Tomokumo N.</td>
<td>65</td>
</tr>
<tr>
<td>Tokunaga M.</td>
<td>70, 96, 117</td>
</tr>
<tr>
<td>Tokunaga S.</td>
<td>99</td>
</tr>
<tr>
<td>Tokunaga M.</td>
<td>129</td>
</tr>
<tr>
<td>Tomezzioli A.</td>
<td>50, 62, 67</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Yong W. P</td>
<td>96, 135</td>
</tr>
<tr>
<td>Yoo H. M.</td>
<td>134</td>
</tr>
<tr>
<td>Yoo M. W.</td>
<td>121</td>
</tr>
<tr>
<td>Yoon C.</td>
<td>66, 87, 91</td>
</tr>
<tr>
<td>Yoon H. M.</td>
<td>87, 121, 130, 132, 138</td>
</tr>
<tr>
<td>Yoon S. S.</td>
<td>32, 37, 66, 87, 91</td>
</tr>
<tr>
<td>Yoon Young C.</td>
<td>68, 90</td>
</tr>
<tr>
<td>Yoo Y. S.</td>
<td>132</td>
</tr>
<tr>
<td>York S.</td>
<td>91</td>
</tr>
<tr>
<td>Yoshida K.</td>
<td>48, 95, 124</td>
</tr>
<tr>
<td>Yoshida M.</td>
<td>118, 127</td>
</tr>
<tr>
<td>Yoshida N.</td>
<td>83, 104, 109, 126</td>
</tr>
<tr>
<td>Yoshifumi B.</td>
<td>109</td>
</tr>
<tr>
<td>Yoshikawa T.</td>
<td>33, 64, 99, 113, 124, 132, 137, 139</td>
</tr>
<tr>
<td>Yoshiki K.</td>
<td>126</td>
</tr>
<tr>
<td>Yoshimitsu K.</td>
<td>102</td>
</tr>
<tr>
<td>Yoshinori I.</td>
<td>92</td>
</tr>
<tr>
<td>Yoshita H.</td>
<td>98</td>
</tr>
<tr>
<td>Yoshito T.</td>
<td>134</td>
</tr>
<tr>
<td>Yoshizawa N.</td>
<td>126–127</td>
</tr>
<tr>
<td>Yoshizumi A.</td>
<td>124</td>
</tr>
<tr>
<td>Young Chul K.</td>
<td>65</td>
</tr>
<tr>
<td>Young-Gil S.</td>
<td>115</td>
</tr>
<tr>
<td>Young-Joon L.</td>
<td>113</td>
</tr>
<tr>
<td>Young-Taek O.</td>
<td>138</td>
</tr>
<tr>
<td>Youn H.</td>
<td>72, 127</td>
</tr>
<tr>
<td>You W. C.</td>
<td>73</td>
</tr>
<tr>
<td>Yuan F.</td>
<td>71, 105</td>
</tr>
<tr>
<td>Yuan X.</td>
<td>136</td>
</tr>
<tr>
<td>Yu B.</td>
<td>79, 99, 102, 115, 120–121, 138, 140</td>
</tr>
<tr>
<td>Yu C.</td>
<td>69</td>
</tr>
<tr>
<td>Yucheng W.</td>
<td>126</td>
</tr>
<tr>
<td>Yue C.</td>
<td>121</td>
</tr>
<tr>
<td>Yu H. J.</td>
<td>94, 129</td>
</tr>
<tr>
<td>Yuichiro D.</td>
<td>137</td>
</tr>
<tr>
<td>Yu J.</td>
<td>70, 82–83, 87, 89, 103, 116, 126</td>
</tr>
<tr>
<td>Yukawa N.</td>
<td>132, 137</td>
</tr>
<tr>
<td>Yukawa Y.</td>
<td>87</td>
</tr>
<tr>
<td>Yuki K.</td>
<td>109</td>
</tr>
<tr>
<td>Yukinori K.</td>
<td>137</td>
</tr>
<tr>
<td>Yuki S.</td>
<td>98</td>
</tr>
<tr>
<td>Yuku K.</td>
<td>129</td>
</tr>
<tr>
<td>Yumiko O.</td>
<td>98</td>
</tr>
<tr>
<td>Yunhe G.</td>
<td>76</td>
</tr>
<tr>
<td>Yura M.</td>
<td>113, 139</td>
</tr>
<tr>
<td>Yurina S.</td>
<td>137</td>
</tr>
<tr>
<td>Yuta T.</td>
<td>113</td>
</tr>
<tr>
<td>Yu X.</td>
<td>70</td>
</tr>
<tr>
<td>Yu Y.</td>
<td>62, 71, 73, 94</td>
</tr>
<tr>
<td>Yu Z.</td>
<td>69</td>
</tr>
<tr>
<td>Zacharoulis D.</td>
<td>108</td>
</tr>
<tr>
<td>Zagaimov V.</td>
<td>114</td>
</tr>
<tr>
<td>Zaidan E.</td>
<td>122</td>
</tr>
<tr>
<td>Zaisheng Y.</td>
<td>89</td>
</tr>
<tr>
<td>Zalberk J.</td>
<td>91</td>
</tr>
<tr>
<td>Zampiga V.</td>
<td>77</td>
</tr>
<tr>
<td>Zander T.</td>
<td>74, 90</td>
</tr>
<tr>
<td>Zang D. Y.</td>
<td>80</td>
</tr>
<tr>
<td>Zang L.</td>
<td>97, 134</td>
</tr>
<tr>
<td>Zang M.</td>
<td>76</td>
</tr>
<tr>
<td>Zanini N.</td>
<td>134</td>
</tr>
<tr>
<td>Zawadzki M.</td>
<td>66, 74, 111</td>
</tr>
<tr>
<td>Zebrowska P.</td>
<td>74</td>
</tr>
<tr>
<td>Zemancova M.</td>
<td>89</td>
</tr>
<tr>
<td>Zhao H.</td>
<td>100</td>
</tr>
<tr>
<td>Zhang C.</td>
<td>100, 127, 134</td>
</tr>
<tr>
<td>Zhang D.</td>
<td>93, 106</td>
</tr>
<tr>
<td>Zhang D. Y.</td>
<td>39</td>
</tr>
<tr>
<td>Zhang H. W.</td>
<td>83</td>
</tr>
<tr>
<td>Zhang J.</td>
<td>79, 105, 123, 127, 140</td>
</tr>
<tr>
<td>Zhang K.</td>
<td>84, 105</td>
</tr>
<tr>
<td>Zhang L.</td>
<td>71, 73, 79, 93, 100–101, 131, 134</td>
</tr>
<tr>
<td>Zhang N.</td>
<td>71, 127, 134</td>
</tr>
<tr>
<td>Zhang P.</td>
<td>103</td>
</tr>
<tr>
<td>Zhang Q.</td>
<td>69, 87, 89</td>
</tr>
<tr>
<td>Zhang S.</td>
<td>90, 105–106</td>
</tr>
<tr>
<td>Zhang W.</td>
<td>86</td>
</tr>
<tr>
<td>Zhang W. H.</td>
<td>68, 71, 84, 111</td>
</tr>
<tr>
<td>Zhang X.</td>
<td>73, 79, 81, 106</td>
</tr>
<tr>
<td>Zhang Y.</td>
<td>69, 73, 91, 94, 111, 136, 139</td>
</tr>
<tr>
<td>Zhang Z.</td>
<td>70, 91, 93, 128, 135</td>
</tr>
<tr>
<td>Zhao A.</td>
<td>140</td>
</tr>
<tr>
<td>Zhao E.</td>
<td>134</td>
</tr>
<tr>
<td>Zhao G.</td>
<td>140</td>
</tr>
<tr>
<td>Zhao H.</td>
<td>81</td>
</tr>
<tr>
<td>Zhao L.</td>
<td>94</td>
</tr>
<tr>
<td>Zhao L. Y.</td>
<td>71, 111</td>
</tr>
<tr>
<td>Zhao Q.</td>
<td>91, 116, 123, 130</td>
</tr>
<tr>
<td>Zhao S.</td>
<td>66, 106, 117</td>
</tr>
<tr>
<td>Zhao X.</td>
<td>91</td>
</tr>
<tr>
<td>Zhao Y.</td>
<td>81, 90, 94</td>
</tr>
<tr>
<td>Zhao Z.</td>
<td>87</td>
</tr>
<tr>
<td>Zheng C.</td>
<td>91</td>
</tr>
<tr>
<td>Zheng M.</td>
<td>134</td>
</tr>
<tr>
<td>Zheng Q.</td>
<td>79</td>
</tr>
<tr>
<td>Zheng S.</td>
<td>94</td>
</tr>
<tr>
<td>Zheng W.</td>
<td>73</td>
</tr>
<tr>
<td>Zheng X.</td>
<td>136</td>
</tr>
<tr>
<td>Zheng Y.</td>
<td>93</td>
</tr>
<tr>
<td>Zheng Z.</td>
<td>94</td>
</tr>
<tr>
<td>Zheng Z. F.</td>
<td>85, 116</td>
</tr>
<tr>
<td>Zhen H.</td>
<td>65</td>
</tr>
<tr>
<td>Zhen L.</td>
<td>140</td>
</tr>
<tr>
<td>Zhibin H.</td>
<td>76, 87</td>
</tr>
<tr>
<td>Zhiming M.</td>
<td>131, 133</td>
</tr>
<tr>
<td>Zhi Q.</td>
<td>76</td>
</tr>
<tr>
<td>Zhitao L.</td>
<td>89</td>
</tr>
<tr>
<td>Zhiyu X.</td>
<td>135</td>
</tr>
<tr>
<td>Zhong C.</td>
<td>80–81</td>
</tr>
<tr>
<td>Zhong Q.</td>
<td>82</td>
</tr>
<tr>
<td>Zhou B.</td>
<td>121</td>
</tr>
<tr>
<td>Zhou F.</td>
<td>123</td>
</tr>
<tr>
<td>Zhou J.</td>
<td>70</td>
</tr>
<tr>
<td>Zhou M. L.</td>
<td>37, 70, 93</td>
</tr>
<tr>
<td>Zhou T.</td>
<td>63</td>
</tr>
<tr>
<td>Zhou Y.</td>
<td>106, 116, 119, 123, 127, 136, 140</td>
</tr>
<tr>
<td>Zhou Z.</td>
<td>103</td>
</tr>
<tr>
<td>Zhuang H.</td>
<td>81</td>
</tr>
<tr>
<td>Zhu C.</td>
<td>106</td>
</tr>
<tr>
<td>Zhu J.</td>
<td>81, 131</td>
</tr>
<tr>
<td>Zhu K.</td>
<td>87</td>
</tr>
<tr>
<td>Zhuo W.</td>
<td>63</td>
</tr>
<tr>
<td>Zhu X.</td>
<td>140</td>
</tr>
<tr>
<td>Zhu Z.</td>
<td>69, 71, 76, 93, 139</td>
</tr>
<tr>
<td>Zhu Z. G.</td>
<td>88, 137</td>
</tr>
<tr>
<td>Zilberstein B.</td>
<td>27, 68, 77, 90, 107, 109, 113, 118, 122</td>
</tr>
<tr>
<td>Zilberstein B.</td>
<td>65</td>
</tr>
<tr>
<td>Zimmer-Zachmann H.</td>
<td>66</td>
</tr>
<tr>
<td>Ziyu L.</td>
<td>126</td>
</tr>
<tr>
<td>Zong X.</td>
<td>79, 105</td>
</tr>
<tr>
<td>Zong Y.</td>
<td>134</td>
</tr>
<tr>
<td>Zonta S.</td>
<td>125</td>
</tr>
<tr>
<td>Zou J.</td>
<td>136</td>
</tr>
<tr>
<td>Zubarev M.</td>
<td>88</td>
</tr>
<tr>
<td>Zuocheng S.</td>
<td>109, 134</td>
</tr>
<tr>
<td>Zwingenberger G.</td>
<td>73</td>
</tr>
<tr>
<td>Zylstra J.</td>
<td>103, 110</td>
</tr>
</tbody>
</table>
IGCC 2019 Mobile App

The IGCC 2019 Congress App is now available for download. The app includes:

- Free download for all Apple and Google mobile devices
- User-friendly navigation
- Multiple networking opportunities
- Personalised program options
- Find your way with venue map
- Paper free and replacing the printed program books

To sign in to the IGCC 2019 App please use an invitation code that you received from the Secretariat. Should you need any assistance please contact us at the Registration Desk.

App download
To download the app please use the QR code below or search for IGCC 2019 in your app store.
International Gastric Cancer Congress

The Evolution of Gastric Cancer Science; The Future of Gastric Cancer Treatment

HOUSTON, USA  |  APRIL 1 – 3, 2021